WO2015153401A1 - Phosphate based linkers for intracellular delivery of drug conjugates - Google Patents
Phosphate based linkers for intracellular delivery of drug conjugates Download PDFInfo
- Publication number
- WO2015153401A1 WO2015153401A1 PCT/US2015/023247 US2015023247W WO2015153401A1 WO 2015153401 A1 WO2015153401 A1 WO 2015153401A1 US 2015023247 W US2015023247 W US 2015023247W WO 2015153401 A1 WO2015153401 A1 WO 2015153401A1
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- antibody
- group
- moiety
- compound
- heterocyclic
- Prior art date
Links
- 239000003814 drug Substances 0.000 title claims abstract description 94
- 229940079593 drug Drugs 0.000 title claims abstract description 66
- 229910019142 PO4 Inorganic materials 0.000 title abstract description 61
- 239000010452 phosphate Substances 0.000 title abstract description 61
- NBIIXXVUZAFLBC-UHFFFAOYSA-K phosphate Chemical compound [O-]P([O-])([O-])=O NBIIXXVUZAFLBC-UHFFFAOYSA-K 0.000 title abstract description 52
- 230000003834 intracellular effect Effects 0.000 title abstract description 23
- 239000003446 ligand Substances 0.000 claims abstract description 104
- 230000008685 targeting Effects 0.000 claims abstract description 74
- 125000000524 functional group Chemical group 0.000 claims abstract description 41
- -1 heteroaliphatic Chemical group 0.000 claims description 271
- 150000001875 compounds Chemical class 0.000 claims description 131
- 229910052760 oxygen Inorganic materials 0.000 claims description 103
- 239000000562 conjugate Substances 0.000 claims description 91
- 229940049595 antibody-drug conjugate Drugs 0.000 claims description 90
- 125000003118 aryl group Chemical group 0.000 claims description 89
- 239000000611 antibody drug conjugate Substances 0.000 claims description 87
- 125000000623 heterocyclic group Chemical group 0.000 claims description 85
- 125000001072 heteroaryl group Chemical group 0.000 claims description 84
- 239000000203 mixture Substances 0.000 claims description 69
- 125000001931 aliphatic group Chemical group 0.000 claims description 67
- 239000000460 chlorine Substances 0.000 claims description 67
- 229910052801 chlorine Inorganic materials 0.000 claims description 67
- 125000005842 heteroatom Chemical group 0.000 claims description 63
- ZAMOUSCENKQFHK-UHFFFAOYSA-N Chlorine atom Chemical compound [Cl] ZAMOUSCENKQFHK-UHFFFAOYSA-N 0.000 claims description 57
- 125000000325 methylidene group Chemical group [H]C([H])=* 0.000 claims description 51
- 125000002252 acyl group Chemical group 0.000 claims description 49
- 229910052799 carbon Inorganic materials 0.000 claims description 49
- 229960003957 dexamethasone Drugs 0.000 claims description 47
- 238000000034 method Methods 0.000 claims description 46
- AOJJSUZBOXZQNB-TZSSRYMLSA-N Doxorubicin Chemical compound O([C@H]1C[C@@](O)(CC=2C(O)=C3C(=O)C=4C=CC=C(C=4C(=O)C3=C(O)C=21)OC)C(=O)CO)[C@H]1C[C@H](N)[C@H](O)[C@H](C)O1 AOJJSUZBOXZQNB-TZSSRYMLSA-N 0.000 claims description 44
- 229910052757 nitrogen Inorganic materials 0.000 claims description 44
- 231100000599 cytotoxic agent Toxicity 0.000 claims description 43
- 229940127089 cytotoxic agent Drugs 0.000 claims description 41
- 239000002254 cytotoxic agent Substances 0.000 claims description 41
- 229940121363 anti-inflammatory agent Drugs 0.000 claims description 40
- 239000002260 anti-inflammatory agent Substances 0.000 claims description 40
- 125000004432 carbon atom Chemical group C* 0.000 claims description 40
- 229920006395 saturated elastomer Polymers 0.000 claims description 40
- UREBDLICKHMUKA-CXSFZGCWSA-N dexamethasone Chemical compound C1CC2=CC(=O)C=C[C@]2(C)[C@]2(F)[C@@H]1[C@@H]1C[C@@H](C)[C@@](C(=O)CO)(O)[C@@]1(C)C[C@@H]2O UREBDLICKHMUKA-CXSFZGCWSA-N 0.000 claims description 38
- 229910052717 sulfur Inorganic materials 0.000 claims description 36
- 125000006239 protecting group Chemical group 0.000 claims description 35
- UIGRBLXJJABSCB-UHFFFAOYSA-N benzo[e]indol-4-one Chemical compound O=C1C=C2C=CC=CC2=C2C1=NC=C2 UIGRBLXJJABSCB-UHFFFAOYSA-N 0.000 claims description 33
- 125000004435 hydrogen atom Chemical group [H]* 0.000 claims description 32
- 108090000765 processed proteins & peptides Proteins 0.000 claims description 30
- 125000005843 halogen group Chemical group 0.000 claims description 28
- JYGXADMDTFJGBT-VWUMJDOOSA-N hydrocortisone Chemical compound O=C1CC[C@]2(C)[C@H]3[C@@H](O)C[C@](C)([C@@](CC4)(O)C(=O)CO)[C@@H]4[C@@H]3CCC2=C1 JYGXADMDTFJGBT-VWUMJDOOSA-N 0.000 claims description 28
- 229960005501 duocarmycin Drugs 0.000 claims description 27
- 229930184221 duocarmycin Natural products 0.000 claims description 27
- 239000001257 hydrogen Substances 0.000 claims description 27
- 229910052739 hydrogen Inorganic materials 0.000 claims description 27
- 102000039446 nucleic acids Human genes 0.000 claims description 27
- 108020004707 nucleic acids Proteins 0.000 claims description 27
- 150000007523 nucleic acids Chemical class 0.000 claims description 27
- 229940124597 therapeutic agent Drugs 0.000 claims description 27
- ZCYVEMRRCGMTRW-UHFFFAOYSA-N 7553-56-2 Chemical compound [I] ZCYVEMRRCGMTRW-UHFFFAOYSA-N 0.000 claims description 26
- 125000003710 aryl alkyl group Chemical group 0.000 claims description 26
- 229910052740 iodine Inorganic materials 0.000 claims description 26
- 239000011630 iodine Substances 0.000 claims description 26
- STQGQHZAVUOBTE-UHFFFAOYSA-N 7-Cyan-hept-2t-en-4,6-diinsaeure Natural products C1=2C(O)=C3C(=O)C=4C(OC)=CC=CC=4C(=O)C3=C(O)C=2CC(O)(C(C)=O)CC1OC1CC(N)C(O)C(C)O1 STQGQHZAVUOBTE-UHFFFAOYSA-N 0.000 claims description 25
- 102000035195 Peptidases Human genes 0.000 claims description 25
- 108091005804 Peptidases Proteins 0.000 claims description 25
- 239000004365 Protease Substances 0.000 claims description 25
- WKBOTKDWSSQWDR-UHFFFAOYSA-N Bromine atom Chemical compound [Br] WKBOTKDWSSQWDR-UHFFFAOYSA-N 0.000 claims description 24
- PXGOKWXKJXAPGV-UHFFFAOYSA-N Fluorine Chemical compound FF PXGOKWXKJXAPGV-UHFFFAOYSA-N 0.000 claims description 24
- AVXURJPOCDRRFD-UHFFFAOYSA-N Hydroxylamine Chemical compound ON AVXURJPOCDRRFD-UHFFFAOYSA-N 0.000 claims description 24
- GDTBXPJZTBHREO-UHFFFAOYSA-N bromine Substances BrBr GDTBXPJZTBHREO-UHFFFAOYSA-N 0.000 claims description 24
- 229910052794 bromium Inorganic materials 0.000 claims description 24
- 229960004679 doxorubicin Drugs 0.000 claims description 24
- 229910052731 fluorine Inorganic materials 0.000 claims description 24
- 239000011737 fluorine Substances 0.000 claims description 24
- QHFKWIKCUHNXAU-UHFFFAOYSA-N (4-nitrophenyl) carbamate Chemical compound NC(=O)OC1=CC=C([N+]([O-])=O)C=C1 QHFKWIKCUHNXAU-UHFFFAOYSA-N 0.000 claims description 23
- 102000004225 Cathepsin B Human genes 0.000 claims description 23
- 108090000712 Cathepsin B Proteins 0.000 claims description 23
- PEEHTFAAVSWFBL-UHFFFAOYSA-N Maleimide Chemical compound O=C1NC(=O)C=C1 PEEHTFAAVSWFBL-UHFFFAOYSA-N 0.000 claims description 23
- 229930012538 Paclitaxel Natural products 0.000 claims description 23
- 150000001345 alkine derivatives Chemical class 0.000 claims description 23
- 229960004436 budesonide Drugs 0.000 claims description 23
- 150000001993 dienes Chemical class 0.000 claims description 23
- ZHCAAFJSYLFLPX-UHFFFAOYSA-N nitrocyclohexatriene Chemical group [O-][N+](=O)C1=CC=C=C[CH]1 ZHCAAFJSYLFLPX-UHFFFAOYSA-N 0.000 claims description 23
- 239000002777 nucleoside Substances 0.000 claims description 23
- IAKHMKGGTNLKSZ-INIZCTEOSA-N (S)-colchicine Chemical compound C1([C@@H](NC(C)=O)CC2)=CC(=O)C(OC)=CC=C1C1=C2C=C(OC)C(OC)=C1OC IAKHMKGGTNLKSZ-INIZCTEOSA-N 0.000 claims description 22
- FERIUCNNQQJTOY-UHFFFAOYSA-N Butyric acid Chemical compound CCCC(O)=O FERIUCNNQQJTOY-UHFFFAOYSA-N 0.000 claims description 22
- 102000005744 Glycoside Hydrolases Human genes 0.000 claims description 22
- 108010031186 Glycoside Hydrolases Proteins 0.000 claims description 22
- NWIBSHFKIJFRCO-WUDYKRTCSA-N Mytomycin Chemical compound C1N2C(C(C(C)=C(N)C3=O)=O)=C3[C@@H](COC(N)=O)[C@@]2(OC)[C@@H]2[C@H]1N2 NWIBSHFKIJFRCO-WUDYKRTCSA-N 0.000 claims description 22
- ZDZOTLJHXYCWBA-VCVYQWHSSA-N N-debenzoyl-N-(tert-butoxycarbonyl)-10-deacetyltaxol Chemical compound O([C@H]1[C@H]2[C@@](C([C@H](O)C3=C(C)[C@@H](OC(=O)[C@H](O)[C@@H](NC(=O)OC(C)(C)C)C=4C=CC=CC=4)C[C@]1(O)C3(C)C)=O)(C)[C@@H](O)C[C@H]1OC[C@]12OC(=O)C)C(=O)C1=CC=CC=C1 ZDZOTLJHXYCWBA-VCVYQWHSSA-N 0.000 claims description 22
- 108010044540 auristatin Proteins 0.000 claims description 22
- STQGQHZAVUOBTE-VGBVRHCVSA-N daunorubicin Chemical compound O([C@H]1C[C@@](O)(CC=2C(O)=C3C(=O)C=4C=CC=C(C=4C(=O)C3=C(O)C=21)OC)C(C)=O)[C@H]1C[C@H](N)[C@H](O)[C@H](C)O1 STQGQHZAVUOBTE-VGBVRHCVSA-N 0.000 claims description 22
- 229960000975 daunorubicin Drugs 0.000 claims description 22
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims description 22
- WKPWGQKGSOKKOO-RSFHAFMBSA-N maytansine Chemical compound CO[C@@H]([C@@]1(O)C[C@](OC(=O)N1)([C@H]([C@@H]1O[C@@]1(C)[C@@H](OC(=O)[C@H](C)N(C)C(C)=O)CC(=O)N1C)C)[H])\C=C\C=C(C)\CC2=CC(OC)=C(Cl)C1=C2 WKPWGQKGSOKKOO-RSFHAFMBSA-N 0.000 claims description 22
- GLVAUDGFNGKCSF-UHFFFAOYSA-N mercaptopurine Chemical compound S=C1NC=NC2=C1NC=N2 GLVAUDGFNGKCSF-UHFFFAOYSA-N 0.000 claims description 22
- 150000003833 nucleoside derivatives Chemical class 0.000 claims description 22
- 229960001592 paclitaxel Drugs 0.000 claims description 22
- RCINICONZNJXQF-MZXODVADSA-N taxol Chemical compound O([C@@H]1[C@@]2(C[C@@H](C(C)=C(C2(C)C)[C@H](C([C@]2(C)[C@@H](O)C[C@H]3OC[C@]3([C@H]21)OC(C)=O)=O)OC(=O)C)OC(=O)[C@H](O)[C@@H](NC(=O)C=1C=CC=CC=1)C=1C=CC=CC=1)O)C(=O)C1=CC=CC=C1 RCINICONZNJXQF-MZXODVADSA-N 0.000 claims description 22
- GETQZCLCWQTVFV-UHFFFAOYSA-N trimethylamine Chemical group CN(C)C GETQZCLCWQTVFV-UHFFFAOYSA-N 0.000 claims description 22
- 125000000538 pentafluorophenyl group Chemical group FC1=C(F)C(F)=C(*)C(F)=C1F 0.000 claims description 21
- OAKJQQAXSVQMHS-UHFFFAOYSA-N Hydrazine Chemical compound NN OAKJQQAXSVQMHS-UHFFFAOYSA-N 0.000 claims description 20
- YJGVMLPVUAXIQN-XVVDYKMHSA-N podophyllotoxin Chemical compound COC1=C(OC)C(OC)=CC([C@@H]2C3=CC=4OCOC=4C=C3[C@H](O)[C@@H]3[C@@H]2C(OC3)=O)=C1 YJGVMLPVUAXIQN-XVVDYKMHSA-N 0.000 claims description 20
- 150000002148 esters Chemical class 0.000 claims description 19
- VOVIALXJUBGFJZ-KWVAZRHASA-N Budesonide Chemical compound C1CC2=CC(=O)C=C[C@]2(C)[C@@H]2[C@@H]1[C@@H]1C[C@H]3OC(CCC)O[C@@]3(C(=O)CO)[C@@]1(C)C[C@@H]2O VOVIALXJUBGFJZ-KWVAZRHASA-N 0.000 claims description 18
- 150000001720 carbohydrates Chemical class 0.000 claims description 18
- 229920001223 polyethylene glycol Polymers 0.000 claims description 18
- 229960000289 fluticasone propionate Drugs 0.000 claims description 17
- 150000004676 glycans Chemical class 0.000 claims description 17
- 102000005962 receptors Human genes 0.000 claims description 17
- 108020003175 receptors Proteins 0.000 claims description 17
- 108090001090 Lectins Proteins 0.000 claims description 16
- 102000004856 Lectins Human genes 0.000 claims description 16
- WMWTYOKRWGGJOA-CENSZEJFSA-N fluticasone propionate Chemical compound C1([C@@H](F)C2)=CC(=O)C=C[C@]1(C)[C@]1(F)[C@@H]2[C@@H]2C[C@@H](C)[C@@](C(=O)SCF)(OC(=O)CC)[C@@]2(C)C[C@@H]1O WMWTYOKRWGGJOA-CENSZEJFSA-N 0.000 claims description 16
- 229940124750 glucocorticoid receptor agonist Drugs 0.000 claims description 16
- 239000002523 lectin Substances 0.000 claims description 16
- 229920001282 polysaccharide Polymers 0.000 claims description 16
- 239000005017 polysaccharide Substances 0.000 claims description 16
- JFUAWXPBHXKZGA-IBGZPJMESA-N 4-fluoro-2-[(4r)-5,5,5-trifluoro-4-hydroxy-2-methyl-4-(1h-pyrrolo[2,3-c]pyridin-2-ylmethyl)pentan-2-yl]phenol Chemical group C([C@@](O)(CC=1NC2=CN=CC=C2C=1)C(F)(F)F)C(C)(C)C1=CC(F)=CC=C1O JFUAWXPBHXKZGA-IBGZPJMESA-N 0.000 claims description 15
- CSCPPACGZOOCGX-UHFFFAOYSA-N Acetone Chemical compound CC(C)=O CSCPPACGZOOCGX-UHFFFAOYSA-N 0.000 claims description 15
- 239000002253 acid Substances 0.000 claims description 15
- 229960002714 fluticasone Drugs 0.000 claims description 15
- 229920001481 poly(stearyl methacrylate) Polymers 0.000 claims description 15
- KUVIULQEHSCUHY-XYWKZLDCSA-N Beclometasone Chemical compound C1CC2=CC(=O)C=C[C@]2(C)[C@]2(Cl)[C@@H]1[C@@H]1C[C@H](C)[C@@](C(=O)COC(=O)CC)(OC(=O)CC)[C@@]1(C)C[C@@H]2O KUVIULQEHSCUHY-XYWKZLDCSA-N 0.000 claims description 14
- ITRJWOMZKQRYTA-RFZYENFJSA-N Cortisone acetate Chemical compound C1CC2=CC(=O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@@](C(=O)COC(=O)C)(O)[C@@]1(C)CC2=O ITRJWOMZKQRYTA-RFZYENFJSA-N 0.000 claims description 14
- FQISKWAFAHGMGT-SGJOWKDISA-M Methylprednisolone sodium succinate Chemical compound [Na+].C([C@@]12C)=CC(=O)C=C1[C@@H](C)C[C@@H]1[C@@H]2[C@@H](O)C[C@]2(C)[C@@](O)(C(=O)COC(=O)CCC([O-])=O)CC[C@H]21 FQISKWAFAHGMGT-SGJOWKDISA-M 0.000 claims description 14
- 230000002494 anti-cea effect Effects 0.000 claims description 14
- 150000001540 azides Chemical class 0.000 claims description 14
- 229960004495 beclometasone Drugs 0.000 claims description 14
- 229960002537 betamethasone Drugs 0.000 claims description 14
- UREBDLICKHMUKA-DVTGEIKXSA-N betamethasone Chemical compound C1CC2=CC(=O)C=C[C@]2(C)[C@]2(F)[C@@H]1[C@@H]1C[C@H](C)[C@@](C(=O)CO)(O)[C@@]1(C)C[C@@H]2O UREBDLICKHMUKA-DVTGEIKXSA-N 0.000 claims description 14
- 229960003290 cortisone acetate Drugs 0.000 claims description 14
- MGNNYOODZCAHBA-GQKYHHCASA-N fluticasone Chemical compound C1([C@@H](F)C2)=CC(=O)C=C[C@]1(C)[C@]1(F)[C@@H]2[C@@H]2C[C@@H](C)[C@@](C(=O)SCF)(O)[C@@]2(C)C[C@@H]1O MGNNYOODZCAHBA-GQKYHHCASA-N 0.000 claims description 14
- XTULMSXFIHGYFS-VLSRWLAYSA-N fluticasone furoate Chemical compound O([C@]1([C@@]2(C)C[C@H](O)[C@]3(F)[C@@]4(C)C=CC(=O)C=C4[C@@H](F)C[C@H]3[C@@H]2C[C@H]1C)C(=O)SCF)C(=O)C1=CC=CO1 XTULMSXFIHGYFS-VLSRWLAYSA-N 0.000 claims description 14
- 229960001469 fluticasone furoate Drugs 0.000 claims description 14
- 229960000890 hydrocortisone Drugs 0.000 claims description 14
- 229960004584 methylprednisolone Drugs 0.000 claims description 14
- 229960001664 mometasone Drugs 0.000 claims description 14
- QLIIKPVHVRXHRI-CXSFZGCWSA-N mometasone Chemical compound C1CC2=CC(=O)C=C[C@]2(C)[C@]2(Cl)[C@@H]1[C@@H]1C[C@@H](C)[C@@](C(=O)CCl)(O)[C@@]1(C)C[C@@H]2O QLIIKPVHVRXHRI-CXSFZGCWSA-N 0.000 claims description 14
- 229960005205 prednisolone Drugs 0.000 claims description 14
- OIGNJSKKLXVSLS-VWUMJDOOSA-N prednisolone Chemical compound O=C1C=C[C@]2(C)[C@H]3[C@@H](O)C[C@](C)([C@@](CC4)(O)C(=O)CO)[C@@H]4[C@@H]3CCC2=C1 OIGNJSKKLXVSLS-VWUMJDOOSA-N 0.000 claims description 14
- 229960004618 prednisone Drugs 0.000 claims description 14
- XOFYZVNMUHMLCC-ZPOLXVRWSA-N prednisone Chemical compound O=C1C=C[C@]2(C)[C@H]3C(=O)C[C@](C)([C@@](CC4)(O)C(=O)CO)[C@@H]4[C@@H]3CCC2=C1 XOFYZVNMUHMLCC-ZPOLXVRWSA-N 0.000 claims description 14
- NQTADLQHYWFPDB-UHFFFAOYSA-N N-Hydroxysuccinimide Chemical compound ON1C(=O)CCC1=O NQTADLQHYWFPDB-UHFFFAOYSA-N 0.000 claims description 13
- 201000010099 disease Diseases 0.000 claims description 13
- IEDXPSOJFSVCKU-HOKPPMCLSA-N [4-[[(2S)-5-(carbamoylamino)-2-[[(2S)-2-[6-(2,5-dioxopyrrolidin-1-yl)hexanoylamino]-3-methylbutanoyl]amino]pentanoyl]amino]phenyl]methyl N-[(2S)-1-[[(2S)-1-[[(3R,4S,5S)-1-[(2S)-2-[(1R,2R)-3-[[(1S,2R)-1-hydroxy-1-phenylpropan-2-yl]amino]-1-methoxy-2-methyl-3-oxopropyl]pyrrolidin-1-yl]-3-methoxy-5-methyl-1-oxoheptan-4-yl]-methylamino]-3-methyl-1-oxobutan-2-yl]amino]-3-methyl-1-oxobutan-2-yl]-N-methylcarbamate Chemical compound CC[C@H](C)[C@@H]([C@@H](CC(=O)N1CCC[C@H]1[C@H](OC)[C@@H](C)C(=O)N[C@H](C)[C@@H](O)c1ccccc1)OC)N(C)C(=O)[C@@H](NC(=O)[C@H](C(C)C)N(C)C(=O)OCc1ccc(NC(=O)[C@H](CCCNC(N)=O)NC(=O)[C@@H](NC(=O)CCCCCN2C(=O)CCC2=O)C(C)C)cc1)C(C)C IEDXPSOJFSVCKU-HOKPPMCLSA-N 0.000 claims description 12
- 108010093470 monomethyl auristatin E Proteins 0.000 claims description 12
- WOWDZACBATWTAU-FEFUEGSOSA-N (2s)-2-[[(2s)-2-(dimethylamino)-3-methylbutanoyl]amino]-n-[(3r,4s,5s)-1-[(2s)-2-[(1r,2r)-3-[[(1s,2r)-1-hydroxy-1-phenylpropan-2-yl]amino]-1-methoxy-2-methyl-3-oxopropyl]pyrrolidin-1-yl]-3-methoxy-5-methyl-1-oxoheptan-4-yl]-n,3-dimethylbutanamide Chemical compound CC(C)[C@H](N(C)C)C(=O)N[C@@H](C(C)C)C(=O)N(C)[C@@H]([C@@H](C)CC)[C@H](OC)CC(=O)N1CCC[C@H]1[C@H](OC)[C@@H](C)C(=O)N[C@H](C)[C@@H](O)C1=CC=CC=C1 WOWDZACBATWTAU-FEFUEGSOSA-N 0.000 claims description 11
- MCEHFIXEKNKSRW-LBPRGKRZSA-N (2s)-2-[[3,5-dichloro-4-[(2,4-diaminopteridin-6-yl)methyl-methylamino]benzoyl]amino]pentanedioic acid Chemical compound C=1N=C2N=C(N)N=C(N)C2=NC=1CN(C)C1=C(Cl)C=C(C(=O)N[C@@H](CCC(O)=O)C(O)=O)C=C1Cl MCEHFIXEKNKSRW-LBPRGKRZSA-N 0.000 claims description 11
- XSAKVDNHFRWJKS-IIZANFQQSA-N (2s)-n-benzyl-1-[(2s)-1-[(2s)-2-[[(2s)-2-[[(2s)-2-(dimethylamino)-3-methylbutanoyl]amino]-3-methylbutanoyl]-methylamino]-3-methylbutanoyl]pyrrolidine-2-carbonyl]pyrrolidine-2-carboxamide Chemical compound CC(C)[C@H](N(C)C)C(=O)N[C@@H](C(C)C)C(=O)N(C)[C@@H](C(C)C)C(=O)N1CCC[C@H]1C(=O)N1[C@H](C(=O)NCC=2C=CC=CC=2)CCC1 XSAKVDNHFRWJKS-IIZANFQQSA-N 0.000 claims description 11
- YIMDLWDNDGKDTJ-QLKYHASDSA-N 3'-deamino-3'-(3-cyanomorpholin-4-yl)doxorubicin Chemical compound N1([C@H]2C[C@@H](O[C@@H](C)[C@H]2O)O[C@H]2C[C@@](O)(CC=3C(O)=C4C(=O)C=5C=CC=C(C=5C(=O)C4=C(O)C=32)OC)C(=O)CO)CCOCC1C#N YIMDLWDNDGKDTJ-QLKYHASDSA-N 0.000 claims description 11
- NDMPLJNOPCLANR-UHFFFAOYSA-N 3,4-dihydroxy-15-(4-hydroxy-18-methoxycarbonyl-5,18-seco-ibogamin-18-yl)-16-methoxy-1-methyl-6,7-didehydro-aspidospermidine-3-carboxylic acid methyl ester Natural products C1C(CC)(O)CC(CC2(C(=O)OC)C=3C(=CC4=C(C56C(C(C(O)C7(CC)C=CCN(C67)CC5)(O)C(=O)OC)N4C)C=3)OC)CN1CCC1=C2NC2=CC=CC=C12 NDMPLJNOPCLANR-UHFFFAOYSA-N 0.000 claims description 11
- TVZGACDUOSZQKY-LBPRGKRZSA-N 4-aminofolic acid Chemical compound C1=NC2=NC(N)=NC(N)=C2N=C1CNC1=CC=C(C(=O)N[C@@H](CCC(O)=O)C(O)=O)C=C1 TVZGACDUOSZQKY-LBPRGKRZSA-N 0.000 claims description 11
- LGZKGOGODCLQHG-CYBMUJFWSA-N 5-[(2r)-2-hydroxy-2-(3,4,5-trimethoxyphenyl)ethyl]-2-methoxyphenol Chemical compound C1=C(O)C(OC)=CC=C1C[C@@H](O)C1=CC(OC)=C(OC)C(OC)=C1 LGZKGOGODCLQHG-CYBMUJFWSA-N 0.000 claims description 11
- FJHBVJOVLFPMQE-QFIPXVFZSA-N 7-Ethyl-10-Hydroxy-Camptothecin Chemical compound C1=C(O)C=C2C(CC)=C(CN3C(C4=C([C@@](C(=O)OC4)(O)CC)C=C33)=O)C3=NC2=C1 FJHBVJOVLFPMQE-QFIPXVFZSA-N 0.000 claims description 11
- AUJXLBOHYWTPFV-BLWRDSOESA-N CS[C@H]1SC[C@H]2N(C)C(=O)[C@@H](C)NC(=O)[C@H](COC(=O)[C@@H](C(C)C)N(C)C(=O)[C@@H]1N(C)C(=O)[C@@H](C)NC(=O)[C@H](COC(=O)[C@@H](C(C)C)N(C)C2=O)NC(=O)c1cnc2ccccc2n1)NC(=O)c1cnc2ccccc2n1 Chemical compound CS[C@H]1SC[C@H]2N(C)C(=O)[C@@H](C)NC(=O)[C@H](COC(=O)[C@@H](C(C)C)N(C)C(=O)[C@@H]1N(C)C(=O)[C@@H](C)NC(=O)[C@H](COC(=O)[C@@H](C(C)C)N(C)C2=O)NC(=O)c1cnc2ccccc2n1)NC(=O)c1cnc2ccccc2n1 AUJXLBOHYWTPFV-BLWRDSOESA-N 0.000 claims description 11
- KLWPJMFMVPTNCC-UHFFFAOYSA-N Camptothecin Natural products CCC1(O)C(=O)OCC2=C1C=C3C4Nc5ccccc5C=C4CN3C2=O KLWPJMFMVPTNCC-UHFFFAOYSA-N 0.000 claims description 11
- UHDGCWIWMRVCDJ-CCXZUQQUSA-N Cytarabine Chemical compound O=C1N=C(N)C=CN1[C@H]1[C@@H](O)[C@H](O)[C@@H](CO)O1 UHDGCWIWMRVCDJ-CCXZUQQUSA-N 0.000 claims description 11
- 108010092160 Dactinomycin Proteins 0.000 claims description 11
- LQKSHSFQQRCAFW-UHFFFAOYSA-N Dolastatin 15 Natural products COC1=CC(=O)N(C(=O)C(OC(=O)C2N(CCC2)C(=O)C2N(CCC2)C(=O)C(C(C)C)N(C)C(=O)C(NC(=O)C(C(C)C)N(C)C)C(C)C)C(C)C)C1CC1=CC=CC=C1 LQKSHSFQQRCAFW-UHFFFAOYSA-N 0.000 claims description 11
- 108010009858 Echinomycin Proteins 0.000 claims description 11
- FBOZXECLQNJBKD-ZDUSSCGKSA-N L-methotrexate Chemical compound C=1N=C2N=C(N)N=C(N)C2=NC=1CN(C)C1=CC=C(C(=O)N[C@@H](CCC(O)=O)C(O)=O)C=C1 FBOZXECLQNJBKD-ZDUSSCGKSA-N 0.000 claims description 11
- LPGWZGMPDKDHEP-HLTPFJCJSA-N Leurosine Chemical compound C([C@]1([C@@H]2O1)CC)N(CCC=1C3=CC=CC=C3NC=11)C[C@H]2C[C@]1(C(=O)OC)C1=CC([C@]23[C@H]([C@@]([C@H](OC(C)=O)[C@]4(CC)C=CCN([C@H]34)CC2)(O)C(=O)OC)N2C)=C2C=C1OC LPGWZGMPDKDHEP-HLTPFJCJSA-N 0.000 claims description 11
- LPGWZGMPDKDHEP-GKWAKPNHSA-N Leurosine Natural products O=C(O[C@H]1[C@](O)(C(=O)OC)[C@@H]2N(C)c3c(cc(c(OC)c3)[C@]3(C(=O)OC)c4[nH]c5c(c4CCN4C[C@]6(CC)O[C@@H]6[C@H](C3)C4)cccc5)[C@@]32[C@H]2[C@@]1(CC)C=CCN2CC3)C LPGWZGMPDKDHEP-GKWAKPNHSA-N 0.000 claims description 11
- 229930126263 Maytansine Natural products 0.000 claims description 11
- HYFMSAFINFJTFH-UHFFFAOYSA-N Mitomycin-A Natural products O=C1C(OC)=C(C)C(=O)C2=C1C(COC(N)=O)C1(OC)N2CC2NC21 HYFMSAFINFJTFH-UHFFFAOYSA-N 0.000 claims description 11
- MQTAVJHICJWXBR-UHFFFAOYSA-N N(1)-acetylspermidine Chemical compound CC(=O)NCCCNCCCCN MQTAVJHICJWXBR-UHFFFAOYSA-N 0.000 claims description 11
- OWPCHSCAPHNHAV-UHFFFAOYSA-N Rhizoxin Natural products C1C(O)C2(C)OC2C=CC(C)C(OC(=O)C2)CC2CC2OC2C(=O)OC1C(C)C(OC)C(C)=CC=CC(C)=CC1=COC(C)=N1 OWPCHSCAPHNHAV-UHFFFAOYSA-N 0.000 claims description 11
- 229930183665 actinomycin Natural products 0.000 claims description 11
- SHGAZHPCJJPHSC-YCNIQYBTSA-N all-trans-retinoic acid Chemical compound OC(=O)\C=C(/C)\C=C\C=C(/C)\C=C\C1=C(C)CCCC1(C)C SHGAZHPCJJPHSC-YCNIQYBTSA-N 0.000 claims description 11
- 229960003896 aminopterin Drugs 0.000 claims description 11
- HXCHCVDVKSCDHU-LULTVBGHSA-N calicheamicin Chemical compound C1[C@H](OC)[C@@H](NCC)CO[C@H]1O[C@H]1[C@H](O[C@@H]2C\3=C(NC(=O)OC)C(=O)C[C@](C/3=C/CSSSC)(O)C#C\C=C/C#C2)O[C@H](C)[C@@H](NO[C@@H]2O[C@H](C)[C@@H](SC(=O)C=3C(=C(OC)C(O[C@H]4[C@@H]([C@H](OC)[C@@H](O)[C@H](C)O4)O)=C(I)C=3C)OC)[C@@H](O)C2)[C@@H]1O HXCHCVDVKSCDHU-LULTVBGHSA-N 0.000 claims description 11
- 229930195731 calicheamicin Natural products 0.000 claims description 11
- VSJKWCGYPAHWDS-FQEVSTJZSA-N camptothecin Chemical compound C1=CC=C2C=C(CN3C4=CC5=C(C3=O)COC(=O)[C@]5(O)CC)C4=NC2=C1 VSJKWCGYPAHWDS-FQEVSTJZSA-N 0.000 claims description 11
- 229940127093 camptothecin Drugs 0.000 claims description 11
- 229930188550 carminomycin Natural products 0.000 claims description 11
- XREUEWVEMYWFFA-CSKJXFQVSA-N carminomycin Chemical compound C1[C@H](N)[C@H](O)[C@H](C)O[C@H]1O[C@@H]1C2=C(O)C(C(=O)C3=C(O)C=CC=C3C3=O)=C3C(O)=C2C[C@@](O)(C(C)=O)C1 XREUEWVEMYWFFA-CSKJXFQVSA-N 0.000 claims description 11
- XREUEWVEMYWFFA-UHFFFAOYSA-N carminomycin I Natural products C1C(N)C(O)C(C)OC1OC1C2=C(O)C(C(=O)C3=C(O)C=CC=C3C3=O)=C3C(O)=C2CC(O)(C(C)=O)C1 XREUEWVEMYWFFA-UHFFFAOYSA-N 0.000 claims description 11
- 229950001725 carubicin Drugs 0.000 claims description 11
- 108010046713 cemadotin Proteins 0.000 claims description 11
- 229950009017 cemadotin Drugs 0.000 claims description 11
- 229960001338 colchicine Drugs 0.000 claims description 11
- LGZKGOGODCLQHG-UHFFFAOYSA-N combretastatin Natural products C1=C(O)C(OC)=CC=C1CC(O)C1=CC(OC)=C(OC)C(OC)=C1 LGZKGOGODCLQHG-UHFFFAOYSA-N 0.000 claims description 11
- 229930187817 disorazole Natural products 0.000 claims description 11
- VSJKWCGYPAHWDS-UHFFFAOYSA-N dl-camptothecin Natural products C1=CC=C2C=C(CN3C4=CC5=C(C3=O)COC(=O)C5(O)CC)C4=NC2=C1 VSJKWCGYPAHWDS-UHFFFAOYSA-N 0.000 claims description 11
- 229960003668 docetaxel Drugs 0.000 claims description 11
- 229930188854 dolastatin Natural products 0.000 claims description 11
- XOPYFXBZMVTEJF-PDACKIITSA-N eleutherobin Chemical compound C(/[C@H]1[C@H](C(=CC[C@@H]1C(C)C)C)C[C@@H]([C@@]1(C)O[C@@]2(C=C1)OC)OC(=O)\C=C\C=1N=CN(C)C=1)=C2\CO[C@@H]1OC[C@@H](O)[C@@H](O)[C@@H]1OC(C)=O XOPYFXBZMVTEJF-PDACKIITSA-N 0.000 claims description 11
- XOPYFXBZMVTEJF-UHFFFAOYSA-N eleutherobin Natural products C1=CC2(OC)OC1(C)C(OC(=O)C=CC=1N=CN(C)C=1)CC(C(=CCC1C(C)C)C)C1C=C2COC1OCC(O)C(O)C1OC(C)=O XOPYFXBZMVTEJF-UHFFFAOYSA-N 0.000 claims description 11
- 229930013356 epothilone Natural products 0.000 claims description 11
- HESCAJZNRMSMJG-KKQRBIROSA-N epothilone A Chemical class C/C([C@@H]1C[C@@H]2O[C@@H]2CCC[C@@H]([C@@H]([C@@H](C)C(=O)C(C)(C)[C@@H](O)CC(=O)O1)O)C)=C\C1=CSC(C)=N1 HESCAJZNRMSMJG-KKQRBIROSA-N 0.000 claims description 11
- FRPJXPJMRWBBIH-RBRWEJTLSA-N estramustine Chemical compound ClCCN(CCCl)C(=O)OC1=CC=C2[C@H]3CC[C@](C)([C@H](CC4)O)[C@@H]4[C@@H]3CCC2=C1 FRPJXPJMRWBBIH-RBRWEJTLSA-N 0.000 claims description 11
- 229960001842 estramustine Drugs 0.000 claims description 11
- 229960005420 etoposide Drugs 0.000 claims description 11
- VJJPUSNTGOMMGY-MRVIYFEKSA-N etoposide Chemical compound COC1=C(O)C(OC)=CC([C@@H]2C3=CC=4OCOC=4C=C3[C@@H](O[C@H]3[C@@H]([C@@H](O)[C@@H]4O[C@H](C)OC[C@H]4O3)O)[C@@H]3[C@@H]2C(OC3)=O)=C1 VJJPUSNTGOMMGY-MRVIYFEKSA-N 0.000 claims description 11
- LIQODXNTTZAGID-OCBXBXKTSA-N etoposide phosphate Chemical compound COC1=C(OP(O)(O)=O)C(OC)=CC([C@@H]2C3=CC=4OCOC=4C=C3[C@@H](O[C@H]3[C@@H]([C@@H](O)[C@@H]4O[C@H](C)OC[C@H]4O3)O)[C@@H]3[C@@H]2C(OC3)=O)=C1 LIQODXNTTZAGID-OCBXBXKTSA-N 0.000 claims description 11
- 229960000752 etoposide phosphate Drugs 0.000 claims description 11
- SGDBTWWWUNNDEQ-LBPRGKRZSA-N melphalan Chemical compound OC(=O)[C@@H](N)CC1=CC=C(N(CCCl)CCCl)C=C1 SGDBTWWWUNNDEQ-LBPRGKRZSA-N 0.000 claims description 11
- 229960001924 melphalan Drugs 0.000 claims description 11
- 229960001428 mercaptopurine Drugs 0.000 claims description 11
- FBOZXECLQNJBKD-UHFFFAOYSA-N methotrexate Chemical compound C=1N=C2N=C(N)N=C(N)C2=NC=1CN(C)C1=CC=C(C(=O)NC(CCC(O)=O)C(O)=O)C=C1 FBOZXECLQNJBKD-UHFFFAOYSA-N 0.000 claims description 11
- 229960000485 methotrexate Drugs 0.000 claims description 11
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 claims description 11
- 229960004857 mitomycin Drugs 0.000 claims description 11
- HYFMSAFINFJTFH-NGSRAFSJSA-N mitomycin A Chemical compound O=C1C(OC)=C(C)C(=O)C2=C1[C@@H](COC(N)=O)[C@]1(OC)N2C[C@@H]2N[C@@H]21 HYFMSAFINFJTFH-NGSRAFSJSA-N 0.000 claims description 11
- AUJXLBOHYWTPFV-UHFFFAOYSA-N quinomycin A Natural products CN1C(=O)C(C)NC(=O)C(NC(=O)C=2N=C3C=CC=CC3=NC=2)COC(=O)C(C(C)C)N(C)C(=O)C2N(C)C(=O)C(C)NC(=O)C(NC(=O)C=3N=C4C=CC=CC4=NC=3)COC(=O)C(C(C)C)N(C)C(=O)C1CSC2SC AUJXLBOHYWTPFV-UHFFFAOYSA-N 0.000 claims description 11
- 230000002829 reductive effect Effects 0.000 claims description 11
- 229930002330 retinoic acid Natural products 0.000 claims description 11
- OWPCHSCAPHNHAV-LMONGJCWSA-N rhizoxin Chemical compound C/C([C@H](OC)[C@@H](C)[C@@H]1C[C@H](O)[C@]2(C)O[C@@H]2/C=C/[C@@H](C)[C@]2([H])OC(=O)C[C@@](C2)(C[C@@H]2O[C@H]2C(=O)O1)[H])=C\C=C\C(\C)=C\C1=COC(C)=N1 OWPCHSCAPHNHAV-LMONGJCWSA-N 0.000 claims description 11
- 108700003774 talisomycin Proteins 0.000 claims description 11
- 229940063683 taxotere Drugs 0.000 claims description 11
- UCFGDBYHRUNTLO-QHCPKHFHSA-N topotecan Chemical compound C1=C(O)C(CN(C)C)=C2C=C(CN3C4=CC5=C(C3=O)COC(=O)[C@]5(O)CC)C4=NC2=C1 UCFGDBYHRUNTLO-QHCPKHFHSA-N 0.000 claims description 11
- 229960000303 topotecan Drugs 0.000 claims description 11
- 229960001727 tretinoin Drugs 0.000 claims description 11
- 229930184737 tubulysin Natural products 0.000 claims description 11
- JXLYSJRDGCGARV-CFWMRBGOSA-N vinblastine Chemical compound C([C@H](C[C@]1(C(=O)OC)C=2C(=CC3=C([C@]45[C@H]([C@@]([C@H](OC(C)=O)[C@]6(CC)C=CCN([C@H]56)CC4)(O)C(=O)OC)N3C)C=2)OC)C[C@@](C2)(O)CC)N2CCC2=C1NC1=CC=CC=C21 JXLYSJRDGCGARV-CFWMRBGOSA-N 0.000 claims description 11
- 229960003048 vinblastine Drugs 0.000 claims description 11
- 229960004528 vincristine Drugs 0.000 claims description 11
- OGWKCGZFUXNPDA-XQKSVPLYSA-N vincristine Chemical compound C([N@]1C[C@@H](C[C@]2(C(=O)OC)C=3C(=CC4=C([C@]56[C@H]([C@@]([C@H](OC(C)=O)[C@]7(CC)C=CCN([C@H]67)CC5)(O)C(=O)OC)N4C=O)C=3)OC)C[C@@](C1)(O)CC)CC1=C2NC2=CC=CC=C12 OGWKCGZFUXNPDA-XQKSVPLYSA-N 0.000 claims description 11
- OGWKCGZFUXNPDA-UHFFFAOYSA-N vincristine Natural products C1C(CC)(O)CC(CC2(C(=O)OC)C=3C(=CC4=C(C56C(C(C(OC(C)=O)C7(CC)C=CCN(C67)CC5)(O)C(=O)OC)N4C=O)C=3)OC)CN1CCC1=C2NC2=CC=CC=C12 OGWKCGZFUXNPDA-UHFFFAOYSA-N 0.000 claims description 11
- UGGWPQSBPIFKDZ-KOTLKJBCSA-N vindesine Chemical compound C([C@@H](C[C@]1(C(=O)OC)C=2C(=CC3=C([C@]45[C@H]([C@@]([C@H](O)[C@]6(CC)C=CCN([C@H]56)CC4)(O)C(N)=O)N3C)C=2)OC)C[C@@](C2)(O)CC)N2CCC2=C1N=C1[C]2C=CC=C1 UGGWPQSBPIFKDZ-KOTLKJBCSA-N 0.000 claims description 11
- 229960004355 vindesine Drugs 0.000 claims description 11
- 229940045696 antineoplastic drug podophyllotoxin derivative Drugs 0.000 claims description 10
- 150000001804 chlorine Chemical class 0.000 claims description 10
- YJGVMLPVUAXIQN-UHFFFAOYSA-N epipodophyllotoxin Natural products COC1=C(OC)C(OC)=CC(C2C3=CC=4OCOC=4C=C3C(O)C3C2C(OC3)=O)=C1 YJGVMLPVUAXIQN-UHFFFAOYSA-N 0.000 claims description 10
- 229960001237 podophyllotoxin Drugs 0.000 claims description 10
- YVCVYCSAAZQOJI-UHFFFAOYSA-N podophyllotoxin Natural products COC1=C(O)C(OC)=CC(C2C3=CC=4OCOC=4C=C3C(O)C3C2C(OC3)=O)=C1 YVCVYCSAAZQOJI-UHFFFAOYSA-N 0.000 claims description 10
- 239000003600 podophyllotoxin derivative Substances 0.000 claims description 10
- GHASVSINZRGABV-UHFFFAOYSA-N Fluorouracil Chemical compound FC1=CNC(=O)NC1=O GHASVSINZRGABV-UHFFFAOYSA-N 0.000 claims description 9
- 208000035475 disorder Diseases 0.000 claims description 9
- 229960002949 fluorouracil Drugs 0.000 claims description 9
- UOWVMDUEMSNCAV-WYENRQIDSA-N rachelmycin Chemical compound C1([C@]23C[C@@H]2CN1C(=O)C=1NC=2C(OC)=C(O)C4=C(C=2C=1)CCN4C(=O)C1=CC=2C=4CCN(C=4C(O)=C(C=2N1)OC)C(N)=O)=CC(=O)C1=C3C(C)=CN1 UOWVMDUEMSNCAV-WYENRQIDSA-N 0.000 claims description 9
- 150000003839 salts Chemical class 0.000 claims description 9
- INAUWOVKEZHHDM-PEDBPRJASA-N (7s,9s)-6,9,11-trihydroxy-9-(2-hydroxyacetyl)-7-[(2r,4s,5s,6s)-5-hydroxy-6-methyl-4-morpholin-4-yloxan-2-yl]oxy-4-methoxy-8,10-dihydro-7h-tetracene-5,12-dione;hydrochloride Chemical compound Cl.N1([C@H]2C[C@@H](O[C@@H](C)[C@H]2O)O[C@H]2C[C@@](O)(CC=3C(O)=C4C(=O)C=5C=CC=C(C=5C(=O)C4=C(O)C=32)OC)C(=O)CO)CCOCC1 INAUWOVKEZHHDM-PEDBPRJASA-N 0.000 claims description 8
- 230000001268 conjugating effect Effects 0.000 claims description 6
- 230000001093 anti-cancer Effects 0.000 claims description 3
- 230000003110 anti-inflammatory effect Effects 0.000 claims description 3
- 125000001183 hydrocarbyl group Chemical group 0.000 claims 16
- 125000002467 phosphate group Chemical group [H]OP(=O)(O[H])O[*] 0.000 abstract description 26
- 210000004369 blood Anatomy 0.000 abstract description 20
- 239000008280 blood Substances 0.000 abstract description 20
- 230000002132 lysosomal effect Effects 0.000 abstract description 15
- 125000006850 spacer group Chemical group 0.000 abstract description 14
- 235000011180 diphosphates Nutrition 0.000 abstract description 11
- 239000001177 diphosphate Substances 0.000 abstract description 10
- XPPKVPWEQAFLFU-UHFFFAOYSA-J diphosphate(4-) Chemical compound [O-]P([O-])(=O)OP([O-])([O-])=O XPPKVPWEQAFLFU-UHFFFAOYSA-J 0.000 abstract description 8
- 239000001226 triphosphate Substances 0.000 abstract description 8
- 235000011178 triphosphate Nutrition 0.000 abstract description 8
- UNXRWKVEANCORM-UHFFFAOYSA-N triphosphoric acid Chemical compound OP(O)(=O)OP(O)(=O)OP(O)(O)=O UNXRWKVEANCORM-UHFFFAOYSA-N 0.000 abstract description 8
- 150000004712 monophosphates Chemical class 0.000 abstract description 7
- YDHWWBZFRZWVHO-UHFFFAOYSA-H [oxido-[oxido(phosphonatooxy)phosphoryl]oxyphosphoryl] phosphate Chemical group [O-]P([O-])(=O)OP([O-])(=O)OP([O-])(=O)OP([O-])([O-])=O YDHWWBZFRZWVHO-UHFFFAOYSA-H 0.000 abstract description 6
- 125000005647 linker group Chemical group 0.000 description 108
- 239000000243 solution Substances 0.000 description 87
- WEVYAHXRMPXWCK-UHFFFAOYSA-N Acetonitrile Chemical compound CC#N WEVYAHXRMPXWCK-UHFFFAOYSA-N 0.000 description 79
- 210000004027 cell Anatomy 0.000 description 59
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 52
- XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 description 48
- 229910001868 water Inorganic materials 0.000 description 44
- YMWUJEATGCHHMB-UHFFFAOYSA-N Dichloromethane Chemical compound ClCCl YMWUJEATGCHHMB-UHFFFAOYSA-N 0.000 description 43
- 150000001721 carbon Chemical group 0.000 description 33
- 150000002430 hydrocarbons Chemical group 0.000 description 33
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical group N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 30
- ZMANZCXQSJIPKH-UHFFFAOYSA-N Triethylamine Chemical compound CCN(CC)CC ZMANZCXQSJIPKH-UHFFFAOYSA-N 0.000 description 30
- 238000006243 chemical reaction Methods 0.000 description 30
- 239000007787 solid Substances 0.000 description 27
- XPPKVPWEQAFLFU-UHFFFAOYSA-N diphosphoric acid Chemical compound OP(O)(=O)OP(O)(O)=O XPPKVPWEQAFLFU-UHFFFAOYSA-N 0.000 description 26
- 125000002887 hydroxy group Chemical group [H]O* 0.000 description 26
- 239000000427 antigen Substances 0.000 description 25
- 102000036639 antigens Human genes 0.000 description 25
- 108091007433 antigens Proteins 0.000 description 25
- 238000003786 synthesis reaction Methods 0.000 description 25
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 24
- 150000001413 amino acids Chemical class 0.000 description 24
- 230000015572 biosynthetic process Effects 0.000 description 24
- 206010028980 Neoplasm Diseases 0.000 description 22
- 125000000217 alkyl group Chemical group 0.000 description 21
- LFGREXWGYUGZLY-UHFFFAOYSA-N phosphoryl Chemical group [P]=O LFGREXWGYUGZLY-UHFFFAOYSA-N 0.000 description 21
- 239000012071 phase Substances 0.000 description 18
- 0 CC*C1C2N=NNC2CCCCC1 Chemical compound CC*C1C2N=NNC2CCCCC1 0.000 description 17
- 239000000126 substance Substances 0.000 description 17
- 125000001424 substituent group Chemical group 0.000 description 17
- 230000021615 conjugation Effects 0.000 description 16
- 238000004458 analytical method Methods 0.000 description 15
- 230000027455 binding Effects 0.000 description 15
- 239000003607 modifier Substances 0.000 description 15
- 235000018102 proteins Nutrition 0.000 description 15
- 108090000623 proteins and genes Proteins 0.000 description 15
- 102000004169 proteins and genes Human genes 0.000 description 15
- 230000002441 reversible effect Effects 0.000 description 15
- KXDHJXZQYSOELW-UHFFFAOYSA-M Carbamate Chemical compound NC([O-])=O KXDHJXZQYSOELW-UHFFFAOYSA-M 0.000 description 14
- NINIDFKCEFEMDL-UHFFFAOYSA-N Sulfur Chemical group [S] NINIDFKCEFEMDL-UHFFFAOYSA-N 0.000 description 14
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 description 14
- 239000001301 oxygen Substances 0.000 description 14
- 239000011593 sulfur Chemical group 0.000 description 14
- VHUUQVKOLVNVRT-UHFFFAOYSA-N Ammonium hydroxide Chemical compound [NH4+].[OH-] VHUUQVKOLVNVRT-UHFFFAOYSA-N 0.000 description 13
- NBIIXXVUZAFLBC-UHFFFAOYSA-L Phosphate ion(2-) Chemical compound OP([O-])([O-])=O NBIIXXVUZAFLBC-UHFFFAOYSA-L 0.000 description 13
- 238000000338 in vitro Methods 0.000 description 13
- 210000003712 lysosome Anatomy 0.000 description 13
- 230000001868 lysosomic effect Effects 0.000 description 13
- 238000004237 preparative chromatography Methods 0.000 description 13
- 101150029707 ERBB2 gene Proteins 0.000 description 12
- 238000001727 in vivo Methods 0.000 description 12
- VLKZOEOYAKHREP-UHFFFAOYSA-N n-Hexane Chemical compound CCCCCC VLKZOEOYAKHREP-UHFFFAOYSA-N 0.000 description 12
- 239000012074 organic phase Substances 0.000 description 12
- 210000002966 serum Anatomy 0.000 description 12
- 108010021625 Immunoglobulin Fragments Proteins 0.000 description 11
- 102000008394 Immunoglobulin Fragments Human genes 0.000 description 11
- XBDQKXXYIPTUBI-UHFFFAOYSA-M Propionate Chemical compound CCC([O-])=O XBDQKXXYIPTUBI-UHFFFAOYSA-M 0.000 description 11
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 11
- 125000003342 alkenyl group Chemical group 0.000 description 11
- 235000001014 amino acid Nutrition 0.000 description 11
- 239000000872 buffer Substances 0.000 description 11
- 101001057504 Homo sapiens Interferon-stimulated gene 20 kDa protein Proteins 0.000 description 10
- 101001055144 Homo sapiens Interleukin-2 receptor subunit alpha Proteins 0.000 description 10
- 102100026878 Interleukin-2 receptor subunit alpha Human genes 0.000 description 10
- KFZMGEQAYNKOFK-UHFFFAOYSA-N Isopropanol Chemical compound CC(C)O KFZMGEQAYNKOFK-UHFFFAOYSA-N 0.000 description 10
- JGFZNNIVVJXRND-UHFFFAOYSA-N N,N-Diisopropylethylamine (DIPEA) Chemical compound CCN(C(C)C)C(C)C JGFZNNIVVJXRND-UHFFFAOYSA-N 0.000 description 10
- JUJWROOIHBZHMG-UHFFFAOYSA-N Pyridine Chemical compound C1=CC=NC=C1 JUJWROOIHBZHMG-UHFFFAOYSA-N 0.000 description 10
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 10
- 125000000304 alkynyl group Chemical group 0.000 description 10
- 201000011510 cancer Diseases 0.000 description 10
- 230000000694 effects Effects 0.000 description 10
- 239000012634 fragment Substances 0.000 description 10
- 229910052736 halogen Inorganic materials 0.000 description 10
- 150000002367 halogens Chemical class 0.000 description 10
- 238000000926 separation method Methods 0.000 description 10
- IAZDPXIOMUYVGZ-UHFFFAOYSA-N Dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 description 9
- 102000004190 Enzymes Human genes 0.000 description 9
- 108090000790 Enzymes Proteins 0.000 description 9
- DHKHKXVYLBGOIT-UHFFFAOYSA-N acetaldehyde Diethyl Acetal Natural products CCOC(C)OCC DHKHKXVYLBGOIT-UHFFFAOYSA-N 0.000 description 9
- 150000001412 amines Chemical class 0.000 description 9
- 231100000433 cytotoxic Toxicity 0.000 description 9
- 230000001472 cytotoxic effect Effects 0.000 description 9
- QJGQUHMNIGDVPM-UHFFFAOYSA-N nitrogen group Chemical group [N] QJGQUHMNIGDVPM-UHFFFAOYSA-N 0.000 description 9
- 239000000741 silica gel Substances 0.000 description 9
- 229910002027 silica gel Inorganic materials 0.000 description 9
- 239000011550 stock solution Substances 0.000 description 9
- ROSDSFDQCJNGOL-UHFFFAOYSA-N Dimethylamine Chemical compound CNC ROSDSFDQCJNGOL-UHFFFAOYSA-N 0.000 description 8
- 101000596277 Homo sapiens TSC22 domain family protein 3 Proteins 0.000 description 8
- 241000699670 Mus sp. Species 0.000 description 8
- 125000004429 atom Chemical group 0.000 description 8
- 239000003153 chemical reaction reagent Substances 0.000 description 8
- 238000011534 incubation Methods 0.000 description 8
- 238000002347 injection Methods 0.000 description 8
- 239000007924 injection Substances 0.000 description 8
- 238000004007 reversed phase HPLC Methods 0.000 description 8
- 239000000725 suspension Substances 0.000 description 8
- HDTRYLNUVZCQOY-UHFFFAOYSA-N α-D-glucopyranosyl-α-D-glucopyranoside Natural products OC1C(O)C(O)C(CO)OC1OC1C(O)C(O)C(O)C(CO)O1 HDTRYLNUVZCQOY-UHFFFAOYSA-N 0.000 description 7
- UIIMBOGNXHQVGW-UHFFFAOYSA-M Sodium bicarbonate Chemical class [Na+].OC([O-])=O UIIMBOGNXHQVGW-UHFFFAOYSA-M 0.000 description 7
- 102100035260 TSC22 domain family protein 3 Human genes 0.000 description 7
- HDTRYLNUVZCQOY-WSWWMNSNSA-N Trehalose Natural products O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@@H]1O[C@@H]1[C@H](O)[C@@H](O)[C@@H](O)[C@@H](CO)O1 HDTRYLNUVZCQOY-WSWWMNSNSA-N 0.000 description 7
- HDTRYLNUVZCQOY-LIZSDCNHSA-N alpha,alpha-trehalose Chemical compound O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@@H]1O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 HDTRYLNUVZCQOY-LIZSDCNHSA-N 0.000 description 7
- 125000002915 carbonyl group Chemical group [*:2]C([*:1])=O 0.000 description 7
- 238000003776 cleavage reaction Methods 0.000 description 7
- 125000004122 cyclic group Chemical group 0.000 description 7
- 238000013461 design Methods 0.000 description 7
- 238000002474 experimental method Methods 0.000 description 7
- 239000008194 pharmaceutical composition Substances 0.000 description 7
- 229920000642 polymer Polymers 0.000 description 7
- 239000000843 powder Substances 0.000 description 7
- 230000007017 scission Effects 0.000 description 7
- 238000003756 stirring Methods 0.000 description 7
- 125000003396 thiol group Chemical class [H]S* 0.000 description 7
- IAZDPXIOMUYVGZ-WFGJKAKNSA-N Dimethyl sulfoxide Chemical compound [2H]C([2H])([2H])S(=O)C([2H])([2H])[2H] IAZDPXIOMUYVGZ-WFGJKAKNSA-N 0.000 description 6
- 108060003951 Immunoglobulin Proteins 0.000 description 6
- PMZURENOXWZQFD-UHFFFAOYSA-L Sodium Sulfate Chemical compound [Na+].[Na+].[O-]S([O-])(=O)=O PMZURENOXWZQFD-UHFFFAOYSA-L 0.000 description 6
- SAHIZENKTPRYSN-UHFFFAOYSA-N [2-[3-(phenoxymethyl)phenoxy]-6-(trifluoromethyl)pyridin-4-yl]methanamine Chemical compound O(C1=CC=CC=C1)CC=1C=C(OC2=NC(=CC(=C2)CN)C(F)(F)F)C=CC=1 SAHIZENKTPRYSN-UHFFFAOYSA-N 0.000 description 6
- 125000001797 benzyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])* 0.000 description 6
- 230000004071 biological effect Effects 0.000 description 6
- VQNATVDKACXKTF-XELLLNAOSA-N duocarmycin Chemical compound COC1=C(OC)C(OC)=C2NC(C(=O)N3C4=CC(=O)C5=C([C@@]64C[C@@H]6C3)C=C(N5)C(=O)OC)=CC2=C1 VQNATVDKACXKTF-XELLLNAOSA-N 0.000 description 6
- 238000009472 formulation Methods 0.000 description 6
- 102000018358 immunoglobulin Human genes 0.000 description 6
- GTCAXTIRRLKXRU-UHFFFAOYSA-N methyl carbamate Chemical compound COC(N)=O GTCAXTIRRLKXRU-UHFFFAOYSA-N 0.000 description 6
- 239000000178 monomer Substances 0.000 description 6
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 description 6
- 102000004196 processed proteins & peptides Human genes 0.000 description 6
- 229910052938 sodium sulfate Inorganic materials 0.000 description 6
- 235000011152 sodium sulphate Nutrition 0.000 description 6
- 239000013076 target substance Substances 0.000 description 6
- CIHOLLKRGTVIJN-UHFFFAOYSA-N tert‐butyl hydroperoxide Chemical compound CC(C)(C)OO CIHOLLKRGTVIJN-UHFFFAOYSA-N 0.000 description 6
- QUIAKSQMOGTDQJ-UHFFFAOYSA-N 2-cyclooct-2-yn-1-yloxyacetic acid Chemical compound OC(=O)COC1CCCCCC#C1 QUIAKSQMOGTDQJ-UHFFFAOYSA-N 0.000 description 5
- JOYRKODLDBILNP-UHFFFAOYSA-N Ethyl urethane Chemical compound CCOC(N)=O JOYRKODLDBILNP-UHFFFAOYSA-N 0.000 description 5
- 108010010803 Gelatin Proteins 0.000 description 5
- 229920002472 Starch Polymers 0.000 description 5
- 230000002378 acidificating effect Effects 0.000 description 5
- 230000002776 aggregation Effects 0.000 description 5
- 238000004220 aggregation Methods 0.000 description 5
- PUJDIJCNWFYVJX-UHFFFAOYSA-N benzyl carbamate Chemical compound NC(=O)OCC1=CC=CC=C1 PUJDIJCNWFYVJX-UHFFFAOYSA-N 0.000 description 5
- 239000002775 capsule Substances 0.000 description 5
- 239000003795 chemical substances by application Substances 0.000 description 5
- 230000001419 dependent effect Effects 0.000 description 5
- 229920000159 gelatin Polymers 0.000 description 5
- 239000008273 gelatin Substances 0.000 description 5
- 235000019322 gelatine Nutrition 0.000 description 5
- 235000011852 gelatine desserts Nutrition 0.000 description 5
- 239000003862 glucocorticoid Substances 0.000 description 5
- HNDVDQJCIGZPNO-UHFFFAOYSA-N histidine Natural products OC(=O)C(N)CC1=CN=CN1 HNDVDQJCIGZPNO-UHFFFAOYSA-N 0.000 description 5
- 238000001114 immunoprecipitation Methods 0.000 description 5
- 208000027866 inflammatory disease Diseases 0.000 description 5
- 102000006495 integrins Human genes 0.000 description 5
- 108010044426 integrins Proteins 0.000 description 5
- 108020004999 messenger RNA Proteins 0.000 description 5
- 239000000546 pharmaceutical excipient Substances 0.000 description 5
- 235000013855 polyvinylpyrrolidone Nutrition 0.000 description 5
- 239000001267 polyvinylpyrrolidone Substances 0.000 description 5
- 229920000036 polyvinylpyrrolidone Polymers 0.000 description 5
- 238000002360 preparation method Methods 0.000 description 5
- 238000000746 purification Methods 0.000 description 5
- UMJSCPRVCHMLSP-UHFFFAOYSA-N pyridine Natural products COC1=CC=CN=C1 UMJSCPRVCHMLSP-UHFFFAOYSA-N 0.000 description 5
- 239000011541 reaction mixture Substances 0.000 description 5
- 239000011780 sodium chloride Substances 0.000 description 5
- 235000000346 sugar Nutrition 0.000 description 5
- FPIRBHDGWMWJEP-UHFFFAOYSA-N 1-hydroxy-7-azabenzotriazole Chemical compound C1=CN=C2N(O)N=NC2=C1 FPIRBHDGWMWJEP-UHFFFAOYSA-N 0.000 description 4
- KUWPCJHYPSUOFW-UHFFFAOYSA-N 2-(hydroxymethyl)-6-(2-nitrophenoxy)oxane-3,4,5-triol Chemical compound OC1C(O)C(O)C(CO)OC1OC1=CC=CC=C1[N+]([O-])=O KUWPCJHYPSUOFW-UHFFFAOYSA-N 0.000 description 4
- DLFVBJFMPXGRIB-UHFFFAOYSA-N Acetamide Chemical class CC(N)=O DLFVBJFMPXGRIB-UHFFFAOYSA-N 0.000 description 4
- 102100025221 CD70 antigen Human genes 0.000 description 4
- PCBZRNYXXCIELG-WYFCWLEVSA-N COC1=CC=C(C[C@H](NC(=O)OC2CCCC3(C2)OOC2(O3)C3CC4CC(C3)CC2C4)C(=O)N[C@@H]2[C@@H](CO)O[C@H]([C@@H]2O)N2C=NC3=C2N=CN=C3N(C)C)C=C1 Chemical compound COC1=CC=C(C[C@H](NC(=O)OC2CCCC3(C2)OOC2(O3)C3CC4CC(C3)CC2C4)C(=O)N[C@@H]2[C@@H](CO)O[C@H]([C@@H]2O)N2C=NC3=C2N=CN=C3N(C)C)C=C1 PCBZRNYXXCIELG-WYFCWLEVSA-N 0.000 description 4
- CURLTUGMZLYLDI-UHFFFAOYSA-N Carbon dioxide Chemical compound O=C=O CURLTUGMZLYLDI-UHFFFAOYSA-N 0.000 description 4
- HEDRZPFGACZZDS-UHFFFAOYSA-N Chloroform Chemical compound ClC(Cl)Cl HEDRZPFGACZZDS-UHFFFAOYSA-N 0.000 description 4
- SNPQTHMHQBXARE-GFCCVEGCSA-N ClC[C@@H]1CN(C2=CC(=C3C(=C12)C=C(N3)C(=O)OC)OP(=O)(O)O)C(=O)C=1NC2=C(C(=C(C=C2C=1)OC)OC)OC Chemical compound ClC[C@@H]1CN(C2=CC(=C3C(=C12)C=C(N3)C(=O)OC)OP(=O)(O)O)C(=O)C=1NC2=C(C(=C(C=C2C=1)OC)OC)OC SNPQTHMHQBXARE-GFCCVEGCSA-N 0.000 description 4
- RKJDBXHTJJCFPB-RUZDIDTESA-N ClC[C@@H]1CN(C=2C=C(C3=C(C1=2)C=CC=C3)OP(=O)(O)OP(=O)(O)OCCNC(OCC1C2=CC=CC=C2C=2C=CC=CC1=2)=O)C(=O)C=1NC2=C(C(=C(C=C2C=1)OC)OC)OC Chemical compound ClC[C@@H]1CN(C=2C=C(C3=C(C1=2)C=CC=C3)OP(=O)(O)OP(=O)(O)OCCNC(OCC1C2=CC=CC=C2C=2C=CC=CC1=2)=O)C(=O)C=1NC2=C(C(=C(C=C2C=1)OC)OC)OC RKJDBXHTJJCFPB-RUZDIDTESA-N 0.000 description 4
- 101000934356 Homo sapiens CD70 antigen Proteins 0.000 description 4
- 206010025323 Lymphomas Diseases 0.000 description 4
- 238000005481 NMR spectroscopy Methods 0.000 description 4
- HEDRZPFGACZZDS-MICDWDOJSA-N Trichloro(2H)methane Chemical compound [2H]C(Cl)(Cl)Cl HEDRZPFGACZZDS-MICDWDOJSA-N 0.000 description 4
- 125000002015 acyclic group Chemical group 0.000 description 4
- 125000002947 alkylene group Chemical group 0.000 description 4
- 239000007864 aqueous solution Substances 0.000 description 4
- 239000011324 bead Substances 0.000 description 4
- 125000002619 bicyclic group Chemical group 0.000 description 4
- 239000012267 brine Substances 0.000 description 4
- 125000002837 carbocyclic group Chemical group 0.000 description 4
- 239000000969 carrier Substances 0.000 description 4
- DIOQZVSQGTUSAI-UHFFFAOYSA-N decane Chemical compound CCCCCCCCCC DIOQZVSQGTUSAI-UHFFFAOYSA-N 0.000 description 4
- 238000001514 detection method Methods 0.000 description 4
- 239000008298 dragée Substances 0.000 description 4
- 239000003937 drug carrier Substances 0.000 description 4
- 230000014509 gene expression Effects 0.000 description 4
- 229940127121 immunoconjugate Drugs 0.000 description 4
- 238000001819 mass spectrum Methods 0.000 description 4
- BDAGIHXWWSANSR-UHFFFAOYSA-N methanoic acid Natural products OC=O BDAGIHXWWSANSR-UHFFFAOYSA-N 0.000 description 4
- 125000002950 monocyclic group Chemical group 0.000 description 4
- XHXFXVLFKHQFAL-UHFFFAOYSA-N phosphoryl trichloride Chemical compound ClP(Cl)(Cl)=O XHXFXVLFKHQFAL-UHFFFAOYSA-N 0.000 description 4
- 125000006413 ring segment Chemical group 0.000 description 4
- 238000013207 serial dilution Methods 0.000 description 4
- HPALAKNZSZLMCH-UHFFFAOYSA-M sodium;chloride;hydrate Chemical compound O.[Na+].[Cl-] HPALAKNZSZLMCH-UHFFFAOYSA-M 0.000 description 4
- 238000012421 spiking Methods 0.000 description 4
- 239000003381 stabilizer Substances 0.000 description 4
- 235000019698 starch Nutrition 0.000 description 4
- UCSJYZPVAKXKNQ-HZYVHMACSA-N streptomycin Chemical compound CN[C@H]1[C@H](O)[C@@H](O)[C@H](CO)O[C@H]1O[C@@H]1[C@](C=O)(O)[C@H](C)O[C@H]1O[C@@H]1[C@@H](NC(N)=N)[C@H](O)[C@@H](NC(N)=N)[C@H](O)[C@H]1O UCSJYZPVAKXKNQ-HZYVHMACSA-N 0.000 description 4
- 239000003826 tablet Substances 0.000 description 4
- AGXXALHNKAMKSX-UHFFFAOYSA-N tert-butyl n-[2-(oxiran-2-yl)ethyl]carbamate Chemical compound CC(C)(C)OC(=O)NCCC1CO1 AGXXALHNKAMKSX-UHFFFAOYSA-N 0.000 description 4
- HCUARRIEZVDMPT-UHFFFAOYSA-M 1h-indole-2-carboxylate Chemical compound C1=CC=C2NC(C(=O)[O-])=CC2=C1 HCUARRIEZVDMPT-UHFFFAOYSA-M 0.000 description 3
- GONFBOIJNUKKST-UHFFFAOYSA-N 5-ethylsulfanyl-2h-tetrazole Chemical compound CCSC=1N=NNN=1 GONFBOIJNUKKST-UHFFFAOYSA-N 0.000 description 3
- DTPYACTXNQSGGF-UHFFFAOYSA-N 9H-fluoren-9-ylmethyl N-(4-phosphonooxyphenyl)carbamate Chemical compound P(=O)(O)(O)OC1=CC=C(C=C1)NC(OCC1C2=CC=CC=C2C=2C=CC=CC1=2)=O DTPYACTXNQSGGF-UHFFFAOYSA-N 0.000 description 3
- YHUHBHVNOVAEMP-UHFFFAOYSA-N 9h-fluoren-9-ylmethyl n-(2-phosphonooxyethyl)carbamate Chemical compound C1=CC=C2C(COC(=O)NCCOP(O)(=O)O)C3=CC=CC=C3C2=C1 YHUHBHVNOVAEMP-UHFFFAOYSA-N 0.000 description 3
- WFDIJRYMOXRFFG-UHFFFAOYSA-N Acetic anhydride Chemical compound CC(=O)OC(C)=O WFDIJRYMOXRFFG-UHFFFAOYSA-N 0.000 description 3
- YDCORTTWDRHSLK-UHFFFAOYSA-O C(C)(C)(C)OC(=O)NCCC(C[N+](C)(C)C)O Chemical compound C(C)(C)(C)OC(=O)NCCC(C[N+](C)(C)C)O YDCORTTWDRHSLK-UHFFFAOYSA-O 0.000 description 3
- RKGGQJYRYAGJKS-UHFFFAOYSA-N CN(CC(CCNC(OC(C)(C)C)=O)O)C Chemical compound CN(CC(CCNC(OC(C)(C)C)=O)O)C RKGGQJYRYAGJKS-UHFFFAOYSA-N 0.000 description 3
- 102000005600 Cathepsins Human genes 0.000 description 3
- 108010084457 Cathepsins Proteins 0.000 description 3
- PGRBFYJWTYJTFQ-MRXNPFEDSA-N ClC[C@@H]1CN(C=2C=C(C3=C(C1=2)C=CC=C3)OP(=O)(O)OP(=O)(O)OCCN)C(=O)C=1NC2=C(C(=C(C=C2C=1)OC)OC)OC Chemical compound ClC[C@@H]1CN(C=2C=C(C3=C(C1=2)C=CC=C3)OP(=O)(O)OP(=O)(O)OCCN)C(=O)C=1NC2=C(C(=C(C=C2C=1)OC)OC)OC PGRBFYJWTYJTFQ-MRXNPFEDSA-N 0.000 description 3
- FBPFZTCFMRRESA-FSIIMWSLSA-N D-Glucitol Natural products OC[C@H](O)[C@H](O)[C@@H](O)[C@H](O)CO FBPFZTCFMRRESA-FSIIMWSLSA-N 0.000 description 3
- FBPFZTCFMRRESA-JGWLITMVSA-N D-glucitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-JGWLITMVSA-N 0.000 description 3
- QMMFVYPAHWMCMS-UHFFFAOYSA-N Dimethyl sulfide Chemical compound CSC QMMFVYPAHWMCMS-UHFFFAOYSA-N 0.000 description 3
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 3
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 3
- 241001465754 Metazoa Species 0.000 description 3
- 241000699666 Mus <mouse, genus> Species 0.000 description 3
- YXFVVABEGXRONW-UHFFFAOYSA-N Toluene Chemical compound CC1=CC=CC=C1 YXFVVABEGXRONW-UHFFFAOYSA-N 0.000 description 3
- 239000007983 Tris buffer Substances 0.000 description 3
- 150000001299 aldehydes Chemical class 0.000 description 3
- 239000003146 anticoagulant agent Substances 0.000 description 3
- 238000003556 assay Methods 0.000 description 3
- 125000000852 azido group Chemical group *N=[N+]=[N-] 0.000 description 3
- 125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 description 3
- 230000015556 catabolic process Effects 0.000 description 3
- 230000001413 cellular effect Effects 0.000 description 3
- 230000008859 change Effects 0.000 description 3
- 125000000753 cycloalkyl group Chemical group 0.000 description 3
- 238000006731 degradation reaction Methods 0.000 description 3
- 239000012636 effector Substances 0.000 description 3
- 102000052116 epidermal growth factor receptor activity proteins Human genes 0.000 description 3
- 108700015053 epidermal growth factor receptor activity proteins Proteins 0.000 description 3
- 125000001301 ethoxy group Chemical group [H]C([H])([H])C([H])([H])O* 0.000 description 3
- 230000006870 function Effects 0.000 description 3
- 239000000499 gel Substances 0.000 description 3
- 125000004475 heteroaralkyl group Chemical group 0.000 description 3
- RAXXELZNTBOGNW-UHFFFAOYSA-N imidazole Natural products C1=CNC=N1 RAXXELZNTBOGNW-UHFFFAOYSA-N 0.000 description 3
- 230000001965 increasing effect Effects 0.000 description 3
- 125000000959 isobutyl group Chemical group [H]C([H])([H])C([H])(C([H])([H])[H])C([H])([H])* 0.000 description 3
- 150000002576 ketones Chemical class 0.000 description 3
- 239000008101 lactose Substances 0.000 description 3
- 239000007788 liquid Substances 0.000 description 3
- 238000004519 manufacturing process Methods 0.000 description 3
- 239000011159 matrix material Substances 0.000 description 3
- 230000035772 mutation Effects 0.000 description 3
- 238000007911 parenteral administration Methods 0.000 description 3
- LCPDWSOZIOUXRV-UHFFFAOYSA-N phenoxyacetic acid Chemical compound OC(=O)COC1=CC=CC=C1 LCPDWSOZIOUXRV-UHFFFAOYSA-N 0.000 description 3
- 229920001184 polypeptide Polymers 0.000 description 3
- 230000003389 potentiating effect Effects 0.000 description 3
- 230000009257 reactivity Effects 0.000 description 3
- 238000003753 real-time PCR Methods 0.000 description 3
- 230000000717 retained effect Effects 0.000 description 3
- 150000003384 small molecules Chemical class 0.000 description 3
- 239000000600 sorbitol Substances 0.000 description 3
- 238000001228 spectrum Methods 0.000 description 3
- 239000000758 substrate Substances 0.000 description 3
- 125000000999 tert-butyl group Chemical group [H]C([H])([H])C(*)(C([H])([H])[H])C([H])([H])[H] 0.000 description 3
- 125000000147 tetrahydroquinolinyl group Chemical group N1(CCCC2=CC=CC=C12)* 0.000 description 3
- 125000004149 thio group Chemical group *S* 0.000 description 3
- 210000004881 tumor cell Anatomy 0.000 description 3
- 239000003981 vehicle Substances 0.000 description 3
- 239000003643 water by type Substances 0.000 description 3
- BZQRXLDDTXBNNT-UHFFFAOYSA-N (1,3-dioxoisoindol-2-yl) 2-cyclooct-2-yn-1-yloxyacetate Chemical compound O=C1C2=CC=CC=C2C(=O)N1OC(=O)COC1CCCCCC#C1 BZQRXLDDTXBNNT-UHFFFAOYSA-N 0.000 description 2
- ZZBOTLREHORFCK-UHFFFAOYSA-N (2,5-dioxopyrrolidin-1-yl) 2-[(2-methylpropan-2-yl)oxycarbonylamino]oxyacetate Chemical compound CC(C)(C)OC(=O)NOCC(=O)ON1C(=O)CCC1=O ZZBOTLREHORFCK-UHFFFAOYSA-N 0.000 description 2
- 125000003088 (fluoren-9-ylmethoxy)carbonyl group Chemical group 0.000 description 2
- 108091032973 (ribonucleotides)n+m Proteins 0.000 description 2
- IXPNQXFRVYWDDI-UHFFFAOYSA-N 1-methyl-2,4-dioxo-1,3-diazinane-5-carboximidamide Chemical compound CN1CC(C(N)=N)C(=O)NC1=O IXPNQXFRVYWDDI-UHFFFAOYSA-N 0.000 description 2
- LJCZNYWLQZZIOS-UHFFFAOYSA-N 2,2,2-trichlorethoxycarbonyl chloride Chemical compound ClC(=O)OCC(Cl)(Cl)Cl LJCZNYWLQZZIOS-UHFFFAOYSA-N 0.000 description 2
- VZSRBBMJRBPUNF-UHFFFAOYSA-N 2-(2,3-dihydro-1H-inden-2-ylamino)-N-[3-oxo-3-(2,4,6,7-tetrahydrotriazolo[4,5-c]pyridin-5-yl)propyl]pyrimidine-5-carboxamide Chemical compound C1C(CC2=CC=CC=C12)NC1=NC=C(C=N1)C(=O)NCCC(N1CC2=C(CC1)NN=N2)=O VZSRBBMJRBPUNF-UHFFFAOYSA-N 0.000 description 2
- 125000000022 2-aminoethyl group Chemical group [H]C([*])([H])C([H])([H])N([H])[H] 0.000 description 2
- 125000001731 2-cyanoethyl group Chemical group [H]C([H])(*)C([H])([H])C#N 0.000 description 2
- HZLCGUXUOFWCCN-UHFFFAOYSA-N 2-hydroxynonadecane-1,2,3-tricarboxylic acid Chemical compound CCCCCCCCCCCCCCCCC(C(O)=O)C(O)(C(O)=O)CC(O)=O HZLCGUXUOFWCCN-UHFFFAOYSA-N 0.000 description 2
- LSBDFXRDZJMBSC-UHFFFAOYSA-N 2-phenylacetamide Chemical class NC(=O)CC1=CC=CC=C1 LSBDFXRDZJMBSC-UHFFFAOYSA-N 0.000 description 2
- 125000001494 2-propynyl group Chemical group [H]C#CC([H])([H])* 0.000 description 2
- OSWFIVFLDKOXQC-UHFFFAOYSA-N 4-(3-methoxyphenyl)aniline Chemical compound COC1=CC=CC(C=2C=CC(N)=CC=2)=C1 OSWFIVFLDKOXQC-UHFFFAOYSA-N 0.000 description 2
- PLIKAWJENQZMHA-UHFFFAOYSA-N 4-aminophenol Chemical compound NC1=CC=C(O)C=C1 PLIKAWJENQZMHA-UHFFFAOYSA-N 0.000 description 2
- JOOXCMJARBKPKM-UHFFFAOYSA-M 4-oxopentanoate Chemical compound CC(=O)CCC([O-])=O JOOXCMJARBKPKM-UHFFFAOYSA-M 0.000 description 2
- HRTOFBWCNHKPDC-NSOVKSMOSA-N 9H-fluoren-9-yl N-[(2S)-1-[[(2S)-5-(carbamoylamino)-1-[4-(hydroxymethyl)anilino]-1-oxopentan-2-yl]amino]-3-methyl-1-oxobutan-2-yl]-N-methylcarbamate Chemical compound C1=CC=CC=2C3=CC=CC=C3C(C1=2)OC(N([C@H](C(=O)N[C@H](C(=O)NC1=CC=C(C=C1)CO)CCCNC(=O)N)C(C)C)C)=O HRTOFBWCNHKPDC-NSOVKSMOSA-N 0.000 description 2
- BQDRQMYZLGTHJW-UHFFFAOYSA-N 9h-fluoren-9-ylmethyl dihydrogen phosphate Chemical compound C1=CC=C2C(COP(O)(=O)O)C3=CC=CC=C3C2=C1 BQDRQMYZLGTHJW-UHFFFAOYSA-N 0.000 description 2
- XAYMTWKHRWOSHJ-UHFFFAOYSA-N 9h-fluoren-9-ylmethyl n-(4-hydroxyphenyl)carbamate Chemical compound C1=CC(O)=CC=C1NC(=O)OCC1C2=CC=CC=C2C2=CC=CC=C21 XAYMTWKHRWOSHJ-UHFFFAOYSA-N 0.000 description 2
- QTBSBXVTEAMEQO-UHFFFAOYSA-M Acetate Chemical compound CC([O-])=O QTBSBXVTEAMEQO-UHFFFAOYSA-M 0.000 description 2
- 229920001817 Agar Polymers 0.000 description 2
- 208000023275 Autoimmune disease Diseases 0.000 description 2
- KXDAEFPNCMNJSK-UHFFFAOYSA-N Benzamide Chemical compound NC(=O)C1=CC=CC=C1 KXDAEFPNCMNJSK-UHFFFAOYSA-N 0.000 description 2
- 206010006187 Breast cancer Diseases 0.000 description 2
- VTYYLEPIZMXCLO-UHFFFAOYSA-L Calcium carbonate Chemical compound [Ca+2].[O-]C([O-])=O VTYYLEPIZMXCLO-UHFFFAOYSA-L 0.000 description 2
- 239000004215 Carbon black (E152) Substances 0.000 description 2
- BVKZGUZCCUSVTD-UHFFFAOYSA-L Carbonate Chemical compound [O-]C([O-])=O BVKZGUZCCUSVTD-UHFFFAOYSA-L 0.000 description 2
- 206010009944 Colon cancer Diseases 0.000 description 2
- 101710112752 Cytotoxin Proteins 0.000 description 2
- 108020004414 DNA Proteins 0.000 description 2
- BWGNESOTFCXPMA-UHFFFAOYSA-N Dihydrogen disulfide Chemical compound SS BWGNESOTFCXPMA-UHFFFAOYSA-N 0.000 description 2
- 239000006144 Dulbecco’s modified Eagle's medium Substances 0.000 description 2
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 2
- ZHNUHDYFZUAESO-UHFFFAOYSA-N Formamide Chemical class NC=O ZHNUHDYFZUAESO-UHFFFAOYSA-N 0.000 description 2
- 102100031181 Glyceraldehyde-3-phosphate dehydrogenase Human genes 0.000 description 2
- 239000012981 Hank's balanced salt solution Substances 0.000 description 2
- COLNVLDHVKWLRT-QMMMGPOBSA-N L-phenylalanine Chemical compound OC(=O)[C@@H](N)CC1=CC=CC=C1 COLNVLDHVKWLRT-QMMMGPOBSA-N 0.000 description 2
- AFVFQIVMOAPDHO-UHFFFAOYSA-N Methanesulfonic acid Chemical compound CS(O)(=O)=O AFVFQIVMOAPDHO-UHFFFAOYSA-N 0.000 description 2
- BAVYZALUXZFZLV-UHFFFAOYSA-N Methylamine Chemical compound NC BAVYZALUXZFZLV-UHFFFAOYSA-N 0.000 description 2
- 230000004988 N-glycosylation Effects 0.000 description 2
- LRYRSNUCRFDJKC-UHFFFAOYSA-N NCCNC(COC1C#CCCCCC1)=O Chemical compound NCCNC(COC1C#CCCCCC1)=O LRYRSNUCRFDJKC-UHFFFAOYSA-N 0.000 description 2
- SAKUHPLHCWAWPU-CQSZACIVSA-N NCCOP(=O)(O)OP(=O)(O)OC1=C2C(=C3[C@@H](CN(C3=C1)C(=O)C=1NC3=C(C(=C(C=C3C=1)OC)OC)OC)CCl)C=C(N2)C(=O)OC Chemical compound NCCOP(=O)(O)OP(=O)(O)OC1=C2C(=C3[C@@H](CN(C3=C1)C(=O)C=1NC3=C(C(=C(C=C3C=1)OC)OC)OC)CCl)C=C(N2)C(=O)OC SAKUHPLHCWAWPU-CQSZACIVSA-N 0.000 description 2
- 208000015914 Non-Hodgkin lymphomas Diseases 0.000 description 2
- YSUMDTRQGPYFSD-UHFFFAOYSA-N OP(=O)(N1C=NC=C1)OCCNC(OCC1C2=CC=CC=C2C=2C=CC=CC1=2)=O Chemical compound OP(=O)(N1C=NC=C1)OCCNC(OCC1C2=CC=CC=C2C=2C=CC=CC1=2)=O YSUMDTRQGPYFSD-UHFFFAOYSA-N 0.000 description 2
- 229930182555 Penicillin Natural products 0.000 description 2
- JGSARLDLIJGVTE-MBNYWOFBSA-N Penicillin G Chemical compound N([C@H]1[C@H]2SC([C@@H](N2C1=O)C(O)=O)(C)C)C(=O)CC1=CC=CC=C1 JGSARLDLIJGVTE-MBNYWOFBSA-N 0.000 description 2
- NBIIXXVUZAFLBC-UHFFFAOYSA-N Phosphoric acid Chemical compound OP(O)(O)=O NBIIXXVUZAFLBC-UHFFFAOYSA-N 0.000 description 2
- NQRYJNQNLNOLGT-UHFFFAOYSA-N Piperidine Chemical compound C1CCNCC1 NQRYJNQNLNOLGT-UHFFFAOYSA-N 0.000 description 2
- WCUXLLCKKVVCTQ-UHFFFAOYSA-M Potassium chloride Chemical compound [Cl-].[K+] WCUXLLCKKVVCTQ-UHFFFAOYSA-M 0.000 description 2
- 201000004681 Psoriasis Diseases 0.000 description 2
- VMHLLURERBWHNL-UHFFFAOYSA-M Sodium acetate Chemical compound [Na+].CC([O-])=O VMHLLURERBWHNL-UHFFFAOYSA-M 0.000 description 2
- DKGAVHZHDRPRBM-UHFFFAOYSA-N Tert-Butanol Chemical compound CC(C)(C)O DKGAVHZHDRPRBM-UHFFFAOYSA-N 0.000 description 2
- GWEVSGVZZGPLCZ-UHFFFAOYSA-N Titan oxide Chemical compound O=[Ti]=O GWEVSGVZZGPLCZ-UHFFFAOYSA-N 0.000 description 2
- NRHDGIYFJJUFKN-CQSZACIVSA-N [(1s)-1-(chloromethyl)-5-hydroxy-1,2-dihydrobenzo[e]indol-3-yl]-(5,6,7-trimethoxy-1h-indol-2-yl)methanone Chemical compound C1=C(O)C2=CC=CC=C2C([C@H](CCl)C2)=C1N2C(=O)C1=CC(C=C(C(=C2OC)OC)OC)=C2N1 NRHDGIYFJJUFKN-CQSZACIVSA-N 0.000 description 2
- 239000004480 active ingredient Substances 0.000 description 2
- 150000001266 acyl halides Chemical class 0.000 description 2
- 239000000443 aerosol Substances 0.000 description 2
- 239000008272 agar Substances 0.000 description 2
- 235000010419 agar Nutrition 0.000 description 2
- 229940040563 agaric acid Drugs 0.000 description 2
- 239000000556 agonist Substances 0.000 description 2
- 235000010443 alginic acid Nutrition 0.000 description 2
- 239000000783 alginic acid Substances 0.000 description 2
- 229920000615 alginic acid Polymers 0.000 description 2
- 229960001126 alginic acid Drugs 0.000 description 2
- 150000004781 alginic acids Chemical class 0.000 description 2
- 125000003545 alkoxy group Chemical group 0.000 description 2
- 125000005377 alkyl thioxy group Chemical group 0.000 description 2
- 150000001408 amides Chemical class 0.000 description 2
- 125000002344 aminooxy group Chemical group [H]N([H])O[*] 0.000 description 2
- 239000012491 analyte Substances 0.000 description 2
- 230000010056 antibody-dependent cellular cytotoxicity Effects 0.000 description 2
- 229940127219 anticoagulant drug Drugs 0.000 description 2
- 125000005165 aryl thioxy group Chemical group 0.000 description 2
- 125000004104 aryloxy group Chemical group 0.000 description 2
- 239000012131 assay buffer Substances 0.000 description 2
- WGQKYBSKWIADBV-UHFFFAOYSA-N benzylamine Chemical compound NCC1=CC=CC=C1 WGQKYBSKWIADBV-UHFFFAOYSA-N 0.000 description 2
- 125000001246 bromo group Chemical group Br* 0.000 description 2
- 210000004899 c-terminal region Anatomy 0.000 description 2
- 150000004657 carbamic acid derivatives Chemical class 0.000 description 2
- 235000013877 carbamide Nutrition 0.000 description 2
- 235000014633 carbohydrates Nutrition 0.000 description 2
- 239000001569 carbon dioxide Substances 0.000 description 2
- 229910002092 carbon dioxide Inorganic materials 0.000 description 2
- 239000011203 carbon fibre reinforced carbon Substances 0.000 description 2
- 150000004649 carbonic acid derivatives Chemical class 0.000 description 2
- PFKFTWBEEFSNDU-UHFFFAOYSA-N carbonyldiimidazole Chemical compound C1=CN=CN1C(=O)N1C=CN=C1 PFKFTWBEEFSNDU-UHFFFAOYSA-N 0.000 description 2
- 150000001735 carboxylic acids Chemical class 0.000 description 2
- 239000001913 cellulose Substances 0.000 description 2
- 229920002678 cellulose Polymers 0.000 description 2
- 235000010980 cellulose Nutrition 0.000 description 2
- 239000013522 chelant Substances 0.000 description 2
- 238000000576 coating method Methods 0.000 description 2
- 238000006352 cycloaddition reaction Methods 0.000 description 2
- 125000000151 cysteine group Chemical group N[C@@H](CS)C(=O)* 0.000 description 2
- 239000002619 cytotoxin Substances 0.000 description 2
- 239000008367 deionised water Substances 0.000 description 2
- 229910021641 deionized water Inorganic materials 0.000 description 2
- HPNMFZURTQLUMO-UHFFFAOYSA-N diethylamine Chemical compound CCNCC HPNMFZURTQLUMO-UHFFFAOYSA-N 0.000 description 2
- ZUOUZKKEUPVFJK-UHFFFAOYSA-N diphenyl Chemical compound C1=CC=CC=C1C1=CC=CC=C1 ZUOUZKKEUPVFJK-UHFFFAOYSA-N 0.000 description 2
- 125000005982 diphenylmethyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C([H])(*)C1=C([H])C([H])=C([H])C([H])=C1[H] 0.000 description 2
- 230000008030 elimination Effects 0.000 description 2
- 238000003379 elimination reaction Methods 0.000 description 2
- 239000000839 emulsion Substances 0.000 description 2
- 210000001163 endosome Anatomy 0.000 description 2
- 239000002532 enzyme inhibitor Substances 0.000 description 2
- 125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 description 2
- 239000010685 fatty oil Substances 0.000 description 2
- 239000000945 filler Substances 0.000 description 2
- 239000000706 filtrate Substances 0.000 description 2
- IRXSLJNXXZKURP-UHFFFAOYSA-N fluorenylmethyloxycarbonyl chloride Chemical compound C1=CC=C2C(COC(=O)Cl)C3=CC=CC=C3C2=C1 IRXSLJNXXZKURP-UHFFFAOYSA-N 0.000 description 2
- 235000019253 formic acid Nutrition 0.000 description 2
- 239000007789 gas Substances 0.000 description 2
- 108020004445 glyceraldehyde-3-phosphate dehydrogenase Proteins 0.000 description 2
- 125000005553 heteroaryloxy group Chemical group 0.000 description 2
- 125000005378 heteroarylthioxy group Chemical group 0.000 description 2
- 238000004128 high performance liquid chromatography Methods 0.000 description 2
- 239000008240 homogeneous mixture Substances 0.000 description 2
- 210000004408 hybridoma Anatomy 0.000 description 2
- 150000004677 hydrates Chemical class 0.000 description 2
- 229930195733 hydrocarbon Natural products 0.000 description 2
- 230000002209 hydrophobic effect Effects 0.000 description 2
- 229940072221 immunoglobulins Drugs 0.000 description 2
- 230000003993 interaction Effects 0.000 description 2
- 238000010255 intramuscular injection Methods 0.000 description 2
- 238000001294 liquid chromatography-tandem mass spectrometry Methods 0.000 description 2
- 210000004185 liver Anatomy 0.000 description 2
- 239000000314 lubricant Substances 0.000 description 2
- 239000006166 lysate Substances 0.000 description 2
- HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 description 2
- 230000014759 maintenance of location Effects 0.000 description 2
- 238000012531 mass spectrometric analysis of intact mass Methods 0.000 description 2
- 230000001404 mediated effect Effects 0.000 description 2
- 125000000956 methoxy group Chemical group [H]C([H])([H])O* 0.000 description 2
- 125000004092 methylthiomethyl group Chemical group [H]C([H])([H])SC([H])([H])* 0.000 description 2
- 230000004048 modification Effects 0.000 description 2
- 238000012986 modification Methods 0.000 description 2
- 238000002703 mutagenesis Methods 0.000 description 2
- 231100000350 mutagenesis Toxicity 0.000 description 2
- 239000002547 new drug Substances 0.000 description 2
- 239000003921 oil Substances 0.000 description 2
- 235000019198 oils Nutrition 0.000 description 2
- 150000002905 orthoesters Chemical class 0.000 description 2
- 150000002923 oximes Chemical class 0.000 description 2
- 230000037361 pathway Effects 0.000 description 2
- 229940049954 penicillin Drugs 0.000 description 2
- 239000000825 pharmaceutical preparation Substances 0.000 description 2
- COLNVLDHVKWLRT-UHFFFAOYSA-N phenylalanine Natural products OC(=O)C(N)CC1=CC=CC=C1 COLNVLDHVKWLRT-UHFFFAOYSA-N 0.000 description 2
- OJMIONKXNSYLSR-UHFFFAOYSA-N phosphorous acid Chemical compound OP(O)O OJMIONKXNSYLSR-UHFFFAOYSA-N 0.000 description 2
- 230000002028 premature Effects 0.000 description 2
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 description 2
- 238000012545 processing Methods 0.000 description 2
- VQGISNOMGHCEPX-UHFFFAOYSA-N propanenitrile Chemical compound C[CH]C#N VQGISNOMGHCEPX-UHFFFAOYSA-N 0.000 description 2
- 230000006920 protein precipitation Effects 0.000 description 2
- 230000017854 proteolysis Effects 0.000 description 2
- 150000003254 radicals Chemical class 0.000 description 2
- 238000006894 reductive elimination reaction Methods 0.000 description 2
- 206010039073 rheumatoid arthritis Diseases 0.000 description 2
- 238000005070 sampling Methods 0.000 description 2
- 230000035945 sensitivity Effects 0.000 description 2
- 239000001632 sodium acetate Substances 0.000 description 2
- 235000017281 sodium acetate Nutrition 0.000 description 2
- 235000010413 sodium alginate Nutrition 0.000 description 2
- 239000000661 sodium alginate Substances 0.000 description 2
- 229940005550 sodium alginate Drugs 0.000 description 2
- AJPJDKMHJJGVTQ-UHFFFAOYSA-M sodium dihydrogen phosphate Chemical compound [Na+].OP(O)([O-])=O AJPJDKMHJJGVTQ-UHFFFAOYSA-M 0.000 description 2
- GEHJYWRUCIMESM-UHFFFAOYSA-L sodium sulfite Chemical compound [Na+].[Na+].[O-]S([O-])=O GEHJYWRUCIMESM-UHFFFAOYSA-L 0.000 description 2
- 239000002904 solvent Substances 0.000 description 2
- 241000894007 species Species 0.000 description 2
- 230000009870 specific binding Effects 0.000 description 2
- 239000008107 starch Substances 0.000 description 2
- 229960005322 streptomycin Drugs 0.000 description 2
- 238000006467 substitution reaction Methods 0.000 description 2
- 150000008163 sugars Chemical class 0.000 description 2
- 239000012134 supernatant fraction Substances 0.000 description 2
- 208000024891 symptom Diseases 0.000 description 2
- 239000000454 talc Substances 0.000 description 2
- 229910052623 talc Inorganic materials 0.000 description 2
- 235000012222 talc Nutrition 0.000 description 2
- ILMRJRBKQSSXGY-UHFFFAOYSA-N tert-butyl(dimethyl)silicon Chemical group C[Si](C)C(C)(C)C ILMRJRBKQSSXGY-UHFFFAOYSA-N 0.000 description 2
- 125000003718 tetrahydrofuranyl group Chemical group 0.000 description 2
- 125000003039 tetrahydroisoquinolinyl group Chemical group C1(NCCC2=CC=CC=C12)* 0.000 description 2
- 125000001412 tetrahydropyranyl group Chemical group 0.000 description 2
- 150000003536 tetrazoles Chemical class 0.000 description 2
- 230000001225 therapeutic effect Effects 0.000 description 2
- 230000001988 toxicity Effects 0.000 description 2
- 231100000419 toxicity Toxicity 0.000 description 2
- 230000032258 transport Effects 0.000 description 2
- 125000000025 triisopropylsilyl group Chemical group C(C)(C)[Si](C(C)C)(C(C)C)* 0.000 description 2
- LWIHDJKSTIGBAC-UHFFFAOYSA-K tripotassium phosphate Chemical compound [K+].[K+].[K+].[O-]P([O-])([O-])=O LWIHDJKSTIGBAC-UHFFFAOYSA-K 0.000 description 2
- 238000004704 ultra performance liquid chromatography Methods 0.000 description 2
- 150000003672 ureas Chemical class 0.000 description 2
- DFNJPPOAVCXQQQ-UHFFFAOYSA-N (1,1,1-trichloro-2-methylpropan-2-yl) carbamate Chemical compound ClC(Cl)(Cl)C(C)(C)OC(N)=O DFNJPPOAVCXQQQ-UHFFFAOYSA-N 0.000 description 1
- FTVXFBJENACRRL-UHFFFAOYSA-N (1-hydroxypiperidin-2-yl) carbamate Chemical compound NC(=O)OC1CCCCN1O FTVXFBJENACRRL-UHFFFAOYSA-N 0.000 description 1
- KLWCNEYVHPBUNM-UHFFFAOYSA-N (1-methylcyclobutyl) carbamate Chemical compound NC(=O)OC1(C)CCC1 KLWCNEYVHPBUNM-UHFFFAOYSA-N 0.000 description 1
- AKIHTGIGOHBKGE-UHFFFAOYSA-N (1-methylcyclohexyl) carbamate Chemical compound NC(=O)OC1(C)CCCCC1 AKIHTGIGOHBKGE-UHFFFAOYSA-N 0.000 description 1
- DXPBUKRLLARTOT-UHFFFAOYSA-N (2,4,6-tributylphenyl) carbamate Chemical compound CCCCC1=CC(CCCC)=C(OC(N)=O)C(CCCC)=C1 DXPBUKRLLARTOT-UHFFFAOYSA-N 0.000 description 1
- ZLIHDHDAJVINAN-UHFFFAOYSA-N (2,4,6-trimethyl-3-pyridin-2-ylphenyl)methanimine Chemical compound CC1=C(C=N)C(C)=CC(C)=C1C1=CC=CC=N1 ZLIHDHDAJVINAN-UHFFFAOYSA-N 0.000 description 1
- KJOPTLWVYZCJBX-UHFFFAOYSA-N (2,4,6-trimethylphenyl)methyl carbamate Chemical class CC1=CC(C)=C(COC(N)=O)C(C)=C1 KJOPTLWVYZCJBX-UHFFFAOYSA-N 0.000 description 1
- LZZRHUUMSXNYBI-UHFFFAOYSA-N (2,4-dichlorophenyl)methyl carbamate Chemical compound NC(=O)OCC1=CC=C(Cl)C=C1Cl LZZRHUUMSXNYBI-UHFFFAOYSA-N 0.000 description 1
- JKHVDAUOODACDU-UHFFFAOYSA-N (2,5-dioxopyrrolidin-1-yl) 3-(2,5-dioxopyrrol-1-yl)propanoate Chemical compound O=C1CCC(=O)N1OC(=O)CCN1C(=O)C=CC1=O JKHVDAUOODACDU-UHFFFAOYSA-N 0.000 description 1
- WMSUFWLPZLCIHP-UHFFFAOYSA-N (2,5-dioxopyrrolidin-1-yl) 9h-fluoren-9-ylmethyl carbonate Chemical compound C12=CC=CC=C2C2=CC=CC=C2C1COC(=O)ON1C(=O)CCC1=O WMSUFWLPZLCIHP-UHFFFAOYSA-N 0.000 description 1
- LEDMDNAHWYVAPC-UHFFFAOYSA-N (2-carbamoylphenyl)methyl benzoate Chemical compound NC(=O)C1=CC=CC=C1COC(=O)C1=CC=CC=C1 LEDMDNAHWYVAPC-UHFFFAOYSA-N 0.000 description 1
- SWHAGWLVMRLFKO-UHFFFAOYSA-N (2-nitrophenyl)methyl carbamate Chemical compound NC(=O)OCC1=CC=CC=C1[N+]([O-])=O SWHAGWLVMRLFKO-UHFFFAOYSA-N 0.000 description 1
- HIPYHINICCKLGX-UHFFFAOYSA-N (3,5-dimethoxyphenyl)methyl carbamate Chemical compound COC1=CC(COC(N)=O)=CC(OC)=C1 HIPYHINICCKLGX-UHFFFAOYSA-N 0.000 description 1
- YVOBGLMMNWZYCL-UHFFFAOYSA-N (3-nitrophenyl) carbamate Chemical compound NC(=O)OC1=CC=CC([N+]([O-])=O)=C1 YVOBGLMMNWZYCL-UHFFFAOYSA-N 0.000 description 1
- WTKQMHWYSBWUBE-UHFFFAOYSA-N (3-nitropyridin-2-yl) thiohypochlorite Chemical compound [O-][N+](=O)C1=CC=CN=C1SCl WTKQMHWYSBWUBE-UHFFFAOYSA-N 0.000 description 1
- AWOKSNNHYRGYIA-UHFFFAOYSA-N (4,5-dimethoxy-2-nitrophenyl)methyl carbamate Chemical compound COC1=CC(COC(N)=O)=C([N+]([O-])=O)C=C1OC AWOKSNNHYRGYIA-UHFFFAOYSA-N 0.000 description 1
- HIIOEWGKFCWTJU-UHFFFAOYSA-N (4-chlorophenyl)methyl carbamate Chemical compound NC(=O)OCC1=CC=C(Cl)C=C1 HIIOEWGKFCWTJU-UHFFFAOYSA-N 0.000 description 1
- QXENIPSNYCZWNY-UHFFFAOYSA-N (4-methoxyphenyl)-diphenylmethanamine Chemical compound C1=CC(OC)=CC=C1C(N)(C=1C=CC=CC=1)C1=CC=CC=C1 QXENIPSNYCZWNY-UHFFFAOYSA-N 0.000 description 1
- OKLFHGKWEQKSDZ-UHFFFAOYSA-N (4-methoxyphenyl)methanimine Chemical compound COC1=CC=C(C=N)C=C1 OKLFHGKWEQKSDZ-UHFFFAOYSA-N 0.000 description 1
- SDEOSHAQCMPJIJ-UHFFFAOYSA-N (4-methoxyphenyl)methyl carbamate Chemical compound COC1=CC=C(COC(N)=O)C=C1 SDEOSHAQCMPJIJ-UHFFFAOYSA-N 0.000 description 1
- WNNZAHBBDIVWBB-UHFFFAOYSA-N (4-methylsulfanylphenyl) carbamate Chemical compound CSC1=CC=C(OC(N)=O)C=C1 WNNZAHBBDIVWBB-UHFFFAOYSA-N 0.000 description 1
- NXLNNXIXOYSCMB-UHFFFAOYSA-N (4-nitrophenyl) carbonochloridate Chemical compound [O-][N+](=O)C1=CC=C(OC(Cl)=O)C=C1 NXLNNXIXOYSCMB-UHFFFAOYSA-N 0.000 description 1
- HQNKOEZESXBYJA-UHFFFAOYSA-N (4-phenyldiazenylphenyl)methyl carbamate Chemical compound C1=CC(COC(=O)N)=CC=C1N=NC1=CC=CC=C1 HQNKOEZESXBYJA-UHFFFAOYSA-N 0.000 description 1
- 125000006569 (C5-C6) heterocyclic group Chemical group 0.000 description 1
- HEVMDQBCAHEHDY-UHFFFAOYSA-N (Dimethoxymethyl)benzene Chemical compound COC(OC)C1=CC=CC=C1 HEVMDQBCAHEHDY-UHFFFAOYSA-N 0.000 description 1
- RASLWNGTMHFPIQ-AATRIKPKSA-N (e)-3-(2-nitrophenyl)prop-2-enamide Chemical compound NC(=O)\C=C\C1=CC=CC=C1[N+]([O-])=O RASLWNGTMHFPIQ-AATRIKPKSA-N 0.000 description 1
- ZOJKRWXDNYZASL-NSCUHMNNSA-N (e)-4-methoxybut-2-enoic acid Chemical compound COC\C=C\C(O)=O ZOJKRWXDNYZASL-NSCUHMNNSA-N 0.000 description 1
- TTXKLVVJWALEOY-UHFFFAOYSA-N 1,2-benzoxazol-5-ylmethyl carbamate Chemical compound NC(=O)OCC1=CC=C2ON=CC2=C1 TTXKLVVJWALEOY-UHFFFAOYSA-N 0.000 description 1
- DDMOUSALMHHKOS-UHFFFAOYSA-N 1,2-dichloro-1,1,2,2-tetrafluoroethane Chemical compound FC(F)(Cl)C(F)(F)Cl DDMOUSALMHHKOS-UHFFFAOYSA-N 0.000 description 1
- 150000000185 1,3-diols Chemical class 0.000 description 1
- VAYTZRYEBVHVLE-UHFFFAOYSA-N 1,3-dioxol-2-one Chemical compound O=C1OC=CO1 VAYTZRYEBVHVLE-UHFFFAOYSA-N 0.000 description 1
- FJANNOJSTOGZHK-UHFFFAOYSA-N 1-adamantyl carbamate Chemical compound C1C(C2)CC3CC2CC1(OC(=O)N)C3 FJANNOJSTOGZHK-UHFFFAOYSA-N 0.000 description 1
- MNCMBBIFTVWHIP-UHFFFAOYSA-N 1-anthracen-9-yl-2,2,2-trifluoroethanone Chemical group C1=CC=C2C(C(=O)C(F)(F)F)=C(C=CC=C3)C3=CC2=C1 MNCMBBIFTVWHIP-UHFFFAOYSA-N 0.000 description 1
- XIUQHVQLGXTGGN-UHFFFAOYSA-N 1-cyclopropylethyl carbamate Chemical compound NC(=O)OC(C)C1CC1 XIUQHVQLGXTGGN-UHFFFAOYSA-N 0.000 description 1
- 125000000530 1-propynyl group Chemical group [H]C([H])([H])C#C* 0.000 description 1
- 238000005160 1H NMR spectroscopy Methods 0.000 description 1
- UPQQXPKAYZYUKO-UHFFFAOYSA-N 2,2,2-trichloroacetamide Chemical class OC(=N)C(Cl)(Cl)Cl UPQQXPKAYZYUKO-UHFFFAOYSA-N 0.000 description 1
- QPLJYAKLSCXZSF-UHFFFAOYSA-N 2,2,2-trichloroethyl carbamate Chemical compound NC(=O)OCC(Cl)(Cl)Cl QPLJYAKLSCXZSF-UHFFFAOYSA-N 0.000 description 1
- 125000000453 2,2,2-trichloroethyl group Chemical group [H]C([H])(*)C(Cl)(Cl)Cl 0.000 description 1
- NRKYWOKHZRQRJR-UHFFFAOYSA-N 2,2,2-trifluoroacetamide Chemical class NC(=O)C(F)(F)F NRKYWOKHZRQRJR-UHFFFAOYSA-N 0.000 description 1
- PXVUDLXXKGSXHH-UHFFFAOYSA-N 2,4,6-trimethoxybenzenesulfonamide Chemical compound COC1=CC(OC)=C(S(N)(=O)=O)C(OC)=C1 PXVUDLXXKGSXHH-UHFFFAOYSA-N 0.000 description 1
- YECJUZIGFPJWGQ-UHFFFAOYSA-N 2,4,6-trimethylbenzenesulfonamide Chemical compound CC1=CC(C)=C(S(N)(=O)=O)C(C)=C1 YECJUZIGFPJWGQ-UHFFFAOYSA-N 0.000 description 1
- FFFIRKXTFQCCKJ-UHFFFAOYSA-M 2,4,6-trimethylbenzoate Chemical compound CC1=CC(C)=C(C([O-])=O)C(C)=C1 FFFIRKXTFQCCKJ-UHFFFAOYSA-M 0.000 description 1
- 125000001917 2,4-dinitrophenyl group Chemical group [H]C1=C([H])C(=C([H])C(=C1*)[N+]([O-])=O)[N+]([O-])=O 0.000 description 1
- YJRISODHEYGPEL-UHFFFAOYSA-N 2,6-dimethoxy-4-methylbenzenesulfonamide Chemical compound COC1=CC(C)=CC(OC)=C1S(N)(=O)=O YJRISODHEYGPEL-UHFFFAOYSA-N 0.000 description 1
- YURLCYGZYWDCHL-UHFFFAOYSA-N 2-(2,6-dichloro-4-methylphenoxy)acetic acid Chemical compound CC1=CC(Cl)=C(OCC(O)=O)C(Cl)=C1 YURLCYGZYWDCHL-UHFFFAOYSA-N 0.000 description 1
- DVCVYHFEWYAJCP-UHFFFAOYSA-N 2-(2-nitrophenoxy)acetamide Chemical compound NC(=O)COC1=CC=CC=C1[N+]([O-])=O DVCVYHFEWYAJCP-UHFFFAOYSA-N 0.000 description 1
- KXKIBGGGFMXVBJ-UHFFFAOYSA-N 2-(4-phenylphenyl)propan-2-yl carbamate Chemical compound C1=CC(C(C)(OC(N)=O)C)=CC=C1C1=CC=CC=C1 KXKIBGGGFMXVBJ-UHFFFAOYSA-N 0.000 description 1
- FGJAPOYTPXTLPY-UHFFFAOYSA-N 2-(benzylideneamino)-4-chlorophenol Chemical compound OC1=CC=C(Cl)C=C1N=CC1=CC=CC=C1 FGJAPOYTPXTLPY-UHFFFAOYSA-N 0.000 description 1
- TYYAMZMDZWXHHA-UHFFFAOYSA-N 2-(dibromomethyl)benzoic acid Chemical compound OC(=O)C1=CC=CC=C1C(Br)Br TYYAMZMDZWXHHA-UHFFFAOYSA-N 0.000 description 1
- JGYNXZIYXGSEJH-UHFFFAOYSA-N 2-(methylsulfanylmethoxymethyl)benzoic acid Chemical compound CSCOCC1=CC=CC=C1C(O)=O JGYNXZIYXGSEJH-UHFFFAOYSA-N 0.000 description 1
- 125000003821 2-(trimethylsilyl)ethoxymethyl group Chemical group [H]C([H])([H])[Si](C([H])([H])[H])(C([H])([H])[H])C([H])([H])C(OC([H])([H])[*])([H])[H] 0.000 description 1
- ANOJXMUSDYSKET-UHFFFAOYSA-N 2-[2-[2-(2-aminoethoxy)ethoxy]ethoxy]ethanol Chemical compound NCCOCCOCCOCCO ANOJXMUSDYSKET-UHFFFAOYSA-N 0.000 description 1
- UJRMHFPTLFNSTA-UHFFFAOYSA-N 2-chloro-2,2-diphenylacetic acid Chemical compound C=1C=CC=CC=1C(Cl)(C(=O)O)C1=CC=CC=C1 UJRMHFPTLFNSTA-UHFFFAOYSA-N 0.000 description 1
- FINYOTLDIHYWPR-UHFFFAOYSA-N 2-cyanoethoxy-n,n-di(propan-2-yl)phosphonamidous acid Chemical compound CC(C)N(C(C)C)P(O)OCCC#N FINYOTLDIHYWPR-UHFFFAOYSA-N 0.000 description 1
- SHHKMWMIKILKQW-UHFFFAOYSA-N 2-formylbenzenesulfonic acid Chemical compound OS(=O)(=O)C1=CC=CC=C1C=O SHHKMWMIKILKQW-UHFFFAOYSA-N 0.000 description 1
- CFMZSMGAMPBRBE-UHFFFAOYSA-N 2-hydroxyisoindole-1,3-dione Chemical compound C1=CC=C2C(=O)N(O)C(=O)C2=C1 CFMZSMGAMPBRBE-UHFFFAOYSA-N 0.000 description 1
- CJNZAXGUTKBIHP-UHFFFAOYSA-M 2-iodobenzoate Chemical compound [O-]C(=O)C1=CC=CC=C1I CJNZAXGUTKBIHP-UHFFFAOYSA-M 0.000 description 1
- UYCIUCIKUGYNBR-UHFFFAOYSA-N 2-iodoethyl carbamate Chemical compound NC(=O)OCCI UYCIUCIKUGYNBR-UHFFFAOYSA-N 0.000 description 1
- LPUAWADEOBHDIP-UHFFFAOYSA-N 2-methyl-2-(2-nitrophenoxy)propanamide Chemical compound NC(=O)C(C)(C)OC1=CC=CC=C1[N+]([O-])=O LPUAWADEOBHDIP-UHFFFAOYSA-N 0.000 description 1
- OBEJXZIQPCOKSK-UHFFFAOYSA-N 2-methyl-2-(2-phenyldiazenylphenoxy)propanamide Chemical compound NC(=O)C(C)(C)OC1=CC=CC=C1N=NC1=CC=CC=C1 OBEJXZIQPCOKSK-UHFFFAOYSA-N 0.000 description 1
- SDJNOBUNFYNROE-UHFFFAOYSA-N 2-methylbut-3-yn-2-yl carbamate Chemical compound C#CC(C)(C)OC(N)=O SDJNOBUNFYNROE-UHFFFAOYSA-N 0.000 description 1
- BRUZQRBVNRKLJG-UHFFFAOYSA-N 2-methylpropyl carbamate Chemical compound CC(C)COC(N)=O BRUZQRBVNRKLJG-UHFFFAOYSA-N 0.000 description 1
- OWXVECVXBTWHPP-UHFFFAOYSA-N 2-methylsulfanylethyl carbamate Chemical compound CSCCOC(N)=O OWXVECVXBTWHPP-UHFFFAOYSA-N 0.000 description 1
- IXTODZAWAAKENF-UHFFFAOYSA-N 2-methylsulfonylethyl carbamate Chemical compound CS(=O)(=O)CCOC(N)=O IXTODZAWAAKENF-UHFFFAOYSA-N 0.000 description 1
- KLGQWSOYKYFBTR-UHFFFAOYSA-N 2-nitrobenzamide Chemical compound NC(=O)C1=CC=CC=C1[N+]([O-])=O KLGQWSOYKYFBTR-UHFFFAOYSA-N 0.000 description 1
- MUAUTBNKPSNTFM-UHFFFAOYSA-N 2-phenylethyl carbamate Chemical compound NC(=O)OCCC1=CC=CC=C1 MUAUTBNKPSNTFM-UHFFFAOYSA-N 0.000 description 1
- UCZSGRLQZLKLCQ-UHFFFAOYSA-N 2-phenylpropan-2-yl carbamate Chemical compound NC(=O)OC(C)(C)C1=CC=CC=C1 UCZSGRLQZLKLCQ-UHFFFAOYSA-N 0.000 description 1
- FCOXSVSQGYUZTB-UHFFFAOYSA-N 2-phosphanylethyl carbamate Chemical compound NC(=O)OCCP FCOXSVSQGYUZTB-UHFFFAOYSA-N 0.000 description 1
- 125000003903 2-propenyl group Chemical group [H]C([*])([H])C([H])=C([H])[H] 0.000 description 1
- WYECGUSLBPACPT-UHFFFAOYSA-N 2-pyridin-4-ylpropan-2-yl carbamate Chemical compound NC(=O)OC(C)(C)C1=CC=NC=C1 WYECGUSLBPACPT-UHFFFAOYSA-N 0.000 description 1
- MZASHBBAFBWNFL-UHFFFAOYSA-N 2-trimethylsilylethanesulfonamide Chemical compound C[Si](C)(C)CCS(N)(=O)=O MZASHBBAFBWNFL-UHFFFAOYSA-N 0.000 description 1
- XSXPJNJLDYOPTF-UHFFFAOYSA-N 2-trimethylsilylethoxymethanamine Chemical compound C[Si](C)(C)CCOCN XSXPJNJLDYOPTF-UHFFFAOYSA-N 0.000 description 1
- QWYTUBPAXJYCTH-UHFFFAOYSA-N 2-trimethylsilylethyl carbamate Chemical compound C[Si](C)(C)CCOC(N)=O QWYTUBPAXJYCTH-UHFFFAOYSA-N 0.000 description 1
- LDZNCSVWVMBVST-UHFFFAOYSA-N 2-trimethylsilylethyl hydrogen carbonate Chemical compound C[Si](C)(C)CCOC(O)=O LDZNCSVWVMBVST-UHFFFAOYSA-N 0.000 description 1
- GPVOTFQILZVCFP-UHFFFAOYSA-N 2-trityloxyacetic acid Chemical compound C=1C=CC=CC=1C(C=1C=CC=CC=1)(OCC(=O)O)C1=CC=CC=C1 GPVOTFQILZVCFP-UHFFFAOYSA-N 0.000 description 1
- 125000002774 3,4-dimethoxybenzyl group Chemical group [H]C1=C([H])C(=C([H])C(OC([H])([H])[H])=C1OC([H])([H])[H])C([H])([H])* 0.000 description 1
- KADQHJDUFKAUEB-UHFFFAOYSA-N 3-(2-nitrophenyl)propanamide Chemical compound NC(=O)CCC1=CC=CC=C1[N+]([O-])=O KADQHJDUFKAUEB-UHFFFAOYSA-N 0.000 description 1
- OEHZEBOCZWCVMK-UHFFFAOYSA-N 3-(4-hydroxyphenyl)propanamide Chemical compound NC(=O)CCC1=CC=C(O)C=C1 OEHZEBOCZWCVMK-UHFFFAOYSA-N 0.000 description 1
- NRZLJLXOGSCRAO-UHFFFAOYSA-N 3-(4-nitrophenyl)prop-2-enyl carbamate Chemical compound NC(=O)OCC=CC1=CC=C([N+]([O-])=O)C=C1 NRZLJLXOGSCRAO-UHFFFAOYSA-N 0.000 description 1
- MTZNODTZOSBYJW-UHFFFAOYSA-N 3-amino-5,5-dimethylcyclohex-2-en-1-one Chemical compound CC1(C)CC(N)=CC(=O)C1 MTZNODTZOSBYJW-UHFFFAOYSA-N 0.000 description 1
- SCLGGNBFBLJQFU-UHFFFAOYSA-N 3-aminopropyl acetate Chemical compound CC(=O)OCCCN SCLGGNBFBLJQFU-UHFFFAOYSA-N 0.000 description 1
- 125000006497 3-methoxybenzyl group Chemical group [H]C1=C([H])C(=C([H])C(OC([H])([H])[H])=C1[H])C([H])([H])* 0.000 description 1
- UVODFYVXDPJZFJ-UHFFFAOYSA-N 3-methyl-3-nitrobutanamide Chemical compound [O-][N+](=O)C(C)(C)CC(N)=O UVODFYVXDPJZFJ-UHFFFAOYSA-N 0.000 description 1
- VYIBCOSBNVFEIW-UHFFFAOYSA-N 3-phenylpropanamide Chemical class NC(=O)CCC1=CC=CC=C1 VYIBCOSBNVFEIW-UHFFFAOYSA-N 0.000 description 1
- XMIIGOLPHOKFCH-UHFFFAOYSA-M 3-phenylpropionate Chemical compound [O-]C(=O)CCC1=CC=CC=C1 XMIIGOLPHOKFCH-UHFFFAOYSA-M 0.000 description 1
- UBARRNXCKBFUEN-UHFFFAOYSA-N 4,5-diphenyl-5h-1,3-oxazol-2-one Chemical compound N=1C(=O)OC(C=2C=CC=CC=2)C=1C1=CC=CC=C1 UBARRNXCKBFUEN-UHFFFAOYSA-N 0.000 description 1
- JAOINXWEFKZYIL-UHFFFAOYSA-N 4-(1-methyl-2-oxoquinolin-4-yl)oxy-n-(4-methylpyridin-2-yl)butanamide;2,2,2-trifluoroacetic acid Chemical compound OC(=O)C(F)(F)F.CC1=CC=NC(NC(=O)CCCOC=2C3=CC=CC=C3N(C)C(=O)C=2)=C1 JAOINXWEFKZYIL-UHFFFAOYSA-N 0.000 description 1
- NDRAHSMAGKWWFZ-UHFFFAOYSA-N 4-(methylsulfanylmethoxy)butanoic acid Chemical compound CSCOCCCC(O)=O NDRAHSMAGKWWFZ-UHFFFAOYSA-N 0.000 description 1
- BLEFBWAGWNSEGB-UHFFFAOYSA-N 4-[(4,8-dimethoxynaphthalen-1-yl)methyl]benzenesulfonamide Chemical compound C12=C(OC)C=CC=C2C(OC)=CC=C1CC1=CC=C(S(N)(=O)=O)C=C1 BLEFBWAGWNSEGB-UHFFFAOYSA-N 0.000 description 1
- WAGMYTXJRVPMGW-UHFFFAOYSA-N 4-azidobutanoic acid Chemical compound OC(=O)CCCN=[N+]=[N-] WAGMYTXJRVPMGW-UHFFFAOYSA-N 0.000 description 1
- QPSBONMVNZJUMM-UHFFFAOYSA-N 4-chloro-2-methanimidoylphenol Chemical compound OC1=CC=C(Cl)C=C1C=N QPSBONMVNZJUMM-UHFFFAOYSA-N 0.000 description 1
- XYOXIERJKILWCG-UHFFFAOYSA-N 4-chlorobutanamide Chemical compound NC(=O)CCCCl XYOXIERJKILWCG-UHFFFAOYSA-N 0.000 description 1
- JVVRCYWZTJLJSG-UHFFFAOYSA-N 4-dimethylaminophenol Chemical compound CN(C)C1=CC=C(O)C=C1 JVVRCYWZTJLJSG-UHFFFAOYSA-N 0.000 description 1
- 229960000549 4-dimethylaminophenol Drugs 0.000 description 1
- VHYFNPMBLIVWCW-UHFFFAOYSA-N 4-dimethylaminopyridine Substances CN(C)C1=CC=NC=C1 VHYFNPMBLIVWCW-UHFFFAOYSA-N 0.000 description 1
- UHAAUDAFKLCPEA-UHFFFAOYSA-N 4-methoxy-2,3,5,6-tetramethylbenzenesulfonamide Chemical compound COC1=C(C)C(C)=C(S(N)(=O)=O)C(C)=C1C UHAAUDAFKLCPEA-UHFFFAOYSA-N 0.000 description 1
- ZJJLGMUSGUYZQP-UHFFFAOYSA-N 4-methoxy-2,6-dimethylbenzenesulfonamide Chemical compound COC1=CC(C)=C(S(N)(=O)=O)C(C)=C1 ZJJLGMUSGUYZQP-UHFFFAOYSA-N 0.000 description 1
- MSFQEZBRFPAFEX-UHFFFAOYSA-N 4-methoxybenzenesulfonamide Chemical compound COC1=CC=C(S(N)(=O)=O)C=C1 MSFQEZBRFPAFEX-UHFFFAOYSA-N 0.000 description 1
- 125000004172 4-methoxyphenyl group Chemical group [H]C1=C([H])C(OC([H])([H])[H])=C([H])C([H])=C1* 0.000 description 1
- KHKJLJHJTQRHSA-UHFFFAOYSA-N 4-methyl-4-nitropentanoic acid Chemical compound [O-][N+](=O)C(C)(C)CCC(O)=O KHKJLJHJTQRHSA-UHFFFAOYSA-N 0.000 description 1
- 125000002471 4H-quinolizinyl group Chemical group C=1(C=CCN2C=CC=CC12)* 0.000 description 1
- GDXXYJRQFQZYNL-UHFFFAOYSA-N 9h-fluoren-1-ylmethyl carbamate Chemical compound C1C2=CC=CC=C2C2=C1C(COC(=O)N)=CC=C2 GDXXYJRQFQZYNL-UHFFFAOYSA-N 0.000 description 1
- XXSCONYSQQLHTH-UHFFFAOYSA-N 9h-fluoren-9-ylmethanol Chemical compound C1=CC=C2C(CO)C3=CC=CC=C3C2=C1 XXSCONYSQQLHTH-UHFFFAOYSA-N 0.000 description 1
- ZZOKVYOCRSMTSS-UHFFFAOYSA-N 9h-fluoren-9-ylmethyl carbamate Chemical compound C1=CC=C2C(COC(=O)N)C3=CC=CC=C3C2=C1 ZZOKVYOCRSMTSS-UHFFFAOYSA-N 0.000 description 1
- XLIFWDZVNRWYKV-UHFFFAOYSA-N 9h-fluoren-9-ylmethyl n-(2-hydroxyethyl)carbamate Chemical compound C1=CC=C2C(COC(=O)NCCO)C3=CC=CC=C3C2=C1 XLIFWDZVNRWYKV-UHFFFAOYSA-N 0.000 description 1
- UZWYVXFJNFHOMM-UHFFFAOYSA-N 9h-fluoren-9-ylmethyl n-[2-[2-[2-(2-hydroxyethoxy)ethoxy]ethoxy]ethyl]carbamate Chemical compound C1=CC=C2C(COC(=O)NCCOCCOCCOCCO)C3=CC=CC=C3C2=C1 UZWYVXFJNFHOMM-UHFFFAOYSA-N 0.000 description 1
- 208000030507 AIDS Diseases 0.000 description 1
- 244000215068 Acacia senegal Species 0.000 description 1
- 208000031261 Acute myeloid leukaemia Diseases 0.000 description 1
- 102100031260 Acyl-coenzyme A thioesterase THEM4 Human genes 0.000 description 1
- VVJKKWFAADXIJK-UHFFFAOYSA-N Allylamine Chemical compound NCC=C VVJKKWFAADXIJK-UHFFFAOYSA-N 0.000 description 1
- GUBGYTABKSRVRQ-XLOQQCSPSA-N Alpha-Lactose Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@H](O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-XLOQQCSPSA-N 0.000 description 1
- 108010032595 Antibody Binding Sites Proteins 0.000 description 1
- 241000416162 Astragalus gummifer Species 0.000 description 1
- 208000010839 B-cell chronic lymphocytic leukemia Diseases 0.000 description 1
- 102100038080 B-cell receptor CD22 Human genes 0.000 description 1
- 102100022005 B-lymphocyte antigen CD20 Human genes 0.000 description 1
- 206010004446 Benign prostatic hyperplasia Diseases 0.000 description 1
- KHBQMWCZKVMBLN-UHFFFAOYSA-N Benzenesulfonamide Chemical compound NS(=O)(=O)C1=CC=CC=C1 KHBQMWCZKVMBLN-UHFFFAOYSA-N 0.000 description 1
- 239000004342 Benzoyl peroxide Substances 0.000 description 1
- OMPJBNCRMGITSC-UHFFFAOYSA-N Benzoylperoxide Chemical compound C=1C=CC=CC=1C(=O)OOC(=O)C1=CC=CC=C1 OMPJBNCRMGITSC-UHFFFAOYSA-N 0.000 description 1
- 108010006654 Bleomycin Proteins 0.000 description 1
- BTBUEUYNUDRHOZ-UHFFFAOYSA-N Borate Chemical compound [O-]B([O-])[O-] BTBUEUYNUDRHOZ-UHFFFAOYSA-N 0.000 description 1
- 208000026310 Breast neoplasm Diseases 0.000 description 1
- 102100024217 CAMPATH-1 antigen Human genes 0.000 description 1
- DSQXDFQELFUIQV-UHFFFAOYSA-N CC(C)(C)COC1CC2N=NNC2CCCC1 Chemical compound CC(C)(C)COC1CC2N=NNC2CCCC1 DSQXDFQELFUIQV-UHFFFAOYSA-N 0.000 description 1
- RKVHNYJPIXOHRW-UHFFFAOYSA-N CC(C)N(C(C)C)P(N(C(C)C)C(C)C)OCCC#N Chemical compound CC(C)N(C(C)C)P(N(C(C)C)C(C)C)OCCC#N RKVHNYJPIXOHRW-UHFFFAOYSA-N 0.000 description 1
- QWOJMRHUQHTCJG-UHFFFAOYSA-N CC([CH2-])=O Chemical compound CC([CH2-])=O QWOJMRHUQHTCJG-UHFFFAOYSA-N 0.000 description 1
- QZIYSFVNRMBENV-PONRWWDOSA-N CCCC(O[C@@H]1C[C@@H]([C@H](CC2)[C@H]3[C@@](C)(C=C4)C2=CC4=O)[C@]2(C)C[C@@H]3O)O[C@]12C(COC(C)=O)=O Chemical compound CCCC(O[C@@H]1C[C@@H]([C@H](CC2)[C@H]3[C@@](C)(C=C4)C2=CC4=O)[C@]2(C)C[C@@H]3O)O[C@]12C(COC(C)=O)=O QZIYSFVNRMBENV-PONRWWDOSA-N 0.000 description 1
- OJOPUJYDZMXNES-JEWNNFKDSA-N CCCC(O[C@@H]1C[C@@H]([C@H](CC2)[C@H]3[C@@](C)(C=C4)C2=CC4=O)[C@]2(C)C[C@@H]3OP(O)(OP(O)(OCCNC(COC3C(C)=CCCCCC3)=O)=O)=O)O[C@]12C(CO)=O Chemical compound CCCC(O[C@@H]1C[C@@H]([C@H](CC2)[C@H]3[C@@](C)(C=C4)C2=CC4=O)[C@]2(C)C[C@@H]3OP(O)(OP(O)(OCCNC(COC3C(C)=CCCCCC3)=O)=O)=O)O[C@]12C(CO)=O OJOPUJYDZMXNES-JEWNNFKDSA-N 0.000 description 1
- KXLXPCKKOPEKQN-RTAVPFKQSA-N CCCC(O[C@@H]1C[C@@H]([C@H](CC2)[C@H]3[C@@](C)(C=C4)C2=CC4=O)[C@]2(C)C[C@@H]3OP(O)(OP(O)(OCCNC(COC3C4C=CC4CCCCC3)=O)=O)=O)O[C@]12C(COC(C)=O)=O Chemical compound CCCC(O[C@@H]1C[C@@H]([C@H](CC2)[C@H]3[C@@](C)(C=C4)C2=CC4=O)[C@]2(C)C[C@@H]3OP(O)(OP(O)(OCCNC(COC3C4C=CC4CCCCC3)=O)=O)=O)O[C@]12C(COC(C)=O)=O KXLXPCKKOPEKQN-RTAVPFKQSA-N 0.000 description 1
- CBCAKZONFALCCU-WKETUCSNSA-N CCCC(O[C@@H]1C[C@@H]([C@H](CC2)[C@H]3[C@@](C)(C=C4)C2=CC4=O)[C@]2(C)C[C@@H]3OP(O)(OP(O)(OCCNC(OCC3c4ccccc4-c4c3cccc4)=O)=O)=O)O[C@]12C(COC(C)=O)=O Chemical compound CCCC(O[C@@H]1C[C@@H]([C@H](CC2)[C@H]3[C@@](C)(C=C4)C2=CC4=O)[C@]2(C)C[C@@H]3OP(O)(OP(O)(OCCNC(OCC3c4ccccc4-c4c3cccc4)=O)=O)=O)O[C@]12C(COC(C)=O)=O CBCAKZONFALCCU-WKETUCSNSA-N 0.000 description 1
- FFVSPXBGPWTTDI-RAEXUPQFSA-N CCCC1O[C@H](C[C@@H]([C@H](CC2)[C@H]3[C@@](C)(C=C4)C2=CC4=O)[C@@](C)(CC(COC(C)=O)=O)C[C@@H]3OP(O)(OP(O)(OCCN)=O)=O)CO1 Chemical compound CCCC1O[C@H](C[C@@H]([C@H](CC2)[C@H]3[C@@](C)(C=C4)C2=CC4=O)[C@@](C)(CC(COC(C)=O)=O)C[C@@H]3OP(O)(OP(O)(OCCN)=O)=O)CO1 FFVSPXBGPWTTDI-RAEXUPQFSA-N 0.000 description 1
- ZRVIHIHTDPBEDE-UHFFFAOYSA-N CCOBO Chemical compound CCOBO ZRVIHIHTDPBEDE-UHFFFAOYSA-N 0.000 description 1
- ATOPUGWGPRXHNO-UHFFFAOYSA-O CCOC1CC2[NH2+]N=NC2CCCC1 Chemical compound CCOC1CC2[NH2+]N=NC2CCCC1 ATOPUGWGPRXHNO-UHFFFAOYSA-O 0.000 description 1
- 108010029697 CD40 Ligand Proteins 0.000 description 1
- 102100032937 CD40 ligand Human genes 0.000 description 1
- 108010065524 CD52 Antigen Proteins 0.000 description 1
- ZUDQNKKQCRIORG-CQRCZTONSA-N C[C@H](C[C@@H]([C@H](C[C@@H](C([C@]1(C)C=C2)=CC2=O)F)[C@@]11F)[C@]2(C)C[C@@H]1OP(O)(O)=O)[C@@]2(C(SC[F]C1)=O)OC1=O Chemical compound C[C@H](C[C@@H]([C@H](C[C@@H](C([C@]1(C)C=C2)=CC2=O)F)[C@@]11F)[C@]2(C)C[C@@H]1OP(O)(O)=O)[C@@]2(C(SC[F]C1)=O)OC1=O ZUDQNKKQCRIORG-CQRCZTONSA-N 0.000 description 1
- DCERHCFNWRGHLK-UHFFFAOYSA-N C[Si](C)C Chemical compound C[Si](C)C DCERHCFNWRGHLK-UHFFFAOYSA-N 0.000 description 1
- 241000283707 Capra Species 0.000 description 1
- OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical group [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 description 1
- 102000004171 Cathepsin K Human genes 0.000 description 1
- 108090000625 Cathepsin K Proteins 0.000 description 1
- 238000003734 CellTiter-Glo Luminescent Cell Viability Assay Methods 0.000 description 1
- 208000001333 Colorectal Neoplasms Diseases 0.000 description 1
- 108010047041 Complementarity Determining Regions Proteins 0.000 description 1
- 229920002261 Corn starch Polymers 0.000 description 1
- 241000557626 Corvus corax Species 0.000 description 1
- 102000005927 Cysteine Proteases Human genes 0.000 description 1
- 108010005843 Cysteine Proteases Proteins 0.000 description 1
- 102100039498 Cytotoxic T-lymphocyte protein 4 Human genes 0.000 description 1
- FBPFZTCFMRRESA-KVTDHHQDSA-N D-Mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 description 1
- 239000012625 DNA intercalator Substances 0.000 description 1
- 230000006820 DNA synthesis Effects 0.000 description 1
- 229920002307 Dextran Polymers 0.000 description 1
- 239000004338 Dichlorodifluoromethane Substances 0.000 description 1
- 108010016626 Dipeptides Proteins 0.000 description 1
- SNRUBQQJIBEYMU-UHFFFAOYSA-N Dodecane Natural products CCCCCCCCCCCC SNRUBQQJIBEYMU-UHFFFAOYSA-N 0.000 description 1
- LVGKNOAMLMIIKO-UHFFFAOYSA-N Elaidinsaeure-aethylester Natural products CCCCCCCCC=CCCCCCCCC(=O)OCC LVGKNOAMLMIIKO-UHFFFAOYSA-N 0.000 description 1
- 241000792859 Enema Species 0.000 description 1
- PIICEJLVQHRZGT-UHFFFAOYSA-N Ethylenediamine Chemical compound NCCN PIICEJLVQHRZGT-UHFFFAOYSA-N 0.000 description 1
- BDAGIHXWWSANSR-UHFFFAOYSA-M Formate Chemical compound [O-]C=O BDAGIHXWWSANSR-UHFFFAOYSA-M 0.000 description 1
- 240000005702 Galium aparine Species 0.000 description 1
- 235000014820 Galium aparine Nutrition 0.000 description 1
- 102100041003 Glutamate carboxypeptidase 2 Human genes 0.000 description 1
- 244000041633 Grewia tenax Species 0.000 description 1
- 235000005612 Grewia tenax Nutrition 0.000 description 1
- 229920000084 Gum arabic Polymers 0.000 description 1
- 102100030595 HLA class II histocompatibility antigen gamma chain Human genes 0.000 description 1
- 101000638510 Homo sapiens Acyl-coenzyme A thioesterase THEM4 Proteins 0.000 description 1
- 101000884305 Homo sapiens B-cell receptor CD22 Proteins 0.000 description 1
- 101000897405 Homo sapiens B-lymphocyte antigen CD20 Proteins 0.000 description 1
- 101000889276 Homo sapiens Cytotoxic T-lymphocyte protein 4 Proteins 0.000 description 1
- 101000892862 Homo sapiens Glutamate carboxypeptidase 2 Proteins 0.000 description 1
- 101001066129 Homo sapiens Glyceraldehyde-3-phosphate dehydrogenase Proteins 0.000 description 1
- 101001082627 Homo sapiens HLA class II histocompatibility antigen gamma chain Proteins 0.000 description 1
- 101000878605 Homo sapiens Low affinity immunoglobulin epsilon Fc receptor Proteins 0.000 description 1
- 101000934338 Homo sapiens Myeloid cell surface antigen CD33 Proteins 0.000 description 1
- 101000914484 Homo sapiens T-lymphocyte activation antigen CD80 Proteins 0.000 description 1
- 101000851376 Homo sapiens Tumor necrosis factor receptor superfamily member 8 Proteins 0.000 description 1
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 1
- 102000009786 Immunoglobulin Constant Regions Human genes 0.000 description 1
- 108010009817 Immunoglobulin Constant Regions Proteins 0.000 description 1
- 108010067060 Immunoglobulin Variable Region Proteins 0.000 description 1
- 102000017727 Immunoglobulin Variable Region Human genes 0.000 description 1
- 102100038007 Low affinity immunoglobulin epsilon Fc receptor Human genes 0.000 description 1
- 208000031422 Lymphocytic Chronic B-Cell Leukemia Diseases 0.000 description 1
- 235000019759 Maize starch Nutrition 0.000 description 1
- 229930195725 Mannitol Natural products 0.000 description 1
- 229930192392 Mitomycin Natural products 0.000 description 1
- FNJSWIPFHMKRAT-UHFFFAOYSA-N Monomethyl phthalate Chemical compound COC(=O)C1=CC=CC=C1C(O)=O FNJSWIPFHMKRAT-UHFFFAOYSA-N 0.000 description 1
- 208000033776 Myeloid Acute Leukemia Diseases 0.000 description 1
- 102100025243 Myeloid cell surface antigen CD33 Human genes 0.000 description 1
- HSHXDCVZWHOWCS-UHFFFAOYSA-N N'-hexadecylthiophene-2-carbohydrazide Chemical compound CCCCCCCCCCCCCCCCNNC(=O)c1cccs1 HSHXDCVZWHOWCS-UHFFFAOYSA-N 0.000 description 1
- NIPNSKYNPDTRPC-UHFFFAOYSA-N N-[2-oxo-2-(2,4,6,7-tetrahydrotriazolo[4,5-c]pyridin-5-yl)ethyl]-2-[[3-(trifluoromethoxy)phenyl]methylamino]pyrimidine-5-carboxamide Chemical compound O=C(CNC(=O)C=1C=NC(=NC=1)NCC1=CC(=CC=C1)OC(F)(F)F)N1CC2=C(CC1)NN=N2 NIPNSKYNPDTRPC-UHFFFAOYSA-N 0.000 description 1
- XUYPXLNMDZIRQH-LURJTMIESA-N N-acetyl-L-methionine Chemical class CSCC[C@@H](C(O)=O)NC(C)=O XUYPXLNMDZIRQH-LURJTMIESA-N 0.000 description 1
- 229910017974 NH40H Inorganic materials 0.000 description 1
- 229910002651 NO3 Inorganic materials 0.000 description 1
- DFPAKSUCGFBDDF-UHFFFAOYSA-N Nicotinamide Chemical class NC(=O)C1=CC=CN=C1 DFPAKSUCGFBDDF-UHFFFAOYSA-N 0.000 description 1
- NHNBFGGVMKEFGY-UHFFFAOYSA-N Nitrate Chemical compound [O-][N+]([O-])=O NHNBFGGVMKEFGY-UHFFFAOYSA-N 0.000 description 1
- ZJOMNAZJZGTYIH-UHFFFAOYSA-N OC(C(C1)S)NC1=O Chemical compound OC(C(C1)S)NC1=O ZJOMNAZJZGTYIH-UHFFFAOYSA-N 0.000 description 1
- 108010038807 Oligopeptides Proteins 0.000 description 1
- 102000015636 Oligopeptides Human genes 0.000 description 1
- 241000283973 Oryctolagus cuniculus Species 0.000 description 1
- 102000017795 Perilipin-1 Human genes 0.000 description 1
- 108010067162 Perilipin-1 Proteins 0.000 description 1
- 206010057249 Phagocytosis Diseases 0.000 description 1
- 239000002202 Polyethylene glycol Substances 0.000 description 1
- 206010060862 Prostate cancer Diseases 0.000 description 1
- 208000004403 Prostatic Hyperplasia Diseases 0.000 description 1
- 208000000236 Prostatic Neoplasms Diseases 0.000 description 1
- 102000001708 Protein Isoforms Human genes 0.000 description 1
- 108010029485 Protein Isoforms Proteins 0.000 description 1
- 206010037549 Purpura Diseases 0.000 description 1
- 241001672981 Purpura Species 0.000 description 1
- 230000006819 RNA synthesis Effects 0.000 description 1
- 108020004511 Recombinant DNA Proteins 0.000 description 1
- 241000283984 Rodentia Species 0.000 description 1
- 239000006146 Roswell Park Memorial Institute medium Substances 0.000 description 1
- 229920002125 Sokalan® Polymers 0.000 description 1
- 108010090804 Streptavidin Proteins 0.000 description 1
- 229930006000 Sucrose Natural products 0.000 description 1
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 1
- QAOWNCQODCNURD-UHFFFAOYSA-L Sulfate Chemical compound [O-]S([O-])(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-L 0.000 description 1
- 206010042971 T-cell lymphoma Diseases 0.000 description 1
- 102100027222 T-lymphocyte activation antigen CD80 Human genes 0.000 description 1
- 229920001615 Tragacanth Polymers 0.000 description 1
- DTQVDTLACAAQTR-UHFFFAOYSA-M Trifluoroacetate Chemical compound [O-]C(=O)C(F)(F)F DTQVDTLACAAQTR-UHFFFAOYSA-M 0.000 description 1
- 102100036857 Tumor necrosis factor receptor superfamily member 8 Human genes 0.000 description 1
- 241000863480 Vinca Species 0.000 description 1
- CLPYVPMXLNNKLB-UHFFFAOYSA-N [(2-nitrophenyl)-phenylmethyl] carbamate Chemical compound C=1C=CC=C([N+]([O-])=O)C=1C(OC(=O)N)C1=CC=CC=C1 CLPYVPMXLNNKLB-UHFFFAOYSA-N 0.000 description 1
- LXKLUWFIBVXFGX-QPJJXVBHSA-N [(e)-3-phenylprop-2-enyl] carbamate Chemical compound NC(=O)OC\C=C\C1=CC=CC=C1 LXKLUWFIBVXFGX-QPJJXVBHSA-N 0.000 description 1
- MQLDYIKXBMSDCL-UHFFFAOYSA-N [2,4-bis(methylsulfanyl)phenyl] carbamate Chemical compound CSC1=CC=C(OC(N)=O)C(SC)=C1 MQLDYIKXBMSDCL-UHFFFAOYSA-N 0.000 description 1
- OJUHIDQVEFLXSE-UHFFFAOYSA-N [2-(4-methoxyphenyl)-2-oxoethyl] carbamate Chemical compound COC1=CC=C(C(=O)COC(N)=O)C=C1 OJUHIDQVEFLXSE-UHFFFAOYSA-N 0.000 description 1
- 235000010489 acacia gum Nutrition 0.000 description 1
- 239000000205 acacia gum Substances 0.000 description 1
- 150000001241 acetals Chemical class 0.000 description 1
- 229940022663 acetate Drugs 0.000 description 1
- DPXJVFZANSGRMM-UHFFFAOYSA-N acetic acid;2,3,4,5,6-pentahydroxyhexanal;sodium Chemical compound [Na].CC(O)=O.OCC(O)C(O)C(O)C(O)C=O DPXJVFZANSGRMM-UHFFFAOYSA-N 0.000 description 1
- GCPWJFKTWGFEHH-UHFFFAOYSA-N acetoacetamide Chemical compound CC(=O)CC(N)=O GCPWJFKTWGFEHH-UHFFFAOYSA-N 0.000 description 1
- 230000021736 acetylation Effects 0.000 description 1
- 238000006640 acetylation reaction Methods 0.000 description 1
- 238000005903 acid hydrolysis reaction Methods 0.000 description 1
- 125000000641 acridinyl group Chemical group C1(=CC=CC2=NC3=CC=CC=C3C=C12)* 0.000 description 1
- 230000009471 action Effects 0.000 description 1
- 230000004913 activation Effects 0.000 description 1
- 125000004423 acyloxy group Chemical group 0.000 description 1
- 125000005585 adamantoate group Chemical group 0.000 description 1
- 230000002411 adverse Effects 0.000 description 1
- 235000004279 alanine Nutrition 0.000 description 1
- 125000003295 alanine group Chemical group N[C@@H](C)C(=O)* 0.000 description 1
- 125000003282 alkyl amino group Chemical group 0.000 description 1
- 125000002877 alkyl aryl group Chemical group 0.000 description 1
- 125000006177 alkyl benzyl group Chemical group 0.000 description 1
- HSFWRNGVRCDJHI-UHFFFAOYSA-N alpha-acetylene Natural products C#C HSFWRNGVRCDJHI-UHFFFAOYSA-N 0.000 description 1
- 229910000147 aluminium phosphate Inorganic materials 0.000 description 1
- 235000011114 ammonium hydroxide Nutrition 0.000 description 1
- 229940035676 analgesics Drugs 0.000 description 1
- 239000002870 angiogenesis inducing agent Substances 0.000 description 1
- 150000008064 anhydrides Chemical class 0.000 description 1
- 238000000137 annealing Methods 0.000 description 1
- 239000005557 antagonist Substances 0.000 description 1
- 239000000730 antalgic agent Substances 0.000 description 1
- DQEFBVRIBYYPLE-UHFFFAOYSA-N anthracen-9-ylmethyl carbamate Chemical compound C1=CC=C2C(COC(=O)N)=C(C=CC=C3)C3=CC2=C1 DQEFBVRIBYYPLE-UHFFFAOYSA-N 0.000 description 1
- FKFZOFZWJNHJDE-UHFFFAOYSA-N anthracene-9-sulfonamide Chemical compound C1=CC=C2C(S(=O)(=O)N)=C(C=CC=C3)C3=CC2=C1 FKFZOFZWJNHJDE-UHFFFAOYSA-N 0.000 description 1
- 229940045799 anthracyclines and related substance Drugs 0.000 description 1
- 125000005428 anthryl group Chemical group [H]C1=C([H])C([H])=C2C([H])=C3C(*)=C([H])C([H])=C([H])C3=C([H])C2=C1[H] 0.000 description 1
- 239000003242 anti bacterial agent Substances 0.000 description 1
- 230000001772 anti-angiogenic effect Effects 0.000 description 1
- 230000001078 anti-cholinergic effect Effects 0.000 description 1
- 230000001773 anti-convulsant effect Effects 0.000 description 1
- 230000001430 anti-depressive effect Effects 0.000 description 1
- 230000003178 anti-diabetic effect Effects 0.000 description 1
- 230000003474 anti-emetic effect Effects 0.000 description 1
- 230000001384 anti-glaucoma Effects 0.000 description 1
- 230000001387 anti-histamine Effects 0.000 description 1
- 230000003276 anti-hypertensive effect Effects 0.000 description 1
- 230000002141 anti-parasite Effects 0.000 description 1
- 230000000648 anti-parkinson Effects 0.000 description 1
- 230000000842 anti-protozoal effect Effects 0.000 description 1
- 230000000561 anti-psychotic effect Effects 0.000 description 1
- 230000001754 anti-pyretic effect Effects 0.000 description 1
- 230000001262 anti-secretory effect Effects 0.000 description 1
- 230000002921 anti-spasmodic effect Effects 0.000 description 1
- 230000000259 anti-tumor effect Effects 0.000 description 1
- 230000000840 anti-viral effect Effects 0.000 description 1
- 229940088710 antibiotic agent Drugs 0.000 description 1
- 229940065524 anticholinergics inhalants for obstructive airway diseases Drugs 0.000 description 1
- 229940125681 anticonvulsant agent Drugs 0.000 description 1
- 239000001961 anticonvulsive agent Substances 0.000 description 1
- 239000000935 antidepressant agent Substances 0.000 description 1
- 229940005513 antidepressants Drugs 0.000 description 1
- 239000003472 antidiabetic agent Substances 0.000 description 1
- 239000002111 antiemetic agent Substances 0.000 description 1
- 229940125683 antiemetic agent Drugs 0.000 description 1
- 230000000890 antigenic effect Effects 0.000 description 1
- 239000000739 antihistaminic agent Substances 0.000 description 1
- 229940125715 antihistaminic agent Drugs 0.000 description 1
- 239000002220 antihypertensive agent Substances 0.000 description 1
- 229940030600 antihypertensive agent Drugs 0.000 description 1
- 239000000939 antiparkinson agent Substances 0.000 description 1
- 239000003904 antiprotozoal agent Substances 0.000 description 1
- 239000002221 antipyretic Substances 0.000 description 1
- 229940125716 antipyretic agent Drugs 0.000 description 1
- 229940124575 antispasmodic agent Drugs 0.000 description 1
- 229960004676 antithrombotic agent Drugs 0.000 description 1
- 239000012736 aqueous medium Substances 0.000 description 1
- 239000008135 aqueous vehicle Substances 0.000 description 1
- 150000004982 aromatic amines Chemical class 0.000 description 1
- 125000001769 aryl amino group Chemical group 0.000 description 1
- 125000005160 aryl oxy alkyl group Chemical group 0.000 description 1
- 208000006673 asthma Diseases 0.000 description 1
- 230000004888 barrier function Effects 0.000 description 1
- 230000008901 benefit Effects 0.000 description 1
- DUXANUSOCMOJSI-UHFFFAOYSA-N benzhydryl carbamate Chemical compound C=1C=CC=CC=1C(OC(=O)N)C1=CC=CC=C1 DUXANUSOCMOJSI-UHFFFAOYSA-N 0.000 description 1
- 125000003785 benzimidazolyl group Chemical group N1=C(NC2=C1C=CC=C2)* 0.000 description 1
- 125000004604 benzisothiazolyl group Chemical group S1N=C(C2=C1C=CC=C2)* 0.000 description 1
- 125000000499 benzofuranyl group Chemical group O1C(=CC2=C1C=CC=C2)* 0.000 description 1
- WPYMKLBDIGXBTP-UHFFFAOYSA-N benzoic acid Chemical compound OC(=O)C1=CC=CC=C1 WPYMKLBDIGXBTP-UHFFFAOYSA-N 0.000 description 1
- 125000001164 benzothiazolyl group Chemical group S1C(=NC2=C1C=CC=C2)* 0.000 description 1
- 125000004196 benzothienyl group Chemical group S1C(=CC2=C1C=CC=C2)* 0.000 description 1
- 235000019400 benzoyl peroxide Nutrition 0.000 description 1
- 125000000649 benzylidene group Chemical group [H]C(=[*])C1=C([H])C([H])=C([H])C([H])=C1[H] 0.000 description 1
- XMIIGOLPHOKFCH-UHFFFAOYSA-N beta-phenylpropanoic acid Natural products OC(=O)CCC1=CC=CC=C1 XMIIGOLPHOKFCH-UHFFFAOYSA-N 0.000 description 1
- 125000002618 bicyclic heterocycle group Chemical group 0.000 description 1
- 230000001588 bifunctional effect Effects 0.000 description 1
- 239000011230 binding agent Substances 0.000 description 1
- 229960000074 biopharmaceutical Drugs 0.000 description 1
- 239000004305 biphenyl Substances 0.000 description 1
- 235000010290 biphenyl Nutrition 0.000 description 1
- HROGQYMZWGPHIB-UHFFFAOYSA-N bis(4-methoxyphenyl)methanamine Chemical compound C1=CC(OC)=CC=C1C(N)C1=CC=C(OC)C=C1 HROGQYMZWGPHIB-UHFFFAOYSA-N 0.000 description 1
- JKJWYKGYGWOAHT-UHFFFAOYSA-N bis(prop-2-enyl) carbonate Chemical compound C=CCOC(=O)OCC=C JKJWYKGYGWOAHT-UHFFFAOYSA-N 0.000 description 1
- OYVAGSVQBOHSSS-UAPAGMARSA-O bleomycin A2 Chemical class N([C@H](C(=O)N[C@H](C)[C@@H](O)[C@H](C)C(=O)N[C@@H]([C@H](O)C)C(=O)NCCC=1SC=C(N=1)C=1SC=C(N=1)C(=O)NCCC[S+](C)C)[C@@H](O[C@H]1[C@H]([C@@H](O)[C@H](O)[C@H](CO)O1)O[C@@H]1[C@H]([C@@H](OC(N)=O)[C@H](O)[C@@H](CO)O1)O)C=1N=CNC=1)C(=O)C1=NC([C@H](CC(N)=O)NC[C@H](N)C(N)=O)=NC(N)=C1C OYVAGSVQBOHSSS-UAPAGMARSA-O 0.000 description 1
- 229920001400 block copolymer Polymers 0.000 description 1
- 201000008274 breast adenocarcinoma Diseases 0.000 description 1
- 125000004369 butenyl group Chemical group C(=CCC)* 0.000 description 1
- 230000000981 bystander Effects 0.000 description 1
- 238000010804 cDNA synthesis Methods 0.000 description 1
- 229910000019 calcium carbonate Inorganic materials 0.000 description 1
- 239000001506 calcium phosphate Substances 0.000 description 1
- 229910000389 calcium phosphate Inorganic materials 0.000 description 1
- 235000011010 calcium phosphates Nutrition 0.000 description 1
- 239000012830 cancer therapeutic Substances 0.000 description 1
- 125000000609 carbazolyl group Chemical group C1(=CC=CC=2C3=CC=CC=C3NC12)* 0.000 description 1
- 229960004424 carbon dioxide Drugs 0.000 description 1
- BVKZGUZCCUSVTD-UHFFFAOYSA-N carbonic acid Chemical class OC(O)=O BVKZGUZCCUSVTD-UHFFFAOYSA-N 0.000 description 1
- AOGYCOYQMAVAFD-UHFFFAOYSA-M carbonochloridate Chemical compound [O-]C(Cl)=O AOGYCOYQMAVAFD-UHFFFAOYSA-M 0.000 description 1
- 239000001768 carboxy methyl cellulose Substances 0.000 description 1
- 239000005018 casein Substances 0.000 description 1
- BECPQYXYKAMYBN-UHFFFAOYSA-N casein, tech. Chemical compound NCCCCC(C(O)=O)N=C(O)C(CC(O)=O)N=C(O)C(CCC(O)=N)N=C(O)C(CC(C)C)N=C(O)C(CCC(O)=O)N=C(O)C(CC(O)=O)N=C(O)C(CCC(O)=O)N=C(O)C(C(C)O)N=C(O)C(CCC(O)=N)N=C(O)C(CCC(O)=N)N=C(O)C(CCC(O)=N)N=C(O)C(CCC(O)=O)N=C(O)C(CCC(O)=O)N=C(O)C(COP(O)(O)=O)N=C(O)C(CCC(O)=N)N=C(O)C(N)CC1=CC=CC=C1 BECPQYXYKAMYBN-UHFFFAOYSA-N 0.000 description 1
- 235000021240 caseins Nutrition 0.000 description 1
- 238000004113 cell culture Methods 0.000 description 1
- 230000006037 cell lysis Effects 0.000 description 1
- 210000000170 cell membrane Anatomy 0.000 description 1
- 229910052729 chemical element Inorganic materials 0.000 description 1
- 238000007385 chemical modification Methods 0.000 description 1
- 230000000973 chemotherapeutic effect Effects 0.000 description 1
- 125000001309 chloro group Chemical group Cl* 0.000 description 1
- VXIVSQZSERGHQP-UHFFFAOYSA-N chloroacetamide Chemical class NC(=O)CCl VXIVSQZSERGHQP-UHFFFAOYSA-N 0.000 description 1
- 229940089960 chloroacetate Drugs 0.000 description 1
- FOCAUTSVDIKZOP-UHFFFAOYSA-M chloroacetate Chemical compound [O-]C(=O)CCl FOCAUTSVDIKZOP-UHFFFAOYSA-M 0.000 description 1
- AOGYCOYQMAVAFD-UHFFFAOYSA-N chlorocarbonic acid Chemical class OC(Cl)=O AOGYCOYQMAVAFD-UHFFFAOYSA-N 0.000 description 1
- 239000000812 cholinergic antagonist Substances 0.000 description 1
- 125000003016 chromanyl group Chemical group O1C(CCC2=CC=CC=C12)* 0.000 description 1
- 238000004587 chromatography analysis Methods 0.000 description 1
- 208000032852 chronic lymphocytic leukemia Diseases 0.000 description 1
- 125000000259 cinnolinyl group Chemical group N1=NC(=CC2=CC=CC=C12)* 0.000 description 1
- 229940110456 cocoa butter Drugs 0.000 description 1
- 235000019868 cocoa butter Nutrition 0.000 description 1
- 230000004540 complement-dependent cytotoxicity Effects 0.000 description 1
- 238000001816 cooling Methods 0.000 description 1
- 229920001577 copolymer Polymers 0.000 description 1
- 229910052802 copper Inorganic materials 0.000 description 1
- 239000010949 copper Substances 0.000 description 1
- LDHQCZJRKDOVOX-NSCUHMNNSA-N crotonic acid Chemical compound C\C=C\C(O)=O LDHQCZJRKDOVOX-NSCUHMNNSA-N 0.000 description 1
- 150000005676 cyclic carbonates Chemical class 0.000 description 1
- 125000000392 cycloalkenyl group Chemical group 0.000 description 1
- LWABFMLTBBNLTA-UHFFFAOYSA-N cyclobutyl carbamate Chemical compound NC(=O)OC1CCC1 LWABFMLTBBNLTA-UHFFFAOYSA-N 0.000 description 1
- 125000001995 cyclobutyl group Chemical group [H]C1([H])C([H])([H])C([H])(*)C1([H])[H] 0.000 description 1
- 125000001162 cycloheptenyl group Chemical group C1(=CCCCCC1)* 0.000 description 1
- 125000000582 cycloheptyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])([H])C([H])(*)C([H])([H])C1([H])[H] 0.000 description 1
- NNGAQKAUYDTUQR-UHFFFAOYSA-N cyclohexanimine Chemical compound N=C1CCCCC1 NNGAQKAUYDTUQR-UHFFFAOYSA-N 0.000 description 1
- UKJLNMAFNRKWGR-UHFFFAOYSA-N cyclohexatrienamine Chemical group NC1=CC=C=C[CH]1 UKJLNMAFNRKWGR-UHFFFAOYSA-N 0.000 description 1
- 125000000596 cyclohexenyl group Chemical group C1(=CCCCC1)* 0.000 description 1
- AUELWJRRASQDKI-UHFFFAOYSA-N cyclohexyl carbamate Chemical compound NC(=O)OC1CCCCC1 AUELWJRRASQDKI-UHFFFAOYSA-N 0.000 description 1
- 125000000113 cyclohexyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])(*)C([H])([H])C1([H])[H] 0.000 description 1
- FNIATMYXUPOJRW-UHFFFAOYSA-N cyclohexylidene Chemical group [C]1CCCCC1 FNIATMYXUPOJRW-UHFFFAOYSA-N 0.000 description 1
- 125000000522 cyclooctenyl group Chemical group C1(=CCCCCCC1)* 0.000 description 1
- 125000000640 cyclooctyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])([H])C([H])(*)C([H])([H])C([H])([H])C1([H])[H] 0.000 description 1
- ZPWOOKQUDFIEIX-UHFFFAOYSA-N cyclooctyne Chemical compound C1CCCC#CCC1 ZPWOOKQUDFIEIX-UHFFFAOYSA-N 0.000 description 1
- 125000002433 cyclopentenyl group Chemical group C1(=CCCC1)* 0.000 description 1
- JMFVWNKPLURQMI-UHFFFAOYSA-N cyclopentyl carbamate Chemical compound NC(=O)OC1CCCC1 JMFVWNKPLURQMI-UHFFFAOYSA-N 0.000 description 1
- 125000001511 cyclopentyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])(*)C1([H])[H] 0.000 description 1
- PWAPCRSSMCLZHG-UHFFFAOYSA-N cyclopentylidene Chemical group [C]1CCCC1 PWAPCRSSMCLZHG-UHFFFAOYSA-N 0.000 description 1
- 125000001559 cyclopropyl group Chemical group [H]C1([H])C([H])([H])C1([H])* 0.000 description 1
- UWYRVVJXSNXVAI-UHFFFAOYSA-N cyclopropylmethyl carbamate Chemical compound NC(=O)OCC1CC1 UWYRVVJXSNXVAI-UHFFFAOYSA-N 0.000 description 1
- 239000000824 cytostatic agent Substances 0.000 description 1
- 238000007405 data analysis Methods 0.000 description 1
- 125000004856 decahydroquinolinyl group Chemical group N1(CCCC2CCCCC12)* 0.000 description 1
- 239000003405 delayed action preparation Substances 0.000 description 1
- 238000011161 development Methods 0.000 description 1
- 206010012601 diabetes mellitus Diseases 0.000 description 1
- 238000003745 diagnosis Methods 0.000 description 1
- 125000002576 diazepinyl group Chemical group N1N=C(C=CC=C1)* 0.000 description 1
- 229940120124 dichloroacetate Drugs 0.000 description 1
- JXTHNDFMNIQAHM-UHFFFAOYSA-N dichloroacetic acid Chemical compound OC(=O)C(Cl)Cl JXTHNDFMNIQAHM-UHFFFAOYSA-N 0.000 description 1
- PXBRQCKWGAHEHS-UHFFFAOYSA-N dichlorodifluoromethane Chemical compound FC(F)(Cl)Cl PXBRQCKWGAHEHS-UHFFFAOYSA-N 0.000 description 1
- 235000019404 dichlorodifluoromethane Nutrition 0.000 description 1
- 229940042935 dichlorodifluoromethane Drugs 0.000 description 1
- BLEBFDYUDVZRFG-UHFFFAOYSA-N dichloromethane;propan-2-ol Chemical compound ClCCl.CC(C)O BLEBFDYUDVZRFG-UHFFFAOYSA-N 0.000 description 1
- 229940087091 dichlorotetrafluoroethane Drugs 0.000 description 1
- 235000014113 dietary fatty acids Nutrition 0.000 description 1
- 230000004069 differentiation Effects 0.000 description 1
- 238000009792 diffusion process Methods 0.000 description 1
- 239000003166 dihydrofolate reductase inhibitor Substances 0.000 description 1
- 239000003085 diluting agent Substances 0.000 description 1
- DCYUBZJZSBAWEZ-UHFFFAOYSA-N dimethyl 2-(carbamoyloxymethylidene)propanedioate Chemical compound COC(=O)C(C(=O)OC)=COC(N)=O DCYUBZJZSBAWEZ-UHFFFAOYSA-N 0.000 description 1
- 125000000532 dioxanyl group Chemical group 0.000 description 1
- 125000005879 dioxolanyl group Chemical group 0.000 description 1
- SXZIXHOMFPUIRK-UHFFFAOYSA-N diphenylmethanimine Chemical compound C=1C=CC=CC=1C(=N)C1=CC=CC=C1 SXZIXHOMFPUIRK-UHFFFAOYSA-N 0.000 description 1
- SEBARIVPCNBHKO-UHFFFAOYSA-N dipyridin-2-ylmethyl carbamate Chemical compound C=1C=CC=NC=1C(OC(=O)N)C1=CC=CC=N1 SEBARIVPCNBHKO-UHFFFAOYSA-N 0.000 description 1
- 230000006806 disease prevention Effects 0.000 description 1
- 239000002270 dispersing agent Substances 0.000 description 1
- 150000002019 disulfides Chemical class 0.000 description 1
- 125000005883 dithianyl group Chemical group 0.000 description 1
- 239000003534 dna topoisomerase inhibitor Substances 0.000 description 1
- 125000003438 dodecyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])* 0.000 description 1
- 239000002552 dosage form Substances 0.000 description 1
- 238000012377 drug delivery Methods 0.000 description 1
- 238000000132 electrospray ionisation Methods 0.000 description 1
- 238000010828 elution Methods 0.000 description 1
- 230000002121 endocytic effect Effects 0.000 description 1
- 230000012202 endocytosis Effects 0.000 description 1
- 239000007920 enema Substances 0.000 description 1
- 229940079360 enema for constipation Drugs 0.000 description 1
- 238000005516 engineering process Methods 0.000 description 1
- 230000002708 enhancing effect Effects 0.000 description 1
- 230000002255 enzymatic effect Effects 0.000 description 1
- 230000007071 enzymatic hydrolysis Effects 0.000 description 1
- 238000006047 enzymatic hydrolysis reaction Methods 0.000 description 1
- LVGKNOAMLMIIKO-QXMHVHEDSA-N ethyl oleate Chemical compound CCCCCCCC\C=C/CCCCCCCC(=O)OCC LVGKNOAMLMIIKO-QXMHVHEDSA-N 0.000 description 1
- 229940093471 ethyl oleate Drugs 0.000 description 1
- 125000002534 ethynyl group Chemical group [H]C#C* 0.000 description 1
- 229930195729 fatty acid Natural products 0.000 description 1
- 239000000194 fatty acid Substances 0.000 description 1
- FGIVSGPRGVABAB-UHFFFAOYSA-N fluoren-9-ylmethyl hydrogen carbonate Chemical compound C1=CC=C2C(COC(=O)O)C3=CC=CC=C3C2=C1 FGIVSGPRGVABAB-UHFFFAOYSA-N 0.000 description 1
- 125000004216 fluoromethyl group Chemical group [H]C([H])(F)* 0.000 description 1
- 230000037406 food intake Effects 0.000 description 1
- 238000013467 fragmentation Methods 0.000 description 1
- 238000006062 fragmentation reaction Methods 0.000 description 1
- RGEAONPOJJBMHO-UHFFFAOYSA-N furan-2-ylmethyl carbamate Chemical compound NC(=O)OCC1=CC=CO1 RGEAONPOJJBMHO-UHFFFAOYSA-N 0.000 description 1
- 125000002541 furyl group Chemical group 0.000 description 1
- 230000004927 fusion Effects 0.000 description 1
- 125000005456 glyceride group Chemical group 0.000 description 1
- 230000013595 glycosylation Effects 0.000 description 1
- 238000006206 glycosylation reaction Methods 0.000 description 1
- 239000008187 granular material Substances 0.000 description 1
- 238000000227 grinding Methods 0.000 description 1
- 239000003966 growth inhibitor Substances 0.000 description 1
- 125000004404 heteroalkyl group Chemical group 0.000 description 1
- 125000005241 heteroarylamino group Chemical group 0.000 description 1
- 125000004415 heterocyclylalkyl group Chemical group 0.000 description 1
- 230000001632 homeopathic effect Effects 0.000 description 1
- 102000047486 human GAPDH Human genes 0.000 description 1
- 102000053000 human TSC22D3 Human genes 0.000 description 1
- 150000007857 hydrazones Chemical class 0.000 description 1
- 230000003301 hydrolyzing effect Effects 0.000 description 1
- HSNUXDIQZKIQRR-UHFFFAOYSA-N hydroxy-imino-bis(phenylmethoxy)-$l^{5}-phosphane Chemical compound C=1C=CC=CC=1COP(=O)(N)OCC1=CC=CC=C1 HSNUXDIQZKIQRR-UHFFFAOYSA-N 0.000 description 1
- QWMUDOFWQWBHFI-UHFFFAOYSA-N hydroxy-imino-diphenoxy-$l^{5}-phosphane Chemical compound C=1C=CC=CC=1OP(=O)(N)OC1=CC=CC=C1 QWMUDOFWQWBHFI-UHFFFAOYSA-N 0.000 description 1
- RIGIWEGXTTUCIQ-UHFFFAOYSA-N hydroxy-imino-diphenyl-$l^{5}-phosphane Chemical compound C=1C=CC=CC=1P(=O)(N)C1=CC=CC=C1 RIGIWEGXTTUCIQ-UHFFFAOYSA-N 0.000 description 1
- 239000001866 hydroxypropyl methyl cellulose Substances 0.000 description 1
- 235000010979 hydroxypropyl methyl cellulose Nutrition 0.000 description 1
- 229920003088 hydroxypropyl methyl cellulose Polymers 0.000 description 1
- 201000001421 hyperglycemia Diseases 0.000 description 1
- 239000003326 hypnotic agent Substances 0.000 description 1
- 230000000147 hypnotic effect Effects 0.000 description 1
- 239000005457 ice water Substances 0.000 description 1
- 239000012216 imaging agent Substances 0.000 description 1
- 125000002883 imidazolyl group Chemical group 0.000 description 1
- 150000002466 imines Chemical class 0.000 description 1
- 125000001841 imino group Chemical group [H]N=* 0.000 description 1
- 229960003444 immunosuppressant agent Drugs 0.000 description 1
- 239000003018 immunosuppressive agent Substances 0.000 description 1
- 238000002513 implantation Methods 0.000 description 1
- 239000012535 impurity Substances 0.000 description 1
- 125000003453 indazolyl group Chemical group N1N=C(C2=C1C=CC=C2)* 0.000 description 1
- 125000003387 indolinyl group Chemical group N1(CCC2=CC=CC=C12)* 0.000 description 1
- 125000003406 indolizinyl group Chemical group C=1(C=CN2C=CC=CC12)* 0.000 description 1
- 125000001041 indolyl group Chemical group 0.000 description 1
- 239000000411 inducer Substances 0.000 description 1
- 230000001939 inductive effect Effects 0.000 description 1
- 238000001802 infusion Methods 0.000 description 1
- 239000003112 inhibitor Substances 0.000 description 1
- 108040006849 interleukin-2 receptor activity proteins Proteins 0.000 description 1
- 230000000968 intestinal effect Effects 0.000 description 1
- 239000007927 intramuscular injection Substances 0.000 description 1
- 238000010253 intravenous injection Methods 0.000 description 1
- 125000002346 iodo group Chemical group I* 0.000 description 1
- INQOMBQAUSQDDS-UHFFFAOYSA-N iodomethane Chemical compound IC INQOMBQAUSQDDS-UHFFFAOYSA-N 0.000 description 1
- 239000003456 ion exchange resin Substances 0.000 description 1
- 229920003303 ion-exchange polymer Polymers 0.000 description 1
- KQNPFQTWMSNSAP-UHFFFAOYSA-N isobutyric acid Chemical compound CC(C)C(O)=O KQNPFQTWMSNSAP-UHFFFAOYSA-N 0.000 description 1
- 239000012948 isocyanate Substances 0.000 description 1
- 150000002513 isocyanates Chemical class 0.000 description 1
- 125000000904 isoindolyl group Chemical group C=1(NC=C2C=CC=CC12)* 0.000 description 1
- FZWBNHMXJMCXLU-BLAUPYHCSA-N isomaltotriose Chemical compound O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@@H]1OC[C@@H]1[C@@H](O)[C@H](O)[C@@H](O)[C@@H](OC[C@@H](O)[C@@H](O)[C@H](O)[C@@H](O)C=O)O1 FZWBNHMXJMCXLU-BLAUPYHCSA-N 0.000 description 1
- 125000001972 isopentyl group Chemical group [H]C([H])([H])C([H])(C([H])([H])[H])C([H])([H])C([H])([H])* 0.000 description 1
- 125000001449 isopropyl group Chemical group [H]C([H])([H])C([H])(*)C([H])([H])[H] 0.000 description 1
- 125000005956 isoquinolyl group Chemical group 0.000 description 1
- 125000001786 isothiazolyl group Chemical group 0.000 description 1
- 125000000842 isoxazolyl group Chemical group 0.000 description 1
- 230000002147 killing effect Effects 0.000 description 1
- 239000004922 lacquer Substances 0.000 description 1
- 150000003951 lactams Chemical class 0.000 description 1
- 150000002596 lactones Chemical class 0.000 description 1
- 229940058352 levulinate Drugs 0.000 description 1
- 230000000670 limiting effect Effects 0.000 description 1
- 239000002502 liposome Substances 0.000 description 1
- 238000004895 liquid chromatography mass spectrometry Methods 0.000 description 1
- 229940057995 liquid paraffin Drugs 0.000 description 1
- 239000003589 local anesthetic agent Substances 0.000 description 1
- 229960005015 local anesthetics Drugs 0.000 description 1
- 239000007937 lozenge Substances 0.000 description 1
- 125000003588 lysine group Chemical group [H]N([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])(N([H])[H])C(*)=O 0.000 description 1
- 229920002521 macromolecule Polymers 0.000 description 1
- 235000019359 magnesium stearate Nutrition 0.000 description 1
- 239000000594 mannitol Substances 0.000 description 1
- 235000010355 mannitol Nutrition 0.000 description 1
- 239000000463 material Substances 0.000 description 1
- 230000007246 mechanism Effects 0.000 description 1
- 239000002609 medium Substances 0.000 description 1
- 201000001441 melanoma Diseases 0.000 description 1
- 239000012528 membrane Substances 0.000 description 1
- 230000002503 metabolic effect Effects 0.000 description 1
- 206010061289 metastatic neoplasm Diseases 0.000 description 1
- HNQIVZYLYMDVSB-UHFFFAOYSA-N methanesulfonimidic acid Chemical compound CS(N)(=O)=O HNQIVZYLYMDVSB-UHFFFAOYSA-N 0.000 description 1
- RMIODHQZRUFFFF-UHFFFAOYSA-M methoxyacetate Chemical compound COCC([O-])=O RMIODHQZRUFFFF-UHFFFAOYSA-M 0.000 description 1
- BKNCSPZEGXUNTP-UHFFFAOYSA-N methyl (4-nitrophenyl) carbonate Chemical compound COC(=O)OC1=CC=C([N+]([O-])=O)C=C1 BKNCSPZEGXUNTP-UHFFFAOYSA-N 0.000 description 1
- 229920000609 methyl cellulose Polymers 0.000 description 1
- 239000001923 methylcellulose Substances 0.000 description 1
- 235000010981 methylcellulose Nutrition 0.000 description 1
- NYEBKUUITGFJAK-UHFFFAOYSA-N methylsulfanylmethanethioic s-acid Chemical compound CSC(O)=S NYEBKUUITGFJAK-UHFFFAOYSA-N 0.000 description 1
- 230000003547 miosis Effects 0.000 description 1
- 239000003604 miotic agent Substances 0.000 description 1
- 230000000116 mitigating effect Effects 0.000 description 1
- 125000002757 morpholinyl group Chemical group 0.000 description 1
- 210000003205 muscle Anatomy 0.000 description 1
- 229940035363 muscle relaxants Drugs 0.000 description 1
- 239000003158 myorelaxant agent Substances 0.000 description 1
- YNTOKMNHRPSGFU-UHFFFAOYSA-N n-Propyl carbamate Chemical compound CCCOC(N)=O YNTOKMNHRPSGFU-UHFFFAOYSA-N 0.000 description 1
- YOHYSYJDKVYCJI-UHFFFAOYSA-N n-[3-[[6-[3-(trifluoromethyl)anilino]pyrimidin-4-yl]amino]phenyl]cyclopropanecarboxamide Chemical compound FC(F)(F)C1=CC=CC(NC=2N=CN=C(NC=3C=C(NC(=O)C4CC4)C=CC=3)C=2)=C1 YOHYSYJDKVYCJI-UHFFFAOYSA-N 0.000 description 1
- HRTWQKJBXAQOCF-UHFFFAOYSA-N n-benzylidenenitramide Chemical compound [O-][N+](=O)N=CC1=CC=CC=C1 HRTWQKJBXAQOCF-UHFFFAOYSA-N 0.000 description 1
- 125000003136 n-heptyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])* 0.000 description 1
- 125000001280 n-hexyl group Chemical group C(CCCCC)* 0.000 description 1
- 125000000740 n-pentyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])* 0.000 description 1
- 125000004123 n-propyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])* 0.000 description 1
- 125000001624 naphthyl group Chemical group 0.000 description 1
- 125000004593 naphthyridinyl group Chemical group N1=C(C=CC2=CC=CN=C12)* 0.000 description 1
- 239000006199 nebulizer Substances 0.000 description 1
- 125000001971 neopentyl group Chemical group [H]C([*])([H])C(C([H])([H])[H])(C([H])([H])[H])C([H])([H])[H] 0.000 description 1
- 239000002581 neurotoxin Substances 0.000 description 1
- 231100000618 neurotoxin Toxicity 0.000 description 1
- SFDJOSRHYKHMOK-UHFFFAOYSA-N nitramide Chemical compound N[N+]([O-])=O SFDJOSRHYKHMOK-UHFFFAOYSA-N 0.000 description 1
- 150000002829 nitrogen Chemical class 0.000 description 1
- XKLJHFLUAHKGGU-UHFFFAOYSA-N nitrous amide Chemical compound ON=N XKLJHFLUAHKGGU-UHFFFAOYSA-N 0.000 description 1
- 239000000041 non-steroidal anti-inflammatory agent Substances 0.000 description 1
- 229940021182 non-steroidal anti-inflammatory drug Drugs 0.000 description 1
- 125000003835 nucleoside group Chemical group 0.000 description 1
- 238000011275 oncology therapy Methods 0.000 description 1
- 229940005483 opioid analgesics Drugs 0.000 description 1
- 238000005457 optimization Methods 0.000 description 1
- 210000000056 organ Anatomy 0.000 description 1
- 239000012044 organic layer Substances 0.000 description 1
- 239000003960 organic solvent Substances 0.000 description 1
- 239000003791 organic solvent mixture Substances 0.000 description 1
- 229940043515 other immunoglobulins in atc Drugs 0.000 description 1
- 125000001715 oxadiazolyl group Chemical group 0.000 description 1
- 125000000160 oxazolidinyl group Chemical group 0.000 description 1
- 125000002971 oxazolyl group Chemical group 0.000 description 1
- 230000001590 oxidative effect Effects 0.000 description 1
- 125000004043 oxo group Chemical group O=* 0.000 description 1
- 125000004430 oxygen atom Chemical group O* 0.000 description 1
- 229940094443 oxytocics prostaglandins Drugs 0.000 description 1
- 125000006503 p-nitrobenzyl group Chemical group [H]C1=C([H])C(=C([H])C([H])=C1[N+]([O-])=O)C([H])([H])* 0.000 description 1
- 125000000636 p-nitrophenyl group Chemical group [H]C1=C([H])C(=C([H])C([H])=C1*)[N+]([O-])=O 0.000 description 1
- 239000002245 particle Substances 0.000 description 1
- 230000001575 pathological effect Effects 0.000 description 1
- 230000006320 pegylation Effects 0.000 description 1
- 108010011903 peptide receptors Proteins 0.000 description 1
- 102000014187 peptide receptors Human genes 0.000 description 1
- 230000000737 periodic effect Effects 0.000 description 1
- 230000035699 permeability Effects 0.000 description 1
- 230000008782 phagocytosis Effects 0.000 description 1
- YNPNZTXNASCQKK-UHFFFAOYSA-N phenanthrene Chemical compound C1=CC=C2C3=CC=CC=C3C=CC2=C1 YNPNZTXNASCQKK-UHFFFAOYSA-N 0.000 description 1
- 125000004934 phenanthridinyl group Chemical group C1(=CC=CC2=NC=C3C=CC=CC3=C12)* 0.000 description 1
- 125000001791 phenazinyl group Chemical group C1(=CC=CC2=NC3=CC=CC=C3N=C12)* 0.000 description 1
- 125000001484 phenothiazinyl group Chemical group C1(=CC=CC=2SC3=CC=CC=C3NC12)* 0.000 description 1
- 125000001644 phenoxazinyl group Chemical group C1(=CC=CC=2OC3=CC=CC=C3NC12)* 0.000 description 1
- DKTXXUNXVCHYDO-UHFFFAOYSA-N phenoxyborinic acid Chemical compound OBOC1=CC=CC=C1 DKTXXUNXVCHYDO-UHFFFAOYSA-N 0.000 description 1
- BSCCSDNZEIHXOK-UHFFFAOYSA-N phenyl carbamate Chemical compound NC(=O)OC1=CC=CC=C1 BSCCSDNZEIHXOK-UHFFFAOYSA-N 0.000 description 1
- FAQJJMHZNSSFSM-UHFFFAOYSA-N phenylglyoxylic acid Chemical compound OC(=O)C(=O)C1=CC=CC=C1 FAQJJMHZNSSFSM-UHFFFAOYSA-N 0.000 description 1
- ABOYDMHGKWRPFD-UHFFFAOYSA-N phenylmethanesulfonamide Chemical compound NS(=O)(=O)CC1=CC=CC=C1 ABOYDMHGKWRPFD-UHFFFAOYSA-N 0.000 description 1
- NIXKBAZVOQAHGC-UHFFFAOYSA-N phenylmethanesulfonic acid Chemical compound OS(=O)(=O)CC1=CC=CC=C1 NIXKBAZVOQAHGC-UHFFFAOYSA-N 0.000 description 1
- AFDMODCXODAXLC-UHFFFAOYSA-N phenylmethanimine Chemical compound N=CC1=CC=CC=C1 AFDMODCXODAXLC-UHFFFAOYSA-N 0.000 description 1
- PTMHPRAIXMAOOB-UHFFFAOYSA-L phosphoramidate Chemical compound NP([O-])([O-])=O PTMHPRAIXMAOOB-UHFFFAOYSA-L 0.000 description 1
- 150000008298 phosphoramidates Chemical class 0.000 description 1
- FAIAAWCVCHQXDN-UHFFFAOYSA-N phosphorus trichloride Chemical compound ClP(Cl)Cl FAIAAWCVCHQXDN-UHFFFAOYSA-N 0.000 description 1
- 125000004592 phthalazinyl group Chemical group C1(=NN=CC2=CC=CC=C12)* 0.000 description 1
- 239000002504 physiological saline solution Substances 0.000 description 1
- IBBMAWULFFBRKK-UHFFFAOYSA-N picolinamide Chemical class NC(=O)C1=CC=CC=N1 IBBMAWULFFBRKK-UHFFFAOYSA-N 0.000 description 1
- 239000000049 pigment Substances 0.000 description 1
- 239000006187 pill Substances 0.000 description 1
- 125000004193 piperazinyl group Chemical group 0.000 description 1
- 125000003386 piperidinyl group Chemical group 0.000 description 1
- 125000005547 pivalate group Chemical group 0.000 description 1
- 239000004014 plasticizer Substances 0.000 description 1
- 229920001308 poly(aminoacid) Polymers 0.000 description 1
- 239000001103 potassium chloride Substances 0.000 description 1
- 235000011164 potassium chloride Nutrition 0.000 description 1
- 229910000160 potassium phosphate Inorganic materials 0.000 description 1
- 235000011009 potassium phosphates Nutrition 0.000 description 1
- 229920001592 potato starch Polymers 0.000 description 1
- 239000003755 preservative agent Substances 0.000 description 1
- 230000002335 preservative effect Effects 0.000 description 1
- 150000003141 primary amines Chemical class 0.000 description 1
- OCAAZRFBJBEVPS-UHFFFAOYSA-N prop-2-enyl carbamate Chemical compound NC(=O)OCC=C OCAAZRFBJBEVPS-UHFFFAOYSA-N 0.000 description 1
- 239000003380 propellant Substances 0.000 description 1
- 125000004368 propenyl group Chemical group C(=CC)* 0.000 description 1
- 150000003180 prostaglandins Chemical class 0.000 description 1
- 210000002307 prostate Anatomy 0.000 description 1
- 230000007925 protein solubilization Effects 0.000 description 1
- 238000001799 protein solubilization Methods 0.000 description 1
- 238000001243 protein synthesis Methods 0.000 description 1
- 230000006337 proteolytic cleavage Effects 0.000 description 1
- CPNGPNLZQNNVQM-UHFFFAOYSA-N pteridine Chemical compound N1=CN=CC2=NC=CN=C21 CPNGPNLZQNNVQM-UHFFFAOYSA-N 0.000 description 1
- 125000001042 pteridinyl group Chemical group N1=C(N=CC2=NC=CN=C12)* 0.000 description 1
- 125000000561 purinyl group Chemical group N1=C(N=C2N=CNC2=C1)* 0.000 description 1
- 125000003373 pyrazinyl group Chemical group 0.000 description 1
- 125000003226 pyrazolyl group Chemical group 0.000 description 1
- 125000002098 pyridazinyl group Chemical group 0.000 description 1
- RWUGBYOALBYTGU-UHFFFAOYSA-N pyridin-4-ylmethyl carbamate Chemical compound NC(=O)OCC1=CC=NC=C1 RWUGBYOALBYTGU-UHFFFAOYSA-N 0.000 description 1
- 125000004076 pyridyl group Chemical group 0.000 description 1
- 125000000714 pyrimidinyl group Chemical group 0.000 description 1
- 125000000719 pyrrolidinyl group Chemical group 0.000 description 1
- 125000004929 pyrrolidonyl group Chemical group N1(C(CCC1)=O)* 0.000 description 1
- 125000001422 pyrrolinyl group Chemical group 0.000 description 1
- 125000000168 pyrrolyl group Chemical group 0.000 description 1
- 150000003242 quaternary ammonium salts Chemical class 0.000 description 1
- 125000002294 quinazolinyl group Chemical group N1=C(N=CC2=CC=CC=C12)* 0.000 description 1
- FLCPORVHXQFBHT-UHFFFAOYSA-N quinolin-8-yl carbamate Chemical compound C1=CN=C2C(OC(=O)N)=CC=CC2=C1 FLCPORVHXQFBHT-UHFFFAOYSA-N 0.000 description 1
- 125000005493 quinolyl group Chemical group 0.000 description 1
- 125000001567 quinoxalinyl group Chemical group N1=C(C=NC2=CC=CC=C12)* 0.000 description 1
- 125000004621 quinuclidinyl group Chemical group N12C(CC(CC1)CC2)* 0.000 description 1
- 229940044601 receptor agonist Drugs 0.000 description 1
- 239000000018 receptor agonist Substances 0.000 description 1
- 238000011084 recovery Methods 0.000 description 1
- 229940100486 rice starch Drugs 0.000 description 1
- YBKWIGSMABMNJZ-UHFFFAOYSA-N s-(2,3,4,5,6-pentachlorophenyl)thiohydroxylamine Chemical compound NSC1=C(Cl)C(Cl)=C(Cl)C(Cl)=C1Cl YBKWIGSMABMNJZ-UHFFFAOYSA-N 0.000 description 1
- RTKRAORYZUBVGQ-UHFFFAOYSA-N s-(2,4-dinitrophenyl)thiohydroxylamine Chemical compound NSC1=CC=C([N+]([O-])=O)C=C1[N+]([O-])=O RTKRAORYZUBVGQ-UHFFFAOYSA-N 0.000 description 1
- LOVVSIULYJABJF-UHFFFAOYSA-N s-(2-nitrophenyl)thiohydroxylamine Chemical compound NSC1=CC=CC=C1[N+]([O-])=O LOVVSIULYJABJF-UHFFFAOYSA-N 0.000 description 1
- BDEZGPKAMAVGBE-UHFFFAOYSA-N s-(3-nitropyridin-2-yl)thiohydroxylamine Chemical compound NSC1=NC=CC=C1[N+]([O-])=O BDEZGPKAMAVGBE-UHFFFAOYSA-N 0.000 description 1
- DAXSYWBYJZACTA-UHFFFAOYSA-N s-(4-methoxy-2-nitrophenyl)thiohydroxylamine Chemical compound COC1=CC=C(SN)C([N+]([O-])=O)=C1 DAXSYWBYJZACTA-UHFFFAOYSA-N 0.000 description 1
- LOFZYSZWOLKUGE-UHFFFAOYSA-N s-benzyl carbamothioate Chemical compound NC(=O)SCC1=CC=CC=C1 LOFZYSZWOLKUGE-UHFFFAOYSA-N 0.000 description 1
- MAGSSGQAJNNDLU-UHFFFAOYSA-N s-phenylthiohydroxylamine Chemical compound NSC1=CC=CC=C1 MAGSSGQAJNNDLU-UHFFFAOYSA-N 0.000 description 1
- PIDYQAYNSQSDQY-UHFFFAOYSA-N s-tritylthiohydroxylamine Chemical compound C=1C=CC=CC=1C(C=1C=CC=CC=1)(SN)C1=CC=CC=C1 PIDYQAYNSQSDQY-UHFFFAOYSA-N 0.000 description 1
- BPELEZSCHIEMAE-UHFFFAOYSA-N salicylaldehyde imine Chemical compound OC1=CC=CC=C1C=N BPELEZSCHIEMAE-UHFFFAOYSA-N 0.000 description 1
- 125000002914 sec-butyl group Chemical group [H]C([H])([H])C([H])([H])C([H])(*)C([H])([H])[H] 0.000 description 1
- 125000003548 sec-pentyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])(*)C([H])([H])[H] 0.000 description 1
- 150000003335 secondary amines Chemical class 0.000 description 1
- 239000008159 sesame oil Substances 0.000 description 1
- 235000011803 sesame oil Nutrition 0.000 description 1
- 238000003998 size exclusion chromatography high performance liquid chromatography Methods 0.000 description 1
- 239000002002 slurry Substances 0.000 description 1
- 229940126586 small molecule drug Drugs 0.000 description 1
- 239000011734 sodium Substances 0.000 description 1
- 229910052708 sodium Inorganic materials 0.000 description 1
- 235000019812 sodium carboxymethyl cellulose Nutrition 0.000 description 1
- 229920001027 sodium carboxymethylcellulose Polymers 0.000 description 1
- 235000010265 sodium sulphite Nutrition 0.000 description 1
- 239000007901 soft capsule Substances 0.000 description 1
- 239000012439 solid excipient Substances 0.000 description 1
- 230000003381 solubilizing effect Effects 0.000 description 1
- 239000007921 spray Substances 0.000 description 1
- 230000000087 stabilizing effect Effects 0.000 description 1
- 239000002294 steroidal antiinflammatory agent Substances 0.000 description 1
- 230000003637 steroidlike Effects 0.000 description 1
- 239000012258 stirred mixture Substances 0.000 description 1
- 238000005556 structure-activity relationship Methods 0.000 description 1
- 238000010254 subcutaneous injection Methods 0.000 description 1
- 239000005720 sucrose Substances 0.000 description 1
- 229940124530 sulfonamide Drugs 0.000 description 1
- 239000006228 supernatant Substances 0.000 description 1
- 239000013589 supplement Substances 0.000 description 1
- 239000000829 suppository Substances 0.000 description 1
- 239000002511 suppository base Substances 0.000 description 1
- 239000000375 suspending agent Substances 0.000 description 1
- 238000010189 synthetic method Methods 0.000 description 1
- 239000006188 syrup Substances 0.000 description 1
- 235000020357 syrup Nutrition 0.000 description 1
- 229940037128 systemic glucocorticoids Drugs 0.000 description 1
- 201000000596 systemic lupus erythematosus Diseases 0.000 description 1
- 150000004579 taxol derivatives Chemical class 0.000 description 1
- GPTXCAZYUMDUMN-UHFFFAOYSA-N tert-butyl n-(2-hydroxyethyl)carbamate Chemical compound CC(C)(C)OC(=O)NCCO GPTXCAZYUMDUMN-UHFFFAOYSA-N 0.000 description 1
- YRQMBQUMJFVZLF-UHFFFAOYSA-N tert-butyl n-(4-hydroxyphenyl)carbamate Chemical compound CC(C)(C)OC(=O)NC1=CC=C(O)C=C1 YRQMBQUMJFVZLF-UHFFFAOYSA-N 0.000 description 1
- YWSXTMBDIBZHBB-UHFFFAOYSA-N tert-butyl n-but-3-enylcarbamate Chemical compound CC(C)(C)OC(=O)NCCC=C YWSXTMBDIBZHBB-UHFFFAOYSA-N 0.000 description 1
- 125000004192 tetrahydrofuran-2-yl group Chemical group [H]C1([H])OC([H])(*)C([H])([H])C1([H])[H] 0.000 description 1
- 125000005958 tetrahydrothienyl group Chemical group 0.000 description 1
- 125000004632 tetrahydrothiopyranyl group Chemical group S1C(CCCC1)* 0.000 description 1
- 125000003831 tetrazolyl group Chemical group 0.000 description 1
- 238000005382 thermal cycling Methods 0.000 description 1
- 125000001113 thiadiazolyl group Chemical group 0.000 description 1
- 125000005308 thiazepinyl group Chemical group S1N=C(C=CC=C1)* 0.000 description 1
- 125000000335 thiazolyl group Chemical group 0.000 description 1
- 125000001544 thienyl group Chemical group 0.000 description 1
- 150000007970 thio esters Chemical class 0.000 description 1
- 125000000464 thioxo group Chemical group S=* 0.000 description 1
- 239000003734 thymidylate synthase inhibitor Substances 0.000 description 1
- UIERETOOQGIECD-ONEGZZNKSA-N tiglic acid Chemical compound C\C=C(/C)C(O)=O UIERETOOQGIECD-ONEGZZNKSA-N 0.000 description 1
- 239000004408 titanium dioxide Substances 0.000 description 1
- JOXIMZWYDAKGHI-UHFFFAOYSA-N toluene-4-sulfonic acid Chemical compound CC1=CC=C(S(O)(=O)=O)C=C1 JOXIMZWYDAKGHI-UHFFFAOYSA-N 0.000 description 1
- 229940044693 topoisomerase inhibitor Drugs 0.000 description 1
- 239000003053 toxin Substances 0.000 description 1
- 231100000765 toxin Toxicity 0.000 description 1
- 239000003204 tranquilizing agent Substances 0.000 description 1
- 230000002936 tranquilizing effect Effects 0.000 description 1
- 230000009466 transformation Effects 0.000 description 1
- 238000000844 transformation Methods 0.000 description 1
- 230000007704 transition Effects 0.000 description 1
- 230000014616 translation Effects 0.000 description 1
- 150000003626 triacylglycerols Chemical class 0.000 description 1
- 125000001425 triazolyl group Chemical group 0.000 description 1
- QORWJWZARLRLPR-UHFFFAOYSA-H tricalcium bis(phosphate) Chemical compound [Ca+2].[Ca+2].[Ca+2].[O-]P([O-])([O-])=O.[O-]P([O-])([O-])=O QORWJWZARLRLPR-UHFFFAOYSA-H 0.000 description 1
- 229940066528 trichloroacetate Drugs 0.000 description 1
- YNJBWRMUSHSURL-UHFFFAOYSA-N trichloroacetic acid Chemical compound OC(=O)C(Cl)(Cl)Cl YNJBWRMUSHSURL-UHFFFAOYSA-N 0.000 description 1
- CYRMSUTZVYGINF-UHFFFAOYSA-N trichlorofluoromethane Chemical compound FC(Cl)(Cl)Cl CYRMSUTZVYGINF-UHFFFAOYSA-N 0.000 description 1
- 229940029284 trichlorofluoromethane Drugs 0.000 description 1
- KAKQVSNHTBLJCH-UHFFFAOYSA-N trifluoromethanesulfonimidic acid Chemical compound NS(=O)(=O)C(F)(F)F KAKQVSNHTBLJCH-UHFFFAOYSA-N 0.000 description 1
- 125000000026 trimethylsilyl group Chemical group [H]C([H])([H])[Si]([*])(C([H])([H])[H])C([H])([H])[H] 0.000 description 1
- BZVJOYBTLHNRDW-UHFFFAOYSA-N triphenylmethanamine Chemical compound C=1C=CC=CC=1C(C=1C=CC=CC=1)(N)C1=CC=CC=C1 BZVJOYBTLHNRDW-UHFFFAOYSA-N 0.000 description 1
- 125000002264 triphosphate group Chemical group [H]OP(=O)(O[H])OP(=O)(O[H])OP(=O)(O[H])O* 0.000 description 1
- 125000002221 trityl group Chemical group [H]C1=C([H])C([H])=C([H])C([H])=C1C([*])(C1=C(C(=C(C(=C1[H])[H])[H])[H])[H])C1=C([H])C([H])=C([H])C([H])=C1[H] 0.000 description 1
- WFKWXMTUELFFGS-UHFFFAOYSA-N tungsten Chemical compound [W] WFKWXMTUELFFGS-UHFFFAOYSA-N 0.000 description 1
- 229910052721 tungsten Inorganic materials 0.000 description 1
- 239000010937 tungsten Substances 0.000 description 1
- NQPDZGIKBAWPEJ-UHFFFAOYSA-M valerate Chemical compound CCCCC([O-])=O NQPDZGIKBAWPEJ-UHFFFAOYSA-M 0.000 description 1
- 239000003071 vasodilator agent Substances 0.000 description 1
- LVLANIHJQRZTPY-UHFFFAOYSA-N vinyl carbamate Chemical compound NC(=O)OC=C LVLANIHJQRZTPY-UHFFFAOYSA-N 0.000 description 1
- 125000000391 vinyl group Chemical group [H]C([*])=C([H])[H] 0.000 description 1
- 229940100445 wheat starch Drugs 0.000 description 1
- 125000001834 xanthenyl group Chemical group C1=CC=CC=2OC3=CC=CC=C3C(C12)* 0.000 description 1
- 239000011701 zinc Substances 0.000 description 1
- 229910052725 zinc Inorganic materials 0.000 description 1
- 239000011592 zinc chloride Substances 0.000 description 1
- JIAARYAFYJHUJI-UHFFFAOYSA-L zinc dichloride Chemical compound [Cl-].[Cl-].[Zn+2] JIAARYAFYJHUJI-UHFFFAOYSA-L 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
- A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
- A61K51/04—Organic compounds
- A61K51/08—Peptides, e.g. proteins, carriers being peptides, polyamino acids, proteins
- A61K51/10—Antibodies or immunoglobulins; Fragments thereof, the carrier being an antibody, an immunoglobulin or a fragment thereof, e.g. a camelised human single domain antibody or the Fc fragment of an antibody
- A61K51/1045—Antibodies or immunoglobulins; Fragments thereof, the carrier being an antibody, an immunoglobulin or a fragment thereof, e.g. a camelised human single domain antibody or the Fc fragment of an antibody against animal or human tumor cells or tumor cell determinants
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2866—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for cytokines, lymphokines, interferons
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
- A61K47/6801—Drug-antibody or immunoglobulin conjugates defined by the pharmacologically or therapeutically active agent
- A61K47/6803—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
- A61K47/6801—Drug-antibody or immunoglobulin conjugates defined by the pharmacologically or therapeutically active agent
- A61K47/6803—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates
- A61K47/6811—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates the drug being a protein or peptide, e.g. transferrin or bleomycin
- A61K47/6817—Toxins
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
- A61K47/6835—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site
- A61K47/6849—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site the antibody targeting a receptor, a cell surface antigen or a cell surface determinant
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
- A61K47/6889—Conjugates wherein the antibody being the modifying agent and wherein the linker, binder or spacer confers particular properties to the conjugates, e.g. peptidic enzyme-labile linkers or acid-labile linkers, providing for an acid-labile immuno conjugate wherein the drug may be released from its antibody conjugated part in an acidic, e.g. tumoural or environment
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
- C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic System
- C07F9/02—Phosphorus compounds
- C07F9/06—Phosphorus compounds without P—C bonds
- C07F9/08—Esters of oxyacids of phosphorus
- C07F9/09—Esters of phosphoric acids
- C07F9/091—Esters of phosphoric acids with hydroxyalkyl compounds with further substituents on alkyl
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
- C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic System
- C07F9/02—Phosphorus compounds
- C07F9/06—Phosphorus compounds without P—C bonds
- C07F9/08—Esters of oxyacids of phosphorus
- C07F9/09—Esters of phosphoric acids
- C07F9/098—Esters of polyphosphoric acids or anhydrides
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
- C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic System
- C07F9/02—Phosphorus compounds
- C07F9/06—Phosphorus compounds without P—C bonds
- C07F9/08—Esters of oxyacids of phosphorus
- C07F9/09—Esters of phosphoric acids
- C07F9/12—Esters of phosphoric acids with hydroxyaryl compounds
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
- C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic System
- C07F9/02—Phosphorus compounds
- C07F9/06—Phosphorus compounds without P—C bonds
- C07F9/22—Amides of acids of phosphorus
- C07F9/24—Esteramides
- C07F9/2454—Esteramides the amide moiety containing a substituent or a structure which is considered as characteristic
- C07F9/2458—Esteramides the amide moiety containing a substituent or a structure which is considered as characteristic of aliphatic amines
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
- C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic System
- C07F9/02—Phosphorus compounds
- C07F9/547—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom
- C07F9/553—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom having one nitrogen atom as the only ring hetero atom
- C07F9/572—Five-membered rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
- C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic System
- C07F9/02—Phosphorus compounds
- C07F9/547—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom
- C07F9/655—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom having oxygen atoms, with or without sulfur, selenium, or tellurium atoms, as the only ring hetero atoms
- C07F9/65515—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom having oxygen atoms, with or without sulfur, selenium, or tellurium atoms, as the only ring hetero atoms the oxygen atom being part of a five-membered ring
- C07F9/65517—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom having oxygen atoms, with or without sulfur, selenium, or tellurium atoms, as the only ring hetero atoms the oxygen atom being part of a five-membered ring condensed with carbocyclic rings or carbocyclic ring systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
- C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic System
- C07F9/02—Phosphorus compounds
- C07F9/547—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom
- C07F9/6558—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom containing at least two different or differently substituted hetero rings neither condensed among themselves nor condensed with a common carbocyclic ring or ring system
- C07F9/65583—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom containing at least two different or differently substituted hetero rings neither condensed among themselves nor condensed with a common carbocyclic ring or ring system each of the hetero rings containing nitrogen as ring hetero atom
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
- C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic System
- C07F9/02—Phosphorus compounds
- C07F9/547—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom
- C07F9/6558—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom containing at least two different or differently substituted hetero rings neither condensed among themselves nor condensed with a common carbocyclic ring or ring system
- C07F9/65586—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom containing at least two different or differently substituted hetero rings neither condensed among themselves nor condensed with a common carbocyclic ring or ring system at least one of the hetero rings does not contain nitrogen as ring hetero atom
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
- C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic System
- C07F9/02—Phosphorus compounds
- C07F9/547—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom
- C07F9/6561—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom containing systems of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring or ring system, with or without other non-condensed hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
- C07H19/00—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof
- C07H19/02—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof sharing nitrogen
- C07H19/04—Heterocyclic radicals containing only nitrogen atoms as ring hetero atom
- C07H19/06—Pyrimidine radicals
- C07H19/10—Pyrimidine radicals with the saccharide radical esterified by phosphoric or polyphosphoric acids
Definitions
- the present invention relates to phosphate-based linkers with tunable stability for intracellular delivery of drug conjugates.
- the phosphate-based linkers comprise a
- phosphate group monophosphate, diphosphate, triphosphate, or tetraphosphate group (phosphate group) and a linker arm comprising a tuning element and optionally a spacer.
- a payload is covalently linked to the phosphate group at the distal end of the linker arm and the functional group at the proximal end of the linker arm is covalently linked to a cell-specific targeting ligand such as an antibody.
- phosphate-based linkers have a differentiated and tunable stability in blood vs. an intracellular environment (e.g. lysosomal compartment).
- conjugates that comprise these phosphate-based linkers are stable in circulation (plasma/blood) but reactive or cleavable in intracellular compartments (lysosome) making them useful for intracellular delivery of drug conjugates, the rate being dependent on the structure of the tuning element.
- Antibody drug conjugates are targeted chemotherapeutic molecules combining the ideal properties of both antibodies and cytotoxic drugs by targeting potent cytotoxic drugs to the antigen-expressing tumor cells, internalizing the ADC, and releasing the drug from the ADC, thereby enhancing the drug's anti-tumor activity.
- This strategy has met limited success in part because many cytotoxic drugs tend to be inactive or less active when conjugated to large antibodies or protein receptor ligands.
- Promising advancements with immunoconjugates has seen cytotoxic drugs linked to antibodies through a linker that is cleaved at the tumor site or inside tumor cells.
- the successful ADC development for a given target antigen depends on optimization of antibody selection, linker design and stability, drug potency and mode of drug and linker conjugation to the antibody.
- Linker properties of pH and redox sensitivities and protease susceptibility influence circulatory stability and release of the drug moiety.
- the intracellular cleavage of disulfide containing linkers of an ADC is limited by the oxidizing potential of endosomes and lysosomes and are probably not released by reductive cleavage within the endocytic pathway (Austin et al., Proc. Natl. Acad. Sci. USA 102: 17987-17992 (2005)).
- Reductive cleavage may occur at the cell membrane and impart a bystander killing effect of tumor and susceptible normal cells by free drug. Inappropriate release of drug likely contributes to toxicity.
- ADC efficacy is dependent on proteolytic cleavage for drug activity.
- Linker stability plays an important role in both the efficacy and toxicity of ADC (Alley et al., Bioconjugate Chem. 19:759-765 (2008)). Stable linkers such as mcc are more efficacious and safer than unstable, disulfide linkers, widening the therapeutic window.
- a chemical solution to targeted delivery of cytotoxic or cytostatic drugs conjugated to cell-specific ligands is the "self-immolative linker", PABC or PAB (para- aminobenzyloxycarbonyl) linker, attaching the drug moiety to the ligand in the conjugate (Carl et al, J. Med. Chem. 24: 479-480 (1981); Chakravarty et al., J. Med. Chem. 26: 638-644 (1983)).
- the PAB linker unit is also referred to as an electronic cascade spacer.
- the amide bond linking the carboxy terminus of a peptide unit and the para-aminobenzyl of PAB may be a substrate and cleavable by certain proteases.
- Cathepsin B is a ubiquitous cysteine protease with increasing activity within low pH environments (i.e. lysosomes). It is an intracellular enzyme, except in pathological conditions, such as metastatic tumors (Sinha et al., Prostate 49: 172-184 (2001)) or rheumatoid arthritis (Hashimoto et al., Biochem. Biophys. Res. Commun. 283: 334-339 (2001)).
- conjugates produced with cathepsin B-cleavable linkers are likely to be stable in circulation.
- the drug Upon cleavage of a peptide bond adjacent to the PABC, i.e. by an intracellular enzyme, the drug is released from the ligand whereby no remaining portion of the linker is bound (de Groot et al., Molecular Cancer Therapeutics 1 : 901-911 (2002); de Groot et al., J. Med. Chem. 42: 5277-5283 (1999)).
- Linkers containing the para-aminobenzyloxycarbonyl (PAB or PABC) unit, in conjunction with a peptide unit, have been developed with a "self-immolating" or “self- immolative” mechanism of 1,6 elimination and fragmentation under enzymatic, hydrolytic, or other metabolic conditions to release a drug moiety from a targeting ligand, such as an antibody (U.S. Pat. No. 6,214,345; 6,677,435 5,621,002; 6,218,519; 6,835,807; 6,268,488; and 6,759,509; US Pat. Pub. Nos. 20030130189; 20030096743; 20040052793; 20040018194; 20040052793; and 20040121940; PCT Pub. Nos. WO 98/13059 and WO2004/032828).
- PAB type self-immolating linkers are the propensity to cause poor solubility and aggregation of the conjugates.
- some PAB-containing conjugates may not be suitable substrates for certain cleaving enzymes or cleave too slowly to achieve efficacy.
- PAB/PABC linkers have been exemplified for amine -terminus payloads that form stable carbamate bonds, for payloads that do not contain a linkable amine, the carbonate that is formed may not be stable and so there is a need for self-immolative linkers that can handle payloads with an oxygen terminus, for example, dexamethasone.
- the present invention provides phosphate -based linkers with tunable stability for intracellular delivery of drug conjugates.
- the phosphate-based linkers comprise a
- phosphate group monophosphate, diphosphate, triphosphate, or tetraphosphate group (phosphate group) covalently linked to the distal end of a linker arm comprising from the distal to the proximal direction a tuning element, optionally a spacer element, and a reactive functional group.
- the phosphate group of the phosphate-based linker is capable of being conjugated to a payload and the reactive functional group is capable of being conjugated to a cell-specific targeting ligand such as an antibody.
- the general structure of the phosphate-based linkers is:
- a phosphate -based linker conjugated to a payload has the general structure: Payload— Phosphate group— Tuning element— Optional spacer element— Functional reactive group and when conjugated to a targeting ligand has the general structure
- Payload Phosphate group— Tuning element— Optional spacer element— Targeting ligand
- phosphate-based linkers have a differentiated and tunable stability in blood vs. an intracellular environment (e.g. lysosomal compartment).
- an intracellular environment e.g. lysosomal compartment.
- the inventors have discovered that the rate at which the phosphate group is cleaved in the intracellular environment to release the payload in its native or active form may be affected by the structure of the tuning element with further effects mediated by substitutions of the phosphate group as well as whether the phosphate group is a monophosphate, diphosphate, triphosphate, or tetraphosphate.
- these phosphate-based linkers provide the ability to construct conjugates such as antibody-drug conjugates in which the propensity of the conjugate to form aggregates is reduced compared to conjugates in which the same payload is conjugated to the antibody or targeting ligand using a linker that is not a phosphate-based linker as disclosed herein.
- the phosphate-based linker is a compound that has the following formula (I) wherein V is selected from O and S; W is selected from O, N, and CH2; X is a tuning element selected from a covalent bond; a carbon atom; a heteroatom; an optionally substituted group selected from the group consisting of acyl, aliphatic, heteroaliphatic, aryl, heteroaryl, and heterocyclic; a carbon atom linked to a trimethylammonium group by a C1-C5 hydrocarbon chain; nucleoside, protease sensitive group, cathepsin B sensitive group, or glycosidase sensitive group; Y is optional but when present it is selected from a covalent bond or a bivalent, straight or branched, saturated or unsaturated, optionally substituted CI -30 hydrocarbon chain wherein one or more methylene units of Y are optionally and independently replaced by -0-, -S-, -N(R)-, - C(I) wherein
- the reactive group Z has the structure
- the distal end of the phosphate group is covalently linked to a payload, which may be a therapeutic agent such as a drug moiety or peptide, a radionuclide, or a protecting element, to provide a payload-phosphate-based linker compound comprising formula (II) wherein V is selected from O and S; W is selected from O, N, and CH 2 ; X is a tuning element selected from a covalent bond; a carbon atom; a heteroatom; an optionally substituted group selected from the group consisting of acyl, aliphatic, heteroaliphatic, aryl, heteroaryl, and heterocyclic; a carbon atom linked to a trimethylammonium group by a C1-C5 hydrocarbon chain; nucleoside, protease sensitive group, cathepsin B sensitive group, or glycosidase sensitive group; Y is optional but when present is selected from a covalent bond or a bivalent, straight or branched, saturated
- halo is iodine (I), bromine (Br), fluorine (F), or chlorine (CI) and hetero is N, O, or S;
- D is a payload; each occurrence of R is independently hydrogen, a suitable protecting group, an acyl moiety, arylalkyl moiety, aliphatic moiety, aryl moiety, heteroaryl moiety, or heteroaliphatic moiety; and n is 1, 2, 3, or 4.
- Y is a covalent bond
- X is not a covalent bond.
- the reactive group Z has the structure
- the reactive functional group at the proximal end of the payload-phosphate-based linker may be covalently linked to a ligand or targeting moiety to provide a conjugate wherein in particular embodiments, the ligand is capable of targeting the conjugate to a particular cellular target when administered to a subject in need of the payload to provide a compound having formula (III) wherein V is selected from O and S; W is selected from O, N, and CH 2 ; X is a tuning element selected from a covalent bond; a carbon atom; a heteroatom; an optionally substituted group selected from the group consisting of acyl, aliphatic, heteroaliphatic, aryl, heteroaryl, and heterocyclic; a carbon atom linked to a trimethylammonium group by a C 1-C5 hydrocarbon chain; nucleoside, protease sensitive group, cathepsin B sensitive group, or glycosidase sensitive group; Y is selected from a covalent bond or a
- halo is iodine (I), bromine (Br), fluorine (F), or chlorine (CI) and hetero is N, O, or S, and (ii) an S, NR, or O group on L; each occurrence of R is independently hydrogen, a suitable protecting group, an acyl moiety, arylalkyl moiety, aliphatic moiety, aryl moiety, heteroaryl moiety, or heteroaliphatic moiety; L is a cell-specific targeting ligand; and n is 1 , 2, 3, or 4.
- Y is a covalent bond
- X is not a covalent bond.
- the linkage Z has the structure
- the payload is a therapeutic agent, a detectable label, radionuclide, or protecting group.
- the therapeutic agent may be any molecule that alters, inhibits, activates, or otherwise affects a biological event. Examples of a therapeutic agent include but are not limited to, cytotoxic agent, an anti-inflammatory agent, peptide, a nucleic acid or nucleic acid analog, a small molecule, and a biomolecule.
- the anti-inflammatory agent is a glucocorticoid receptor agonist.
- the anti-inflammatory agent is a glucocorticoid, for example, Cortisol, cortisone acetate, beclometasone, prednisone, prednisolone,
- methylprednisolone betamethasone, trimcinolone, budesonide, dexamethasone, fluticasone, fluticasone propionate, fluticasone furoate, compound 15-5, or mometasone.
- the targeting ligand is an antibody or monoclonal antibody (e.g., chimeric, humanized, or human), ligand for a receptor, lectin, saccharide, poly(ethylene glycol), polysaccharide, or polyamino acid.
- antibody or monoclonal antibody e.g., chimeric, humanized, or human
- ligand for a receptor e.g., lectin, saccharide, poly(ethylene glycol), polysaccharide, or polyamino acid.
- the chimeric, humanized, or human antibody or monoclonal antibody is an anti-Her2 antibody, anti-CD4 antibody, anti-CD20 antibody, anti- EGFR antibody, anti-CD22 antibody, anti-CD23 antibody, anti-CD25 antibody, anti-CD52 antibody, anti-CD30 antibody, anti-CD33 antibody, anti-CD40L antibody, anti-CD70 antibody, anti-CD74 antibody, anti-CD80 antibody, anti-CD 163 antibody, anti-Mucl8 antibody, anti- integrin antibody, anti-PSMA antibody, anti-CEA antibody, anti-CDl la antibody, anti-CTLA4 antibody, or anti-BLys antibody.
- the present invention further provides a composition
- a composition comprising a compound having formula (III) wherein V is selected from O and S; W is selected from O, N, and CH 2 ;
- X is a tuning element selected from a covalent bond; a carbon atom; a heteroatom; an optionally substituted group selected from the group consisting of acyl, aliphatic, heteroaliphatic, aryl, heteroaryl, and heterocyclic; a carbon atom linked to a trimethylammonium group by a C1-C5 hydrocarbon chain; nucleoside, protease sensitive group, cathepsin B sensitive group, or glycosidase sensitive group;
- Y is selected from a covalent bond or a bivalent, straight or branched, saturated or unsaturated, optionally substituted Ci_30 hydrocarbon chain wherein one or more methylene units of Y are optionally and independently replaced by -0-, -S-, -N(R)-, -C(O)-
- halo is iodine (I), bromine (Br), fluorine (F), or chlorine (CI) and hetero is N, O, or S, and (ii) an S, NR, or O group on L; each occurrence of R is independently hydrogen, a suitable protecting group, an acyl moiety, arylalkyl moiety, aliphatic moiety, aryl moiety, heteroaryl moiety, or heteroaliphatic moiety; L is a cell-specific targeting ligand; and n is 1, 2, 3, or 4; and a pharmaceutically acceptable salt or carrier.
- the composition is aqueous or lyophilized.
- X is not a covalent bond
- the linkage Z has the structure
- Y is a covalent bond, or W when Y and X are a covalent bond (on the left) and Z and L (on the right), respectively.
- the payload is a therapeutic agent, a detectable label, radionuclide, or protecting group.
- the therapeutic agent may be cytotoxic agent, an anti- inflammatory agent, peptide, or nucleic acid or nucleic acid analog.
- the anti-inflammatory agent is a glucocorticoid receptor agonist.
- the anti-inflammatory agent is a glucocorticoid, for example, Cortisol, cortisone acetate, beclometasone, prednisone, prednisolone,
- methylprednisolone betamethasone, trimcinolone, budesonide, dexamethasone, fluticasone, fluticasone propionate, fluticasone furoate, compound 15-5, or mometasone.
- the targeting ligand is an antibody or monoclonal antibody (e.g., chimeric, humanized, or human) or fragment thereof, ligand for a receptor, lectin; saccharide, poly(ethylene glycol); polysaccharide, or polyamino acid.
- antibody or monoclonal antibody e.g., chimeric, humanized, or human
- fragment thereof ligand for a receptor, lectin; saccharide, poly(ethylene glycol); polysaccharide, or polyamino acid.
- the chimeric, humanized, or human antibody or monoclonal antibody is an anti-Her2 antibody, anti-CD4 antibody, anti-CD20 antibody, anti- EGFR antibody, anti-CD22 antibody, anti-CD23 antibody, anti-CD25 antibody, anti-CD52 antibody, anti-CD30 antibody, anti-CD33 antibody, anti-CD40L antibody, anti-CD70 antibody, anti-CD74 antibody, anti-CD80 antibody, anti-CD 163 antibody, anti-Mucl8 antibody, anti- integrin antibody, anti-PSMA antibody, anti-CEA antibody, anti-CDl la antibody, anti-CTLA4 antibody, or anti-BLys antibody.
- the present invention further provides a method for treating a disease or disorder by providing to a subject having the disease or disorder a composition comprising a compound having formula (III)
- V is selected from O and S; W is selected from O, N, and CH 2 ;
- X is a tuning element selected from a covalent bond; a carbon atom; a heteroatom; an optionally substituted group selected from the group consisting of acyl, aliphatic, heteroaliphatic, aryl, heteroaryl, and heterocyclic; a carbon atom linked to a trimethylammonium group by a C1-C5 hydrocarbon chain; nucleoside, protease sensitive group, cathepsin B sensitive group, or glycosidase sensitive group;
- Y is selected from a covalent bond or a bivalent, straight or branched, saturated or unsaturated, optionally substituted Ci .39 hydrocarbon chain wherein one or more methylene units of Y are optionally and independently replaced by -0-, -S-, -N(R)-, -C(O)-, C(0)0-, OC(O)-, -N(R)C(0)-, -
- halo is iodine (I), bromine (Br), fluorine (F), or chlorine (CI) and hetero is N, O, or S, and (ii) an S, NR, or O group on L; each occurrence of R is independently hydrogen, a suitable protecting group, an acyl moiety, arylalkyl moiety, aliphatic moiety, aryl moiety, heteroaryl moiety, or heteroaliphatic moiety; L is a cell-specific targeting ligand; and n is 1 , 2, 3, or 4; and a pharmaceutically acceptable salt or carrier.
- Y is a covalent bond
- X is not a covalent bond.
- the linkage Z has the structure , or , wherein the wavy lines mark the covalent bond between Z and Y, or X when
- Y is a covalent bond, or W when Y and X are a covalent bond (on the left) and Z and L (on the right), respectively.
- the disease or disorder is an inflammatory disease or cancer.
- the payload is a therapeutic agent, which may be a cytotoxic agent, an anti-inflammatory agent, peptide, or nucleic acid or nucleic acid analog.
- the anti-inflammatory agent is a glucocorticoid receptor agonist.
- the anti-inflammatory agent is a glucocorticoid, for example, Cortisol, cortisone acetate, beclometasone, prednisone, prednisolone,
- the targeting ligand is an antibody or monoclonal antibody (e.g., chimeric, humanized, or human) or fragment thereof, ligand for a receptor, lectin, saccharide, poly(ethylene glycol), polysaccharide, or polyamino acid.
- the chimeric, humanized, or human antibody or monoclonal antibody is an anti-Her2 antibody, anti-CD4 antibody, anti-CD20 antibody, anti- EGF antibody, anti-CD22 antibody, anti-CD23 antibody, anti-CD25 antibody, anti-CD52 antibody, anti-CD30 antibody, anti-CD33 antibody, anti-CD40L antibody, anti-CD70 antibody, anti-CD74 antibody, anti-CD80 antibody, anti-CD 163 antibody, anti-Mucl8 antibody, anti- integrin antibody, anti-PSMA antibody, anti-CEA antibody, anti-CDl la antibody, anti-CTLA4 antibody, or anti-BLys antibody.
- composition comprising a compound having formula (III)
- V is selected from O and S; W is selected from O, N, and CH 2 ;
- X is a tuning element selected from a covalent bond; a carbon atom; a heteroatom; an optionally substituted group selected from the group consisting of acyl, aliphatic, heteroaliphatic, aryl, heteroaryl, and heterocyclic; a carbon atom linked to a trimethylammonium group by a C1-C5 hydrocarbon chain; nucleoside, protease sensitive group, cathepsin B sensitive group, or glycosidase sensitive group;
- Y is selected from a covalent bond or a bivalent, straight or branched, saturated or unsaturated, optionally substituted Ci .39 hydrocarbon chain wherein one or more methylene units of Y are optionally and independently replaced by -0-, -S-, -N(R)-, -C(O)-, C(0)0-, OC(O)-, -N(R)C(0)-, -
- halo is iodine (I), bromine (Br), fluorine (F), or chlorine (CI) and hetero is N, O, or S, and (ii) an S, NR, or O group on L; each occurrence of R is independently hydrogen, a suitable protecting group, an acyl moiety, arylalkyl moiety, aliphatic moiety, aryl moiety, heteroaryl moiety, or heteroaliphatic moiety; L is a cell-specific targeting ligand; and n is 1, 2, 3, or 4; and a pharmaceutically acceptable salt or carrier for the treatment of a disease or disorder.
- Y is a covalent bond
- X is not a covalent bond.
- Y is a covalent bond, or W when Y and X are a covalent bond (on the left) and Z and L (on the right), respectively.
- the disease or disorder is an inflammatory disease or cancer.
- the payload is a therapeutic agent such as a cytotoxic agent, an anti-inflammatory agent, peptide, or nucleic acid or nucleic acid analog.
- the cytotoxic agent selected from duocarmycins and
- CC-1065 and analogues thereof, including CBI (1,2,9,9a- tetrahydrocyclopropa[c]benz[e]indol- 4-one)-based analogues, MCBI (7-methoxy- 1,2,9,9a- tetra-hydrocyclopropa[c]benz[e]indol-4- one)-based analogues and CCBI (7-cyano- 1,2,9,9a- tetra-hydrocyclo-propa[c]benz[e]-indol-4- one)-based analogues of the duocarmycins and CC- 1065, doxorubicin and doxorubicin conjugates such as morpholino-doxorubicin and cyanomorpholino-doxorubicin, dolastatins such as dolestatin-10, combretastatin, calicheamicin, maytansine, maytansine analogs, DM-I, auri
- the anti-inflammatory agent is a glucocorticoid receptor agonist.
- the anti-inflammatory agent is a glucocorticoid, for example, Cortisol, cortisone acetate, beclometasone, prednisone, prednisolone,
- the targeting ligand is an antibody or monoclonal antibody (e.g., chimeric, humanized, or human), ligand for a receptor, lectin, saccharide, poly(ethylene glycol), polysaccharide, or polyamino acid.
- the chimeric, humanized, or human antibody or monoclonal antibody is an anti-Her2 antibody, anti-CD4 antibody, anti-CD20 antibody, anti- EGF antibody, anti-CD22 antibody, anti-CD23 antibody, anti-CD25 antibody, anti-CD52 antibody, anti-CD30 antibody, anti-CD33 antibody, anti-CD40L antibody, anti-CD70 antibody, anti-CD74 antibody, anti-CD80 antibody, anti-CD 163 antibody, anti-Mucl8 antibody, anti- integrin antibody, anti-PSMA antibody, anti-CEA antibody, anti-CDl la antibody, anti-CTLA4 antibody, or anti-BLys antibody.
- the present invention further provides an anti-inflammatory compound comprising the formula
- V is selected from O and S;
- W is selected from O, N, and CH2;
- X is selected from a covalent bond; a carbon atom; a heteroatom; an optionally substituted group selected from the group consisting of acyl, aliphatic, heteroaliphatic, aryl, heteroaryl, and heterocyclic; a carbon atom linked to a trimethylammonium group by a C1-C5 hydrocarbon chain; nucleoside, protease sensitive group, cathepsin B sensitive group, or glycosidase sensitive group;
- Y is selected from a covalent bond or a bivalent, straight or branched, saturated or unsaturated, optionally substituted CI -30 hydrocarbon chain wherein one or more methylene units of Y are optionally and independently replaced by -0-, -S-, -N(R)-, -C(O)-, C(0)0-, OC(O)-, -N(R)C(0)-, -C(0)N(R)-, -S(O)-, -S(0)2-, -N(R)S02-, S02N(R , a heterocyclic group, an aryl group, or a heteroaryl group;
- T is an R, CR2, O, or S
- D is an anti-inflammatory agent
- Z is a linkage formed between (i) a reactive functional group selected from the group consisting of N-hydroxysuccinimide, para-nitrophenyl carbonate, para-nitrophenyl carbamate, pentafluorophenyl, haloacetamide, maleimide, hydroxylamine, strained cycloalkyne, and heterocycloalkyne, alkyne, diene, azadiene, and heterocyclic azadiene, wherein halo is iodine (I), bromine (Br), fluorine (F), or chlorine (CI) and hetero is N, O, or S, and (ii) an S, NR, or O group on the cell-specific targeting ligand (L);
- Each occurrence of R is independently hydrogen, a suitable protecting group, an acyl moiety, arylalkyl moiety, aliphatic moiety, aryl moiety, heteroaryl moiety, or heteroaliphatic moiety;
- L is a cell-specific targeting ligand
- n 1, 2, 3, or 4.
- Y is a covalent bond
- X is not a covalent bond.
- the anti-inflammatory agent is a glucocorticoid receptor agonist.
- the anti-inflammatory agent is Cortisol, cortisone acetate, beclometasone, prednisone, prednisolone, methylprednisolone, betamethasone, trimcinolone, budesonide, dexamethasone, fluticasone, fluticasone propionate, fluticasone furoate, compound 15-5, or mometasone.
- the targeting ligand is an antibody or monoclonal antibody (e.g., chimeric, humanized, or human), ligand for a receptor, lectin, saccharide, poly(ethylene glycol), polysaccharide, or polyamino acid.
- antibody or monoclonal antibody e.g., chimeric, humanized, or human
- ligand for a receptor e.g., lectin, saccharide, poly(ethylene glycol), polysaccharide, or polyamino acid.
- the targeting ligand is a chimeric, humanized, or human anti- Her2 antibody, anti-CD4 antibody, anti-CD20 antibody, anti-EGFR antibody, anti-CD22 antibody, anti-CD23 antibody, anti-CD25 antibody, anti-CD52 antibody, anti-CD30 antibody, anti-CD33 antibody, anti-CD40L antibody, anti-CD70 antibody, anti-CD74 antibody, anti-CD80 antibody, anti-CD 163 antibody, anti-Mucl8 antibody, anti-integrin antibody, anti-PSMA antibody, anti-CEA antibody, anti-CDl la antibody, anti-CTLA4 antibody, or anti-BLys antibody.
- the linkage Z has the structure
- Y is a covalent bond, or W when Y and X are a covalent bond (on the left) and Z and L (on the right), respectively.
- the present invention further provides an anti-cancer compound comprising the formula
- V is selected from O and S;
- W is selected from O, N, and CH2;
- X is selected from a covalent bond; a carbon atom; a heteroatom; an optionally substituted group selected from the group consisting of acyl, aliphatic, heteroaliphatic, aryl, heteroaryl, and heterocyclic; a carbon atom linked to a trimethylammonium group by a C1-C5 hydrocarbon chain; nucleoside, protease sensitive group, cathepsin B sensitive group, or glycosidase sensitive group;
- Y is selected from a covalent bond or a bivalent, straight or branched, saturated or unsaturated, optionally substituted CI -30 hydrocarbon chain wherein one or more methylene units of Y are optionally and independently replaced by -0-, -S-, -N(R)-, -C(O)-, C(0)0-, OC(O)-, -N(R)C(0>, -C(0)N(R)-, -S(O)-, -S(0)2-, -N(R)S02-, S02N(R , a heterocyclic group, an aryl group, or a heteroaryl group;
- T is an R, CR2, O, or S
- D is a cytotoxic agent
- Z is a linkage formed between (i) a reactive functional group selected from the group consisting of N-hydroxysuccinimide, para-nitrophenyl carbonate, para-nitrophenyl carbamate, pentafluorophenyl, haloacetamide, maleimide, hydroxylamine, strained cycloalkyne, and heterocycloalkyne, alkyne, diene, azadiene, and heterocyclic azadiene, wherein halo is iodine (I), bromine (Br), fluorine (F), or chlorine (CI) and hetero is N, O, or S, and (ii) an S, NR, or O group on the cell-specific targeting ligand (L);
- a reactive functional group selected from the group consisting of N-hydroxysuccinimide, para-nitrophenyl carbonate, para-nitrophenyl carbamate, pentafluorophenyl, haloacetamide, maleimide, hydroxylamine,
- R is independently hydrogen, a suitable protecting group, an acyl moiety, arylalkyl moiety, aliphatic moiety, aryl moiety, heteroaryl moiety, or heteroaliphatic moiety;
- L is a cell-specific targeting ligand
- n 1, 2, 3, or 4.
- Y is a covalent bond
- X is not a covalent bond.
- cytotoxic agent is selected from duocarmycins and
- the cytotoxic agent is selected from a CBI (1,2,9,9a- tetrahydrocyclopropa[c]benz[e]indol-4-one)-based analogues, MCBI (7-methoxy- 1,2,9,9a- tetra-hydrocyclopropa[c]benz[e]indol-4-one)-based analogues and CCBI (7-cyano- 1,2,9,9a- tetra-hydrocyclo-propa[c]benz[e]-indol-4-one)-based analogue of the duocarmycins and CC- 1065.
- the cytotoxic agent is selected from doxorubicin and doxorubicin conjugates such as morpholino-doxorubicin and cyanomorpholino-doxorubicin.
- the cytotoxic agent is selected from dolastatins such as dolestatin- 10, combretastatin, calicheamicin, maytansine, maytansine analogs, DM-I, auristatin E, auristatin EB (AEB), auristatin EFP (AEFP), monomethyl auristatin E (MMAE), 5- benzoylvaleric acid- AE ester (AEVB), tubulysins, disorazole, epothilones, Paclitaxel, docetaxel, SN-38, Topotecan, rhizoxin, echinomycin, colchicine, vinblastin, vindesine, estramustine, cemadotin, eleutherobin, methotrexate, methopterin, dichloro methotrexate, 5-fluorouracil, 6- mercaptopurine, cytosine arabinoside, melphalan, leurosine, leuroside
- the targeting ligand is an antibody or monoclonal antibody (e.g., chimeric, humanized, or human), ligand for a receptor, lectin, saccharide, poly(ethylene glycol), polysaccharide, or polyamino acid.
- antibody or monoclonal antibody e.g., chimeric, humanized, or human
- ligand for a receptor e.g., lectin, saccharide, poly(ethylene glycol), polysaccharide, or polyamino acid.
- the targeting ligand is a chimeric, humanized, or human anti- Her2 antibody, anti-CD4 antibody, anti-CD20 antibody, anti-EGFR antibody, anti-CD22 antibody, anti-CD23 antibody, anti-CD25 antibody, anti-CD52 antibody, anti-CD30 antibody, anti-CD33 antibody, anti-CD40L antibody, anti-CD70 antibody, anti-CD74 antibody, anti-CD80 antibody, anti-CD 163 antibody, anti-Mucl8 antibody, anti-integrin antibody, anti-PSMA antibody, anti-CEA antibody, anti-CDl la antibody, anti-CTLA4 antibody, or anti-BLys antibody.
- the linkage Z has the structure
- Y is a covalent bond, or W when Y and X are a covalent bond (on the left) and Z and L (on the right), respectively.
- the present invention further provides a method for making an antibody-drug conjugate that has reduced propensity for forming aggregates comprising:
- V is selected from O and S;
- W is selected from O, N, and CH2;
- X is selected from a covalent bond; a carbon atom; a heteroatom; an optionally substituted group selected from the group consisting of acyl, aliphatic, heteroaliphatic, aryl, heteroaryl, and heterocyclic; a carbon atom linked to a trimethylammonium group by a C1-C5 hydrocarbon chain; nucleoside, protease sensitive group, cathepsin B sensitive group, or glycosidase sensitive group;
- Y is selected from a covalent bond or a bivalent, straight or branched, saturated or unsaturated, optionally substituted CI -30 hydrocarbon chain wherein one or more methylene units of Y are optionally and independently replaced by -0-, -S-, -N(R)-, -C(O)-, C(0)0-, OC(O)-, -N(R)C(0)-, -C(0)N(R)-, -S(O)-, -S(0)2-, -N(R)S02-, S02N(R)-, a heterocyclic group, an aryl group, or a heteroaryl group;
- T is an R, CR2, O, or S
- Z is a reactive functional group selected from the group consisting of N- hydroxysuccinimidyl ester, para-nitrophenyl carbonate, para-nitrophenyl carbamate, methyl ketone, azide, hydrazine, pentafluorophenyl, haloacetamide, maleimide, hydroxylamine, strained cycloalkyne, and heterocycloalkyne, alkyne, diene, azadiene, and heterocyclic azadiene, wherein halo is iodine (I), bromine (Br), fluorine (F), or chlorine (CI) and hetero is N, O, or S;
- D is a payload
- R is independently hydrogen, a suitable protecting group, an acyl moiety, arylalkyl moiety, aliphatic moiety, aryl moiety, heteroaryl moiety, or heteroaliphatic moiety;
- n 1, 2, 3, or 4;
- the payload is a therapeutic agent, a detectable label, radionuclide, or protecting group.
- the therapeutic agent is a cytotoxic agent, an anti-inflammatory agent, peptide, or nucleic acid or nucleic acid analog.
- the anti-inflammatory agent is a glucocorticoid receptor agonist.
- the anti-inflammatory agent is Cortisol, cortisone acetate, beclometasone, prednisone, prednisolone, methylprednisolone, betamethasone, trimcinolone, budesonide, dexamethasone, fluticasone, fluticasone propionate, fluticasone furoate, compound 15-5, or mometasone.
- the cytotoxic agent is selected from duocarmycins and CC- 1065.
- the cytotoxic agent is selected from a CBI (1,2,9,9a- tetrahydrocyclopropa[c]benz[e]indol-4-one)-based analogues, MCBI (7-methoxy- 1,2,9,9a- tetra- hydrocyclopropa[c]benz[e]indol-4-one)-based analogues and CCBI (7-cyano- 1,2,9,9a- tetra- hydrocyclo-propa[c]benz[e]-indol-4-one)-based analogue of the duocarmycins and CC- 1065.
- the cytotoxic agent is selected from doxorubicin and doxorubicin conjugates such as morpholino-doxorubicin and cyanomorpholino-doxorubicin.
- the cytotoxic agent is selected from dolastatins such as dolestatin- 10, combretastatin, calicheamicin, maytansine, maytansine analogs, DM-I, auristatin E, auristatin EB (AEB), auristatin EFP (AEFP), monomethyl auristatin E (MMAE), 5- benzoylvaleric acid- AE ester (AEVB), tubulysins, disorazole, epothilones, Paclitaxel, docetaxel, SN-38, Topotecan, rhizoxin, echinomycin, colchicine, vinblastin, vindesine, estramustine, cemadotin, eleutherobin, methotrexate, methopterin, dichloro methotrexate, 5-fluorouracil, 6- mercaptopurine, cytosine arabinoside, melphalan, leurosine, leuroside
- the targeting ligand is an antibody or monoclonal antibody (e.g., chimeric, humanized, or human), ligand for a receptor, lectin, saccharide, poly(ethylene glycol), polysaccharide, or polyamino acid.
- antibody or monoclonal antibody e.g., chimeric, humanized, or human
- ligand for a receptor e.g., lectin, saccharide, poly(ethylene glycol), polysaccharide, or polyamino acid.
- the targeting ligand is a chimeric, humanized, or human anti- Her2 antibody, anti-CD4 antibody, anti-CD20 antibody, anti-EGFR antibody, anti-CD22 antibody, anti-CD23 antibody, anti-CD25 antibody, anti-CD52 antibody, anti-CD30 antibody, anti-CD33 antibody, anti-CD40L antibody, anti-CD70 antibody, anti-CD74 antibody, anti-CD80 antibody, anti-CD163 antibody, anti-Mucl8 antibody, anti-integrin antibody, anti-PSMA antibody, anti-CEA antibody, anti-CDl la antibody, anti-CTLA4 antibody, or anti-BLys antibody.
- the reactive group Z has the structure wherein the wavy line is the covalent bond between Z and Y, or X when Y is a covalent bond, or W when Y and X are a covalent bond.
- the present invention further provides a method for making a composition of antibody-drug conjugates in which the propensity of the antibody-drug conjugates in the composition to form aggregates is reduced comprising:
- V is selected from O and S;
- W is selected from O, N, and CH2;
- X is selected from a covalent bond; a carbon atom; a heteroatom; an optionally substituted group selected from the group consisting of acyl, aliphatic, heteroaliphatic, aryl, heteroaryl, and heterocyclic; a carbon atom linked to a trimethylammonium group by a C1-C5 hydrocarbon chain; nucleoside, protease sensitive group, cathepsin B sensitive group, or glycosidase sensitive group;
- Y is selected from a covalent bond or a bivalent, straight or branched, saturated or unsaturated, optionally substituted CI -30 hydrocarbon chain wherein one or more methylene units of Y are optionally and independently replaced by -0-, -S-, -N(R)-, -C(O)-, C(0)0-, OC(O)-, -N(R)C(0)-, -C(0)N(R)-, -S(O)-, -S(0)2-, -N(R)S02-, S02N(R , a heterocyclic group, an aryl group, or a heteroaryl group;
- T is an R, CR2, O, or S
- Z is a reactive functional group selected from the group consisting of N- hydroxysuccinimidyl ester, para-nitrophenyl carbonate, para-nitrophenyl carbamate, methyl ketone, azide, hydrazine, pentafluorophenyl, haloacetamide, maleimide, hydroxylamine, strained cycloalkyne, and heterocycloalkyne, alkyne, diene, azadiene, and heterocyclic azadiene, wherein halo is iodine (I), bromine (Br), fluorine (F), or chlorine (CI) and hetero is N, O, or S;
- D is a payload; each occurrence of R is independently hydrogen, a suitable protecting group, an acyl moiety, arylalkyl moiety, aliphatic moiety, aryl moiety, heteroaryl moiety, or heteroaliphatic moiety; and
- n 1, 2, 3, or 4;
- the payload is a therapeutic agent, a detectable label, radionuclide, or protecting group.
- the therapeutic agent is a cytotoxic agent, an anti-inflammatory agent, peptide, or nucleic acid or nucleic acid analog.
- the anti-inflammatory agent is a glucocorticoid receptor agonist.
- the anti-inflammatory agent is Cortisol, cortisone acetate, beclometasone, prednisone, prednisolone, methylprednisolone, betamethasone, trimcinolone, budesonide, dexamethasone, fluticasone, fluticasone propionate, fluticasone furoate, compound 15-5, or mometasone.
- the cytotoxic agent is selected from duocarmycins and CC- 1065.
- the cytotoxic agent is selected from a CBI (1,2,9,9a- tetrahydrocyclopropa[c]benz[e]indol-4-one)-based analogues, MCBI (7-methoxy- 1,2,9,9a- tetra- hydrocyclopropa[c]benz[e]indol-4-one)-based analogues and CCBI (7-cyano- 1,2,9,9a- tetra- hydrocyclo-propa[c]benz[e]-indol-4-one)-based analogue of the duocarmycins and CC- 1065.
- the cytotoxic agent is selected from doxorubicin and doxorubicin conjugates such as mo holino-doxorubicin and cyanomorpholino-doxorubicin.
- the cytotoxic agent is selected from dolastatins such as dolestatin- 10, combretastatin, calicheamicin, maytansine, maytansine analogs, DM-I, auristatin E, auristatin EB (AEB), auristatin EFP (AEFP), monomethyl auristatin E (MMAE), 5- benzoylvaleric acid- AE ester (AEVB), tubulysins, disorazole, epothilones, Paclitaxel, docetaxel, SN-38, Topotecan, rhizoxin, echinomycin, colchicine, vinblastin, vindesine, estramustine, cemadotin, eleutherobin, methotrexate, methopterin, dichloro methotrexate, 5-fluorouracil, 6- mercaptopurine, cytosine arabinoside, melphalan, leurosine, leuroside
- At least 90%, 95%, 96%, 97% 98%, 99%, 99.5%, 99.4%, 99.3%, or 99.2% of the antibody-drug conjugates in the composition is not aggregated.
- the targeting ligand is an antibody or monoclonal antibody (e.g., chimeric, humanized, or human), ligand for a receptor, lectin, saccharide, poly(ethylene glycol), polysaccharide, or polyamino acid.
- antibody or monoclonal antibody e.g., chimeric, humanized, or human
- ligand for a receptor e.g., lectin, saccharide, poly(ethylene glycol), polysaccharide, or polyamino acid.
- the targeting ligand is a chimeric, humanized, or human anti- Her2 antibody, anti-CD4 antibody, anti-CD20 antibody, anti-EGFR antibody, anti-CD22 antibody, anti-CD23 antibody, anti-CD25 antibody, anti-CD52 antibody, anti-CD30 antibody, anti-CD33 antibody, anti-CD40L antibody, anti-CD70 antibody, anti-CD74 antibody, anti-CD80 antibody, anti-CD 163 antibody, anti-Mucl8 antibody, anti-integrin antibody, anti-PSMA antibody, anti-CEA antibody, anti-CDl la antibody, anti-CTLA4 antibody, or anti-BLys antibody.
- the reactive group Z has the structure
- R X1 is hydrogen; halogen; substituted or unsubstituted hydroxyl; substituted or unsubstituted thiol; substituted or unsubstituted amino; substituted or unsubstituted acyl; cyclic or acyclic, substituted or unsubstituted, branched or unbranched aliphatic; cyclic or acyclic, substituted or unsubstituted, branched or unbranched heteroaliphatic; cyclic or acyclic, substituted or unsubstituted, branched or unbranched alkyl; cyclic or acyclic, substituted or unsubstituted, branched or unbranched alkenyl; substituted or unsubstituted alkynyl, substituted or unsubstituted aryl, substituted
- acyl groups include aldehydes (-CHO), carboxylic acids (-CO2H), ketones, acyl halides, esters, amides, imines, carbonates, carbamates, and ureas.
- Acyl substituents include, but are not limited to, any of the substituents described herein, that result in the formation of a stable moiety (e.g., aliphatic, alkyl, alkenyl, alkynyl, heteroaliphatic, heterocyclic, aryl, heteroaryl, acyl, oxo, imino, thiooxo, cyano, isocyano, amino, azido, nitro, hydroxyl, thiol, halo, aliphaticamino, heteroaliphaticamino, alkylamino, heteroalkylamino, arylamino,
- a stable moiety e.g., aliphatic, alkyl, alkenyl, alkynyl, heteroaliphatic, heterocyclic, aryl, heteroaryl, acyl, oxo, imino, thiooxo, cyano, isocyano, amino, azido, nitro, hydroxyl,
- heteroarylamino alkylaryl, arylalkyl, aliphaticoxy, heteroaliphaticoxy, alkyloxy, heteroalkyloxy, aryloxy, heteroaryloxy, aliphaticthioxy, heteroaliphaticthioxy, alkylthioxy, heteroalkylthioxy, arylthioxy, heteroarylthioxy, acyloxy, and the like, each of which may or may not be further substituted).
- Aliphatic - As used herein, the term "aliphatic” or “aliphatic group” denotes an optionally substituted hydrocarbon moiety that may be straight-chain (i.e., unbranched), branched, or cyclic ("carbocyclic") and may be completely saturated or may contain one or more units of unsaturation, but which is not aromatic. Unless otherwise specified, aliphatic groups contain 1-12 carbon atoms. In some embodiments, aliphatic groups contain 1-6 carbon atoms. In some embodiments, aliphatic groups contain 1-4 carbon atoms, and in yet other embodiments aliphatic groups contain 1-3 carbon atoms. Suitable aliphatic groups include, but are not limited to, linear or branched, alkyl, alkenyl, and alkynyl groups, and hybrids thereof such as
- alkenyl denotes an optionally substituted monovalent group derived from a straight- or branched-chain aliphatic moiety having at least one carbon-carbon double bond by the removal of a single hydrogen atom.
- the alkenyl group employed in the invention contains 2-6 carbon atoms.
- the alkenyl group employed in the invention contains 2-5 carbon atoms.
- the alkenyl group employed in the invention contains 2-4 carbon atoms.
- the alkenyl group employed contains 2-3 carbon atoms.
- Alkenyl groups include, for example, ethenyl, propenyl, butenyl, l-methyl-2-buten-l-yl, and the like.
- alkyl refers to optionally substituted saturated, straight- or branched-chain hydrocarbon radicals derived from an aliphatic moiety containing between 1-6 carbon atoms by removal of a single hydrogen atom.
- the alkyl group employed in the invention contains 1 -5 carbon atoms.
- the alkyl group employed contains 1-4 carbon atoms.
- the alkyl group contains 1-3 carbon atoms.
- the alkyl group contains 1-2 carbons.
- alkyl radicals include, but are not limited to, methyl, ethyl, n-propyl, isopropyl, n- butyl, iso-butyl, sec-butyl, sec-pentyl, iso-pentyl, tert-butyl, n-pentyl, neopentyl, n-hexyl, sec- hexyl, n-heptyl, n-octyl, n-decyl, n-undecyl, dodecyl, and the like.
- alkynyl refers to an optionally substituted monovalent group derived from a straight- or branched-chain aliphatic moiety having at least one carbon-carbon triple bond by the removal of a single hydrogen atom.
- the alkynyl group employed in the invention contains 2-6 carbon atoms. In certain embodiments, the alkynyl group employed in the invention contains 2-5 carbon atoms. In some embodiments, the alkynyl group employed in the invention contains 2-4 carbon atoms. In another embodiment, the alkynyl group employed contains 2-3 carbon atoms.
- Representative alkynyl groups include, but are not limited to, ethynyl, 2-propynyl (propargyl), 1-propynyl, and the like.
- aryl used alone or as part of a larger moiety as in “aralkyl”, “aralkoxy”, or “aryloxyalkyl”, refers to an optionally substituted monocyclic and bicyclic ring systems having a total of five to 10 ring members, wherein at least one ring in the system is aromatic and wherein each ring in the system contains three to seven ring members.
- aryl may be used interchangeably with the term “aryl ring”.
- “aryl” refers to an aromatic ring system which includes, but not limited to, phenyl, biphenyl, naphthyl, anthracyl and the like, which may bear one or more substituents.
- arylalkyl refers to an alkyl group substituted with an aryl group (e.g., an aromatic or heteroaromatic group).
- Bivalent hydrocarbon chain - is a polymethylene group, i.e., -(CH 2 ) Z - wherein z is a positive integer from 1 to 30, from 1 to 20, from 1 to 12, from 1 to 8, from 1 to 6, from 1 to 4, from 1 to 3, from 1 to 2, from 2 to 30, from 2 to 20, from 2 to 10, from 2 to 8, from 2 to 6, from 2 to 4, or from 2 to 3.
- a substituted bivalent hydrocarbon chain is a polymethylene group in which one or more methylene hydrogen atoms are replaced with a substituent. Suitable substituents include those described below for a substituted aliphatic group.
- Non-limiting examples of carbonyl groups include aldehydes, ketones, carboxylic acids, ester, amide, enones, acyl halides, anhydrides, ureas, carbamates, carbonates, thioesters, lactones, lactams, hydroxamates, isocyanates, and chloroformates.
- Cycloaliphatic As used herein, the terms “cycloaliphatic”, “carbocycle”, or “carbocyclic”, used alone or as part of a larger moiety, refer to an optionally substituted saturated or partially unsaturated cyclic aliphatic monocyclic or bicyclic ring systems, as described herein, having from 3 to 10 members.
- Cycloaliphatic groups include, without limitation, cyclopropyl, cyclobutyl, cyclopentyl, cyclopentenyl, cyclohexyl, cyclohexenyl, cycloheptyl, cycloheptenyl, cyclooctyl, cyclooctenyl, and cyclooctadienyl.
- the cycloalkyl has 3-6 carbons.
- Halogen - refers to an atom selected from fluorine (fiuoro, -F), chlorine (chloro, -CI), bromine (bromo, -Br), and iodine (iodo, -I).
- heteroaliphatic or “heteroaliphatic group” denote an optionally substituted hydrocarbon moiety having, in addition to carbon atoms, from one to five heteroatoms, that may be straight-chain (i.e., unbranched), branched, or cyclic ("heterocyclic”) and may be completely saturated or may contain one or more units of unsaturation, but which is not aromatic.
- heteroaliphatic groups contain 1-6 carbon atoms wherein 1-3 carbon atoms are optionally and independently replaced with heteroatoms selected from oxygen, nitrogen and sulfur.
- heteroaliphatic groups contain 1-4 carbon atoms, wherein 1-2 carbon atoms are optionally and independently replaced with heteroatoms selected from oxygen, nitrogen and sulfur. In yet other embodiments, heteroaliphatic groups contain 1 -3 carbon atoms, wherein 1 carbon atom is optionally and independently replaced with a heteroatom selected from oxygen, nitrogen and sulfur. Suitable heteroaliphatic groups include, but are not limited to, linear or branched, heteroalkyl, heteroalkenyl, and heteroalkynyl groups.
- heteroaryl refers to an alkyl group substituted by a heteroaryl, wherein the alkyl and heteroaryl portions independently are optionally substituted.
- heteroaryl used alone or as part of a larger moiety, e.g., “heteroaralkyl”, or “heteroaralkoxy”, refers to an optionally substituted group having 5 to 10 ring atoms, preferably 5, 6, or 9 ring atoms; having 6, 10, or 14 ⁇ electrons shared in a cyclic array; and having, in addition to carbon atoms, from one to five heteroatoms.
- Heteroaryl groups include, without limitation, thienyl, furanyl, pyrrolyl, imidazolyl, pyrazolyl, triazolyl, tetrazolyl, oxazolyl, isoxazolyl, oxadiazolyl, thiazolyl, isothiazolyl, thiadiazolyl, pyridyl, pyridazinyl, pyrimidinyl, pyrazinyl, indolizinyl, purinyl, naphthyridinyl, and pteridinyl.
- heteroaryl and “heteroar-”, as used herein, also include groups in which a heteroaromatic ring is fused to one or more aryl, carbocyclic, or heterocyclic rings, where the radical or point of attachment is on the heteroaromatic ring.
- Non limiting examples include indolyl, isoindolyl, benzothienyl, benzofuranyl, dibenzofuranyl, indazolyl, benzimidazolyl, benzthiazolyl, quinolyl, isoquinolyl, cinnolinyl, phthalazinyl, quinazolinyl, quinoxalinyl, 4H- quinolizinyl, carbazolyl, acridinyl, phenazinyl, phenothiazinyl, phenoxazinyl,
- heteroaryl group may be mono- or bicyclic.
- heteroaryl may be used interchangeably with the terms “heteroaryl ring”, “heteroaryl group”, or “heteroaromatic”, any of which terms include rings that are optionally substituted.
- Heteroatom refers to nitrogen, oxygen, or sulfur, and includes any oxidized form of nitrogen or sulfur, and any quaternized form of a basic nitrogen.
- nitrogen also includes a substituted nitrogen.
- heterocyclic As used herein, the terms “heterocycle”, “heterocyclyl”,
- heterocyclic radical and “heterocyclic ring” are used interchangeably and refer to a stable optionally substituted 5- to 7-membered monocyclic or 7- to 10-membered bicyclic heterocyclic moiety that is either saturated or partially unsaturated, and having, in addition to carbon atoms, one or more heteroatoms, as defined above.
- a heterocyclic ring can be attached to its pendant group at any heteroatom or carbon atom that results in a stable structure and any of the ring atoms can be optionally substituted.
- saturated or partially unsaturated heterocyclic radicals include, without limitation, tetrahydrofuranyl, tetrahydrothienyl, pyrrolidinyl, pyrrolidonyl, piperidinyl, pyrrolinyl, tetrahydroquinolinyl, tetrahydroisoquinolinyl, decahydroquinolinyl, oxazolidinyl, piperazinyl, dioxanyl, dioxolanyl, diazepinyl, oxazepinyl, thiazepinyl, morpholinyl, and quinuclidinyl.
- heterocycle "heterocyclyl”
- heterocyclyl ring refers to an alkyl group substituted by a heterocyclyl, wherein the alkyl and heterocyclyl portions independently are optionally substituted.
- Unsaturated As used herein, the term "unsaturated”, means that a moiety has one or more double or triple bonds.
- Partially unsaturated refers to a ring moiety that includes at least one double or triple bond.
- the term “partially unsaturated” is intended to encompass rings having multiple sites of unsaturation, but is not intended to include aryl or heteroaryl moieties, as herein defined.
- compounds of the invention may contain “optionally substituted” moieties.
- substituted whether preceded by the term “optionally” or not, means that one or more hydrogens of the designated moiety are replaced with a suitable substituent.
- an “optionally substituted” group may have a suitable substituent at each substitutable position of the group, and when more than one position in any given structure may be substituted with more than one substituent selected from a specified group, the substituent may be either the same or different at every position.
- Combinations of substituents envisioned by this invention are preferably those that result in the formation of stable or chemically feasible compounds.
- stable refers to compounds that are not substantially altered when subjected to conditions to allow for their production, detection, and, in certain embodiments, their recovery, purification, and use for one or more of the purposes disclosed herein.
- Suitable monovalent substituents on a substitutable carbon atom of an "optionally substituted" group are independently halogen; -(CH 2 )o-4R °; -(CH 2 )o- 4 0R°; -O-(CH 2 ) 0 _
- heteroatoms independently selected from nitrogen, oxygen, or sulfur, which may be substituted as defined below.
- Suitable monovalent substituents on R° are independently halogen, -(CH 2 ) 0 _ 2 R*, -(haloR*), -(CH 2 ) 0 _ 2 OH, -(CH 2 ) 0 2 OR*, -(CH 2 ) 0 2 CH(OR*) 2 ; - O(haloR'), -CN, -N 3 , -(CH 2 ) 0 2 C(0)R*, -(CH 2 ) 0 2 C(0)OH, -(CH 2 ) 0 2 C(0)OR*, -(CH 2 ) 0 2 SR*, -(CH 2 )o 2 SH, -(CH 2 )o 2 NH 2 , -(CH 2 ) 0 2 NHR*, -(CH 2 ) 0 2 NR* 2 , -N0 2 , -SiR «
- Suitable divalent substituents that are bound to vicinal substitutable carbons of an "optionally substituted” group include: -0(CR * 2 ) 2 3O-, wherein each independent occurrence of R * is selected from hydrogen, Ci_6 aliphatic which may be substituted as defined below, or an unsubstituted 5-6-membered saturated, partially unsaturated, or aryl ring having 0-4 heteroatoms independently selected from nitrogen, oxygen, or sulfur.
- Suitable substituents on the aliphatic group of R * include halogen, -R*, - (haloR*), -OH, -OR*, -0(haloR*), -CN, -C(0)OH, -C(0)OR', -NH 2 , -NHR*, -NR* 2 , or - N0 2 , wherein each R" is unsubstituted or where preceded by "halo" is substituted only with one or more halogens, and is independently Ci_ 4 aliphatic, -CH 2 Ph, -O(CH 2 ) 0 _iPh, or a 5-6- membered saturated, partially unsaturated, or aryl ring having 0-4 heteroatoms independently selected from nitrogen, oxygen, or sulfur.
- Suitable substituents on a substitutable nitrogen of an "optionally substituted" group include -R ⁇ , -NR ⁇ 2 , -C(0)R ⁇ , -C(0)OR ⁇ , -C(0)C(0)R ⁇ , -C(0)CH 2 C(0)R ⁇ , -S(0) 2 R ⁇ , - S(0) 2 NR ⁇ 2 , -C(S)NR ⁇ 2 , -C(NH)NR ⁇ 2 , or -N(R ⁇ )S(0) 2 R ⁇ ; wherein each R ⁇ is independently hydrogen, Ci_6 aliphatic which may be substituted as defined below, unsubstituted -OPh, or an unsubstituted 5-6-membered saturated, partially unsaturated, or aryl ring having 0-4 heteroatoms independently selected from nitrogen, oxygen, or sulfur, or, notwithstanding the definition above, two independent occurrences of R ⁇ , taken together with their intervening atom(s) form an
- Suitable substituents on the aliphatic group of R ⁇ are independently halogen, R*, -(haloR*), - OH, -OR*, -O(haloR'), -CN, -C(0)OH, -C(0)OR*, -NH 2 , -NHR*, -NR* 2 , or -N0 2 , wherein each R* is unsubstituted or where preceded by "halo" is substituted only with one or more halogens, and is independently aliphatic, -CH 2 Ph, -O(CH 2 ) 0 _iPh, or a 5-6-membered saturated, partially unsaturated, or aryl ring having 0-4 heteroatoms independently selected from nitrogen, oxygen, or sulfur.
- Suitable protecting group refers to amino protecting groups or hydroxyl protecting groups depending on its location within the compound and includes those described in detail in Protecting Groups in Organic Synthesis, T. W. Greene and P. G. M. Wuts, 3 rd edition, John Wiley & Sons, 1999.
- Suitable amino-protecting groups include methyl carbamate, ethyl carbamante, 9-fluorenylmethyl carbamate (Fmoc), 9-(2-sulfo)fluorenylmethyl carbamate, 9-(2,7- dibromo)fluoroenylmethyl carbamate, 2,7-di-t-butyl-[9-( 10,10-dioxo-l 0, 10,10,10- tetrahydrothioxanthyl)]methyl carbamate (DBD-Tmoc), 4-methoxyphenacyl carbamate
- tungsten)carbonyl] amine N-copper chelate, N-zinc chelate, N-nitroamine, N-nitrosoamine, amine N-oxide, diphenylphosphinamide (Dpp), dimethylthiophosphinamide (Mpt),
- diphenylthiophosphinamide Ppt
- dialkyl phosphoramidates dibenzyl phosphoramidate, diphenyl phosphoramidate
- benzenesulfenamide o-nitrobenzenesulfenamide (Nps)
- 2,4- dinitrobenzenesulfenamide pentachlorobenzenesulfenamide, 2-nitro-4- methoxybenzenesulfenamide, triphenylmethylsulfenamide, 3-nitropyridinesulfenamide (Npys),?-toluenesulfonamide (Ts)
- benzenesulfonamide 2,3,6,-trimethyl-4- methoxybenzenesulfonamide (Mtr), 2,4,6-trimethoxybenzenesulfonamide (Mtb), 2,6-dimethyl- 4-methoxybenzenesulfonamide (Pme), 2,3 ,5 ,6-tetramethyl-4-meth
- Suitable hydroxyl protecting groups include methyl, methoxylmethyl (MOM), methylthiomethyl (MTM), i-butylthiomethyl, (phenyldimethylsilyl)methoxymethyl (SMOM), benzyloxymethyl (BOM), /?-methoxybenzyloxymethyl (PMBM), (4-methoxyphenoxy)methyl (p-AOM), guaiacolmethyl (GUM), /-butoxymethyl, 4-pentenyloxymethyl (POM), siloxymethyl, 2- methoxyethoxymethyl (MEM), 2,2,2-trichloroethoxymethyl, bis(2-chloroethoxy)methyl, 2- (trimethylsilyl)ethoxymethyl (SEMOR), tetrahydropyranyl (THP), 3-bromotetrahydropyranyl, tetrahydrothiopyranyl, 1-methoxycyclohexyl, 4-methoxytetrahydropyranyl (MTHP), 4- methoxyt
- the protecting groups include methylene acetal, ethylidene acetal, 1-i-butylethylidene ketal, 1-phenylethylidene ketal, (4- methoxyphenyl)ethylidene acetal, 2,2,2-trichloroethylidene acetal, acetonide, cyclopentylidene ketal, cyclohexylidene ketal, cycloheptylidene ketal, benzylidene acetal, /?-methoxybenzylidene acetal, 2,4-dimethoxybenzylidene ketal, 3,4-dimethoxybenzylidene acetal, 2-nitrobenzylidene acetal, methoxymethylene acetal, ethoxymethylene acetal, dimethoxymethylene ortho ester, 1- methoxy ethylidene
- a chemical variable e.g., an R group
- R group on such a ring can be attached at any suitable position, this is generally understood to mean that the group is attached in place of a hydrogen atom on the parent ring. This includes the possibility that two R groups can be attached to the same ring atom.
- each may be the same or different than other R groups attached thereto, and each group is defined independently of other groups that may be attached elsewhere on the same molecule, even though they may be represented by the same identifier.
- Antibody includes monoclonal antibodies, polyclonal antibodies, monospecific antibodies, and multispecific antibodies (e.g., bispecific antibodies) and the term “antibody” is used interchangeably with the terms “immunoglobulin,” “immunoglobulins” and “immunoglobulin molecule”.
- Each antibody molecule has a unique structure that allows it to bind its specific antigen, but all antibodies have the same overall structure as described herein.
- the basic immunoglobulin structural unit is known to comprise a tetramer of subunits.
- Each tetramer has two identical pairs of polypeptide chains, each pair having one "light” chain (about 25 kDa) and one "heavy” chain (about 50-70 kDa).
- the amino- terminal portion of each chain includes a variable region of about 100 to 110 or more amino acids primarily responsible for antigen recognition.
- the carboxy-terminal portion of each chain defines a constant region primarily responsible for effector function.
- Light chains are classified as either kappa or lambda.
- Heavy chains are classified as gamma, mu, alpha, delta, or epsilon, and define the antibody's isotype as IgG, IgM, IgA, IgD and IgE, respectively.
- an antibody as defined herein can be of any type or class (e.g., IgG, IgE, IgM, IgD, and IgA) or subclass (e.g., IgGl , IgG2, IgG3, IgG4, IgAl and IgA2).
- variable regions and constant regions See generally, Fundamental Immunology (Paul, W., ed., 2nd ed. Raven Press, N.Y., 1989), Ch. 7.
- the variable regions of each light/heavy chain pair form the antibody binding site.
- an intact antibody has two binding sites. Except in bifunctional or bispecific antibodies, the two binding sites are the same.
- the chains all exhibit the same general structure of relatively conserved framework regions (FR) joined by three hypervariable regions, also called FR
- CDRs complementarity determining regions or CDRs.
- the CDRs from the two chains of each pair are aligned by the framework regions, enabling binding to a specific epitope.
- the terms include naturally occurring forms, as well as fragments and derivatives. Included within the scope of the term are classes of immunoglobulins (Igs), namely, IgG, IgA, IgE, IgM, and IgD. Also included within the scope of the terms are the subtypes of IgGs, namely, IgGl , IgG2, IgG3 and IgG4.
- Igs immunoglobulins
- the term is used in the broadest sense and includes single monoclonal antibodies (including agonist and antagonist antibodies) as well as antibody compositions which will bind to multiple epitopes or antigens.
- the terms specifically cover monoclonal antibodies (including full length monoclonal antibodies), polyclonal antibodies, multispecific antibodies (for example, bispecific antibodies), and antibody fragments so long as they contain or are modified to contain at least the portion of the Cfj2 domain of the heavy chain immunoglobulin constant region which comprises an N-linked glycosylation site of the Cpj2 domain, or a variant thereof. Included within the terms are molecules comprising only the Fc region, such as immunoadhesins (U.S. Published Patent Application No. 20040136986), Fc fusions, and antibody-like molecules. Alternatively, these terms can refer to an antibody fragment of at least the Fab region that at least contains an immunoadhesins (U.S. Published Patent Application No. 20040136986), Fc fusions, and antibody-like molecules. Alternatively, these terms can refer to an antibody fragment of at least the Fab region that at least contains an immunoadhesins (U.S. Published Patent Application No. 20040136986), Fc
- Fc refers to the 'fragment crystallized' C-terminal region of the antibody containing the CH2 and CH3 domains.
- Fab fragment refers to the 'fragment antigen binding' region of the antibody containing the V f, Cpjl , L and CL domains.
- antibodies further includes chemical analogues and derivatives of antibodies and antibody fragments, provided that the antibody or antibody fragment maintains its ability to bind specifically to its target antigen.
- chemical modifications are possible (e.g., glycosylation, acetylation, PEGylation and other modifications without limitation) provided specific binding ability of the antibody is retained.
- An antibody may be, for example, human, humanized, or chimeric
- a “monoclonal antibody” is an antibody obtained from a population of substantially homogeneous antibodies, i.e., individual antibodies comprising the population are identical except for possible naturally-occurring mutations that may be present in minor amounts.
- Monoclonal antibodies (mAbs) are highly specific, being directed against a single antigenic site.
- mAbs monoclonal antibodies
- each mAb is directed against a single determinant on the antigen.
- monoclonal antibodies are advantageous in that they can be synthesized by hybridoma culture, uncontaminated by other immunoglobulins.
- the term "monoclonal” indicates the character of the antibody as being obtained from a substantially homogeneous population of antibodies, and is not to be construed as requiring production of the antibody by any particular method.
- the monoclonal antibodies to be used in accordance with the present invention may be made by the hybridoma method first described by Kohler et al., (1975) Nature, 256:495, or may be made by recombinant DNA methods (See, for example, U.S. Pat. No. 4,816,567 to Cabilly et al.).
- Monoclonal antibodies further include chimeric antibodies in which a portion of the heavy and/or light chain is identical to or homologous with the corresponding s of antibodies derived from a particular species or belonging to a particular antibody class or subclass, while the remainder of the chain(s) is identical to or homologous with the corresponding sequences of antibodies derived from another species or belonging to another antibody class or subclass, as well as fragments of such antibodies, so long as they exhibit the desired biological activity.
- an “intact antibody” is one that comprises an antigen-binding variable region as well as a light chain constant domain (CL) and heavy chain constant domains, Cpjl , C j2, C j3 and Cpj4, as appropriate for the antibody class.
- the constant domains may be native sequence constant domains such as human native sequence constant domains or amino acid sequence variants thereof.
- An intact antibody may or may not have one or more "effector functions", which refers to those biological activities attributable to the Fc region (e.g., a native sequence Fc region or amino acid sequence variant Fc region) of an antibody. Examples of antibody effector functions include complement dependent cytotoxicity, antibody-dependent cell-mediated cytotoxicity (ADCC) and antibody-dependent cell-mediated phagocytosis.
- ADCC antibody-dependent cell-mediated cytotoxicity
- antibody fragment comprises a portion of an intact antibody, preferably comprising the antigen-binding or variable region thereof.
- antibody fragments include Fab, Fab', F(ab')2, and Fv fragments, diabodies, triabodies, tetrabodies, linear antibodies, single-chain antibody molecules, scFv, scFv-Fc, multispecific antibody fragments formed from antibody fragment(s), a fragment(s) produced by a Fab expression library, camelids, or an epitope-binding fragments of any of the above which immunospecifically bind to a target antigen (e.g. , a cancer cell antigen).
- a target antigen e.g. , a cancer cell antigen
- “Humanized” forms of non-human (e.g., rodent) antibodies are chimeric antibodies that contain minimal sequence derived from non-human immunoglobulin.
- the term “capable of specific binding” refers to protein or peptide (e.g., antibody) binding to a predetermined target substance (e.g., an antigen and/or groups of antigens), e.g. a target substance that is expressed on the surface of a cell; thus the term “binding to a target cell” or “binding to a cancer cell” is to be understand as referring to protein or peptide (e.g., antibody) binding to a predetermined target substance (e.g. antigen or antigens) that is expressed on such a cell.
- a predetermined target substance e.g. antigen or antigens
- the protein or peptide binds with an affinity of at least about 1x107 M 1 , and/or binds to the predetermined target substance (e.g., antigen, antigens or cell) with an affinity that is at least two-fold greater than its affinity for binding to a non-specific control substance (e.g., BSA, casein, non-cancer cells) other than the predetermined target substance or a closely-related target substance.
- a non-specific control substance e.g., BSA, casein, non-cancer cells
- drugs refers to small molecules or biomolecules that alter, inhibit, activate, or otherwise affect a biological event.
- drugs may include, but are not limited to, anti-AIDS substances, anti-cancer substances, antibiotics, anti- diabetic substances, immunosuppressants, anti-viral substances, enzyme inhibitors, neurotoxins, opioids, hypnotics, anti-histamines, lubricants, tranquilizers, anti-convulsants, muscle relaxants and anti-Parkinson substances, anti-spasmodics and muscle contractants including channel blockers, miotics and anti-cholinergics, anti-glaucoma compounds, anti-parasite and/or antiprotozoal compounds, modulators of cell-extracellular matrix interactions including cell growth inhibitors and anti-adhesion molecules, vasodilating agents, inhibitors of DNA, RNA or protein synthesis, anti-hypertensives, analgesics, anti-pyretics, steroidal and non-steroidal antiinflammatory
- polymer As used herein, a "polymer” or “polymeric structure” is a structure that includes a string of covalently bound monomers.
- a polymer can be made from one type of monomer or more than one type of monomer.
- the term “polymer” therefore encompasses copolymers, including block-copolymers in which different types of monomer are grouped separately within the overall polymer.
- a polymer can be linear or branched.
- Treat - As used herein, the term “treat” refers to the administration of a conjugate of the present disclosure to a subject in need thereof with the purpose to alleviate, relieve, alter, ameliorate, improve or affect a condition (e.g., diabetes, cancer, inflammatory disease), a symptom or symptoms of a condition (e.g., hyperglycemia), or the predisposition toward a condition.
- a condition e.g., diabetes, cancer, inflammatory disease
- a symptom or symptoms of a condition e.g., hyperglycemia
- Figure 1 shows a scheme for synthesis of ADC 12-1 and ADC 12-2.
- Figure 2 is a graph showing stability of ADC 12-1 in mouse serum.
- Figure 3 is a graph showing deconvoluted intact mass spectrum for ADC 12-1 stock solution.
- Figure 4 is a graph showing deconvoluted intact mass spectra for in-vitro stability samples of ADC 12-1. incubated at 37°C for: A) 1 hour, B) 8 hours, C) 14 days and D) 21 days.
- Figure 5 is a graph showing In vivo stability of ADC 12-1 versus "naked" antibody (non-conjugated) following IV dosing to DBA1 mice.
- Figure 6 is a graph showing deconvoluted intact mass spectra for the in vivo stability samples of ADC 12-1 from Figure 5: A) sample Bl at 1 hour, B) sample H3 at 5 days, C) sample B7 at 1 hour and D) sample H9 at 5 days.
- Figure 7 is a graph showing In vitro activity of ADC 12-2 versus "naked" antibody (non-conjugated) in 786-0 cells.
- Figure 8 shows the activity of aHer2-Duo-405 compared to that of a non- targeting antibody conjugated to Duo-405 on Her2 expressing SKBR3 cells.
- Figure 9 shows the activity of Her2-Duo-405 on Her2 negative MDA-MD-468 cells.
- the present invention provides phosphate-based linkers comprising a monophosphate, diphosphate, triphosphate, or tetraphosphate group and a linker arm comprising a tuning element, an optional spacer element, and a reactive functional group.
- the phosphate- based linkers have a distal end and a proximal end.
- the distal end of the phosphate-based linker comprises a monophosphate, diphosphate, or triphosphate group (phosphate group) linked to the distal end of the tuning element comprising the linker arm.
- the proximal end of the linker arm comprises a reactive functional group capable of reacting with a group on a ligand or targeting moiety to covalently link the phosphate -based linker to the ligand or targeting moiety.
- Interspersed between the tuning element and the reactive functional group of the linker arm may be an optional spacer element.
- the phosphate-based linker is a compound that has the following formula (I)
- V is selected from O and S; W is selected from O, N, and CH2;
- X is a tuning element selected from a covalent bond; a carbon atom; a heteroatom; an optionally substituted group selected from the group consisting of acyl, aliphatic, heteroaliphatic, aryl, heteroaryl, and heterocyclic; a carbon atom linked to a trimethylammonium group by a C 1-C5 hydrocarbon chain; nucleoside, protease sensitive group, cathepsin B sensitive group, or glycosidase sensitive group;
- Y is optional but when present it is selected from a covalent bond or a bivalent, straight or branched, saturated or unsaturated, optionally substituted C1.30 hydrocarbon chain wherein one or more methylene units of Y are optionally and independently replaced by -0-, -S-, -N(R)-, - C(O)-, C(0)0-, OC(O)-, -N(R)C(0)-
- the reactive group Z has the structure
- the distal end of the phosphate group is covalently linked to a payload, which may be a therapeutic agent such as a drug moiety or peptide, a radionuclide, or a protecting element, to provide a payload-phosphate-based linker compound comprising formula (II)
- V is selected from O and S; W is selected from O, N, and CH 2 ;
- X is a tuning element selected from a covalent bond; a carbon atom; a heteroatom; an optionally substituted group selected from the group consisting of acyl, aliphatic, heteroaliphatic, aryl, heteroaryl, and heterocyclic; a carbon atom linked to a trimethylammonium group by a C1-C5 hydrocarbon chain; nucleoside, protease sensitive group, cathepsin B sensitive group, or glycosidase sensitive group;
- Y is optional but when present is selected from a covalent bond or a bivalent, straight or branched, saturated or unsaturated, optionally substituted C1.30 hydrocarbon chain wherein one or more methylene units of Y are optionally and independently replaced by -0-, -S-, -N(R)-, - C(O)-, C(0)0-, OC(O)-, -N(R)C(0)
- halo is iodine (I), bromine (Br), fluorine (F), or chlorine (CI) and hetero is N, O, or S;
- D is a payload; each occurrence of R is independently hydrogen, a suitable protecting group, an acyl moiety, arylalkyl moiety, aliphatic moiety, aryl moiety, heteroaryl moiety, or heteroaliphatic moiety; and n is 1, 2, 3, or 4.
- the reactive group Z has the structure
- the reactive functional group at the proximal end of the payload-phosphate-based linker may be covalently linked to a ligand or targeting moiety to provide a conjugate wherein in particular embodiments, the ligand is capable of targeting the conjugate to a particular cellular target when administered to a subject in need of the payload.
- Such a compound comprises formula (III)
- V is selected from O and S; W is selected from O, N, and CH 2 ;
- X is a tuning element selected from a covalent bond; a carbon atom; a heteroatom; an optionally substituted group selected from the group consisting of acyl, aliphatic, heteroaliphatic, aryl, heteroaryl, and heterocyclic; a carbon atom linked to a trimethylammonium group by a C1-C5 hydrocarbon chain; nucleoside, protease sensitive group, cathepsin K sensitive group, or glycosidase sensitive group;
- Y is selected from a covalent bond or a bivalent, straight or branched, saturated or unsaturated, optionally substituted Ci .39 hydrocarbon chain wherein one or more methylene units of Y are optionally and independently replaced by -0-, -S-, -N(R)-, -C(O)-, C(0)0-, OC(O)-, -N(R)C(0)-, -
- halo is iodine (I), bromine (Br), fluorine (F), or chlorine (CI) and hetero is N, O, or S, and (ii) an S, NR, or O group on L; each occurrence of R is independently hydrogen, a suitable protecting group, an acyl moiety, arylalkyl moiety, aliphatic moiety, aryl moiety, heteroaryl moiety, or heteroaliphatic moiety; L is a cell-specific targeting ligand; and n is 1, 2, 3, or 4.
- the linkage Z has the structure
- the payload-ligand conjugate compound comprising a cell-specific targeting ligand conjugated to a drug moiety comprises the formula (IV)
- wavy line 1 indicates the covalent attachment site to the payloand and wavy line 2 indicates the covalent attachment site of the cell-specific targeting ligand and wherein
- X is a tuning element selected from a covalent bond; a carbon atom; a heteroatom; an optionally substituted group selected from the group consisting of acyl, aliphatic, heteroaliphatic, aryl, heteroaryl, and heterocyclic; a carbon atom linked to a trimethylammonium group by a C 1 -C5 hydrocarbon chain; nucleoside, protease sensitive group, cathepsin B sensitive group, or glycosidase sensitive group;
- Y is optional but when present is selected from a covalent bond or a bivalent, straight or branched, saturated or unsaturated, optionally substituted Ci .30 hydrocarbon chain wherein one or more methylene units of Y are optionally and independently replaced by -0-, -S-, -N( )-, -C(O)-, 0(0)0-, OC(O)-, -N(
- the linkage Z has the structure
- Y is a covalent bond, or W when Y and X are a covalent bond (on the left) and Z and L (on the right), respectively.
- the phosphate-payload linkage is stabile extracellularly and labile intracellularly, for example, when present in the lysosomal compartment of the target cell.
- the tuning element provides a tunable stability to the phosphate-drug linkage when the conjugate is within the lysosomal compartment of the target cell.
- the intracellular stability of the phosphate-payload linkage or rate of intracellular release of the payload from the conjugate may be adjusted or tuned by the particular tuning element adjacent to the phosphate group and/or by adjusting the number of the phosphate groups.
- conjugates disclosed herein are particularly useful in embodiments in which the ligand is an antibody or antibody fragment and the payload is a therapeutic agent, for example, a cytotoxin or a glucocorticoid receptor agonist, which herein is referred to as an "antibody drug conjugate" or "ADC".
- a therapeutic agent for example, a cytotoxin or a glucocorticoid receptor agonist, which herein is referred to as an "antibody drug conjugate" or "ADC”.
- ADC antibody drug conjugate
- ADC delivery of a drug moiety to its intracellular target occurs via a multistep sequence of events: binding to the cell surface, endocytosis, trafficking (within an endosome) to a lysosome, proteolytic degradation of the conjugate, and diffusion of the released drug moiety across the lysosomal or endosomal membrane toward its intracellular target and its interaction with the target.
- the linker should be sufficiently stable while in circulation to allow delivery of the intact ADC to the target cell but, on the other hand, sufficiently labile to allow release of the drug moiety from the ADC once inside the targeted cell.
- linkers have been used for preparation of ADCs that have currently entered the clinic: (a) acid-labile linkers, exploiting the acidic endosomal and lysosomal intracellular microenvironment (Hamann et al, op. cit; Blattler et al, op. cil); (b) linkers cleavable by lysosomal proteases (Dronina et al. op. cit.; King et al. op.
- the tuning element of the phosphate-based linkers disclosed herein may include a di-peptide.
- the payload-linker conjugates of the present invention wherein the payload is covalently linked to a tuning element of the linker via a monophosphate, diphosphate, triphosphate, or tetraphosphate linkage have a differentiated and tunable stability of the phosphate linkage in blood vs. an intracellular environment (e.g. lysosomal compartment). Due to location of enzymes that recognize the phosphate linkage, conjugates that have a phosphate group linking a payload to a tuning element of the linker are stable in circulation (plasma or blood) but reactive in intracellular compartments (e.g., lysosomes) making them suitable for intracellular delivery of payload conjugates.
- the exemplary payload-phosphate-based linker conjugates in the Examples show that the payload-phosphate-based linker conjugates of the present invention are stable in blood, which is advantageous for extending the half-life and to prevent premature release of payload from the conjugates.
- the inventors have discovered that by modifying the tuning element and/or V and/or W, and/or the number of phosphate groups, the ability to tune reactivity or cleavage of the phosphate linkage in a lysosomal environment so as to release the payload from the conjugate.
- the rate of release of the payload is dependent on the proximal substitution of the tuning element.
- the ability to cleave the phosphate linkage between the payload and the tuning element efficiently in a lysosome is advantageous for the release of the payload from the conjugate once it has been delivered to a cell and internalized through an endosomal pathway.
- the phosphate-based linkers of the present invention there is no need to for the phosphate-based linkers of the present invention to be self-immolative.
- the excellent solubility of the payload-phosphate-based linker facilitates conjugation to a ligand or cell-targeting moiety and minimizes aggregation of the conjugates.
- the phosphate contributes to retention of the payload to the conjugate within cell until phosphate linkage is fully cleaved and limits permeability of conjugates containing the payload from entering non- target cells.
- the phosphate -based linkers provide greater solubility relative to disulfide linkers, cathepsin B-cleavable linkers, esters and acid-sensitive linkers such as hydrazones. They enable the release of the payload in its parent or unadultered form unlike some of the alternative linkers, and may offer an improved blood/lysosome stability profile. Specifically, these phosphate -based linkers will provide superior blood stability relative to esters and disuflides.
- Phosphate-based linkers following lysosomal cleavage will release an alcohol or amine-containing payload whereas the other linker formats may require self-immolative tethers to accomplish this or leave residual linker on the payload after lysosomal cleavage.
- the phosphate-based linker may have greater blood stability relative to the self-immolative cathepsin B linkers in the art, particularly when attached via the oxygen atom of a hydroxyl group of an alcohol-containing payload.
- the enzymatic hydrolysis of the phosphate linkage may be more rapid than the acid-hydrolysis of hyrdazones.
- the phosphate-based linkers disclosed herein minimize the propensity for conjugates comprising particular payloads to aggregate.
- antibody-drug conjugates comprising duocarmycin are known to have a propensity to aggregate.
- antibodies conjugated to duocarmycin via a phosphate-based linker disclosed herein did not produce detectable aggregates.
- the phosphate-based linkers disclosed herein are particularly useful for conjugating payloads that are prone to forming aggregates to a cell-specific targeting ligand to provide a conjugate with a reduced or no detectable propensity for aggregation.
- the phosphate-based linkers disclosed herein provide an ideal design for antibody-drug conjugates and the like.
- the phosphate group comprising the phosphate-based linkers disclosed herein may comprise 1 , 2, 3, or 4 phosphate atoms.
- the phosphate group may be a phosphate ester OH ? pyrophosphate ester * 0 °H o ? triphosphate ester .
- the phosphate group may be a phosphoramidate
- Payloads are provided in the current invention as part of a payload-ligand conjugate where the payload is linked to a ligand via a phosphate-based linker comprising reactive functional group selected from the group consisting of N- hydroxysuccinimidyl ester, para-nitrophenyl carbonate, para-nitrophenyl carbamate, methyl ketone, azide, hydrazine, pentafluorophenyl, haloacetamide, maleimide, hydroxylamine, strained cycloalkyne, and heterocycloalkyne, alkyne, diene, azadiene, and heterocyclic azadiene, wherein halo is iodine (I), bromine (Br), fluorine (F), or chlorine (CI) and hetero is N, O, or S.
- a phosphate-based linker comprising reactive functional group selected from the group consisting of N- hydroxysuccinimidyl ester, para-nitropheny
- the payload must possess a desired biological activity and contain a reactive functional group capable of forming a covalent linkage to the phosphate group of the phosphate-based linker.
- the desired biological activity includes the diagnosis, cure, mitigation, treatment, or prevention of disease in an animal such as a human.
- the term "payload” refers to chemicals recognized as drugs in the official United States Pharmacopeia, official Homeopathic Pharmacopeia of the United States, or official National Formulary, or any supplement thereof. Exemplary drugs are set forth in the Physician's Desk Reference (PDR) and in the Orange Book maintained by the U.S. Food and Drug Administration (FDA).
- the functional groups on the drug include primary or secondary amines, hydroxyls, sulfhydryls, carboxyls, aldehydes, and ketones.
- the drug must have at least one, but may have 2, 3, 4, 5, 6 or more reactive functional groups.
- the payload may also be a biomolecule such as a peptide, polypeptide, or protein; a nucleic acid molecule or analog thereof, a carbohydrate, polysaccharide, a saccharide, or any other therapeutic agent that has a biological effect.
- the payload-ligand conjugate is effective for the usual purposes for which the corresponding drugs are effective, but have superior efficacy because of the ability, inherent in the ligand, to transport the drug to the desired cell where it is of particular benefit.
- exemplary drugs include proteins, peptides, and small molecule drugs containing a functional group for linkage to the phosphate moiety of the linker.
- these drugs include, for example, the enzyme inhibitors such as dihydrofolate reductase inhibitors, and thymidylate synthase inhibitors, DNA intercalators, glutocorticoid receptor agonists, nuclear recemptor agonists, antinflammatory agents, DNA cleavers, topoisomerase inhibitors, the anthracycline family of drugs, the vinca drugs, the mitomycins, the bleomycins, the cytotoxic nucleosides, the pteridine family of drags, diynenes, the podophyllotoxins, differentiation inducers, and taxols.
- the enzyme inhibitors such as dihydrofolate reductase inhibitors, and thymidylate synthase inhibitors
- DNA intercalators glutocorticoid receptor agonists, nuclear recemptor agonists, antinflammatory agents, DNA cleavers, topoisomerase inhibitors, the anthracycline family of drugs, the vinca drugs, the
- the drugs of the current invention include cytotoxic drugs useful in cancer therapy and other small molecules, proteins or polypeptides with desired biological activity, such as a toxin.
- the drug may be selected to be activated at a tumor cells by conjugation to a tumor- specific ligand.
- These tumor specific drug-ligand conjugates have tumor specificity arising from the specificity of the ligand. Examples of this are drug-ligand conjugates that are highly selective substrates for tumor specific enzymes, where these enzymes are present in the proximity of the tumor in sufficient amounts to generate cytotoxic levels of free drug in the vicinity of the tumor.
- Cytotoxic drugs useful in the current invention include, for example, duocarmycins and CC-1065, and analogues thereof, including CBI (1,2,9,9a- tetrahydrocyclopropa[c]benz[e]indol-4-one)-based analogues, MCBI (7-methoxy- 1,2,9,9a- tetra- hydrocyclopropa[c]benz[e]indol-4-one)-based analogues and CCBI (7-cyano- 1,2,9,9a- tetra- hydrocyclo-propa[c]benz[e]-indol-4-one)-based analogues of the duocarmycins and CC- 1065, doxorubicin and doxorubicin conjugates such as morpholino-doxorubicin and cyanomorpholino- doxorubicin, dolastatins such as dolestatin-10, combretastatin, calicheamicin,
- Anti-inflammatory agents such as glucocorticoid receptor agonists include glucocorticoids such as Cortisol, cortisone acetate, beclometasone, prednisone, prednisolone, methylprednisolone, betamethasone, trimcinolone, budesonide, dexamethasone, fluticasone, fluticasone propionate, fluticasone furoate, compound 15-5, or mometasone.
- glucocorticoids such as Cortisol, cortisone acetate, beclometasone, prednisone, prednisolone, methylprednisolone, betamethasone, trimcinolone, budesonide, dexamethasone, fluticasone, fluticasone propionate, fluticasone furoate, compound 15-5, or mometasone.
- the linker arm of the phosphate-based linkers disclosed herein comprises a tuning element at the distal end covalently linked to a phosphate group and a functional reactive group at the proximal end capable of covalent linkage to a cell-targeting ligand.
- the linker arm may further include a spacer element interposed between the tuning element and the reactive functional group. Examples of tuning elements include but are not limited to
- R j and R 2 each independently any amino acid
- the wavy lines mark the covalent bond to the O, N, or CH2 of a phosphate group at the distal end (left) and the covalent bond to an atom of the functional reactive group on the proximal end (right), or optionally, a spacer element.
- tuning elements include but are not limited to
- the wavy lines mark the covalent bond to the O, N, or CH2 of a phosphate group at the distal end (left) and the covalent bond to an atom of the functional reactive group on the proximal end (right), or optionally, a spacer element.
- the spacer element is to allow for distance control away from the cell- targeting ligand. In some embodiments, this distance may have an impact on the
- spacer elements include straight polyethylglycol (PEG) chains (of a defined length), straight carbon chains with or without solubilizing groups attached thereto, a dipeptide, a tripeptide, a tetrapeptide, an enzyme cleavage site, for eample, a cathepsin cleavage site haing the structure
- the present invention further provides a compound comprising a glucocorticoid receptor agonist conjugated to a phosphate-based linker, wherein the compound has the structure of compound 1-4, 2-7, 3-4, 4-3, 5-3, 6-2, 7-1, 8-5, 9-4, 10-1, 11-5, 12-3, 13-7, 14-5, 15-5, 16-5, 17-5, 18-3, 19-5, 20-5, or 21-5.
- the structures of these compounds are shown in Examples 1-21.
- the present invention further provides antibody drug conjugates in which one or more of compounds 1-4, 2-7, 3-4, 4-3, 5-3, 6-2, 7-1, 8-5, 9-4, 10-1, 11-5, 12-3, 13-7, 14-5, 15-5, 16-5, 17-5, 18-3, 19-5, 20-5, or 21-5 is conjugated to the antibody.
- the antibody comprises one or more a non-natural amino acid having a reactive site capable of binding to compound 1-4, 2-7, 3-4, 4-3, 5-3, 6-2, 7-1, 8-5, 9-4, 10-1, 11-5, 12-3, 13-7, 14-5, 15- 5, 16-5, 17-5, 18-3, 19-5, 20-5, or 21-5.
- the antibody comprises one or more para-azido-phenylalanine residues or para-acetyl-phenylalanine residues.
- the antibody-drug conjugate comprises compound 1-4, 2-7, 3-4, 4-3, 5-3, 6-2, 8-5, 9-4, 11-5, 12-3, 13-7, 14-5, 15-5, 16-5, 17-5, 18-3, or 19-5 conjugated to the azido group on a para-azido-phenylalanine residue within the antibody amino acid sequence.
- the antibody drug conjugate comprises compound 7-1 or 10-1 conjugated to a free thiol group within the amino acid sequence of the antibody, for example, the thio group of a cysteine residue, on the antibody.
- the antibody-drug conjugate comprises compound 20-5 or 21-5 conjugated to the methyl ketone group on a para-acetyl- phenylalanine residue within the antibody amino acid sequence
- the present invention further provides compositions comprising one or more antibody drug conjugates wherein at least one antibody drug conjugate is conjugated to compound 1-4, 2-7, 3-4, 4-3, 5-3, 6-2, 7-1, 8-5, 9-4, 10-1, 11-5, 12-3, 13-7, 14-5, 15-5, 16-5, 17- 5, 18-3, 19-5 , 20-5, or 21-5.
- the antibody comprises one or more a non-natural amino acid having a reactive site capable of binding to compound 1-4, 2-7, 3-4, 4-3, 5-3, 6-2, 7-1, 8-5, 9-4, 10-1, 11-5, 12-3, 13-7, 14-5, 15-5, 16-5, 17-5, 18-3, 19-5, 20-5, or 21-5.
- the antibody comprises one or more para-azido-phenylalanine residues or para-acetyl-phenylalanine residues.
- the antibody-drug conjugate comprises compound 1-4, 2-7, 3-4, 4-3, 5-3, 6-2, 8-5, 9-4, 11-5, 12-3, 13-7, 14-5, 15- 5, 16-5, 17-5, 18-3, or 19-5 conjugated to the azido group on a para-azido-phenylalanine residue within the antibody amino acid sequence.
- the antibody drug conjugate comprises compound 7-1 or 10-1 conjugated to a free thiol group within the amino acid sequence of the antibody, for example, the thio group of a cysteine residue, on the antibody.
- the antibody-drug conjugate comprises compound 20-5 or 21-5 conjugated to the methyl ketone group on a para-acetyl-phenylalanine residue within the antibody amino acid sequence.
- the linker arm and payload of the invention may be linked to a targeting ligand that selectively delivers a pay load to a cell, organ, or region of the body.
- exemplary targeting ligands such as antibodies (e.g., chimeric, humanized and human), ligands for receptors, lectins, saccharides, antibodies, and the like are recognized in the art and are useful without limitation in practicing the present invention.
- Other targeting ligands include a class of compounds that do not include specific molecular recognition motifs include macromolecules such as poly(ethylene glycol), polysaccharide, polyamino acids and the like, which add molecular mass to the cytotoxin. The additional molecular mass affects the pharmacokinetics of the payload, e.g., serum half-life.
- the invention provides a payload, linker or payload- linker conjugate with a targeting ligand that is a biomolecule, e.g, an antibody, receptor, peptide, lectin, saccharide, nucleic acid or a combination thereof.
- a targeting ligand that is a biomolecule, e.g, an antibody, receptor, peptide, lectin, saccharide, nucleic acid or a combination thereof.
- Biomolecules useful in practicing the present invention may be derived from any source. The biomolecules may be isolated from natural sources or may be produced by synthetic methods. Proteins may be natural proteins or mutated proteins. Mutations may be effected by chemical mutagenesis, site-directed
- Proteins useful in practicing the instant invention include, for example, enzymes, antigens, antibodies and receptors.
- Antibodies may be either polyclonal or monoclonal, but most preferably are monoclonal and may be human, humanized, or human chimeric antibodies.
- Peptides and nucleic acids may be isolated from natural sources or can be wholly or partially synthetic in origin.
- the targeting ligand is an antibody, or antibody fragment, that is selected based on its specificity for an antigen expressed on a target cell, or at a target site, of interest.
- an antibody or antibody fragment
- a wide variety of tumor-specific or other disease-specific antigens have been identified and antibodies to those antigens have been used or proposed for use in the treatment of such tumors or other diseases.
- the antibodies that are known in the art may be used in the conjugates of the invention, in particular for the treatment of the disease with which the target antigen is associated.
- Non-limiting examples of target antigens (and their associated diseases) to which a conjugate of the invention may be targeted include: Her2 (breast cancer), CD4 (lymphomas, autoimmune diseases, including rheumatoid arthritis), CD20 (lymphomas), EGFR (solid tumors), CD22 (lymphomas, including non-Hodgkin's lymphoma), CD23 (asthma), CD25, CD52 (chronic lymphocytic leukemia), CD30 (lymphomas, including non-Hodgkin's lymphoma), CD33 (acute myelogenous leukemia), CD40L (immune thromobcytopenic purpura), CD70, CD74, CD80 (psoriasis), CD 163, Mucl8 (melanoma), integrins (solid tumors), PSMA (prostate cancer, benign prostatic hyperplasia), CEA (colorectal cancer), CD1 la (psoriasis), CTLA
- Targeting ligands may be attached to the linker arm by any available reactive group that can react with the reactive functional group on the proximal end of the linker arm.
- peptides and proteins may be attached through an amine, carboxyl, sulfhydryl, or hydroxyl group. Such a group may reside at a peptide terminus or at a site internal to the peptide chain.
- Nucleic acids may be attached through a reactive group on a base (e.g., exocyclic amine) or an available hydroxyl group on a sugar moiety (e.g., 3'- or 5'- hydroxyl).
- the peptide or protein may be further derivatized at one or more sites to allow for the attachment of appropriate reactive groups onto the peptide or protein. See, Chrisey et al. Nucleic Acids Res. 24:3031-3039 (1996).
- the protein or peptide may be synthesized to contain one or more non-natural amino acids which may then serve as a site for attachment of the linker arm comprising the payload-phosphate-based linker.
- Antibodies comprising non-natural amino acids for conjugation and methods for making such antibodies have been disclosed in U.S. Patent No. 7,632,924, which is incorporated herein in its entirety. Examples of non-natural amino acids include but are not limited to para-azido-phenylalanine and para-acetyl-phenylalanine.
- conjugates disclosed herein are useful for the manufacture of medicaments for the treatment of diseases or disorders such as an inflammatory disease or cancer.
- the conjugates disclosed herein may be formulated into pharmaceutical formulations for use in treating diseases or disorders such as an inflammatory disease or cancer.
- the present invention provides a pharmaceutical formulation comprising a compound of the invention and a pharmaceutically acceptable carrier.
- the compounds described herein including pharmaceutically acceptable carriers such as addition salts or hydrates thereof, can be delivered to a patient using a wide variety of routes or modes of administration. Suitable routes of administration include, but are not limited to, inhalation, transdermal, oral, rectal, transmucosal, intestinal and parenteral administration, including intramuscular, subcutaneous and intravenous injections.
- the conjugates of the invention comprising an antibody or antibody fragment as the targeting moiety are administered parenterally, more preferably intravenously.
- administering or “administration” are intended to encompass all means for directly and indirectly delivering a compound to its intended site of action.
- the compounds described herein, or pharmaceutically acceptable salts and/or hydrates thereof may be administered singly, in combination with other compounds of the invention, and/or in cocktails combined with other therapeutic agents.
- the choice of therapeutic agents that can be co-administered with the compounds of the invention will depend, in part, on the condition being treated.
- the active compound(s) of the invention are administered per se or in the form of a pharmaceutical composition wherein the active compound(s) is in admixture with one or more pharmaceutically acceptable carriers, excipients or diluents.
- Pharmaceutical compositions for use in accordance with the present invention are typically formulated in a conventional manner using one or more physiologically acceptable carriers comprising excipients and auxiliaries, which facilitate processing of the active compounds into preparations which, can be used pharmaceutically. Proper formulation is dependent upon the route of administration chosen.
- penetrants appropriate to the barrier to be permeated are used in the formulation.
- penetrants are generally known in the art.
- the compounds can be formulated readily by combining the active compound(s) with pharmaceutically acceptable carriers well known in the art.
- Such carriers enable the compounds of the invention to be formulated as tablets, pills, dragees, capsules, liquids, gels, syrups, slurries, suspensions and the like, for oral ingestion by a patient to be treated.
- Pharmaceutical preparations for oral use can be obtained solid excipient, optionally grinding a resulting mixture, and processing the mixture of granules, after adding suitable auxiliaries, if desired, to obtain tablets or dragee cores.
- Suitable excipients are, in particular, fillers such as sugars, including lactose, sucrose, mannitol, or sorbitol; cellulose preparations such as, for example, maize starch, wheat starch, rice starch, potato starch, gelatin, gum tragacanth, methyl cellulose,
- hydroxypropylmethyl-cellulose sodium carboxyniethylcellulose, and/or polyvinylpyrrolidone (PVP).
- disintegrating agents may be added, such as the cross-linked polyvinyl pyrrolidone, agar, or alginic acid or a salt thereof such as sodium alginate.
- Dragee cores are provided with suitable coatings.
- suitable coatings For this purpose, concentrated sugar solutions may be used, which may optionally contain gum arabic, talc, polyvinyl pyrrolidone, carbopol gel, polyethylene glycol, and/or titanium dioxide, lacquer solutions, and suitable organic solvents or solvent mixtures.
- Dyestuffs or pigments may be added to the tablets or dragee coatings for identification or to characterize different combinations of active compound doses.
- compositions which can be used orally, include push- fit capsules made of gelatin, as well as soft, sealed capsules made of gelatin and a plasticizer, such as glycerol or sorbitol.
- the push-fit capsules can contain the active ingredients in admixture with filler such as lactose, binders such as starches, and/or lubricants such as talc or magnesium stearate and, optionally, stabilizers.
- the active compounds may be dissolved or suspended in suitable liquids, such as fatty oils, liquid paraffin, or liquid polyethylene glycols.
- stabilizers may be added. All formulations for oral administration should be in dosages suitable for such administration.
- compositions may take the form of tablets or lozenges formulated in conventional manner.
- the compounds for use according to the present invention are conveniently delivered in the form of an aerosol spray presentation from pressurized packs or a nebulizer, with the use of a suitable propellant, e.g.,
- the dosage unit may be determined by providing a valve to deliver a metered amount.
- Capsules and cartridges of e.g., gelatin for use in an inhaler or insufflator may be formulated containing a powder mix of the compound and a suitable powder base such as lactose or starch.
- the compounds may be formulated for parenteral administration by injection, e.g., by bolus injection or continuous infusion. Injection is a preferred method of administration for the compositions of the current invention.
- Formulations for injection may be presented in unit dosage form, e.g., in ampoules or in multi-dose containers, with an added preservative.
- the compositions may take such forms as suspensions, solutions or emulsions in oily or aqueous vehicles, and may contain formulatory agents such as suspending, stabilizing and/or dispersing agents may be added, such as the cross-linked polyvinyl pyrrolidone, agar, or alginic acid or a salt thereof such as sodium alginate.
- compositions for parenteral administration include aqueous solutions of the active compounds in water-soluble form. Additionally, suspensions of the active compounds may be prepared as appropriate oily injection suspensions. Suitable lipophilic solvents or vehicles include fatty oils such as sesame oil, or synthetic fatty acid esters, such as ethyl oleate or triglycerides, or liposomes. Aqueous injection suspensions may contain substances, which increase the viscosity of the suspension, such as sodium carboxymethyl cellulose, sorbitol, or dextran. Optionally, the suspension may also contain suitable stabilizers or agents, which increase the solubility of the compounds to allow for the preparation of highly, concentrated solutions.
- the agents of the invention may be formulated in aqueous solutions, preferably in physiologically compatible buffers such as Hanks's solution, Ringer's solution, or physiological saline buffer.
- physiologically compatible buffers such as Hanks's solution, Ringer's solution, or physiological saline buffer.
- the active ingredient may be in powder form for constitution with a suitable vehicle, e.g., sterile pyrogen-free water, before use.
- the compounds may also be formulated in rectal compositions such as suppositories or retention enemas, e.g., containing conventional suppository bases such as cocoa butter or other glycerides.
- the compounds may also be formulated as a depot preparation. Such long acting formulations may be administered by implantation or transcutaneous delivery (e.g., subcutaneously or intramuscularly), intramuscular injection or a transdermal patch.
- the compounds may be formulated with suitable polymeric or hydrophobic materials (e.g., as an emulsion in an acceptable oil) or ion exchange resins, or as sparingly soluble derivatives, for example, as a sparingly soluble salt.
- the pharmaceutical compositions also may comprise suitable solid or gel phase carriers or excipients.
- Such carriers or excipients include but are not limited to calcium carbonate, calcium phosphate, various sugars, starches, cellulose derivatives, gelatin, and polymers such as polyethylene glycols. The following examples are intended to promote a further understanding of the present invention.
- Step A 2-((8S, 9R, 1 OS, 11S,13S,14S, 16R, 17R)-9-fluoro-ll, 17-dihydroxy- 10, 13,16-trimethyl-3- oxo-6, 7, 8, 9,10,11,12,13,14,15,16,17-dodecahydro-3H-cyclopenta[a]phenanthren-l 7-yl)-2- oxoethyl dihydrogen phosphate (1-1)
- Step B (9H-fluoren-9-yl)methyl (2- ((hydroxy (lH-imidazol-l-yl)phosphoryl)oxy)ethyl)carbamate (1-2)
- the title compound was prepared from N-(9- fluorenylmethoxycarbonyl)ethanolamine according to the protocol outlined in Example 1-1 to afford 1-2.
- Step D 2-(2-(cyclooct-2-yn-l-yloxy)acetamido)ethyl (2-((8S,9R,10S, l lS,13S, 14S,16R,17R)-9- fiuoro-11, 17 -dihydroxy-10,13,16-trimethyl-3-oxo-6, 7, 8, 9, 10,11, 12,13,14,15, 16,17-dodecahydro- 3H-cyclopenta[a]phenanthren-17-yl)-2-oxoethyl) dihydrogen pyrophosphate (1-4)
- dexamethasone linker 2-(2-(cyclooct-2-yn-l- yloxy)acetamido)ethyl (2-((8S,9R, 10S,11 S, 13S,14S, 16R, 17R)-9-fluoro- 1 1 ,17-dihydroxy- 10,13, 16-trimethyl-3-oxo-6,7,8,9,10, l 1,12,13, 14, 15, 16, 17-dodecahydro-3H- cyclopenta[a]phenanthren- 17-yl)-2-oxoethyl) trihydrogen triphosphate (2-7) was as follows.
- Step A 1 ,3-dioxoisoindolin-2-yl 2-(cyclooct-2-yn-l-yloxy)acetate (2-1)
- Step B (9H-fluoren-9-yl)methyl dihydrogen phosphate (2-2)
- Step D 2-((8S,9R,10S,l lS,13S, 14S,16R,17R)-9-fluoro-ll,17-dihydroxy-10 3,16-trimethyl-3- oxo-6, 7, 8, 9,10,11,12,13,14, 15,16, 17-dodecahydro-3H-cyclopenta[a]phenanthren-l 7-yl)-2- oxoethyl trihydrogen diphosphate (2-4)
- Step E (9H-fluoren-9-yl)methyl (2-((((((((((((((2-((8S,9R, 10S,llS, 13S,14S,16R, 17R)-9-fluoro-ll, 17- dihydroxy-10, 13,16-trimethyl-3-oxo-6, 7, 8, 9,10,11 ,12, 13,14, 15,16,17-dodecahydro-3H- cyclopenta[a]phenanthren-l 7-yl)-2- oxoethoxy) (hydroxy)phosphoryl)oxy) (hydroxy)phosphoryl)oxy) (hydroxy)phosphoryl)oxy) (hydroxy)phosphoryl)oxy)ethyl)ca rbamate (2-5)
- Step F 2-amionethyl (2-((8S,9R,10S,llS,13S, 14S,16R,17R)-9-fluoro-ll, 17-dihydroxy-10,13,16- trimethyl-3-oxo-6, 7, 8, 9,10, 11,12,13,14, 15,16, 17-dodecahydro-3H-cyclopenta[ a] phenanthren- 17-yl)-2-oxoethyl) trihydrogen triphosphate (2-6)
- Step G 2-(2-(cyclooct-2-yn-l-yloxy)acetamido) ethyl (2-((8S,9R,10S, llS,13S, 14S,16R,17R)-9- fluoro-11, 17-dihydroxy-l 0,13,16-trimethyl-3-oxo-6, 7, 8, 9, 10,11, 12,13,14,15, 16,17 -dodecahydro- 3H-cyclopenta[a]phenanthren-17-yl)-2-oxoethyl) trihydrogen triphosphate (2-7)
- Step D 4-(2-(cyclooct-2-yn-l-yloxy)acetamido)phenyl (2-((8S,9R,10S, l lS,13S,14S,16R,17R)-9- fluoro-11, 17-dihydroxy-l 0,13,16-trimethyl-3-oxo-6, 7, 8, 9, 10,11, 12,13,14,15, 16,17-dodecahydro- 3H-cyclopenta[a]phenanthren-17-yl)-2-oxoethyl) dihydrogen pyrophosphate (3-4)
- Step B 2-aminoethyl (2-((8S,9R,10S,llS,13S, 14S,16R,17R)-9-fluoro-ll, 17-dihydroxy-10,13,16- trimethyl-3-oxo-6, 7, 8, 9,10, 11,12,13,14, 15,16, 17-dodecahydro-3H-cyclopenta[a]phenanthren- 17-yl)-2-oxoethyl) hydrogen phosphate, HCl (4-2)
- Step C 2-(2-(cyclooct-2-yn-l-yloxy)acetamido)ethyl (2-((8S,9R,10S, llS,13S, 14S,16R, 17R)-9- fluoro-11, 17-dihydroxy-l 0,13,16-trimethyl-3-oxo-6, 7, 8, 9, 10,11, 12,13,14,15, 16,17-dodecahydro- 3H-cyclopenta[a] phenanthren- 17-yl)-2-oxoethyl) hydrogen phosphate (4-3) To a stirred solution of 2-(cyclooct-2-yn-l-yloxy)acetic acid (0.036 g, 0.20 mmol) in dichloromethane (1 ml) was added HOAT (0.027 g, 0.20 mmol), EDC (0.041 g, 0.22 mmol) and triethylamine (0.05 mL, 0.36 mmol).
- Step A tert-butyl (4-(((2-((8S,9R, 10S, llS,13S, 14S,16R,17R)-9-fluoro-ll,17-dihydroxy-10,13, 16- trimethyl-3-oxo-6, 7, 8, 9,10, 11,12,13,14, 15,16, 17-dodecahydro-3H-cyclopenta[ a] phenanthren- 17-yl)-2-oxoethoxy)(hydroxy)phosphoryl)oxy)phenyl)carbamate (5-1)
- Step B 4-aminophenyl (2-((8S,9R,10S, llS,13S, 14S,16R, 17R)-9-fluoro-ll,17-dihydroxy- 10,13,16-trimethyl-3-oxo-6, 7, 8,9, 10,11, 12,13,14,15,16,17-dodecahydro-3H-cycl
- Step C 4-(2-(cyclooct-2-yn-l-yloxy)acetamido)phenyl (2-((8S,9R,10S, llS, 13S,14S, 16R,17R)-9- fluoro-11, 17-dihydroxy-l 0,13,16-trimethyl-3-oxo-6, 7, 8, 9, 10,11, 12,13,14,15, 16,17 -dodecahydro- 3H-cyclopenta[a] phenanthren- 17-yl)-2-oxoethyl) hydrogen phosphate (5-3)
- Step A N-(2-aminoethyl)-2-(cyclooct-2-yn-l-yloxy)acetamide (6-1)
- Step B 2-((8S, 9R, 1 OS, 11S,13S,14S, 16R, 17R)-9-fluoro-ll, 17-dihydroxy-10, 13, 16-trimethyl-3- oxo-6, 7, 8, 9,10,11,12,13,14, 15,16, 17-dodecahydro-3H-cyclopenta[ a] phenanthren- 17-yl)-2- oxoethyl hydrogen (2-(2-(cyclooct-2-yn-l-yloxy)acetamido)ethyl)phosphoramidate (6-2)
- dexamethasone linker ((2R,3S,4R,5 )-5-(2,4-dioxo-3,4- dihydropyrimidin-l(2H)-yl)-3-(((2-((8S,9R,10S,H S,13S, 14S,16R,17R)-9-fluoro-l l,17- dihydroxy-10,13, 16-trimethyl-3-oxo-6,7,8,9, 10,l 1,12,13, 14,15, 16,17-dodecahydro-3H- cyclopenta[a]phenanthren-17-yl)-2-oxoethoxy)(hydroxy)phosphoryl)oxy)-4- hydroxytetrahydrofuran-2-yl)methyl (2-(2-(cyclooct-2-yn- 1 -yloxy)acetamido)ethyl)carbamate (8-5) was as follows.
- Step A (2R,3R,4R,5R)-2-((bis(4-methoxyphenyl)(phenyl)methoxy)methyl)-4-((tert- butyldimethylsilyl)oxy)-5-(2,4-dioxo-3,4-dihydropyrimidin-l(2H) (2- cyanoethyl) (2-((8S,9R,10S,l 1S,13S,14S, 16R, 17R)-9-fluoro-ll, 17-dihydroxy- 10,13, 16-trimethyl- 3-oxo-6, 7, 8, 9, 10,11,12,13, 14,15, 16,17-dodecahydro-3H-cyclopenta[ a] phenanthren- 17-yl)-2- oxoethyl) phosphite (8-1)
- Step B (2R,3R,4R,5R)-4-((tert-butyldimethylsilyl)oxy)-5-(2,4-dioxo-3,4-dihydropyrimidin- l(2H)-yl)-2-(hydroxymethyl)tetrahydrofuran-3-yl (2-cyanoethyl) (2-
- Step C ((2R,3R,4R,5R)-4-((tert-bu1yldimethylsilyl)oxy)-5-(2,4-dioxo-3,4-dihydropyrimidin- l(2H)-yl)-3-(((2-((8S,9R,10S,US, 13S,14S, 16R,17R)-9-fluoro-ll,17-dihyd
- Step D ((2R,3R,4R,5R)-4-((tert-butyldimethylsilyl)oxy)-5-(2,4-dioxo-3,4-dihydropyrimidin- l(2H)-yl)-3-(((2-((8S,9R,10S,llS 3S,14S, 16R,17R)-9-fluoro-ll,17-dihydroxy- trimethyl-3-oxo-6, 7, 8, 9,10, 11,12,13,14, 15,16, 17-dodecahydro-3H-cyclopenta[ a] phenanthren- 17-yl)-2-oxoethoxy) (hydroxy)phosphoryl)oxy)tetrahydrofuran-2-yl)methyl (2- aminoethyl)carbamate (8-4)
- Step E ((2R, 3S, 4R, 5R)-5-(2, 4-dioxo-3, 4-dihydropyrimidin- 1 (2H)-yl)-3-(((2- ((8S, 9R, 1 OS, 11S,13S,14S, 16R, 17R)-9-fluoro-ll, 17-dihydroxy-10, 13, 16-trimethyl-3-oxo- 6, 7, 8,9, 10,11, 12,13, 14,15,16,17-dodecahydro-3H-cyclopenta[a]phenanthren-l 7-yl)-2- oxoethoxy)(hydroxy)phosphoryl)oxy)-4-hydroxytetrahydrofuran-2-yl)methyl (2-(2-(cyclooct-2- yn-l-yloxy)acetamido)ethyl)carbamate (8-5)
- Step A 2-((6aR,6bS, 7S,8aS,8bS, l laR,12aS,12bS)-7-hydroxy-6a,8a-dimethyl-4-oxo-10-propyl- 2,4, 6a, 6b, 7,8,8a,8b, lla,12, 12a,12b-dodecahydro-lH-naphtho[2 ', 1 ':4,5]indeno[ 1,2- d] [l,3]dioxol-8b-yl)-2-oxoethyl dihydrogen phosphate (9-1)
- Step B (9H-fluoren-9-yl)methyl (2-((hydroxy((hydroxy(2- ((6aR, 6bS, 7S, 8aS,8bS, llaR, 12aS, 12bS)- 7 -hydroxy-6a, 8a-dimethyl-4-oxo-l 0-propyl-
- Step C 2-aminoethyl (2-((6aR,6bS, 7S,8aS,8bS,llaR,12aS, 12bS)-7-hydroxy-6a,8a-dimethyl-4- oxo-1 O-propyl-2, 4, 6a, 6b, 7, 8, 8a, 8b, 11a, 12, 12a, 12b-dodecahydro-lH- naphtho[2 ', ⁇ : 4,5]indeno[ 1 ,2-d] [ 1 ,3] dioxol-8b-yl)-2-oxoethyl) dihydrogen pyrophosphate (9-3)
- Step D 2-(2-(cyclooct-2-yn-l-yloxy)acetamido)ethyl (2-((6aR, 6bS, 7S,8aS,8bS, llaR, 12aS,12bS)- 7-hydroxy-6a, 8a-dimethyl-4-oxo-l O-propyl-2, 4, 6a, 6b, 7, 8, 8a, 8b, 11a, 12, 12a, 12b-dodecahydro- lH-naphtho[2',l ':4,5]indeno[l,2-d] [l,3]dioxol-8b-yl)-2-oxoethyl) dihydrogen pyrophosphate (9-4)
- Step A (9H-fluoren-9-yl)methyl (2-(2-(2-(2-(2-hydroxyethoxy)ethoxy)ethyl)carbamate (11- 1)
- Step B (9H-fluoren-9-yl)methyl (2-(2-(2-(2- (phosphonooxy)ethoxy)ethoxy)ethoxy) ethyl) carbamate (11-2)
- Step C (9H-fluoren-9-yl)methyl (2-(2-(2-(2-(2-((hydroxy((hydroxy(2- (( 6aR, 6bS, 7S, 8aS,8bS, llaR, 12aS, 12bS)- 7-hydroxy-6a, 8a-dimethyl-4-oxo-l 0-propyl- 2,4, 6a, 6b, 7,8,8a,8b, lla,12, 12a,12b-dodecahydro-lH-naphtho[2 ', 1 ':4,5]indeno[ 1,2- djfl, 3 ] dioxol-8b-yl)-2- oxoethoxy)phosphoryl)oxy)phosphoryl)oxy)ethoxy)ethoxy)ethoxy)ethyl)carbamate
- Step D 2-(2-(2-(2-aminoethoxy)ethoxy)ethyl (2-((6aR,6bS, 7S,8aS,8bS,llaR,12aS,12bS)- 7-hydroxy-6a, 8a-dimethyl-4-oxo-l 0-propyl-2, 4, 6a, 6b, 7, 8, 8a, 8b, 11a, 12, 12a, 12b-dodecahydro- lH-naphtho[2',l ':4,5]indeno[l,2-d] [l,3]dioxol-8b-yl)-2-oxoethyl) dihydrogen pyrophosphate (11-4)
- Step E l-(cyclooct-2-yn-l-yloxy)-2-oxo-6,9,12-trioxa-3-azatetradecan-14-yl (2- ( ( 6aR, 6bS, 7S, 8aS,8bS, llaR, 12aS, 12bS)- 7 -hydroxy-6a, 8a-dimethyl-4-oxo-l 0-propyl- 2, 4, 6a, 6b, 7, 8, 8a, 8b, lla,12, 12 a, 12b-dodecahydro-lH-naphtho[2 ', 1 ':4,5Jindeno[l,2- d] [l,3]dioxol-8b-yl)-2-oxoethyl) dihydrogen pyrophosphate (11-5)
- Step B 4-((S)-2-((S)-2-amino-3-methylbutanamido)-5-ureidopentanamido)benzyl
- Step C 4-( (2S)-2-( (2S)-2-(2-(cyclooct-2-yn-l-yloxy)acetamido)-3-methylbutanamido)-5- ureidopentanamido)benzyl (2-( ( 6aR, 6bS, 7S,8aS,8bS, l laR, 12aS, 12bS)-7-hydroxy-6a,8a- dimethyl-4-oxo-10-propyl-2, 4, 6a, 6b, 7, 8, 8a, 8b, 1 la, 12, 12a, 12b-dodecahydro-lH- naphtho[2 ', l ':4,5]indeno[l,2-d] [l,3]dioxol-8b-yl)-2-oxoethyl) hydrogen phosphate (12-3)
- Step A synthesis 2-(( 6aR, 6bS, 7S, 8aS, 8bS, llaR, 12aS, 12bS)- 7-hydroxy-6a, 8a-dimethyl-4-oxo-10- propyl-2, 4, 6a, 6b, 7, 8, 8a, 8b,lla,12, 12a, 12b-dodecahydro- lH-naphtho[2',l ': 4, 5]indeno[ 1,2- d] [1,3] dioxol-8b-yl)-2-oxoethyl acetate (13-1)
- Step B 2-((6aR,6bS, 7S,8aS,8bS, llaR,12aS,12bS)-7-((hydroxyhydrophosphoryl)oxy)-6a,8a- dimethyl-4-oxo-10-propyl-2, 4, 6a, 6b, 7, 8, 8a, 8b, 1 la, 12, 12a, 12b-dodecahydro-lH- naphtho[2 ', l ':4,5]indeno[l,2-d] [l,3]dioxol-8b-yl)-2-oxoethyl acetate (13-2)
- Step C 2-((6aR,6bS, 7S,8aS,8bS, llaR, 12aS,12bS)-7-((hydroxy(lH-imidazol-l-yl)
- Step D 2-((6aR,6bS, 7S,8aS,8bS,llaR, 12aS,12bS)-7-(((((2-((((9H-fluoren-9- yl)methoxy)carbonyl)amino)ethoxy)(hydroxy)phosphoryl)oxy)(hydroxy)phosphoryl)oxy)-6a,8a- dimethyl-4-oxo-10-propyl-2, 4, 6a, 6b, 7, 8, 8a, 8b, 1 la, 12, 12a, 12b-dodecahydro-lH- naphtho[2 ' ':4,5]indeno[l,2-d] [l,3]dioxol-8b-yl)-2-oxoethyl acetate (13-4)
- Step E 2-((6aR,6bS, 7S,8aS,8bS, llaR,12aS,12bS)-7-(((((2- aminoethoxy) (hydroxy)phosphoryl)oxy) (hydroxy)phosphoryl)oxy)-6a, 8a-dimethyl-4-oxo-10- propyl-2,4, 6a, 6b, 7 ,8,8a,8b,lla, 12, 12a,12b-dodecahydro-lH-naphtho[2 ', 1 ':4, 5]indeno[l,2- d] [l,3]dioxol-8b-yl)-2-oxoethyl acetate (13-5)
- Step F 2-((6aR,6bS, 7S,8aS,8bS,llaR,12aS,12bS)-7-(((((2-(2-(cyclooct-2-yn-l- yloxy)acetamido)ethoxy) (hydroxy)phosphoryl)oxy) (hydroxy)phosphoryl)oxy)-6a, 8a-dimethyl-4- oxo-10-propyl-2, 4, 6a, 6b, 7, 8, 8a, 8b, 11a, 12, 12a, 12b-dodecahydro-lH- naphtho[2' ':4,5Jindeno[l,2-dJ ' [l,3]dioxol-8b-yl)-2-oxoethyl acetate (13-6)
- Step G 2-((6aR,6bS, 7S,8aS,8bS,llaR,12aS,12bS)-7-hydroxy-6a,8a-dimethyl-4-oxo-10-propyl- 2,4, 6a, 6b, 7,8,8a,8b,lla,12, 12a,l 2b-dodecahydro-lH-naphtho[2', 1 ':4,5]indeno[ 1,2- d] [l,3]dioxol-8b-yl)-2-oxoethyl acetate (13-7)
- Step A (6S, 8S,9R, 1 OS, 11S 3S 4S 6R, 17R)-6, 9-difluoro-l 7-(((fluoromethyl)thio)carbonyl)-ll- ( (hydroxyhydrophosphoryl)oxy)-! 0,13, 16-trim ethyl-3-oxo- 6, 7,8,9,10,11,12, 13,14, 15,16,17- dodecahydro-3H-cyclopenta[a]phenanthren-l 7-yl propionate (14-1)
- Step B (6S,8S,9R,10S, 1 lS,13S, 14S,16R,17R)-6,9-difluoro-17-(((fluoromethyl)thio)carbonyl)-ll- ((hydroxy(lH-imidazol-l-yl)phosphoryl)oxy)-10,13,16-trimethyl-3-oxo- 6, 7, 8,9, 10,11, 12,13, 14,15,16,17-dodecahydro-3H-cyclopenta[a]phenanthren-l 7-yl propionate (14-2)
- Step C (6S,8S,9R,10S, llS,13S,14S,16R, 17R)-ll-(((((2-((((9H-fluoren-9- yl)methoxy)carbonyl)amino)ethoxy)(hydroxy)phosphoryl)oxy)(hydroxy)phosphoryl)oxy)-6,9- difluoro-17-( ( (fluoromethyl)thio)carbonyl)-10, 13, 16-trimethyl-3-oxo-
- Step D (6S,8S,9R,10S,llS,13S,14S,16R,17R)-ll-(((((2- aminoethoxy) (hydroxy)phosphoryl)oxy) (hydroxy)phosphoryl)oxy)-6, 9-difluoro-l 7- (((fluoromethyl)thio)carbonyl)-10, 13,16-trimethyl-3-oxo-6, 7, 8, 9,10,11,12,13,14,15,16,17- dodecahydro-3H-cyclopenta[a]phenanthren-l 7-yl propionate (14-4)
- Step F (6S,8S,9R,10S,llS,13S,14S,16R,17R)-ll-(((((2-(2-(cyclooct-2-yn-l- yloxy)acetamido)ethoxy)(hydroxy)phosphoryl)oxy)(hydroxy)phosphoryl)oxy)-6,9-difluoro-17- (((fluoromethyl)thio)carbonyl)-10, 13,16-trimethyl-3-oxo-6, 7, 8, 9,10,11,12,13,14,15,16,17- dodecahydro-3H-cyclopenta[a]phenanthren-l 7-yl propionate (14-5)
- Step A (6S,8S,9R,10S,llS,13S,14S, 16R, 17R)-6,9-difluoro-17-(((fluoromethyl)thio)carbonyl) ⁇ 10,13, 16-trimethyl-ll-((methylthio)methoxy)-3-oxo-6, 7,8,9, 10, 11,12, 13, 14, 15, 16, 17- dodecahydro-3H-cyclopenta[a ]phenanthren-l 7-yl propionate (15-1,)
- Step B (6S, 8S, 9R, 1 OS, 1 IS, 13S, 14S, 16R, 17R)-6, 9-difluoro-l 7-(((fluoromethyl) thio)carbonyl)- 10,13,16-trim ethyl-3-oxo- ll-( (phosphonooxy)m ethoxy)-6, 7 ',8,9, 10, 11,12, 13,14, 15,16, 17- dodecahydro-3H-cyclopenta[a]phenanthren-l 7-yl propionate (15-2)
- Phosphoric acid (0.09 g, 0.89 mmol) was heated under nitrogen at 120°C for 30minutes. This was allowed to cool and to it was added molecular seives and 15-1 (0.07 g, 0.13 mmol). This mixture was dissolved in THF (1.3 mL) and NIS (0.04 g, 0.19 mmol) was added. The resulting solution was allowed to stir overnight at room temperature. The mixture was filtered and concentrated.
- Step C (6S,8S,9R,10S, llS,13S,14S,16R, 17R)-ll-((((((2-((((9H-fluoren-9- yl)methoxy)carbonyl)amino)ethoxy)(hydroxy)phosphoryl)oxy)( ydroxy)phosphoryl)oxy)methoxy) -6, 9-difluoro-l 7-(( (fluoromethyl)thio)carbonyl)-10, 13, 16-trimethyl-3-oxo- 6, 7, 8,9, 10,11, 12,13, 14,15,16,17-dodecahydro-3H-cyclopenta[a]phenanthren-l 7-yl propionate
- Step E (6S, 8S,9R,10S,11S,13S,14S, 16R, 17R)-ll-(((((((2-(2-(cyclooct-2-yn-l- yloxy)acetamido)ethoxy) (hydroxy)phosphoryl)oxy) (hydroxy)phosphoryl)oxy)methoxy)-6, 9- difluoro-l 7-( ( (fluoromethyl)thio)carbonyl)-10, 13, 16-trimethyl-3-oxo-
- Step A (9H-fluoren-9-yl)methyl (71-hydroxy- 3,6,9,12,15,18,21,24,27,30,33,36,39,42,45,48,51,54,57, 60, 63, 66, 69- tricosaoxahenheptacontyl)carbamate (16-1)
- Step B (9H-fluoren-9-yl)methyl (71 -(phosphonooxy)- 3,6,9,12,15,18,21,24,27,30,33,36,39,42,45,48,51,54,57,60,63,66,69- tricosaoxahenheptacontyljcarbamate (16-2)
- Step D 72-amino-3,6,9,12, 15, 18,21,24,27,30,33,36,39,42,45,48,51,54,57,60,63,66,69- tricosaoxahenheptacontanyl (2-(( 6aR, 6bS, 7S, 8aS, 8bS, HaR,12aS, 12bS)- 7 -hydroxy-6a, 8a- dimethyl-4-oxo-10-propyl-2, 4, 6a, 6b, 7, 8, 8a, 8b, 1 la, 12, 12a, 12b-dodecahydro-lH- naphtho[2', l ':4,5]indeno[l ,2-d] [1 ,3] dioxol-8b-yl)-2-oxoethyl) dihydrogen pyrophosphate (16-4)
- Step E l-(cyclooct-2-yn-l-yloxy)-2-oxo-3-aza- 6,9, 12,15, 18,21,24,27,30,33,36,39,42,45,48,51, 54,57,60,63,66,69, 72-tricosaoxahenheptacont-
- Step A 4-((S)-2-((S)-2-amino-3-methylbutanamido)-5-ureidopentanamido)benzyl
- Step B 4-( (2S)-2-((2S)-2-(2-(cyclooct-2-yn-l-yloxy)acetamido)-3-methylbutanamido)-5- ureidopentanamido) benzyl (2-( ( 6aR, 6bS, 7S,8aS,8bS, llaR, 12aS, 12bS)-7-hydroxy-6a,8a- dimethyl-4-oxo-l 0-propyl-2, 4, 6a, 6b, 7, 8, 8a, 8b, 1 la, 12, 12a, 12b-dodecahydro-lH- naphtho[2 ', ⁇ : 4,5]indeno[ 1 ,2-d] [ 1 ,3] dioxol-8b-yl)-2-oxoethyl) dihydrogen pyrophosphate (17-2)
- Fluticasone linker (6S,8S,9R, 10S,11 S,13S,14S,16R, 17R)-1 1- ((((((4-((2S)-2-((2S)-2-(2-(cyclooct-2-yn-l-yloxy)acetamido)-3-methylbutanamido)-5- ureidopentanamido)benzyl)oxy)(hydroxy)phosphoryl)oxy)(hydroxy)phosphoryl)oxy)-6,9- difluoro- 17-(((fluoromethyl)thio)carbonyl)- 10,13,16-trimethyl-3 -oxo-
- Step A (6S, 8S, 9R, 1 OS, 1 IS, 13S, 14S, 16R, 17R)-6, 9-difluoro-l 7-(((fluoromethyl) thiojcarbonyl)- 10,13,16-trim ethyl-3-oxo- 11- (phosphonooxy)-6, 7, 8, 9,10, 11,12,13,14,15,16, 17-dodecahydro-3H- cyclopenta[a]phenanthren-l 7-yl propionate (18-1) To a stirred solution of 14-1 (0.20 g, 0.35 mmol) in pyridine (3.0 mL) at room temperature was added TMS-C1 (0.45 mL, 3.54 mmol) and the resulting solution was stirred for 10 minutes.
- Step B (6S, 8S, 9R, 10S 1S 3S, 14S, 16R, 17R)-ll-((((((4-((S)-2-((S)-2-amino-3- methylbutanamido)-5- ureidopentanamido)benzyl)oxy)(hydroxy)phosphoryl)oxy)-6,9- difluoro-17-( ( (fluoromethyl)thio)carbonyl)-10, 13, 16-trimethyl-3-oxo-
- Step C (6S,8S,9R,10S, llS,13S, 14S,16R,17R)-ll-(((((4-((2S)-2-((2S)-2-(2- ⁇
- Step B tert-butyl (4-(dimethylamino)-3-hydroxybutyl)carbamate (19-2)
- Step C 4-((tert-butoxycarbonyl)amino)-2-hydroxy-N,N,N-trimethylbutan-l-aminium (19-3)
- Step D 4-((tert-butoxycarbonyl)amino)-2-((hydroxy(2-((6aR, 6bS, 7S, 8aS, 8bS,l laR,12aS, 12bS)- 7- hydroxy-6a, 8a-dimethyl-4-oxo-10-propyl-2, 4, 6a, 6b, 7,8, 8a, 8b, 11 a, 12, 12a, 12b-dodecahydro-lH- naphtho[2',l ':4,5]indeno[l,2-d] [l,3]dioxol-8b-yl)-2-oxoethoxy)phosphoryl)oxy)-N,N,N-trimethylbutan-l- aminium (19-4)
- Step E 4-(2-(cyclooct-2-yn-l-yloxy)acetamido)-l-(trimethylammonio)butan-2-yl
- This example shows the synthesis of a duocarmycin analog comprising a diphosphate linker.
- Step A (9H-fluoren-9-yl)methyl 2-((((S)-l-(chloromethyl)-3-(5,6, 7-trimethoxy-lH-indole-2- carbonyl)-2, 3-dihydro-lH-benzo[e]indol-5- yloxy)(hydroxy)phosphoryloxy)(hydroxy)phosphoryloxy)ethylcarbamate (20-2)
- reaction mixture was cooled down to -30 °C and (9H- fluoren-9-yl)methyl 2-(phosphonooxy)ethylcarbamate (234 mg, 0.64 mmol) was then added followed by another portion of diisopropylethylamine (1 15 ⁇ , 0.64 mmol).
- the reaction was kept at -30°C for 30 min then allowed to warm up to 0°C for 40 min. Additional amount of 1.0 eq of (9H-fluoren-9-yl)methyl 2-(phosphonooxy)ethylcarbamate (46.8 mg, 0.13 mmol) and diisopropylethylamine (22 ⁇ , 0.13 mmol) were added and kept for another 10 min at 0 °C.
- Step B 2-((( (S)-l-(chloromethyl)-3-( 5, 6, 7-trimethoxy-lH-indole-2-carbonyl)-2, 3-dihydro-lH- benzo[e]indol-5-yloxy)(hydroxy)phosphoryloxy)(hydroxy)phosphoryloxy)ethylamine (20-3)
- Step C tert-Butyl 2-(2-( ( ( (S)-l-(chloromethyl)-3-(5, 6, 7-trimethoxy-lH-indole-2-carbonyl)-2, 3- dihydro-lH-benzo[e]indol-5- yloxy)(hydroxy)phosphoryloxy)(hydroxy)phosphoryloxy)ethylamino)-2-oxoethoxycarbamate (20- 4)
- Step D 2-(Aminooxy)-N-(2-((((S)-l-(chloromethyl)-3-(5,6, 7-trimethoxy-lH-indole-2-carbonyl)- 2, 3-dihydro-lH-benzo[e]indol-5-yloxy) (hydroxy)phosphoryloxy) (hydroxy)phosphoryloxy)ethyl)- acetamide (20-5)
- This example shows the synthesis of duocarmycin comprising a diphosphate linker.
- Step A (S)-methyl 8-(chloromethyl)-4-(phosphonooxy)-6-(5, 6, 7-trimethoxy-lH-indole-2- carbonyl)-3 ,6, 7 ,8-tetrahydropyrrolo[3 ,2-e] indole-2-carboxylate (21-2)
- Duocarmycin 21-1 ( 85.0 mg, 0.165 mmol) was dissolved in THF/acetonitrile (3 mL / 3 mL) and treated with phosphoryl chloride (0.139 mL, 1.49 mmol) and diisopropylethyl amine (0.144 mL, 0.825 mmol) with ice-water bath cooling. The reaction was kept at the same temperature for lh and sodium phosphate monobasic solution (1M, 10 mL) was added and kept the mixture at 4 °C overnight.
- Step B (8S) -methyl 4-(((2-aminoethoxy)(hydroxy)phosphoryloxy)(hydroxy)phosphoryloxy)-8- (chloromethyl)-6-(5,6, 7-trimethoxy-lH-indole-2-carbonyl)-3,6, 7,8-tetrahydropyrrolo[3,2- e] indole-2-carboxylate (21-3)
- Step C (SS)-methyl 8-(chloromethyl)-4-( ((2, 2-dimethyl-4, 8-dioxo-3, 6-dioxa-5, 9-diazaundecan- ll-yloxy)(hydroxy)phosphoryloxy)(hydroxy)phosphoryloxy)-6-(5,6, 7-trimethoxy-lH-indole-2- carbonyl)-3 ,6, 7 ,8-tetrahydropyrrolo[3 ,2-e] indole-2-carboxylate (21-4)
- Linkers utilized in drug conjugates may have aqueous solubility to enable conjugation in aqueous media amenable to protein solubilization. Furthermore, linkers with aqueous solubility are considered hydrophilic, and may confer to the drug conjugate a reduced propensity to aggregate relative to standard hydrophobic linkers in the literature.
- the following exemplary drug-linkers were tested in an aqueous solution comprising 20% acetonitrile
- Exemplary dexamethasone-linkers 4-3, 5-3, 1-4, 3-4, and 2-7 were incubated in relevant biomatrices to measure their stability and propensity to release free drug (Tables 2 to 4).
- the exemplary dexamethasone-linkers were studied for their stability (Table 1) and propensity to release dexamethasone (Table 2) in human blood. As shown in the tables, all the dexamethasone linkers were stable in blood with little detectable degradation or release of free dexamethasone.
- Human blood was pre -warmed in a 37°C water bath in an appropriate volume to collect samples over a time course from 0 through 6 hours. Incubating blood was mixed well just prior to sampling to give a homogenous mixture. Aliquots of blood were removed at appropriate time points, added to cold stopping solution, which was methanol containing an appropriate internal standard, and mixed rigorously. The samples were centrifuged at 4000 RPM for 10 minutes after which equal volumes of the supernatant fractions were diluted with cold deionized water. The samples were then ready for analysis. A time 0 sample was prepared by spiking blood, which had been pretreated with the same stopping reagent used above with the drug-linker. This sample is referred to in the tables as the matrix spiking.
- dexamethasone-linkers 4-3, 5-3, 1-4, 3-4, and 2-7 were studied for their stability (Table 4) and propensity to release dexamethasone (Table 5) in purified rat liver lysosomal lysates. Tables 4 and 5 show that the different dexamethasone-linkers released dexamethasone at different rates depending on the structure of the tuning element. For example,
- Rat Liver lysosomes were available commercially with a pool of 6 animals. All linker compounds were solubilized in DMSO to form each lOmM stock solution. Dosing solution for each linker was prepared by serial dilution of each stock solution using 1 :3 acetonitrile: water. All solutions were kept on ice during the experiment.
- Rat lysosomes were pre -warmed in a 37°C water bath in an appropriate volume to collect samples over a time course from 0 minutes through 6 hours. Incubating lysosomes were mixed well just prior to sampling to give a homogenous mixture. Aliquots of lysosomes were removed at appropriate time points, added to cold stopping solution, which was methanol containing an appropriate internal standard, and mixed rigorously. The samples were centrifuged at 4000 RPM for 10 minutes after which equal volumes of supernatant were diluted with cold deionized water. The samples were ready for analysis. A time 0 sample was prepared by spiking the drug-linker to lysosomes which had been pretreated with the same stopping reagent as above. This sample is referred to as matrix spiking in the tables.
- exemplary drug-linker 1-4 was conjugated to an anti-mouse CD25 antibody (IgGl) (mCD25) to produce antibody-drug conjugate ADC 12-1 or anti-human CD70 antibody 2H5 antibody (hCD70) to produce ADC 12-2.
- the drug-linker was conjugated to the unnatural amino acid para-azido-phenylalanine (pAF) replacing the alanine at position 1 of CHI of the antibody using copper- free 3+2 cycloaddition chemistry as shown in Figure 1.
- pAF para-azido-phenylalanine
- the amino acid sequence of the anti-mouse CD25 heavy chain comprising the pAF at position 115 is shown in SEQ ID NO:3 and the amino acid sequence of the light chain is shown in SEQ ID NO:4.
- the amino acid sequence of the anti-human CD70 heavy chain comprising pAF at position 119 is shown in SEQ ID NO: 1 and the amino acid sequence of the light chain is shown in SEQ ID NO:2.
- the antibody conjugates were purified over a SP 650S column (Tosoh Biosciences) to remove excess reagents. The conjugates were buffer exchanged into 50 mM Histidine; 100 mM NaCl; 2.5% Trehalose; pH 6.0, 0.22 ⁇ filtered, and stored at 4°C.
- Conjugation analysis Conjugation efficiency and DAR values were determined by reversed phase HPLC.
- the ADC was run over a Zorbax 300SB-C3 column, 4.6x150mm (Agilent) at 80°C and eluted with a linear gradient from 30% B to 90%B (A: water, 0.1% TFA; B: acetonitrile, 0.1% TFA).
- An Agilent 1200 series HPLC system and Chemstation software were used to resolve and quantify percentage of antibody conjugated with drug-linker.
- Drug conjugates may be designed with a stable linker to ensure that the attached payload adopts the pharmacokinetic properties of the carrier.
- premature release of the payload will reduce the total payload delivered to a target cell.
- ADC 12-1 was incubated in mouse serum and monitored for degradation or loss of payload (dexamethasone). As shown in Figure 2, no measurable loss of dexamethasone was observed over three weeks incubation in serum.
- the ADC 12-1 was spiked in DBA1 mice serum at 0.1 mg/niL. Samples were sealed under nitrogen, placed at 37°C in a cell culture incubator and stored at -80°C until analysis. Time points from 0 min to 21 days of incubation were evaluated.
- ADC 12-1 was pulled down from mice serum using immunoprecipitation (IP) with streptavidin magnetic beads (Dynabeads M-280) coupled to biotinylated CD25 (antigen). Beads were washed 3 times with 100 ⁇ L of TBS lx. Two microliters of 1 mg/mL biotinylated CD25 was added to 30 ⁇ ⁇ of each sample (serum from each time point) and incubated for 10 minures at room temperature (RT). Samples were added to the pre-washed beads and incubated for 30 minutes at RT under gentle shaking. The flow through was discarded and beads were washed twice with 0.02% Rapigest in TBS lx. Elution was performed with 30 of TFA 0.1% and 5 ⁇ of each sample was analyzed in an UPLC/Synapt G2-S (Waters, Milford) equipped with a POROS column (ABSciex) using reverse phase gradient.
- IP immunoprecipitation
- Figure 3 shows a deconvoluted intact mass spectrum for the ADC 12-1 stock solution.
- G0F, GIF and G2F in the figure refer to the carbohydrate iso forms on the antibody portion of the antibody-drug conjugate.
- the deconvoluted spectra of the stock solution revealed that the antibody-drug conjugate 12-1 intact mass in its predominant DAR 2 form contained two G0F sugar motifs. Additional peaks at about 162 Da apart showed two other glycoforms containing G0F/G1F (peak at 148701 Da) and 2 x GIF (peak at 148863 Da).
- the glycan profile is typical of that for an IgG.
- Figure 4 shows the deconvoluted spectra of time points 1 hour, 8 hours, 14 days and 21 days from the in vitro stability study. The data analysis showed that no significant mass change occurred for the ADC over the incubation period evaluated in the study (Table 6: intact mass results for the in-vitro stability study).
- the study showed that the inherent pharmacokinetics of naked (non-conjugated) anti-mouse CD25 was not adversely affected by the conjugation of two molecules of drug-linker 1-4 to the antibody. Furthermore, the study showed that no loss of drug linker and no measurable dexamethasone were observed over the course of the 5 day study. The data shows that drug-linker 1-4 was stable in circulation and retained payload on the carrier in this example of an antibody-drug conjugate.
- PK study samples were evaluated for free dexamethasone using the method described above. For increased sensitivity, 100 of serum from one mice of each time point was submitted to protein precipitation with acetonitrile. Free dexamethasone was not detected in any PK samples.
- Plasma samples from in vivo P study were analyzed for naked Antibody/total Antibody ADC 12-1 concentrations using Meso Scale Discovery (MSD) based electro- chemiluminescence method.
- the capture reagent is recombinant mouse IL-2R alpha (CD25) for both assays.
- the detection reagent may be goat anti-rat IgG for naked antibody/total Antibody and anti-dex mAb (e.g., Rabbit polyclonal anti-dexamethasone (Abeam Cat# ab35000)) may be used to detect ADC 12-1, respectively. Briefly, 96 well MSD plates were coated with the capture reagent and then washed. Plates were blocked for 1 hour and washed again. Samples were then added and incubated for 2 hours. Following incubation, plates were washed, incubated with the detection antibody for 1 hour, and washed again. The reading buffer was added and the plates were read using MSD plate reader. EXAMPLE 26
- the payload-linkers made in Examples 20 and 21 were conjugated to an anti- human Her2 antibody (hHer2) comprising a para-acetyl phenylalanine (pAcF).
- hHer2 anti- human Her2 antibody
- pAcF para-acetyl phenylalanine
- Para-acetyl phenylalanine (pAcF) containing antibodies were buffer exchanged into 50mM sodium acetate; 2.5% trehalose; 0-20% Dimethylamine, pH 4.0-4.5 and concentrated to l-20mg/mL. 10-15 molar equivalents of amino-oxy drug-linker were added and reacted for 16-72 hours at 28-30°C.
- the antibody conjugates were purified over a SP 650S column (Tosoh Biosciences) to remove excess reagents.
- the conjugates were buffer exchanged into 50 mM Histidine; 100 mM NaCl; 2.5% Trehalose; pH 6.0, 0.22 ⁇ filtered, and stored at 4°C. Conjugation analysis.
- Conjugation efficiency and DAR values were determined by reversed phase HPLC.
- the antibody-drug conjugate was run over a Zorbax 300SB-C3 column, 4.6x150mm (Agilent) at 80°C and eluted with a linear gradient from 30% B to 90% B (A: water, 0.1% TFA; B: acetonitrile, 0.1 % TFA).
- An Agilent 1200 series HPLC system and Chemstation software were used to resolve and quantify percentage of antibody conjugated with drug-linker.
- Her2 positive SKBR3 and Her2 negative MDA-MD-468 breast adenocarcinoma cell lines were cultured in DMEM medium supplemented with 10% FBS and 100 ⁇ /mL penicillin, 100 ⁇ g/mL streptomycin, or DMEM/F12 supplemented with 10%) FBS and 100 ⁇ /mL penicillin, 100 ⁇ g mL streptomycin respectively.
- the cells were incubated with serial dilutions of Duocarmycin-405 conjugated to anti-Her2 or a non-targeting antibody, Duocarmycin free drug and naked anti-Her2 controls for 6 days. Live cells were measured with CellTiter Glo luminescent cell viability assay kit (Promega, Madison, WI, USA) and the percentage of live cells determined relative to untreated cells.
- Figure 8 shows that aHer2-Duo-405 was able to deliver its payload to Her2 expressing SKBR3 cells whereas a non-targeting antibody conjugated to Duo-405 was unable to.
- the Figure shows the specificity of the aHer2- Duo-405 conjugate and its ability to effectively deliver the payload.
- Figure 9 shows that aHer2- Duo-405 had no activity on Her2 negative MDA-MD-468 cells.
- the example shows that conjugates comprising the phosphate-based links have little or no propensity to form aggregates.
- An SE-HPLC method was used to conduct the aggregation/%monomer analysis.
- An isocratic gradient using 0.2 M potassium phosphate, 0.25 M potassium chloride pH 6.0 was used as the mobile phase at a flowrate of 0.5mL/min.
- the column used was a Sepax Zenix-C SEC-300, 3 ⁇ , 300 A, 7.8 x 300mm (Cat# 233300-7830). Detection of signal was monitored at 214nm (280 for FIO). For a representative run, the analyte load was 10 ⁇ g.
- ADC 12-2 ( Figure 1) is anti-CD70 antibody 2H5 conjugated to exemplary drug- linker 1-4 as described in Example 24.
- GILZ glucocorticoid-induced leucine zipper
- ADC 12-2 displayed potent in vitro activity (0.7 ug/ml IP value) in 786-0 cells that were confirmed to express CD70. This activity reflects dexamethasone conjugation and targeted delivery as the nonconjugated IgG variant and anti-hexon controls did not induce and observable GILZ in this cell line.
- 786-0 cells were plated at 30K cells/well overnight at 37°C in RPMI Media as suggested by ATCC (+ 10% HI FBS). Cells were stimulated with ADCs for 2, 6, or 24 hours at 37°C. Cells were lysed using RLT and RNA is isolated using RNeasy 96 Kits. PCR was used to measure GAPDH, PERI , or TSC22D3
- GILZ Glucocorticoid-induced leucine zipper
- Dosing solutions for free drug, ADCs and parental antibodies were prepared by serial dilution of each stock solution using 1 :3 in in HBSS+2% FBS supplemented with 1% final concentration of (50mM Histidine, lOOmM NaCl, 5% Trehalose, pH 6.0), and incubated with cells final concentrations ranging from 20 to 0.002 ⁇ g/ml and 100 to 0.0 lng dexamethasone/ml for 18 hours.
- Cell lysis, cDNA synthesis, and real-time PCR were performed according to manufacturer's instructions using TaqMan Gene Expression Cells-to-C ⁇ TM Kit (Invitrogen, Carlsbad, CA).
- the differential expression signal were expressed as delta Ct (ACt) by subtracting the Ct values of the un-stimulated samples (containing only assay buffer or DMSO vehicle) from those of the stimulated samples and expressed as relative fold of change using the formula: 2 AACT .
- Anti-CD70 2H5 IgGl OVOLVESGGGVVOPGRSLRLSCAASGFTFSSYIM X at position 119 is HWVROAPGKGLEWVAVISYDGRNKYYADSVKG para-azido- RFTISRDNSI NTLYLQMNSLRAEDTAVYYCARDT phenylalanine (pAF) DGYDFDYWGOGTLVTVSSXSTKGPSVFPLAPSSK (CDR 1,2, and 3 bold STSGGTAALGCLVKDYFPEPVTVSWNSGALTSGV type; Fc underlined) HTFPAVLOSSGLYSLSSVVTVPSSSLGTOTYICNV
Abstract
Phosphate-based linkers with tunable stability for intracellular delivery of drug conjugates are described. The phosphate-based linkers comprise a monophosphate, diphosphate, triphosphate, or tetraphosphate group (phosphate group) and a linker arm comprising a tuning element and optionally a spacer. A payload is covalently linked to the phosphate group at the distal end of the linker arm and the functional group at the proximal end of the linker arm is covalently linked to a cell-specific targeting ligand such as an antibody. These phosphate-based linkers have a differentiated and tunable stability in blood vs. an intracellular environment (e.g. lysosomal compartment).
Description
TITLE OF THE INVENTION
PHOSPHATE BASED LINKERS FOR INTRACELLULAR DELIVERY OF DRUG CONJUGATES CROSS REFERENCE TO RELATED APPLICATIONS
BACKGROUND OF THE INVENTION
(1) Field of the Invention
The present invention relates to phosphate-based linkers with tunable stability for intracellular delivery of drug conjugates. The phosphate-based linkers comprise a
monophosphate, diphosphate, triphosphate, or tetraphosphate group (phosphate group) and a linker arm comprising a tuning element and optionally a spacer. A payload is covalently linked to the phosphate group at the distal end of the linker arm and the functional group at the proximal end of the linker arm is covalently linked to a cell-specific targeting ligand such as an antibody. These phosphate-based linkers have a differentiated and tunable stability in blood vs. an intracellular environment (e.g. lysosomal compartment). Thus, conjugates that comprise these phosphate-based linkers are stable in circulation (plasma/blood) but reactive or cleavable in intracellular compartments (lysosome) making them useful for intracellular delivery of drug conjugates, the rate being dependent on the structure of the tuning element.
(2) Description of Related Art
Antibody drug conjugates (ADC) are targeted chemotherapeutic molecules combining the ideal properties of both antibodies and cytotoxic drugs by targeting potent cytotoxic drugs to the antigen-expressing tumor cells, internalizing the ADC, and releasing the drug from the ADC, thereby enhancing the drug's anti-tumor activity. This strategy has met limited success in part because many cytotoxic drugs tend to be inactive or less active when conjugated to large antibodies or protein receptor ligands. Promising advancements with immunoconjugates has seen cytotoxic drugs linked to antibodies through a linker that is cleaved at the tumor site or inside tumor cells.
The successful ADC development for a given target antigen depends on optimization of antibody selection, linker design and stability, drug potency and mode of drug and linker conjugation to the antibody. Linker properties of pH and redox sensitivities and protease susceptibility influence circulatory stability and release of the drug moiety. The intracellular cleavage of disulfide containing linkers of an ADC is limited by the oxidizing potential of endosomes and lysosomes and are probably not released by reductive cleavage within the endocytic pathway (Austin et al., Proc. Natl. Acad. Sci. USA 102: 17987-17992 (2005)). Reductive cleavage may occur at the cell membrane and impart a bystander killing effect of tumor and susceptible normal cells by free drug. Inappropriate release of drug likely
contributes to toxicity. Once internalized, ADC efficacy is dependent on proteolytic cleavage for drug activity. Linker stability plays an important role in both the efficacy and toxicity of ADC (Alley et al., Bioconjugate Chem. 19:759-765 (2008)). Stable linkers such as mcc are more efficacious and safer than unstable, disulfide linkers, widening the therapeutic window.
However, while mcc linkers are more stable than disulfides, they can only be used for drugs that can tolerate residual linker on it and still be potent. Thus, self-immolative linkers are needed for drugs that do not have this flexible structure activity relationship (SA ).
A chemical solution to targeted delivery of cytotoxic or cytostatic drugs conjugated to cell-specific ligands is the "self-immolative linker", PABC or PAB (para- aminobenzyloxycarbonyl) linker, attaching the drug moiety to the ligand in the conjugate (Carl et al, J. Med. Chem. 24: 479-480 (1981); Chakravarty et al., J. Med. Chem. 26: 638-644 (1983)). The PAB linker unit is also referred to as an electronic cascade spacer. The amide bond linking the carboxy terminus of a peptide unit and the para-aminobenzyl of PAB may be a substrate and cleavable by certain proteases. The aromatic amine becomes electron-donating and initiates an electronic cascade that leads to the expulsion of the leaving group, which releases the free drug after elimination of carbon dioxide (de Groot, et al. Journal of Organic Chemistry 66: 8815-8830 (2001)). Cathepsin B is a ubiquitous cysteine protease with increasing activity within low pH environments (i.e. lysosomes). It is an intracellular enzyme, except in pathological conditions, such as metastatic tumors (Sinha et al., Prostate 49: 172-184 (2001)) or rheumatoid arthritis (Hashimoto et al., Biochem. Biophys. Res. Commun. 283: 334-339 (2001)). Therefore, conjugates produced with cathepsin B-cleavable linkers are likely to be stable in circulation. Upon cleavage of a peptide bond adjacent to the PABC, i.e. by an intracellular enzyme, the drug is released from the ligand whereby no remaining portion of the linker is bound (de Groot et al., Molecular Cancer Therapeutics 1 : 901-911 (2002); de Groot et al., J. Med. Chem. 42: 5277-5283 (1999)).
Linkers containing the para-aminobenzyloxycarbonyl (PAB or PABC) unit, in conjunction with a peptide unit, have been developed with a "self-immolating" or "self- immolative" mechanism of 1,6 elimination and fragmentation under enzymatic, hydrolytic, or other metabolic conditions to release a drug moiety from a targeting ligand, such as an antibody (U.S. Pat. No. 6,214,345; 6,677,435 5,621,002; 6,218,519; 6,835,807; 6,268,488; and 6,759,509; US Pat. Pub. Nos. 20030130189; 20030096743; 20040052793; 20040018194; 20040052793; and 20040121940; PCT Pub. Nos. WO 98/13059 and WO2004/032828).
Limitations of the PAB type self-immolating linkers are the propensity to cause poor solubility and aggregation of the conjugates. In addition, some PAB-containing conjugates may not be suitable substrates for certain cleaving enzymes or cleave too slowly to achieve efficacy. While the PAB/PABC linkers have been exemplified for amine -terminus payloads that form stable carbamate bonds, for payloads that do not contain a linkable amine, the carbonate
that is formed may not be stable and so there is a need for self-immolative linkers that can handle payloads with an oxygen terminus, for example, dexamethasone.
In light of the above, there is a need for linkers for constructing drug-ligand conjugates with improved therapeutic efficacy.
BRIEF SUMMARY OF THE INVENTION
The present invention provides phosphate -based linkers with tunable stability for intracellular delivery of drug conjugates. The phosphate-based linkers comprise a
monophosphate, diphosphate, triphosphate, or tetraphosphate group (phosphate group) covalently linked to the distal end of a linker arm comprising from the distal to the proximal direction a tuning element, optionally a spacer element, and a reactive functional group. The phosphate group of the phosphate-based linker is capable of being conjugated to a payload and the reactive functional group is capable of being conjugated to a cell-specific targeting ligand such as an antibody. The general structure of the phosphate-based linkers is:
Phosphate group— Tuning element— Optional spacer element— Functional reactive group
A phosphate -based linker conjugated to a payload has the general structure: Payload— Phosphate group— Tuning element— Optional spacer element— Functional reactive group and when conjugated to a targeting ligand has the general structure
Payload— Phosphate group— Tuning element— Optional spacer element— Targeting ligand
These phosphate-based linkers have a differentiated and tunable stability in blood vs. an intracellular environment (e.g. lysosomal compartment). The inventors have discovered that the rate at which the phosphate group is cleaved in the intracellular environment to release the payload in its native or active form may be affected by the structure of the tuning element with further effects mediated by substitutions of the phosphate group as well as whether the phosphate group is a monophosphate, diphosphate, triphosphate, or tetraphosphate. The inventors further discovered that these phosphate-based linkers provide the ability to construct conjugates such as antibody-drug conjugates in which the propensity of the conjugate to form aggregates is reduced compared to conjugates in which the same payload is conjugated to the antibody or targeting ligand using a linker that is not a phosphate-based linker as disclosed herein.
In particular embodiments, the phosphate-based linker is a compound that has the following formula (I)
wherein V is selected from O and S; W is selected from O, N, and CH2; X is a tuning element selected from a covalent bond; a carbon atom; a heteroatom; an optionally substituted group selected from the group consisting of acyl, aliphatic, heteroaliphatic, aryl, heteroaryl, and heterocyclic; a carbon atom linked to a trimethylammonium group by a C1-C5 hydrocarbon chain; nucleoside, protease sensitive group, cathepsin B sensitive group, or glycosidase sensitive group; Y is optional but when present it is selected from a covalent bond or a bivalent, straight or branched, saturated or unsaturated, optionally substituted CI -30 hydrocarbon chain wherein one or more methylene units of Y are optionally and independently replaced by -0-, -S-, -N(R)-, - C(O)-, C(0)0-, OC(O)-, -N(R)C(0)-, -C(0)N(R)-, -S(O)-, -S(0)2-, -N(R)S02-, S02N(R)-, a heterocyclic group, an aryl group, or a heteroaryl group; Z is a reactive functional group selected from the group consisting of N-hydroxysuccinimidyl ester, para-nitrophenyl carbonate, para- nitrophenyl carbamate, methyl ketone, azide, hydrazine, pentafiuorophenyl, haloacetamide, maleimide, hydroxylamine, strained cycloalkyne, heterocycloalkyne, alkyne, diene, azadiene, and heterocyclic azadiene, wherein halo is iodine (I), bromine (Br), fluorine (F), or chlorine (CI) and hetero is N, O, or S; each occurrence of R is independently hydrogen, a suitable protecting group, an acyl moiety, arylalkyl moiety, aliphatic moiety, aryl moiety, heteroaryl moiety, or heteroaliphatic moiety; and n is 1, 2, 3, or 4. In particular embodiments, when Y is a covalent bond, X is not a covalent bond.
In particular aspect, the reactive group Z has the structure
wherein the wavy line marks the covalent bond between Z and Y, or X when Y is a covalent bond, or W when Y and X are a covalent bond.
In a further embodiment, the distal end of the phosphate group is covalently linked to a payload, which may be a therapeutic agent such as a drug moiety or peptide, a radionuclide, or a protecting element, to provide a payload-phosphate-based linker compound comprising formula (II)
wherein V is selected from O and S; W is selected from O, N, and CH2; X is a tuning element selected from a covalent bond; a carbon atom; a heteroatom; an optionally substituted group selected from the group consisting of acyl, aliphatic, heteroaliphatic, aryl, heteroaryl, and heterocyclic; a carbon atom linked to a trimethylammonium group by a C1-C5 hydrocarbon chain; nucleoside, protease sensitive group, cathepsin B sensitive group, or glycosidase sensitive group; Y is optional but when present is selected from a covalent bond or a bivalent, straight or branched, saturated or unsaturated, optionally substituted CI -30 hydrocarbon chain wherein one or more methylene units of Y are optionally and independently replaced by -0-, -S-, -N(R)-, - C(O)-, C(0)0-, OC(O)-, -N(R)C(0)-, -C(0)N(R)-, -S(O)-, -S(0)2-, -N(R)S02-, S02N(R)-, a heterocyclic group, an aryl group, or a heteroaryl group; T is an NR, CR2, O, or S; Z is a reactive functional group selected from the group consisting of N-hydroxysuccinimidyl ester, para- nitrophenyl carbonate, para-nitrophenyl carbamate, methyl ketone, azide, hydrazine,
pentafluorophenyl, haloacetamide, maleimide, hydroxylamine, strained cycloalkyne, and heterocycloalkyne, alkyne, diene, azadiene, and heterocyclic azadiene, wherein halo is iodine (I), bromine (Br), fluorine (F), or chlorine (CI) and hetero is N, O, or S; D is a payload; each occurrence of R is independently hydrogen, a suitable protecting group, an acyl moiety, arylalkyl moiety, aliphatic moiety, aryl moiety, heteroaryl moiety, or heteroaliphatic moiety; and n is 1, 2, 3, or 4. In particular embodiments, when Y is a covalent bond, X is not a covalent bond.
In particular aspect, the reactive group Z has the structure
wherein the wavy line marks the covalent bond between Z and Y, or X when Y is a covalent bond, or W when Y and X are a covalent bond.
In a further embodiment, the reactive functional group at the proximal end of the payload-phosphate-based linker may be covalently linked to a ligand or targeting moiety to provide a conjugate wherein in particular embodiments, the ligand is capable of targeting the conjugate to a particular cellular target when administered to a subject in need of the payload to provide a compound having formula (III)
wherein V is selected from O and S; W is selected from O, N, and CH2; X is a tuning element selected from a covalent bond; a carbon atom; a heteroatom; an optionally substituted group selected from the group consisting of acyl, aliphatic, heteroaliphatic, aryl, heteroaryl, and heterocyclic; a carbon atom linked to a trimethylammonium group by a C 1-C5 hydrocarbon chain; nucleoside, protease sensitive group, cathepsin B sensitive group, or glycosidase sensitive group; Y is selected from a covalent bond or a bivalent, straight or branched, saturated or unsaturated, optionally substituted Ci .39 hydrocarbon chain wherein one or more methylene units of Y are optionally and independently replaced by -0-, -S-, -N(R)-, -C(O)-, C(0)0-, OC(O)-, -N(R)C(0)-, -C(0)N(R)-, -S(O)-, -S(0)2-, -N(R)S02-, S02N(R)-, a heterocyclic group, an aryl group, or a heteroaryl group; T is an NR, CR2, O, or S; D is a payload; Z is a linkage formed between (i) a reactive functional group selected from the group consisting of N- hydroxysuccinimide, para-nitrophenyl carbonate, para-nitrophenyl carbamate,
pentafluorophenyl, haloacetamide, maleimide, hydroxylamine, strained cycloalkyne, and heterocycloalkyne, alkyne, diene, azadiene, and heterocyclic azadiene, wherein halo is iodine (I), bromine (Br), fluorine (F), or chlorine (CI) and hetero is N, O, or S, and (ii) an S, NR, or O group on L; each occurrence of R is independently hydrogen, a suitable protecting group, an acyl moiety, arylalkyl moiety, aliphatic moiety, aryl moiety, heteroaryl moiety, or heteroaliphatic moiety; L is a cell-specific targeting ligand; and n is 1 , 2, 3, or 4. In particular embodiments, when Y is a covalent bond, X is not a covalent bond.
In particular aspects, the linkage Z has the structure
, or , wherein the wavy lines represent the covalent bond between Z and Y, or X when Y is a covalent bond, or W when Y and X are a covalent bond (on the left) and Z and L (on the right), respectively.
In particular embodiments, the payload is a therapeutic agent, a detectable label, radionuclide, or protecting group. The therapeutic agent may be any molecule that alters, inhibits, activates, or otherwise affects a biological event. Examples of a therapeutic agent include but are not limited to, cytotoxic agent, an anti-inflammatory agent, peptide, a nucleic acid or nucleic acid analog, a small molecule, and a biomolecule.
In particular embodiments, the cytotoxic agent selected from duocarmycins and CC-1065, and analogues thereof, including CBI (1,2,9,9a- tetrahydrocyclopropa[c]benz[e]indol- 4-one)-based analogues, MCBI (7-methoxy- 1,2,9,9a- tetra-hydrocyclopropa[c]benz[e]indol-4- one)-based analogues and CCBI (7-cyano- 1,2,9,9a- tetra-hydrocyclo-propa[c]benz[e]-indol-4- one)-based analogues of the duocarmycins and CC- 1065, doxorubicin and doxorubicin conjugates such as morpholino-doxorubicin and cyanomorpholino-doxorubicin, dolastatins such as dolestatin-10, combretastatin, calicheamicin, maytansine, maytansine analogs, DM-I, auristatin E, auristatin EB (AEB), auristatin EFP (AEFP), monomethyl aunstatin E (MMAE), 5- benzoylvaleric acid- AE ester (AEVB), tubulysins, disorazole, epothilones , Paclitaxel, docetaxel, SN-38, Topotecan, rhizoxin, echinomycin, colchicine, vinblastin, vindesine, estramustine, cemadotin, eleutherobin, methotrexate, methopterin, dichloro methotrexate, 5- fiuorouracil, 6- mercaptopurine, cytosine arabinoside, melphalan, leurosine, leurosideine, actinomycin, daunorubicin and daunorubicin conjugates, mitomycin C, mitomycin A, carminomycin, aminopterin, tallysomycin, podophyllotoxin and podophyllotoxin derivatives such as etoposide or etoposide phosphate, vincristine, taxol, taxotere retinoic acid, butyric acid, N - acetyl spermidine, camptothecin, and their analogs.
In particular embodiments, the anti-inflammatory agent is a glucocorticoid receptor agonist. In a further aspect, the anti-inflammatory agent is a glucocorticoid, for example, Cortisol, cortisone acetate, beclometasone, prednisone, prednisolone,
methylprednisolone, betamethasone, trimcinolone, budesonide, dexamethasone, fluticasone, fluticasone propionate, fluticasone furoate, compound 15-5, or mometasone.
In particular embodiments, the targeting ligand is an antibody or monoclonal antibody (e.g., chimeric, humanized, or human), ligand for a receptor, lectin, saccharide, poly(ethylene glycol), polysaccharide, or polyamino acid.
In particular embodiments, the chimeric, humanized, or human antibody or monoclonal antibody is an anti-Her2 antibody, anti-CD4 antibody, anti-CD20 antibody, anti- EGFR antibody, anti-CD22 antibody, anti-CD23 antibody, anti-CD25 antibody, anti-CD52 antibody, anti-CD30 antibody, anti-CD33 antibody, anti-CD40L antibody, anti-CD70 antibody, anti-CD74 antibody, anti-CD80 antibody, anti-CD 163 antibody, anti-Mucl8 antibody, anti- integrin antibody, anti-PSMA antibody, anti-CEA antibody, anti-CDl la antibody, anti-CTLA4 antibody, or anti-BLys antibody.
The present invention further provides a composition comprising a compound having formula (III)
wherein V is selected from O and S; W is selected from O, N, and CH2; X is a tuning element selected from a covalent bond; a carbon atom; a heteroatom; an optionally substituted group selected from the group consisting of acyl, aliphatic, heteroaliphatic, aryl, heteroaryl, and heterocyclic; a carbon atom linked to a trimethylammonium group by a C1-C5 hydrocarbon chain; nucleoside, protease sensitive group, cathepsin B sensitive group, or glycosidase sensitive group; Y is selected from a covalent bond or a bivalent, straight or branched, saturated or unsaturated, optionally substituted Ci_30 hydrocarbon chain wherein one or more methylene units of Y are optionally and independently replaced by -0-, -S-, -N(R)-, -C(O)-, C(0)0-, OC(O)-, -N(R)C(0)-, -C(0)N(R , -S(O)-, -S(0)2-, -N(R)S02-, S02N(R , a heterocyclic group, an aryl group, or a heteroaryl group; T is an NR, CR2, O, or S; D is a payload; Z is a linkage formed between (i) a reactive functional group selected from the group consisting of N- hydroxysuccinimide, para-nitrophenyl carbonate, para-nitrophenyl carbamate,
pentafluorophenyl, haloacetamide, maleimide, hydroxylamine, strained cycloalkyne, and heterocycloalkyne, alkyne, diene, azadiene, and heterocyclic azadiene, wherein halo is iodine (I), bromine (Br), fluorine (F), or chlorine (CI) and hetero is N, O, or S, and (ii) an S, NR, or O group on L; each occurrence of R is independently hydrogen, a suitable protecting group, an acyl moiety, arylalkyl moiety, aliphatic moiety, aryl moiety, heteroaryl moiety, or heteroaliphatic moiety; L is a cell-specific targeting ligand; and n is 1, 2, 3, or 4; and a pharmaceutically acceptable salt or carrier. In particular aspects, the composition is aqueous or lyophilized. In particular embodiments, when Y is a covalent bond, X is not a covalent bond.
In particular aspects, the linkage Z has the structure
Y is a covalent bond, or W when Y and X are a covalent bond (on the left) and Z and L (on the right), respectively.
In particular embodiments, the payload is a therapeutic agent, a detectable label, radionuclide, or protecting group. The therapeutic agent may be cytotoxic agent, an anti- inflammatory agent, peptide, or nucleic acid or nucleic acid analog.
In particular embodiments, the cytotoxic agent selected from duocarmycins and CC-1065, and analogues thereof, including CBI (1,2,9,9a- tetrahydrocyclopropa[c]benz[e]indol- 4-one)-based analogues, MCBI (7-methoxy- 1,2,9,9a- tetra-hydrocyclopropa[c]benz[e]indol-4- one)-based analogues and CCBI (7-cyano- 1,2,9,9a- tetra-hydrocyclo-propa[c]benz[e]-indol-4- one)-based analogues of the duocarmycins and CC- 1065, doxorubicin and doxorubicin conjugates such as morpholino-doxorubicin and cyanomorpholino-doxorubicin, dolastatins such as dolestatin-10, combretastatin, calicheamicin, maytansine, maytansine analogs, DM-I, auristatin E, auristatin EB (AEB), auristatin EFP (AEFP), monomethyl auristatin E (MMAE), 5- benzoylvaleric acid- AE ester (AEVB), tubulysins, disorazole, epothilones , Paclitaxel, docetaxel, SN-38, Topotecan, rhizoxin, echinomycin, colchicine, vinblastin, vindesine, estramustine, cemadotin, eleutherobin, methotrexate, methopterin, dichloro methotrexate, 5- fiuorouracil, 6- mercaptopurine, cytosine arabinoside, melphalan, leurosine, leurosideine, actinomycin, daunorubicin and daunorubicin conjugates, mitomycin C, mitomycin A, carminomycin, aminopterin, tallysomycin, podophyllotoxin and podophyllotoxin derivatives such as etoposide or etoposide phosphate, vincristine, taxol, taxotere retinoic acid, butyric acid, N - acetyl spermidine, camptothecin, and their analogs.
In particular embodiments, the anti-inflammatory agent is a glucocorticoid receptor agonist. In a further aspect, the anti-inflammatory agent is a glucocorticoid, for example, Cortisol, cortisone acetate, beclometasone, prednisone, prednisolone,
methylprednisolone, betamethasone, trimcinolone, budesonide, dexamethasone, fluticasone, fluticasone propionate, fluticasone furoate, compound 15-5, or mometasone.
In particular embodiments, the targeting ligand is an antibody or monoclonal antibody (e.g., chimeric, humanized, or human) or fragment thereof, ligand for a receptor, lectin; saccharide, poly(ethylene glycol); polysaccharide, or polyamino acid.
In particular embodiments, the chimeric, humanized, or human antibody or monoclonal antibody is an anti-Her2 antibody, anti-CD4 antibody, anti-CD20 antibody, anti- EGFR antibody, anti-CD22 antibody, anti-CD23 antibody, anti-CD25 antibody, anti-CD52 antibody, anti-CD30 antibody, anti-CD33 antibody, anti-CD40L antibody, anti-CD70 antibody, anti-CD74 antibody, anti-CD80 antibody, anti-CD 163 antibody, anti-Mucl8 antibody, anti- integrin antibody, anti-PSMA antibody, anti-CEA antibody, anti-CDl la antibody, anti-CTLA4 antibody, or anti-BLys antibody.
The present invention further provides a method for treating a disease or disorder by providing to a subject having the disease or disorder a composition comprising a compound having formula (III)
wherein V is selected from O and S; W is selected from O, N, and CH2; X is a tuning element selected from a covalent bond; a carbon atom; a heteroatom; an optionally substituted group selected from the group consisting of acyl, aliphatic, heteroaliphatic, aryl, heteroaryl, and heterocyclic; a carbon atom linked to a trimethylammonium group by a C1-C5 hydrocarbon chain; nucleoside, protease sensitive group, cathepsin B sensitive group, or glycosidase sensitive group; Y is selected from a covalent bond or a bivalent, straight or branched, saturated or unsaturated, optionally substituted Ci .39 hydrocarbon chain wherein one or more methylene units of Y are optionally and independently replaced by -0-, -S-, -N(R)-, -C(O)-, C(0)0-, OC(O)-, -N(R)C(0)-, -C(0)N(R)-, -S(O)-, -S(0)2-, -N(R)S02-, S02N(R)-, a heterocyclic group, an aryl group, or a heteroaryl group; T is an NR, CR2, O, or S; D is a payload; Z is a linkage formed between (i) a reactive functional group selected from the group consisting of N- hydroxysuccinimide, para-nitrophenyl carbonate, para-nitrophenyl carbamate,
pentafluorophenyl, haloacetamide, maleimide, hydroxylamine, strained cycloalkyne, and heterocycloalkyne, alkyne, diene, azadiene, and heterocyclic azadiene, wherein halo is iodine (I), bromine (Br), fluorine (F), or chlorine (CI) and hetero is N, O, or S, and (ii) an S, NR, or O group on L; each occurrence of R is independently hydrogen, a suitable protecting group, an acyl moiety, arylalkyl moiety, aliphatic moiety, aryl moiety, heteroaryl moiety, or heteroaliphatic moiety; L is a cell-specific targeting ligand; and n is 1 , 2, 3, or 4; and a pharmaceutically acceptable salt or carrier. In particular embodiments, when Y is a covalent bond, X is not a covalent bond.
In particular aspects, the linkage Z has the structure
, or , wherein the wavy lines mark the covalent bond between Z and Y, or X when
Y is a covalent bond, or W when Y and X are a covalent bond (on the left) and Z and L (on the right), respectively.
In particular aspects, the disease or disorder is an inflammatory disease or cancer.
In particular embodiments, the payload is a therapeutic agent, which may be a cytotoxic agent, an anti-inflammatory agent, peptide, or nucleic acid or nucleic acid analog.
In particular embodiments, the cytotoxic agent selected from duocarmycins and CC-1065, and analogues thereof, including CBI (1,2,9,9a- tetrahydrocyclopropa[c]benz[e]indol- 4-one)-based analogues, MCBI (7-methoxy- 1,2,9,9a- tetra-hydrocyclopropa[c]benz[e]indol-4- one)-based analogues and CCBI (7-cyano- 1,2,9,9a- tetra-hydrocyclo-propa[c]benz[e]-indol-4- one)-based analogues of the duocarmycins and CC- 1065, doxorubicin and doxorubicin conjugates such as morpholino-doxorubicin and cyanomorpholino-doxorubicin, dolastatins such as dolestatin-10, combretastatin, calicheamicin, maytansine, maytansine analogs, DM-I, auristatin E, auristatin EB (AEB), auristatin EFP (AEFP), monomethyl auristatin E (MMAE), 5- benzoylvaleric acid- AE ester (AEVB), tubulysins, disorazole, epothilones , Paclitaxel, docetaxel, SN-38, Topotecan, rhizoxin, echinomycin, colchicine, vinblastin, vindesine, estramustine, cemadotin, eleutherobin, methotrexate, methopterin, dichloro methotrexate, 5- fluorouracil, 6- mercaptopurine, cytosine arabinoside, melphalan, leurosine, leurosideine, actinomycin, daunorubicin and daunorubicin conjugates, mitomycin C, mitomycin A, carminomycin, aminopterin, tallysomycin, podophyllotoxin and podophyllotoxin derivatives such as etoposide or etoposide phosphate, vincristine, taxol, taxotere retinoic acid, butyric acid, N - acetyl spermidine, camptothecin, and their analogs.
In particular embodiments, the anti-inflammatory agent is a glucocorticoid receptor agonist. In a further aspect, the anti-inflammatory agent is a glucocorticoid, for example, Cortisol, cortisone acetate, beclometasone, prednisone, prednisolone,
methylprednisolone, betamethasone, trimcinolone, budesonide, dexamethasone, fluticasone, fluticasone propionate, fluticasone furoate, compound 15-5, or mometasone.
In particular embodiments, the targeting ligand is an antibody or monoclonal antibody (e.g., chimeric, humanized, or human) or fragment thereof, ligand for a receptor, lectin, saccharide, poly(ethylene glycol), polysaccharide, or polyamino acid.
In particular embodiments, the chimeric, humanized, or human antibody or monoclonal antibody is an anti-Her2 antibody, anti-CD4 antibody, anti-CD20 antibody, anti- EGF antibody, anti-CD22 antibody, anti-CD23 antibody, anti-CD25 antibody, anti-CD52 antibody, anti-CD30 antibody, anti-CD33 antibody, anti-CD40L antibody, anti-CD70 antibody, anti-CD74 antibody, anti-CD80 antibody, anti-CD 163 antibody, anti-Mucl8 antibody, anti- integrin antibody, anti-PSMA antibody, anti-CEA antibody, anti-CDl la antibody, anti-CTLA4 antibody, or anti-BLys antibody.
The present invention further provides for the use of composition comprising a compound having formula (III)
wherein V is selected from O and S; W is selected from O, N, and CH2; X is a tuning element selected from a covalent bond; a carbon atom; a heteroatom; an optionally substituted group selected from the group consisting of acyl, aliphatic, heteroaliphatic, aryl, heteroaryl, and heterocyclic; a carbon atom linked to a trimethylammonium group by a C1-C5 hydrocarbon chain; nucleoside, protease sensitive group, cathepsin B sensitive group, or glycosidase sensitive group; Y is selected from a covalent bond or a bivalent, straight or branched, saturated or unsaturated, optionally substituted Ci .39 hydrocarbon chain wherein one or more methylene units of Y are optionally and independently replaced by -0-, -S-, -N(R)-, -C(O)-, C(0)0-, OC(O)-, -N(R)C(0)-, -C(0)N(R)-, -S(O)-, -S(0)2-, -N(R)S02-, S02N(R)-, a heterocyclic group, an aryl group, or a heteroaryl group; T is an NR, CR2, O, or S; D is a payload; Z is a linkage formed between (i) a reactive functional group selected from the group consisting of N- hydroxysuccinimide, para-nitrophenyl carbonate, para-nitrophenyl carbamate,
pentafiuorophenyl, haloacetamide, maleimide, hydroxylamine, strained cycloalkyne, and heterocycloalkyne, alkyne, diene, azadiene, and heterocyclic azadiene, wherein halo is iodine (I), bromine (Br), fluorine (F), or chlorine (CI) and hetero is N, O, or S, and (ii) an S, NR, or O group on L; each occurrence of R is independently hydrogen, a suitable protecting group, an acyl moiety, arylalkyl moiety, aliphatic moiety, aryl moiety, heteroaryl moiety, or heteroaliphatic moiety; L is a cell-specific targeting ligand; and n is 1, 2, 3, or 4; and a pharmaceutically acceptable salt or carrier for the treatment of a disease or disorder. In particular embodiments, when Y is a covalent bond, X is not a covalent bond.
In particular aspects, the linkage Z has the structure
Y is a covalent bond, or W when Y and X are a covalent bond (on the left) and Z and L (on the right), respectively.
In particular aspects, the disease or disorder is an inflammatory disease or cancer. In particular embodiments, the payload is a therapeutic agent such as a cytotoxic agent, an anti-inflammatory agent, peptide, or nucleic acid or nucleic acid analog.
In particular embodiments, the cytotoxic agent selected from duocarmycins and
CC-1065, and analogues thereof, including CBI (1,2,9,9a- tetrahydrocyclopropa[c]benz[e]indol- 4-one)-based analogues, MCBI (7-methoxy- 1,2,9,9a- tetra-hydrocyclopropa[c]benz[e]indol-4- one)-based analogues and CCBI (7-cyano- 1,2,9,9a- tetra-hydrocyclo-propa[c]benz[e]-indol-4- one)-based analogues of the duocarmycins and CC- 1065, doxorubicin and doxorubicin conjugates such as morpholino-doxorubicin and cyanomorpholino-doxorubicin, dolastatins such as dolestatin-10, combretastatin, calicheamicin, maytansine, maytansine analogs, DM-I, auristatin E, auristatin EB (AEB), auristatin EFP (AEFP), monomethyl aunstatin E (MMAE), 5- benzoylvaleric acid- AE ester (AEVB), tubulysins, disorazole, epothilones , Paclitaxel, docetaxel, SN-38, Topotecan, rhizoxin, echinomycin, colchicine, vinblastin, vindesine, estramustine, cemadotin, eleutherobin, methotrexate, methopterin, dichloro methotrexate, 5- fluorouracil, 6- mercaptopurine, cytosine arabinoside, melphalan, leurosine, leurosideine, actinomycin, daunorubicin and daunorubicin conjugates, mitomycin C, mitomycin A, carminomycin, aminopterin, tallysomycin, podophyllotoxin and podophyllotoxin derivatives such as etoposide or etoposide phosphate, vincristine, taxol, taxotere retinoic acid, butyric acid, N - acetyl spermidine, camptothecin, and their analogues.
In particular embodiments, the anti-inflammatory agent is a glucocorticoid receptor agonist. In a further aspect, the anti-inflammatory agent is a glucocorticoid, for example, Cortisol, cortisone acetate, beclometasone, prednisone, prednisolone,
methylprednisolone, betamethasone, trimcinolone, budesonide, dexamethasone, fluticasone, fluticasone propionate, fluticasone furoate, compound 15-5, or mometasone.
In particular embodiments, the targeting ligand is an antibody or monoclonal antibody (e.g., chimeric, humanized, or human), ligand for a receptor, lectin, saccharide, poly(ethylene glycol), polysaccharide, or polyamino acid.
In particular embodiments, the chimeric, humanized, or human antibody or monoclonal antibody is an anti-Her2 antibody, anti-CD4 antibody, anti-CD20 antibody, anti- EGF antibody, anti-CD22 antibody, anti-CD23 antibody, anti-CD25 antibody, anti-CD52 antibody, anti-CD30 antibody, anti-CD33 antibody, anti-CD40L antibody, anti-CD70 antibody, anti-CD74 antibody, anti-CD80 antibody, anti-CD 163 antibody, anti-Mucl8 antibody, anti- integrin antibody, anti-PSMA antibody, anti-CEA antibody, anti-CDl la antibody, anti-CTLA4 antibody, or anti-BLys antibody.
The present invention further provides an anti-inflammatory compound comprising the formula
wherein
V is selected from O and S;
W is selected from O, N, and CH2;
X is selected from a covalent bond; a carbon atom; a heteroatom; an optionally substituted group selected from the group consisting of acyl, aliphatic, heteroaliphatic, aryl, heteroaryl, and heterocyclic; a carbon atom linked to a trimethylammonium group by a C1-C5 hydrocarbon chain; nucleoside, protease sensitive group, cathepsin B sensitive group, or glycosidase sensitive group;
Y is selected from a covalent bond or a bivalent, straight or branched, saturated or unsaturated, optionally substituted CI -30 hydrocarbon chain wherein one or more methylene units of Y are optionally and independently replaced by -0-, -S-, -N(R)-, -C(O)-, C(0)0-, OC(O)-, -N(R)C(0)-, -C(0)N(R)-, -S(O)-, -S(0)2-, -N(R)S02-, S02N(R , a heterocyclic group, an aryl group, or a heteroaryl group;
T is an R, CR2, O, or S;
D is an anti-inflammatory agent;
Z is a linkage formed between (i) a reactive functional group selected from the group consisting of N-hydroxysuccinimide, para-nitrophenyl carbonate, para-nitrophenyl carbamate, pentafluorophenyl, haloacetamide, maleimide, hydroxylamine, strained cycloalkyne, and heterocycloalkyne, alkyne, diene, azadiene, and heterocyclic azadiene, wherein halo is iodine (I), bromine (Br), fluorine (F), or chlorine (CI) and hetero is N, O, or S, and (ii) an S, NR, or O group on the cell-specific targeting ligand (L);
Each occurrence of R is independently hydrogen, a suitable protecting group, an acyl moiety, arylalkyl moiety, aliphatic moiety, aryl moiety, heteroaryl moiety, or heteroaliphatic moiety;
L is a cell-specific targeting ligand; and
n is 1, 2, 3, or 4. In particular embodiments, when Y is a covalent bond, X is not a covalent bond.
In further aspects, the anti-inflammatory agent is a glucocorticoid receptor agonist.
In further aspects, the anti-inflammatory agent is Cortisol, cortisone acetate, beclometasone, prednisone, prednisolone, methylprednisolone, betamethasone, trimcinolone, budesonide, dexamethasone, fluticasone, fluticasone propionate, fluticasone furoate, compound 15-5, or mometasone.
In further aspects, the targeting ligand is an antibody or monoclonal antibody (e.g., chimeric, humanized, or human), ligand for a receptor, lectin, saccharide, poly(ethylene glycol), polysaccharide, or polyamino acid.
In further aspects, the targeting ligand is a chimeric, humanized, or human anti- Her2 antibody, anti-CD4 antibody, anti-CD20 antibody, anti-EGFR antibody, anti-CD22 antibody, anti-CD23 antibody, anti-CD25 antibody, anti-CD52 antibody, anti-CD30 antibody, anti-CD33 antibody, anti-CD40L antibody, anti-CD70 antibody, anti-CD74 antibody, anti-CD80 antibody, anti-CD 163 antibody, anti-Mucl8 antibody, anti-integrin antibody, anti-PSMA antibody, anti-CEA antibody, anti-CDl la antibody, anti-CTLA4 antibody, or anti-BLys antibody.
In particular aspects, the linkage Z has the structure
, or ? , wherein the wavy lines mark the covalent bond between Z and Y, or X when
Y is a covalent bond, or W when Y and X are a covalent bond (on the left) and Z and L (on the right), respectively.
wherein
V is selected from O and S;
W is selected from O, N, and CH2;
X is selected from a covalent bond; a carbon atom; a heteroatom; an optionally substituted group selected from the group consisting of acyl, aliphatic, heteroaliphatic, aryl, heteroaryl, and heterocyclic; a carbon atom linked to a trimethylammonium group by a C1-C5 hydrocarbon chain; nucleoside, protease sensitive group, cathepsin B sensitive group, or glycosidase sensitive group;
Y is selected from a covalent bond or a bivalent, straight or branched, saturated or unsaturated, optionally substituted CI -30 hydrocarbon chain wherein one or more methylene units of Y are optionally and independently replaced by -0-, -S-, -N(R)-, -C(O)-, C(0)0-, OC(O)-, -N(R)C(0>, -C(0)N(R)-, -S(O)-, -S(0)2-, -N(R)S02-, S02N(R , a heterocyclic group, an aryl group, or a heteroaryl group;
T is an R, CR2, O, or S;
D is a cytotoxic agent;
Z is a linkage formed between (i) a reactive functional group selected from the group consisting of N-hydroxysuccinimide, para-nitrophenyl carbonate, para-nitrophenyl carbamate, pentafluorophenyl, haloacetamide, maleimide, hydroxylamine, strained cycloalkyne, and heterocycloalkyne, alkyne, diene, azadiene, and heterocyclic azadiene, wherein halo is iodine (I), bromine (Br), fluorine (F), or chlorine (CI) and hetero is N, O, or S, and (ii) an S, NR, or O group on the cell-specific targeting ligand (L);
Each occurrence of R is independently hydrogen, a suitable protecting group, an acyl moiety, arylalkyl moiety, aliphatic moiety, aryl moiety, heteroaryl moiety, or heteroaliphatic moiety;
L is a cell-specific targeting ligand; and
n is 1, 2, 3, or 4. In particular embodiments, when Y is a covalent bond, X is not a covalent bond.
In further aspects, wherein the cytotoxic agent is selected from duocarmycins and
CC-1065;
28. The compound of claim 26, wherein the cytotoxic agent is selected from a CBI (1,2,9,9a- tetrahydrocyclopropa[c]benz[e]indol-4-one)-based analogues, MCBI (7-methoxy- 1,2,9,9a- tetra-hydrocyclopropa[c]benz[e]indol-4-one)-based analogues and CCBI (7-cyano- 1,2,9,9a- tetra-hydrocyclo-propa[c]benz[e]-indol-4-one)-based analogue of the duocarmycins and CC- 1065.
In further aspects, the cytotoxic agent is selected from doxorubicin and doxorubicin conjugates such as morpholino-doxorubicin and cyanomorpholino-doxorubicin.
In further aspects, the cytotoxic agent is selected from dolastatins such as dolestatin- 10, combretastatin, calicheamicin, maytansine, maytansine analogs, DM-I, auristatin E, auristatin EB (AEB), auristatin EFP (AEFP), monomethyl auristatin E (MMAE), 5- benzoylvaleric acid- AE ester (AEVB), tubulysins, disorazole, epothilones, Paclitaxel, docetaxel, SN-38, Topotecan, rhizoxin, echinomycin, colchicine, vinblastin, vindesine, estramustine, cemadotin, eleutherobin, methotrexate, methopterin, dichloro methotrexate, 5-fluorouracil, 6- mercaptopurine, cytosine arabinoside, melphalan, leurosine, leurosideine, actinomycin, daunorubicin and daunorubicin conjugates, mitomycin C, mitomycin A, carminomycin, aminopterin, tallysomycin, podophyllotoxm and podophyllotoxm derivatives such as etoposide or etoposide phosphate, vincristine, taxol, taxotere retinoic acid, butyric acid, N - acetyl spermidine, camptothecin, and analogs thereof.
In further aspects, the targeting ligand is an antibody or monoclonal antibody (e.g., chimeric, humanized, or human), ligand for a receptor, lectin, saccharide, poly(ethylene glycol), polysaccharide, or polyamino acid.
In further aspects, the targeting ligand is a chimeric, humanized, or human anti- Her2 antibody, anti-CD4 antibody, anti-CD20 antibody, anti-EGFR antibody, anti-CD22 antibody, anti-CD23 antibody, anti-CD25 antibody, anti-CD52 antibody, anti-CD30 antibody, anti-CD33 antibody, anti-CD40L antibody, anti-CD70 antibody, anti-CD74 antibody, anti-CD80 antibody, anti-CD 163 antibody, anti-Mucl8 antibody, anti-integrin antibody, anti-PSMA antibody, anti-CEA antibody, anti-CDl la antibody, anti-CTLA4 antibody, or anti-BLys antibody.
In particular aspects, the linkage Z has the structure
Y is a covalent bond, or W when Y and X are a covalent bond (on the left) and Z and L (on the right), respectively.
The present invention further provides a method for making an antibody-drug conjugate that has reduced propensity for forming aggregates comprising:
(a) providing a compound comprising the formula
wherein
V is selected from O and S;
W is selected from O, N, and CH2;
X is selected from a covalent bond; a carbon atom; a heteroatom; an optionally substituted group selected from the group consisting of acyl, aliphatic, heteroaliphatic, aryl, heteroaryl, and heterocyclic; a carbon atom linked to a trimethylammonium group by a C1-C5 hydrocarbon chain; nucleoside, protease sensitive group, cathepsin B sensitive group, or glycosidase sensitive group;
Y is selected from a covalent bond or a bivalent, straight or branched, saturated or unsaturated, optionally substituted CI -30 hydrocarbon chain wherein one or more methylene units of Y are optionally and independently replaced by -0-, -S-, -N(R)-, -C(O)-, C(0)0-, OC(O)-, -N(R)C(0)-, -C(0)N(R)-, -S(O)-, -S(0)2-, -N(R)S02-, S02N(R)-, a heterocyclic group, an aryl group, or a heteroaryl group;
T is an R, CR2, O, or S;
Z is a reactive functional group selected from the group consisting of N- hydroxysuccinimidyl ester, para-nitrophenyl carbonate, para-nitrophenyl carbamate, methyl ketone, azide, hydrazine, pentafluorophenyl, haloacetamide, maleimide, hydroxylamine, strained cycloalkyne, and heterocycloalkyne, alkyne, diene, azadiene, and heterocyclic azadiene, wherein halo is iodine (I), bromine (Br), fluorine (F), or chlorine (CI) and hetero is N, O, or S;
D is a payload;
Each occurrence of R is independently hydrogen, a suitable protecting group, an acyl moiety, arylalkyl moiety, aliphatic moiety, aryl moiety, heteroaryl moiety, or heteroaliphatic moiety; and
n is 1, 2, 3, or 4; and
(b) conjugating the compound to an antibody to make the antibody-drug conjugate that has reduced propensity for forming aggregates compared to an antibody-drug conjugate not conjugated to the compound.
In further aspects, the payload is a therapeutic agent, a detectable label, radionuclide, or protecting group. In particular embodiments, when Y is a covalent bond, X is not a covalent bond.
In further aspects, the therapeutic agent is a cytotoxic agent, an anti-inflammatory agent, peptide, or nucleic acid or nucleic acid analog.
In further aspects, the anti-inflammatory agent is a glucocorticoid receptor agonist.
In further aspects, the anti-inflammatory agent is Cortisol, cortisone acetate, beclometasone, prednisone, prednisolone, methylprednisolone, betamethasone, trimcinolone, budesonide, dexamethasone, fluticasone, fluticasone propionate, fluticasone furoate, compound 15-5, or mometasone.
In further aspects, the cytotoxic agent is selected from duocarmycins and CC- 1065.
In further aspects, the cytotoxic agent is selected from a CBI (1,2,9,9a- tetrahydrocyclopropa[c]benz[e]indol-4-one)-based analogues, MCBI (7-methoxy- 1,2,9,9a- tetra- hydrocyclopropa[c]benz[e]indol-4-one)-based analogues and CCBI (7-cyano- 1,2,9,9a- tetra- hydrocyclo-propa[c]benz[e]-indol-4-one)-based analogue of the duocarmycins and CC- 1065.
In further aspects, the cytotoxic agent is selected from doxorubicin and doxorubicin conjugates such as morpholino-doxorubicin and cyanomorpholino-doxorubicin.
In further aspects, the cytotoxic agent is selected from dolastatins such as dolestatin- 10, combretastatin, calicheamicin, maytansine, maytansine analogs, DM-I, auristatin E, auristatin EB (AEB), auristatin EFP (AEFP), monomethyl auristatin E (MMAE), 5- benzoylvaleric acid- AE ester (AEVB), tubulysins, disorazole, epothilones, Paclitaxel, docetaxel, SN-38, Topotecan, rhizoxin, echinomycin, colchicine, vinblastin, vindesine, estramustine, cemadotin, eleutherobin, methotrexate, methopterin, dichloro methotrexate, 5-fluorouracil, 6- mercaptopurine, cytosine arabinoside, melphalan, leurosine, leurosideine, actinomycin, daunorubicin and daunorubicin conjugates, mitomycin C, mitomycin A, carminomycin, aminopterin, tallysomycin, podophyllotoxin and podophyllotoxin derivatives such as etoposide or etoposide phosphate, vincristine, taxol, taxotere retinoic acid, butyric acid, N - acetyl spermidine, camptothecin, and analogs thereof.
In further aspects, the targeting ligand is an antibody or monoclonal antibody (e.g., chimeric, humanized, or human), ligand for a receptor, lectin, saccharide, poly(ethylene glycol), polysaccharide, or polyamino acid.
In further aspects, the targeting ligand is a chimeric, humanized, or human anti- Her2 antibody, anti-CD4 antibody, anti-CD20 antibody, anti-EGFR antibody, anti-CD22 antibody, anti-CD23 antibody, anti-CD25 antibody, anti-CD52 antibody, anti-CD30 antibody, anti-CD33 antibody, anti-CD40L antibody, anti-CD70 antibody, anti-CD74 antibody, anti-CD80 antibody, anti-CD163 antibody, anti-Mucl8 antibody, anti-integrin antibody, anti-PSMA antibody, anti-CEA antibody, anti-CDl la antibody, anti-CTLA4 antibody, or anti-BLys antibody.
In particular aspect, the reactive group Z has the structure
wherein the wavy line is the covalent bond between Z and Y, or X when Y is a covalent bond, or W when Y and X are a covalent bond.
The present invention further provides a method for making a composition of antibody-drug conjugates in which the propensity of the antibody-drug conjugates in the composition to form aggregates is reduced comprising:
(a) providing a multiplicity of compounds comprising the formula
wherein
V is selected from O and S;
W is selected from O, N, and CH2;
X is selected from a covalent bond; a carbon atom; a heteroatom; an optionally substituted group selected from the group consisting of acyl, aliphatic, heteroaliphatic, aryl, heteroaryl, and heterocyclic; a carbon atom linked to a trimethylammonium group by a C1-C5 hydrocarbon chain; nucleoside, protease sensitive group, cathepsin B sensitive group, or glycosidase sensitive group;
Y is selected from a covalent bond or a bivalent, straight or branched, saturated or unsaturated, optionally substituted CI -30 hydrocarbon chain wherein one or more methylene units of Y are optionally and independently replaced by -0-, -S-, -N(R)-, -C(O)-, C(0)0-, OC(O)-, -N(R)C(0)-, -C(0)N(R)-, -S(O)-, -S(0)2-, -N(R)S02-, S02N(R , a heterocyclic group, an aryl group, or a heteroaryl group;
T is an R, CR2, O, or S;
Z is a reactive functional group selected from the group consisting of N- hydroxysuccinimidyl ester, para-nitrophenyl carbonate, para-nitrophenyl carbamate, methyl ketone, azide, hydrazine, pentafluorophenyl, haloacetamide, maleimide, hydroxylamine, strained cycloalkyne, and heterocycloalkyne, alkyne, diene, azadiene, and heterocyclic azadiene, wherein halo is iodine (I), bromine (Br), fluorine (F), or chlorine (CI) and hetero is N, O, or S;
D is a payload;
each occurrence of R is independently hydrogen, a suitable protecting group, an acyl moiety, arylalkyl moiety, aliphatic moiety, aryl moiety, heteroaryl moiety, or heteroaliphatic moiety; and
n is 1, 2, 3, or 4; and
(b) conjugating the compounds to a multiplicity of antibodies to make the composition in which the propensity of the antibody-drug conjugates therein to form aggregates is reduced compared to an antibody-drug conjugate that are not conjugated to the compound. In particular embodiments, when Y is a covalent bond, X is not a covalent bond.
In further aspects, the payload is a therapeutic agent, a detectable label, radionuclide, or protecting group.
In further aspects, the therapeutic agent is a cytotoxic agent, an anti-inflammatory agent, peptide, or nucleic acid or nucleic acid analog.
In further aspects, the anti-inflammatory agent is a glucocorticoid receptor agonist.
In further aspects, the anti-inflammatory agent is Cortisol, cortisone acetate, beclometasone, prednisone, prednisolone, methylprednisolone, betamethasone, trimcinolone, budesonide, dexamethasone, fluticasone, fluticasone propionate, fluticasone furoate, compound 15-5, or mometasone.
In further aspects, the cytotoxic agent is selected from duocarmycins and CC- 1065.
In further aspects, the cytotoxic agent is selected from a CBI (1,2,9,9a- tetrahydrocyclopropa[c]benz[e]indol-4-one)-based analogues, MCBI (7-methoxy- 1,2,9,9a- tetra- hydrocyclopropa[c]benz[e]indol-4-one)-based analogues and CCBI (7-cyano- 1,2,9,9a- tetra- hydrocyclo-propa[c]benz[e]-indol-4-one)-based analogue of the duocarmycins and CC- 1065.
In further aspects, the cytotoxic agent is selected from doxorubicin and doxorubicin conjugates such as mo holino-doxorubicin and cyanomorpholino-doxorubicin.
In further aspects, the cytotoxic agent is selected from dolastatins such as dolestatin- 10, combretastatin, calicheamicin, maytansine, maytansine analogs, DM-I, auristatin E, auristatin EB (AEB), auristatin EFP (AEFP), monomethyl auristatin E (MMAE), 5- benzoylvaleric acid- AE ester (AEVB), tubulysins, disorazole, epothilones, Paclitaxel, docetaxel, SN-38, Topotecan, rhizoxin, echinomycin, colchicine, vinblastin, vindesine, estramustine, cemadotin, eleutherobin, methotrexate, methopterin, dichloro methotrexate, 5-fluorouracil, 6- mercaptopurine, cytosine arabinoside, melphalan, leurosine, leurosideine, actinomycin, daunorubicin and daunorubicin conjugates, mitomycin C, mitomycin A, carminomycin, aminopterin, tallysomycin, podophyllotoxin and podophyllotoxin derivatives such as etoposide or etoposide phosphate, vincristine, taxol, taxotere retinoic acid, butyric acid, N - acetyl spermidine, camptothecin, and analogs thereof.
In further aspects, the percent of aggregated antibody-drug-conjugate in the composition is 2% or less, 1.5% or less, 1.0% or less, 5% or less, 1% or less, or undetectable.
In further aspects, at least 90%, 95%, 96%, 97% 98%, 99%, 99.5%, 99.4%, 99.3%, or 99.2% of the antibody-drug conjugates in the composition is not aggregated.
In further aspects, the targeting ligand is an antibody or monoclonal antibody (e.g., chimeric, humanized, or human), ligand for a receptor, lectin, saccharide, poly(ethylene glycol), polysaccharide, or polyamino acid.
In further aspects, the targeting ligand is a chimeric, humanized, or human anti- Her2 antibody, anti-CD4 antibody, anti-CD20 antibody, anti-EGFR antibody, anti-CD22 antibody, anti-CD23 antibody, anti-CD25 antibody, anti-CD52 antibody, anti-CD30 antibody, anti-CD33 antibody, anti-CD40L antibody, anti-CD70 antibody, anti-CD74 antibody, anti-CD80 antibody, anti-CD 163 antibody, anti-Mucl8 antibody, anti-integrin antibody, anti-PSMA antibody, anti-CEA antibody, anti-CDl la antibody, anti-CTLA4 antibody, or anti-BLys antibody.
In particular aspect, the reactive group Z has the structure
wherein the wavy line marks the covalent bond between Z and Y, or X when Y is a covalent bond, or W when Y and X are a covalent bond.
DEFINITIONS
Definitions of specific functional groups, chemical terms, and general terms used throughout the specification are described in more detail below. For purposes of this invention, the chemical elements are identified in accordance with the Periodic Table of the Elements, CAS version, Handbook of Chemistry and Physics, 75th Ed., inside cover, and specific functional groups are generally defined as described therein. Additionally, general principles of organic chemistry, as well as specific functional moieties and reactivity, are described in Organic Chemistry, Thomas Sorrell, University Science Books, Sausalito, 1999; Smith and March March's Advanced Organic Chemistry, 5th Edition, John Wiley & Sons, Inc., New York, 2001; Larock, Comprehensive Organic Transformations, VCH Publishers, Inc., New York, 1989; Carruthers, Some Modern Methods of Organic Synthesis, 3rd Edition, Cambridge University Press, Cambridge, 1987.
Acyl - As used herein, the term "acyl," refers to a group having the general formula -C(=0)RX1, -C(=0)ORxl, -C(=0)-0-C(=0)Rxl, -C(=0)SRX1, -C(=0)N(RX1)2, -
C(=S)R , -C(=S)N(RA1)2, and -C(=S)S(RA1), -C(=NRA1)R , -C(=NRA1)OR , -
C(=NRX1)SRX1, and -C(=NRX1)N(RX1)2, wherein RX1 is hydrogen; halogen; substituted or unsubstituted hydroxyl; substituted or unsubstituted thiol; substituted or unsubstituted amino; substituted or unsubstituted acyl; cyclic or acyclic, substituted or unsubstituted, branched or unbranched aliphatic; cyclic or acyclic, substituted or unsubstituted, branched or unbranched heteroaliphatic; cyclic or acyclic, substituted or unsubstituted, branched or unbranched alkyl; cyclic or acyclic, substituted or unsubstituted, branched or unbranched alkenyl; substituted or unsubstituted alkynyl, substituted or unsubstituted aryl, substituted or unsubstituted heteroaryl, aliphaticoxy, heteroaliphaticoxy, alkyloxy, heteroalkyloxy, aryloxy, heteroaryloxy,
aliphaticthioxy, heteroaliphaticthioxy, alkylthioxy, heteroalkylthioxy, arylthioxy,
heteroarylthioxy, mono- or di- aliphaticamino, mono- or di- heteroaliphaticamino, mono- or di- alkylamino, mono- or di- heteroalkylamino, mono- or di- arylamino, or mono- or di- heteroarylamino; or two RX1 groups taken together form a 5- to 6- membered heterocyclic ring. Exemplary acyl groups include aldehydes (-CHO), carboxylic acids (-CO2H), ketones, acyl halides, esters, amides, imines, carbonates, carbamates, and ureas. Acyl substituents include, but are not limited to, any of the substituents described herein, that result in the formation of a stable moiety (e.g., aliphatic, alkyl, alkenyl, alkynyl, heteroaliphatic, heterocyclic, aryl, heteroaryl, acyl, oxo, imino, thiooxo, cyano, isocyano, amino, azido, nitro, hydroxyl, thiol, halo, aliphaticamino, heteroaliphaticamino, alkylamino, heteroalkylamino, arylamino,
heteroarylamino, alkylaryl, arylalkyl, aliphaticoxy, heteroaliphaticoxy, alkyloxy, heteroalkyloxy, aryloxy, heteroaryloxy, aliphaticthioxy, heteroaliphaticthioxy, alkylthioxy, heteroalkylthioxy, arylthioxy, heteroarylthioxy, acyloxy, and the like, each of which may or may not be further substituted).
Aliphatic - As used herein, the term "aliphatic" or "aliphatic group" denotes an optionally substituted hydrocarbon moiety that may be straight-chain (i.e., unbranched), branched, or cyclic ("carbocyclic") and may be completely saturated or may contain one or more units of unsaturation, but which is not aromatic. Unless otherwise specified, aliphatic groups contain 1-12 carbon atoms. In some embodiments, aliphatic groups contain 1-6 carbon atoms. In some embodiments, aliphatic groups contain 1-4 carbon atoms, and in yet other embodiments aliphatic groups contain 1-3 carbon atoms. Suitable aliphatic groups include, but are not limited to, linear or branched, alkyl, alkenyl, and alkynyl groups, and hybrids thereof such as
(cycloalkyl)alkyl, (cycloalkenyl)alkyl or (cycloalkyl)alkenyl.
Alkenyl - As used herein, the term "alkenyl" denotes an optionally substituted monovalent group derived from a straight- or branched-chain aliphatic moiety having at least one carbon-carbon double bond by the removal of a single hydrogen atom. In certain embodiments, the alkenyl group employed in the invention contains 2-6 carbon atoms. In certain embodiments, the alkenyl group employed in the invention contains 2-5 carbon atoms. In some embodiments, the alkenyl group employed in the invention contains 2-4 carbon atoms. In
another embodiment, the alkenyl group employed contains 2-3 carbon atoms. Alkenyl groups include, for example, ethenyl, propenyl, butenyl, l-methyl-2-buten-l-yl, and the like.
Alky I - As used herein, the term "alkyl" refers to optionally substituted saturated, straight- or branched-chain hydrocarbon radicals derived from an aliphatic moiety containing between 1-6 carbon atoms by removal of a single hydrogen atom. In some embodiments, the alkyl group employed in the invention contains 1 -5 carbon atoms. In another embodiment, the alkyl group employed contains 1-4 carbon atoms. In still other embodiments, the alkyl group contains 1-3 carbon atoms. In yet another embodiment, the alkyl group contains 1-2 carbons. Examples of alkyl radicals include, but are not limited to, methyl, ethyl, n-propyl, isopropyl, n- butyl, iso-butyl, sec-butyl, sec-pentyl, iso-pentyl, tert-butyl, n-pentyl, neopentyl, n-hexyl, sec- hexyl, n-heptyl, n-octyl, n-decyl, n-undecyl, dodecyl, and the like.
Alkynyl - As used herein, the term "alkynyl" refers to an optionally substituted monovalent group derived from a straight- or branched-chain aliphatic moiety having at least one carbon-carbon triple bond by the removal of a single hydrogen atom. In certain
embodiments, the alkynyl group employed in the invention contains 2-6 carbon atoms. In certain embodiments, the alkynyl group employed in the invention contains 2-5 carbon atoms. In some embodiments, the alkynyl group employed in the invention contains 2-4 carbon atoms. In another embodiment, the alkynyl group employed contains 2-3 carbon atoms. Representative alkynyl groups include, but are not limited to, ethynyl, 2-propynyl (propargyl), 1-propynyl, and the like.
Aryl - As used herein, the term "aryl" used alone or as part of a larger moiety as in "aralkyl", "aralkoxy", or "aryloxyalkyl", refers to an optionally substituted monocyclic and bicyclic ring systems having a total of five to 10 ring members, wherein at least one ring in the system is aromatic and wherein each ring in the system contains three to seven ring members. The term "aryl" may be used interchangeably with the term "aryl ring". In certain embodiments of the present invention, "aryl" refers to an aromatic ring system which includes, but not limited to, phenyl, biphenyl, naphthyl, anthracyl and the like, which may bear one or more substituents.
Arylalkyl - As used herein, the term "arylalkyl" refers to an alkyl group substituted with an aryl group (e.g., an aromatic or heteroaromatic group).
Bivalent hydrocarbon chain - As used herein, the term "bivalent hydrocarbon chain" (also referred to as a "bivalent alkylene group") is a polymethylene group, i.e., -(CH2)Z- wherein z is a positive integer from 1 to 30, from 1 to 20, from 1 to 12, from 1 to 8, from 1 to 6, from 1 to 4, from 1 to 3, from 1 to 2, from 2 to 30, from 2 to 20, from 2 to 10, from 2 to 8, from 2 to 6, from 2 to 4, or from 2 to 3. A substituted bivalent hydrocarbon chain is a polymethylene group in which one or more methylene hydrogen atoms are replaced with a substituent. Suitable substituents include those described below for a substituted aliphatic group.
Carbonyl - As used herein, the term "carbonyl" refers to a monovalent or bivalent moiety containing a carbon-oxygen double bond. Non-limiting examples of carbonyl groups
include aldehydes, ketones, carboxylic acids, ester, amide, enones, acyl halides, anhydrides, ureas, carbamates, carbonates, thioesters, lactones, lactams, hydroxamates, isocyanates, and chloroformates.
Cycloaliphatic - As used herein, the terms "cycloaliphatic", "carbocycle", or "carbocyclic", used alone or as part of a larger moiety, refer to an optionally substituted saturated or partially unsaturated cyclic aliphatic monocyclic or bicyclic ring systems, as described herein, having from 3 to 10 members. Cycloaliphatic groups include, without limitation, cyclopropyl, cyclobutyl, cyclopentyl, cyclopentenyl, cyclohexyl, cyclohexenyl, cycloheptyl, cycloheptenyl, cyclooctyl, cyclooctenyl, and cyclooctadienyl. In some embodiments, the cycloalkyl has 3-6 carbons.
Halogen - As used herein, the terms "halo" and "halogen" refer to an atom selected from fluorine (fiuoro, -F), chlorine (chloro, -CI), bromine (bromo, -Br), and iodine (iodo, -I).
Heteroaliphatic - As used herein, the terms "heteroaliphatic" or "heteroaliphatic group", denote an optionally substituted hydrocarbon moiety having, in addition to carbon atoms, from one to five heteroatoms, that may be straight-chain (i.e., unbranched), branched, or cyclic ("heterocyclic") and may be completely saturated or may contain one or more units of unsaturation, but which is not aromatic. Unless otherwise specified, heteroaliphatic groups contain 1-6 carbon atoms wherein 1-3 carbon atoms are optionally and independently replaced with heteroatoms selected from oxygen, nitrogen and sulfur. In some embodiments, heteroaliphatic groups contain 1-4 carbon atoms, wherein 1-2 carbon atoms are optionally and independently replaced with heteroatoms selected from oxygen, nitrogen and sulfur. In yet other embodiments, heteroaliphatic groups contain 1 -3 carbon atoms, wherein 1 carbon atom is optionally and independently replaced with a heteroatom selected from oxygen, nitrogen and sulfur. Suitable heteroaliphatic groups include, but are not limited to, linear or branched, heteroalkyl, heteroalkenyl, and heteroalkynyl groups.
Heteroaralkyl - As used herein, the term "heteroaralkyl" refers to an alkyl group substituted by a heteroaryl, wherein the alkyl and heteroaryl portions independently are optionally substituted.
Heteroaryl - As used herein, the term "heteroaryl" used alone or as part of a larger moiety, e.g., "heteroaralkyl", or "heteroaralkoxy", refers to an optionally substituted group having 5 to 10 ring atoms, preferably 5, 6, or 9 ring atoms; having 6, 10, or 14 π electrons shared in a cyclic array; and having, in addition to carbon atoms, from one to five heteroatoms.
Heteroaryl groups include, without limitation, thienyl, furanyl, pyrrolyl, imidazolyl, pyrazolyl, triazolyl, tetrazolyl, oxazolyl, isoxazolyl, oxadiazolyl, thiazolyl, isothiazolyl, thiadiazolyl, pyridyl, pyridazinyl, pyrimidinyl, pyrazinyl, indolizinyl, purinyl, naphthyridinyl, and pteridinyl. The terms "heteroaryl" and "heteroar-", as used herein, also include groups in which a heteroaromatic ring is fused to one or more aryl, carbocyclic, or heterocyclic rings, where the radical or point of attachment is on the heteroaromatic ring. Non limiting examples include
indolyl, isoindolyl, benzothienyl, benzofuranyl, dibenzofuranyl, indazolyl, benzimidazolyl, benzthiazolyl, quinolyl, isoquinolyl, cinnolinyl, phthalazinyl, quinazolinyl, quinoxalinyl, 4H- quinolizinyl, carbazolyl, acridinyl, phenazinyl, phenothiazinyl, phenoxazinyl,
tetrahydroquinolinyl, and tetrahydroisoquinolinyl. A heteroaryl group may be mono- or bicyclic. The term "heteroaryl" may be used interchangeably with the terms "heteroaryl ring", "heteroaryl group", or "heteroaromatic", any of which terms include rings that are optionally substituted.
Heteroatom - As used herein, the term "heteroatom" refers to nitrogen, oxygen, or sulfur, and includes any oxidized form of nitrogen or sulfur, and any quaternized form of a basic nitrogen. The term "nitrogen" also includes a substituted nitrogen.
Heterocyclic - As used herein, the terms "heterocycle", "heterocyclyl",
"heterocyclic radical", and "heterocyclic ring" are used interchangeably and refer to a stable optionally substituted 5- to 7-membered monocyclic or 7- to 10-membered bicyclic heterocyclic moiety that is either saturated or partially unsaturated, and having, in addition to carbon atoms, one or more heteroatoms, as defined above. A heterocyclic ring can be attached to its pendant group at any heteroatom or carbon atom that results in a stable structure and any of the ring atoms can be optionally substituted. Examples of such saturated or partially unsaturated heterocyclic radicals include, without limitation, tetrahydrofuranyl, tetrahydrothienyl, pyrrolidinyl, pyrrolidonyl, piperidinyl, pyrrolinyl, tetrahydroquinolinyl, tetrahydroisoquinolinyl, decahydroquinolinyl, oxazolidinyl, piperazinyl, dioxanyl, dioxolanyl, diazepinyl, oxazepinyl, thiazepinyl, morpholinyl, and quinuclidinyl. The terms "heterocycle", "heterocyclyl",
"heterocyclyl ring", "heterocyclic group", "heterocyclic moiety", and "heterocyclic radical", are used interchangeably herein, and also include groups in which a heterocyclyl ring is fused to one or more aryl, heteroaryl, or carbocyclic rings, such as indolinyl, 3H-indolyl, chromanyl, phenanthridinyl, or tetrahydroquinolinyl, where the radical or point of attachment is on the heterocyclyl ring. A heterocyclyl group may be mono- or bicyclic. The term "heterocyclylalkyl" refers to an alkyl group substituted by a heterocyclyl, wherein the alkyl and heterocyclyl portions independently are optionally substituted.
Unsaturated - As used herein, the term "unsaturated", means that a moiety has one or more double or triple bonds.
Partially unsaturated - As used herein, the term "partially unsaturated" refers to a ring moiety that includes at least one double or triple bond. The term "partially unsaturated" is intended to encompass rings having multiple sites of unsaturation, but is not intended to include aryl or heteroaryl moieties, as herein defined.
Optionally substituted - As described herein, compounds of the invention may contain "optionally substituted" moieties. In general, the term "substituted", whether preceded by the term "optionally" or not, means that one or more hydrogens of the designated moiety are replaced with a suitable substituent. Unless otherwise indicated, an "optionally substituted" group may have a suitable substituent at each substitutable position of the group, and when more
than one position in any given structure may be substituted with more than one substituent selected from a specified group, the substituent may be either the same or different at every position. Combinations of substituents envisioned by this invention are preferably those that result in the formation of stable or chemically feasible compounds. The term "stable", as used herein, refers to compounds that are not substantially altered when subjected to conditions to allow for their production, detection, and, in certain embodiments, their recovery, purification, and use for one or more of the purposes disclosed herein.
Suitable monovalent substituents on a substitutable carbon atom of an "optionally substituted" group are independently halogen; -(CH2)o-4R °; -(CH2)o-40R°; -O-(CH2)0_
4C(0)OR°; -(CH2)0 4CH(OR°)2; -(CH2)0^SR°; -(CH2)0^Ph, which may be substituted with R°; -(CH2)o_40(CH2)o_iPh which may be substituted with R°; -CH=CHPh, which may be substituted with R°; -N02; -CN; -N3; -(CH2)0_4N(R°)2; -(CH2)0 4N(R0)C(0)R°; -N(R°)C(S)R°; -(CH2)0 4N(R0)C(0)NR0 2; -N(R°)C(S)NR°2; -(CH2)0 4N(R°)C(0)OR°; -N(R°)N(R°)C(0)R°; - N(R°)N(R°)C(0)NR°2; -N(R°)N(R°)C(0)OR°; -(CH2)0^C(O)R°; -C(S)R°; -(CH2)0^C(O)OR°; -(CH2)o 4C(0)SR°; -(CH2)0^C(O)OSiR°3; -(CH2)0 4OC(0)R°; -OC(O)(CH2)0^SR-,
SC(S)SR°; -(CH2)o^SC(0)R°; -(CH2)0 4C(0)NR°2; -C(S)NR°2; -C(S)SR°; -SC(S)SR°, - (CH2)o 4OC(0)NR°2; -C(0)N(OR°)R°; -C(0)C(0)R°; -C(0)CH2C(0)R°; -C( OR°)R°; - (CH2)o 4SSR°; -(CH2)o 4S(0)2R°; -(CH2)0^S(O)2OR°; -(CH2)0 4OS(0)2R°; -S(0)2NR°2; - (CH2)o_4S(0)R°; -N(R°)S(0)2NR°2; -N(R°)S(0)2R°; -N(OR°)R°; -C(NH)NR°2; -P(0)2R°; - P(0)R°2; -OP(0)R°2; -OP(0)(OR°)2; SiR°3; -(Ci_4 straight or branched alkylene)0-N(R°)2; or -(Ci_4 straight or branched alkylene)C(0)0-N(R°)2, wherein each R° may be substituted as defined below and is independently hydrogen, Ci_6 aliphatic, -CH2Ph, -O(CH2)0_iPh, or a 5-6- membered saturated, partially unsaturated, or aryl ring having 0-4 heteroatoms independently selected from nitrogen, oxygen, or sulfur, or, notwithstanding the definition above, two independent occurrences of R°, taken together with their intervening atom(s), form a 3—12— membered saturated, partially unsaturated, or aryl mono- or bicyclic ring having 0-4
heteroatoms independently selected from nitrogen, oxygen, or sulfur, which may be substituted as defined below.
Suitable monovalent substituents on R° (or the ring formed by taking two independent occurrences of R° together with their intervening atoms), are independently halogen, -(CH2)0_2R*, -(haloR*), -(CH2)0_2OH, -(CH2)0 2OR*, -(CH2)0 2CH(OR*)2; - O(haloR'), -CN, -N3, -(CH2)0 2C(0)R*, -(CH2)0 2C(0)OH, -(CH2)0 2C(0)OR*, -(CH2)0 2SR*, -(CH2)o 2SH, -(CH2)o 2NH2, -(CH2)0 2NHR*, -(CH2)0 2NR*2, -N02, -SiR« 3, -OSiR« 3, - C(0)SR* -(Ci_4 straight or branched alkylene)C(0)OR*, or -SSR' wherein each R* is unsubstituted or where preceded by "halo" is substituted only with one or more halogens, and is independently selected from Ci_4 aliphatic, -CH2Ph, -O(CH2)0_iPh, or a 5-6-membered saturated, partially unsaturated, or aryl ring having 0-4 heteroatoms independently selected from
nitrogen, oxygen, or sulfur. Suitable divalent substituents on a saturated carbon atom of R° include =0 and =S.
Suitable divalent substituents on a saturated carbon atom of an "optionally substituted" group include the following: =0, =S, =NNR* 2, =NNHC(0)R*, =NNHC(0)OR*, = HS(0)2R*, =NR*, =NOR*, -0(C(R* 2))2 30- or -S(C(R* 2))2-3S-, wherein each independent occurrence of R* is selected from hydrogen, Ci_6 aliphatic which may be substituted as defined below, or an unsubstituted 5-6-membered saturated, partially unsaturated, or aryl ring having 0- 4 heteroatoms independently selected from nitrogen, oxygen, or sulfur. Suitable divalent substituents that are bound to vicinal substitutable carbons of an "optionally substituted" group include: -0(CR* 2)2 3O-, wherein each independent occurrence of R* is selected from hydrogen, Ci_6 aliphatic which may be substituted as defined below, or an unsubstituted 5-6-membered saturated, partially unsaturated, or aryl ring having 0-4 heteroatoms independently selected from nitrogen, oxygen, or sulfur.
Suitable substituents on the aliphatic group of R* include halogen, -R*, - (haloR*), -OH, -OR*, -0(haloR*), -CN, -C(0)OH, -C(0)OR', -NH2, -NHR*, -NR*2, or - N02, wherein each R" is unsubstituted or where preceded by "halo" is substituted only with one or more halogens, and is independently Ci_4 aliphatic, -CH2Ph, -O(CH2)0_iPh, or a 5-6- membered saturated, partially unsaturated, or aryl ring having 0-4 heteroatoms independently selected from nitrogen, oxygen, or sulfur.
Suitable substituents on a substitutable nitrogen of an "optionally substituted" group include -R†, -NR† 2, -C(0)R†, -C(0)OR†, -C(0)C(0)R†, -C(0)CH2C(0)R†, -S(0)2R†, - S(0)2NR† 2, -C(S)NR† 2, -C(NH)NR† 2, or -N(R†)S(0)2R†; wherein each R† is independently hydrogen, Ci_6 aliphatic which may be substituted as defined below, unsubstituted -OPh, or an unsubstituted 5-6-membered saturated, partially unsaturated, or aryl ring having 0-4 heteroatoms independently selected from nitrogen, oxygen, or sulfur, or, notwithstanding the definition above, two independent occurrences of R^, taken together with their intervening atom(s) form an unsubstituted 3-12-membered saturated, partially unsaturated, or aryl mono- or bicyclic ring having 0-4 heteroatoms independently selected from nitrogen, oxygen, or sulfur. Suitable substituents on the aliphatic group of R† are independently halogen, R*, -(haloR*), - OH, -OR*, -O(haloR'), -CN, -C(0)OH, -C(0)OR*, -NH2, -NHR*, -NR*2, or -N02, wherein each R* is unsubstituted or where preceded by "halo" is substituted only with one or more halogens, and is independently
aliphatic, -CH2Ph, -O(CH2)0_iPh, or a 5-6-membered saturated, partially unsaturated, or aryl ring having 0-4 heteroatoms independently selected from nitrogen, oxygen, or sulfur.
Suitable protecting group - As used herein, the term "suitable protecting group," refers to amino protecting groups or hydroxyl protecting groups depending on its location within the compound and includes those described in detail in Protecting Groups in Organic Synthesis, T. W. Greene and P. G. M. Wuts, 3rd edition, John Wiley & Sons, 1999.
Suitable amino-protecting groups include methyl carbamate, ethyl carbamante, 9-fluorenylmethyl carbamate (Fmoc), 9-(2-sulfo)fluorenylmethyl carbamate, 9-(2,7- dibromo)fluoroenylmethyl carbamate, 2,7-di-t-butyl-[9-( 10,10-dioxo-l 0, 10,10,10- tetrahydrothioxanthyl)]methyl carbamate (DBD-Tmoc), 4-methoxyphenacyl carbamate
(Phenoc), 2,2,2-trichloroethyl carbamate (Troc), 2-trimethylsilylethyl carbamate (Teoc), 2- phenylethyl carbamate (hZ), l-(l-adamantyl)-l-methylethyl carbamate (Adpoc), 1, 1-dimethyl- 2-haloethyl carbamate, l, l-dimethyl-2,2-dibromoethyl carbamate (DB-i-BOC), 1 ,1-dimethyl- 2,2,2-trichloroethyl carbamate (TCBOC), 1 -methyl- l-(4-biphenylyl)ethyl carbamate (Bpoc), l-(3,5-di-i-butylphenyl)-l-methylethyl carbamate (i-Bumeoc), 2-(2'- and 4'-pyridyl)ethyl carbamate (Pyoc), 2-(NN-dicyclohexylcarboxamido)ethyl carbamate, i-butyl carbamate (BOC), 1-adamantyl carbamate (Adoc), vinyl carbamate (Voc), allyl carbamate (Alloc), 1-isopropylallyl carbamate (Ipaoc), cinnamyl carbamate (Coc), 4-nitrocinnamyl carbamate (Noc), 8-quinolyl carbamate, N-hydroxypiperidinyl carbamate, alkyldithio carbamate, benzyl carbamate (Cbz), p- methoxybenzyl carbamate (Moz), >-nitobenzyl carbamate, ?-bromobenzyl carbamate, p- chlorobenzyl carbamate, 2,4-dichlorobenzyl carbamate, 4-methylsulfmylbenzyl carbamate
(Msz), 9-anthrylmethyl carbamate, diphenylmethyl carbamate, 2-methylthioethyl carbamate, 2- methylsulfonylethyl carbamate, 2-( ?-toluenesulfonyl)ethyl carbamate, [2— (1 ,3—
dithianyl)]methyl carbamate (Dmoc), 4-methylthiophenyl carbamate (Mtpc), 2,4- dimethylthiophenyl carbamate (Bmpc), 2-phosphonioethyl carbamate (Peoc), 2- triphenylphosphonioisopropyl carbamate (Ppoc), l ,l-dimethyl-2-cyanoethyl carbamate, m- chloro- 7-acyloxybenzyl carbamate, /^-(dihydroxyboryl)benzyl carbamate, 5- benzisoxazolylmethyl carbamate, 2-(trifluoromethyl)-6-chromonylmethyl carbamate (Tcroc), m-nitrophenyl carbamate, 3,5-dimethoxybenzyl carbamate, o-nitrobenzyl carbamate, 3,4- dimethoxy-6-nitrobenzyl carbamate, phenyl(o-nitrophenyl)methyl carbamate, phenothiazinyl- (lO)-carbonyl derivative, N'-/?-toluenesulfonylaminocarbonyl derivative, N - phenylaminothiocarbonyl derivative, i-amyl carbamate, ^S-benzyl thiocarbamate, 7-cyanobenzyl carbamate, cyclobutyl carbamate, cyclohexyl carbamate, cyclopentyl carbamate,
cyclopropylmethyl carbamate, /7-decyloxybenzyl carbamate, 2,2-dimethoxycarbonylvinyl carbamate, o-(NN-dimethylcarboxamido)benzyl carbamate, l ,l-dimethyl-3-(N,N- dimethylcarboxamido)propyl carbamate, 1 ,1-dimethylpropynyl carbamate, di(2-pyridyl)methyl carbamate, 2-furanylmethyl carbamate, 2-iodoethyl carbamate, isoborynl carbamate, isobutyl carbamate, isonicotinyl carbamate, p-(p '-methoxyphenylazo)benzyl carbamate, 1- methylcyclobutyl carbamate, 1-methylcyclohexyl carbamate, 1 -methyl- 1 -cyclopropylmethyl carbamate, l-methyl-l-(3,5-dimethoxyphenyl)ethyl carbamate, 1 -methyl- \-{p- phenylazophenyl)ethyl carbamate, 1 -methyl- 1-phenylethyl carbamate, 1 -methyl- 1 -(4- pyridyl)ethyl carbamate, phenyl carbamate, p-(phenylazo)benzyl carbamate, 2,4,6— tri—i— butylphenyl carbamate, 4-(trimethylammonium)benzyl carbamate, 2,4,6-trimethylbenzyl carbamate, formamide, acetamide, chloroacetamide, trichloroacetamide, trifluoroacetamide,
phenylacetamide, 3-phenylpropanamide, picolinamide, 3-pyridylcarboxamide, N- benzoylphenylalanyl derivative, benzamide, /7-phenylbenzamide, o-nitophenylacetamide, o- nitrophenoxyacetamide, acetoacetamide, (N'-dithiobenzyloxycarbonylamino)acetamide, 3-(p- hydroxyphenyl)propanamide, 3-(o-nitrophenyl)propanamide, 2-methyl-2-(o- nitrophenoxy)propanamide, 2-methyl-2-(o-phenylazophenoxy)propanamide, 4- chlorobutanamide, 3-methyl-3-nitrobutanamide, o-nitrocinnamide, N-acetylmethionine derivative, o-nitrobenzamide, o-(benzoyloxymethyl)benzamide, 4,5-diphenyl-3-oxazolin-2- one, N-phthalimide, N-dithiasuccinimide (Dts), N-2,3-diphenylmaleimide, N-2,5- dimethylpyrrole, N-l,l,4,4-tetramethyldisilylazacyclopentane adduct (STABASE), 5- substituted l,3-dimethyl-l,3,5-triazacyclohexan-2-one, 5-substituted l,3-dibenzyl-l,3,5- triazacyclohexan-2-one, 1-substituted 3,5-dinitro-4-pyridone, N-methylamine, N-allylamine, N-[2-(trimethylsilyl)ethoxy]methylamine (SEM), N-3-acetoxypropylamine, N-(l-isopropyl-4- nitro-2-oxo-3-pyroolin-3-yl)amine, quaternary ammonium salts, N-benzylamine, N-di(4- methoxyphenyl)methylamine, N-5-dibenzosuberylamine, N-triphenylmethylamine (Tr), N-[(4- methoxyphenyl)diphenylmethyl]amine (MMTr), N-9-phenylf uorenylamine (PhF), N-2,7- dichloro-9-fluorenylmethyleneamine, N-ferrocenylmethylamino (Fcm), N-2-picolylamino N - oxide, N-l,l-dimethylthiomethyleneamine, N-benzylideneamine, N-p- methoxybenzylideneamine, N-diphenylmethyleneamine, N-[(2- pyridyl)mesityl]methyleneamine, N-(N',N'-dimethylaminomethylene)amine, Ν,Ν'- isopropylidenediamine, N- -nitrobenzylideneamine, N-salicylideneamine, N-5- chlorosalicylideneamine, N-(5-chloro-2-hydroxyphenyl)phenylmethyleneamine, N- cyclohexylideneamine, N-(5,5-dimethyl-3-oxo-l-cyclohexenyl)amine, N-borane derivative, N-diphenylborinic acid derivative, N-[phenyl(pentacarbonylchromium- or
tungsten)carbonyl] amine, N-copper chelate, N-zinc chelate, N-nitroamine, N-nitrosoamine, amine N-oxide, diphenylphosphinamide (Dpp), dimethylthiophosphinamide (Mpt),
diphenylthiophosphinamide (Ppt), dialkyl phosphoramidates, dibenzyl phosphoramidate, diphenyl phosphoramidate, benzenesulfenamide, o-nitrobenzenesulfenamide (Nps), 2,4- dinitrobenzenesulfenamide, pentachlorobenzenesulfenamide, 2-nitro-4- methoxybenzenesulfenamide, triphenylmethylsulfenamide, 3-nitropyridinesulfenamide (Npys),?-toluenesulfonamide (Ts), benzenesulfonamide, 2,3,6,-trimethyl-4- methoxybenzenesulfonamide (Mtr), 2,4,6-trimethoxybenzenesulfonamide (Mtb), 2,6-dimethyl- 4-methoxybenzenesulfonamide (Pme), 2,3 ,5 ,6-tetramethyl-4-methoxybenzenesulfonamide (Mte), 4-methoxybenzenesulfonamide (Mbs), 2,4,6-trimethylbenzenesulfonamide (Mts), 2,6- dimethoxy-4-methylbenzenesulfonamide (iMds), 2,2, ,7,8-pentamethylchroman-6- sulfonamide (Pmc), methanesulfonamide (Ms), β-trimethylsilylethanesulfonamide (SES), 9- anthracenesulfonamide, 4-(4' ,8 '-dimethoxynaphthylmethyl)benzenesulfonamide (DNMBS), benzylsulfonamide, trifluoromethylsulfonamide, and phenacylsulfonamide.
Suitable hydroxyl protecting groups include methyl, methoxylmethyl (MOM), methylthiomethyl (MTM), i-butylthiomethyl, (phenyldimethylsilyl)methoxymethyl (SMOM), benzyloxymethyl (BOM), /?-methoxybenzyloxymethyl (PMBM), (4-methoxyphenoxy)methyl (p-AOM), guaiacolmethyl (GUM), /-butoxymethyl, 4-pentenyloxymethyl (POM), siloxymethyl, 2- methoxyethoxymethyl (MEM), 2,2,2-trichloroethoxymethyl, bis(2-chloroethoxy)methyl, 2- (trimethylsilyl)ethoxymethyl (SEMOR), tetrahydropyranyl (THP), 3-bromotetrahydropyranyl, tetrahydrothiopyranyl, 1-methoxycyclohexyl, 4-methoxytetrahydropyranyl (MTHP), 4- methoxytetrahydrothiopyranyl, 4-methoxytetrahydrothiopyranyl S,S-dioxide, l-[(2-chloro-4- methyl)phenyl]-4-methoxypiperidin- -yl (CTMP), 1 ,4-dioxan-2-yl, tetrahydrofuranyl, tetrahydrothiofuranyl, 2,3,3a,4,5,6,7,7a-octahydro-7,8,8-trimethyl-4,7-methanobenzofuran-2- yl, 1-ethoxy ethyl, l-(2-chloroethoxy)ethyl, 1 -methyl- 1-methoxy ethyl, 1-methyl-l- benzyloxyethyl, 1 -methyl- l-benzyloxy-2-fluoroethyl, 2,2,2-trichloroethyl, 2- trimethylsilylethyl, 2-(phenylselenyl)ethyl, i-butyl, allyl, /?-chlorophenyl, 5-methoxyphenyl, 2,4-dinitrophenyl, benzyl, /3-methoxybenzyl, 3,4-dimethoxybenzyl, o-nitrobenzyl, p- nitrobenzyl, /?-halobenzyl, 2,6-dichlorobenzyl, /^-cyanobenzyl, /?-phenylbenzyl, 2-picolyl, 4- picolyl, 3-methyl-2-picolyl N-oxido, diphenylmethyl, p,p '-dinitrobenzhydryl, 5- dibenzosuberyl, triphenylmethyl, a-naphthyldiphenylmethyl, /?-methoxyphenyldiphenylmethyl, di(p-methoxyphenyl)phenylmethyl, tri(p-methoxyphenyl)methyl, 4-(4 '- bromophenacyloxyphenyl)diphenylmethyl, 4,4',4"-tris(4,5-dichlorophthalimidophenyl)methyl, 4,4',4"-tris(levulinoyloxyphenyl)methyl, 4,4',4"-tris(benzoyloxyphenyl)methyl, 3-(imidazol- 1 -yl)bis(4 ' ,4 " -dimethoxyphenyl)methyl, 1 , 1 -bis(4-methoxyphenyl)- 1 ' -pyrenylmethyl, 9- anthryl, 9-(9-phenyl)xanthenyl, 9-(9-phenyl-10-oxo)anthryl, 1 ,3-benzodithiolan-2-yl, benzisothiazolyl S,S-dioxido, trimethylsilyl (TMS), triethylsilyl (TES), triisopropylsilyl (TIPS), dimethylisopropylsilyl (IPDMS), diethylisopropylsilyl (DEIPS), dimethylthexylsilyl, t- butyldimethylsilyl (TBDMS), i-butyldiphenylsilyl (TBDPS), tribenzylsilyl, tri-/?-xylylsilyl, triphenylsilyl, diphenylmethylsilyl (DPMS), i-butylmethoxyphenylsilyl (TBMPS), formate, benzoylformate, acetate, chloroacetate, dichloroacetate, trichloroacetate, trifluoroacetate, methoxyacetate, triphenylmethoxyacetate, phenoxyacetate, /?-chlorophenoxy acetate, 3- phenylpropionate, 4-oxopentanoate (levulinate), 4,4-(ethylenedithio)pentanoate
(levulinoyldithioacetal), pivaloate, adamantoate, crotonate, 4-methoxycrotonate, benzoate, ?- phenylbenzoate, 2,4,6-trimethylbenzoate (mesitoate), alkyl methyl carbonate, 9-fluorenylmethyl carbonate (Fmoc), alkyl ethyl carbonate, alkyl 2,2,2-trichloroethyl carbonate (Troc), 2- (trimethylsilyl)ethyl carbonate (TMSEC), 2-(phenylsulfonyl) ethyl carbonate (Psec), 2- (triphenylphosphonio) ethyl carbonate (Peoc), alkyl isobutyl carbonate, alkyl vinyl carbonate alkyl allyl carbonate, alkyl 7-nitrophenyl carbonate, alkyl benzyl carbonate, alkyl p- methoxybenzyl carbonate, alkyl 3,4-dimethoxybenzyl carbonate, alkyl o-nitrobenzyl carbonate, alkyl ?-nitrobenzyl carbonate, alkyl iS-benzyl thiocarbonate, 4-ethoxy-l-napththyl carbonate, methyl dithiocarbonate, 2-iodobenzoate, 4-azidobutyrate, 4-nitro-4-methylpentanoate, o-
(dibromomethyl)benzoate, 2-formylbenzenesulfonate, 2-(methylthiomethoxy)ethyl, 4- (methylthiomethoxy)butyrate, 2-(methylthiomethoxymethyl)benzoate, 2,6-dichloro-4- methylphenoxyacetate, 2,6-dichloro-4-(l,l,3,3-tetramethylbutyl)phenoxyacetate, 2,4— bis(l , l— dimethylpropyl)phenoxyacetate, chlorodiphenylacetate, isobutyrate, monosuccinoate, (E)-2- methyl-2-butenoate, o-(methoxycarbonyl)benzoate, -naphthoate, nitrate, alkyl Ν,Ν,Ν',Ν'- tetramethylphosphorodiamidate, alkyl N-phenylcarbamate, borate, dimethylphosphinothioyl, alkyl 2,4-dinitrophenylsulfenate, sulfate, methanesulfonate (mesylate), benzylsulfonate, and tosylate (Ts). For protecting 1 ,2- or 1,3-diols, the protecting groups include methylene acetal, ethylidene acetal, 1-i-butylethylidene ketal, 1-phenylethylidene ketal, (4- methoxyphenyl)ethylidene acetal, 2,2,2-trichloroethylidene acetal, acetonide, cyclopentylidene ketal, cyclohexylidene ketal, cycloheptylidene ketal, benzylidene acetal, /?-methoxybenzylidene acetal, 2,4-dimethoxybenzylidene ketal, 3,4-dimethoxybenzylidene acetal, 2-nitrobenzylidene acetal, methoxymethylene acetal, ethoxymethylene acetal, dimethoxymethylene ortho ester, 1- methoxy ethylidene ortho ester, 1-ethoxyethylidine ortho ester, 1 ,2-dimethoxy ethylidene ortho ester, a-methoxybenzylidene ortho ester, l-(NN-dimethylamino)ethylidene derivative, a- (NN'-dimethylamino)benzylidene derivative, 2-oxacyclopentylidene ortho ester, di-t- butylsilylene group (DTBS), l ,3-(l ,l ,3,3-tetraisopropyldisiloxanylidene) derivative (TIPDS), tetra-/-butoxydisiloxane-l,3-diylidene derivative (TBDS), cyclic carbonates, cyclic boronates, ethyl boronate, and phenyl boronate.
In any case where a chemical variable (e.g., an R group) is shown attached to a bond that crosses a bond of ring, this means that one or more such variables are optionally attached to the ring having the crossed bond. Each R group on such a ring can be attached at any suitable position, this is generally understood to mean that the group is attached in place of a hydrogen atom on the parent ring. This includes the possibility that two R groups can be attached to the same ring atom. Furthermore, when more than one R group is present on a ring, each may be the same or different than other R groups attached thereto, and each group is defined independently of other groups that may be attached elsewhere on the same molecule, even though they may be represented by the same identifier.
Antibody - As used herein the term "antibody" includes monoclonal antibodies, polyclonal antibodies, monospecific antibodies, and multispecific antibodies (e.g., bispecific antibodies) and the term "antibody" is used interchangeably with the terms "immunoglobulin," "immunoglobulins" and "immunoglobulin molecule". Each antibody molecule has a unique structure that allows it to bind its specific antigen, but all antibodies have the same overall structure as described herein. The basic immunoglobulin structural unit is known to comprise a tetramer of subunits. Each tetramer has two identical pairs of polypeptide chains, each pair having one "light" chain (about 25 kDa) and one "heavy" chain (about 50-70 kDa). The amino- terminal portion of each chain includes a variable region of about 100 to 110 or more amino acids primarily responsible for antigen recognition. The carboxy-terminal portion of each chain
defines a constant region primarily responsible for effector function. Light chains are classified as either kappa or lambda. Heavy chains are classified as gamma, mu, alpha, delta, or epsilon, and define the antibody's isotype as IgG, IgM, IgA, IgD and IgE, respectively. Thus, an antibody as defined herein can be of any type or class (e.g., IgG, IgE, IgM, IgD, and IgA) or subclass (e.g., IgGl , IgG2, IgG3, IgG4, IgAl and IgA2).
The light and heavy chains are subdivided into variable regions and constant regions (See generally, Fundamental Immunology (Paul, W., ed., 2nd ed. Raven Press, N.Y., 1989), Ch. 7. The variable regions of each light/heavy chain pair form the antibody binding site. Thus, an intact antibody has two binding sites. Except in bifunctional or bispecific antibodies, the two binding sites are the same. The chains all exhibit the same general structure of relatively conserved framework regions (FR) joined by three hypervariable regions, also called
complementarity determining regions or CDRs. The CDRs from the two chains of each pair are aligned by the framework regions, enabling binding to a specific epitope. The terms include naturally occurring forms, as well as fragments and derivatives. Included within the scope of the term are classes of immunoglobulins (Igs), namely, IgG, IgA, IgE, IgM, and IgD. Also included within the scope of the terms are the subtypes of IgGs, namely, IgGl , IgG2, IgG3 and IgG4. The term is used in the broadest sense and includes single monoclonal antibodies (including agonist and antagonist antibodies) as well as antibody compositions which will bind to multiple epitopes or antigens. The terms specifically cover monoclonal antibodies (including full length monoclonal antibodies), polyclonal antibodies, multispecific antibodies (for example, bispecific antibodies), and antibody fragments so long as they contain or are modified to contain at least the portion of the Cfj2 domain of the heavy chain immunoglobulin constant region which comprises an N-linked glycosylation site of the Cpj2 domain, or a variant thereof. Included within the terms are molecules comprising only the Fc region, such as immunoadhesins (U.S. Published Patent Application No. 20040136986), Fc fusions, and antibody-like molecules. Alternatively, these terms can refer to an antibody fragment of at least the Fab region that at least contains an
N-linked glycosylation site.
The term "Fc" fragment refers to the 'fragment crystallized' C-terminal region of the antibody containing the CH2 and CH3 domains. The term "Fab" fragment refers to the 'fragment antigen binding' region of the antibody containing the V f, Cpjl , L and CL domains.
The term "antibodies" further includes chemical analogues and derivatives of antibodies and antibody fragments, provided that the antibody or antibody fragment maintains its ability to bind specifically to its target antigen. Thus, for example, chemical modifications are possible (e.g., glycosylation, acetylation, PEGylation and other modifications without limitation) provided specific binding ability of the antibody is retained. An antibody may be, for example, human, humanized, or chimeric
A "monoclonal antibody" is an antibody obtained from a population of substantially homogeneous antibodies, i.e., individual antibodies comprising the population are
identical except for possible naturally-occurring mutations that may be present in minor amounts. Monoclonal antibodies (mAbs) are highly specific, being directed against a single antigenic site. Furthermore, in contrast to conventional (polyclonal) antibody preparations which typically include different antibodies directed against different determinants (epitopes), each mAb is directed against a single determinant on the antigen. In addition to their specificity, monoclonal antibodies are advantageous in that they can be synthesized by hybridoma culture, uncontaminated by other immunoglobulins. The term "monoclonal" indicates the character of the antibody as being obtained from a substantially homogeneous population of antibodies, and is not to be construed as requiring production of the antibody by any particular method. For example, the monoclonal antibodies to be used in accordance with the present invention may be made by the hybridoma method first described by Kohler et al., (1975) Nature, 256:495, or may be made by recombinant DNA methods (See, for example, U.S. Pat. No. 4,816,567 to Cabilly et al.).
Monoclonal antibodies further include chimeric antibodies in which a portion of the heavy and/or light chain is identical to or homologous with the corresponding s of antibodies derived from a particular species or belonging to a particular antibody class or subclass, while the remainder of the chain(s) is identical to or homologous with the corresponding sequences of antibodies derived from another species or belonging to another antibody class or subclass, as well as fragments of such antibodies, so long as they exhibit the desired biological activity.
An "intact antibody" is one that comprises an antigen-binding variable region as well as a light chain constant domain (CL) and heavy chain constant domains, Cpjl , C j2, C j3 and Cpj4, as appropriate for the antibody class. The constant domains may be native sequence constant domains such as human native sequence constant domains or amino acid sequence variants thereof. An intact antibody may or may not have one or more "effector functions", which refers to those biological activities attributable to the Fc region (e.g., a native sequence Fc region or amino acid sequence variant Fc region) of an antibody. Examples of antibody effector functions include complement dependent cytotoxicity, antibody-dependent cell-mediated cytotoxicity (ADCC) and antibody-dependent cell-mediated phagocytosis.
An "antibody fragment" comprises a portion of an intact antibody, preferably comprising the antigen-binding or variable region thereof. Examples of antibody fragments include Fab, Fab', F(ab')2, and Fv fragments, diabodies, triabodies, tetrabodies, linear antibodies, single-chain antibody molecules, scFv, scFv-Fc, multispecific antibody fragments formed from antibody fragment(s), a fragment(s) produced by a Fab expression library, camelids, or an epitope-binding fragments of any of the above which immunospecifically bind to a target antigen (e.g. , a cancer cell antigen).
"Humanized" forms of non-human (e.g., rodent) antibodies are chimeric antibodies that contain minimal sequence derived from non-human immunoglobulin.
The term "capable of specific binding" refers to protein or peptide (e.g., antibody) binding to a predetermined target substance (e.g., an antigen and/or groups of antigens), e.g. a target substance that is expressed on the surface of a cell; thus the term "binding to a target cell" or "binding to a cancer cell" is to be understand as referring to protein or peptide (e.g., antibody) binding to a predetermined target substance (e.g. antigen or antigens) that is expressed on such a cell.
Typically, the protein or peptide (e.g., antibody) binds with an affinity of at least about 1x107 M1, and/or binds to the predetermined target substance (e.g., antigen, antigens or cell) with an affinity that is at least two-fold greater than its affinity for binding to a non-specific control substance (e.g., BSA, casein, non-cancer cells) other than the predetermined target substance or a closely-related target substance.
Drug - As used herein, the term "drug" refers to small molecules or biomolecules that alter, inhibit, activate, or otherwise affect a biological event. For example, drugs may include, but are not limited to, anti-AIDS substances, anti-cancer substances, antibiotics, anti- diabetic substances, immunosuppressants, anti-viral substances, enzyme inhibitors, neurotoxins, opioids, hypnotics, anti-histamines, lubricants, tranquilizers, anti-convulsants, muscle relaxants and anti-Parkinson substances, anti-spasmodics and muscle contractants including channel blockers, miotics and anti-cholinergics, anti-glaucoma compounds, anti-parasite and/or antiprotozoal compounds, modulators of cell-extracellular matrix interactions including cell growth inhibitors and anti-adhesion molecules, vasodilating agents, inhibitors of DNA, RNA or protein synthesis, anti-hypertensives, analgesics, anti-pyretics, steroidal and non-steroidal antiinflammatory agents, anti-angiogenic factors, anti-secretory factors, anticoagulants and/or antithrombotic agents, local anesthetics, ophthalmics, prostaglandins, anti-depressants, antipsychotic substances, anti-emetics, and imaging agents. A more complete listing of exemplary drugs suitable for use in the present invention may be found in "Pharmaceutical Substances: Syntheses, Patents, Applications" by Axel Kleemann and Jurgen Engel, Thieme Medical Publishing, 1999; the "Merck Index: An Encyclopedia of Chemicals, Drugs, and Biologicals", edited by Susan Budavari et al, CRC Press, 1996, and the United States Pharmacopeia- 25 National Formulary-20, published by the United States Pharmcopeial Convention, Inc., Rockville MD, 2001.
Polymer - As used herein, a "polymer" or "polymeric structure" is a structure that includes a string of covalently bound monomers. A polymer can be made from one type of monomer or more than one type of monomer. The term "polymer" therefore encompasses copolymers, including block-copolymers in which different types of monomer are grouped separately within the overall polymer. A polymer can be linear or branched.
Treat - As used herein, the term "treat" (or "treating", "treated", "treatment", etc.) refers to the administration of a conjugate of the present disclosure to a subject in need thereof with the purpose to alleviate, relieve, alter, ameliorate, improve or affect a condition (e.g.,
diabetes, cancer, inflammatory disease), a symptom or symptoms of a condition (e.g., hyperglycemia), or the predisposition toward a condition.
BRIEF DESCRIPTION OF THE DRAWINGS
Figure 1 shows a scheme for synthesis of ADC 12-1 and ADC 12-2.
Figure 2 is a graph showing stability of ADC 12-1 in mouse serum. (aDEX is
ADC 12-1).
Figure 3 is a graph showing deconvoluted intact mass spectrum for ADC 12-1 stock solution.
Figure 4 is a graph showing deconvoluted intact mass spectra for in-vitro stability samples of ADC 12-1. incubated at 37°C for: A) 1 hour, B) 8 hours, C) 14 days and D) 21 days.
Figure 5 is a graph showing In vivo stability of ADC 12-1 versus "naked" antibody (non-conjugated) following IV dosing to DBA1 mice.
Figure 6 is a graph showing deconvoluted intact mass spectra for the in vivo stability samples of ADC 12-1 from Figure 5: A) sample Bl at 1 hour, B) sample H3 at 5 days, C) sample B7 at 1 hour and D) sample H9 at 5 days.
Figure 7 is a graph showing In vitro activity of ADC 12-2 versus "naked" antibody (non-conjugated) in 786-0 cells.
Figure 8 shows the activity of aHer2-Duo-405 compared to that of a non- targeting antibody conjugated to Duo-405 on Her2 expressing SKBR3 cells.
Figure 9 shows the activity of Her2-Duo-405 on Her2 negative MDA-MD-468 cells.
DETAILED DESCRIPTION OF THE INVENTION
The present invention provides phosphate-based linkers comprising a monophosphate, diphosphate, triphosphate, or tetraphosphate group and a linker arm comprising a tuning element, an optional spacer element, and a reactive functional group. The phosphate- based linkers have a distal end and a proximal end. The distal end of the phosphate-based linker comprises a monophosphate, diphosphate, or triphosphate group (phosphate group) linked to the distal end of the tuning element comprising the linker arm. The proximal end of the linker arm comprises a reactive functional group capable of reacting with a group on a ligand or targeting moiety to covalently link the phosphate -based linker to the ligand or targeting moiety.
Interspersed between the tuning element and the reactive functional group of the linker arm may be an optional spacer element.
Wherein V is selected from O and S; W is selected from O, N, and CH2; X is a tuning element selected from a covalent bond; a carbon atom; a heteroatom; an optionally substituted group selected from the group consisting of acyl, aliphatic, heteroaliphatic, aryl, heteroaryl, and heterocyclic; a carbon atom linked to a trimethylammonium group by a C 1-C5 hydrocarbon chain; nucleoside, protease sensitive group, cathepsin B sensitive group, or glycosidase sensitive group; Y is optional but when present it is selected from a covalent bond or a bivalent, straight or branched, saturated or unsaturated, optionally substituted C1.30 hydrocarbon chain wherein one or more methylene units of Y are optionally and independently replaced by -0-, -S-, -N(R)-, - C(O)-, C(0)0-, OC(O)-, -N(R)C(0)-, -C(0)N(R)-, -S(O)-, -S(0)2-, -N(R)S02-, S02N(R)-, a heterocyclic group, an aryl group, or a heteroaryl group; Z is a reactive functional group selected from the group consisting of N-hydroxysuccmimidyl ester, para-nitrophenyl carbonate, para- nitrophenyl carbamate, methyl ketone, azide, hydrazine, pentafluorophenyl, haloacetamide, maleimide, hydroxylamine, strained cycloalkyne, and heterocycloalkyne, alkyne, diene, azadiene, and heterocyclic azadiene, wherein halo is iodine (I), bromine (Br), fluorine (F), or chlorine (CI) and hetero is N, O, or S; each occurrence of R is independently hydrogen, a suitable protecting group, an acyl moiety, arylalkyl moiety, aliphatic moiety, aryl moiety, heteroaryl moiety, or heteroaliphatic moiety; and n is 1, 2, 3, or 4.
In particular aspect, the reactive group Z has the structure
wherein the wavy line marks the bond between Z and Y, or X when Y is a covalent bond, or W when Y and X are a covalent bond.
In a further embodiment, the distal end of the phosphate group is covalently linked to a payload, which may be a therapeutic agent such as a drug moiety or peptide, a radionuclide, or a protecting element, to provide a payload-phosphate-based linker compound comprising formula (II)
Wherein V is selected from O and S; W is selected from O, N, and CH2; X is a tuning element selected from a covalent bond; a carbon atom; a heteroatom; an optionally substituted group selected from the group consisting of acyl, aliphatic, heteroaliphatic, aryl, heteroaryl, and heterocyclic; a carbon atom linked to a trimethylammonium group by a C1-C5 hydrocarbon chain; nucleoside, protease sensitive group, cathepsin B sensitive group, or glycosidase sensitive group; Y is optional but when present is selected from a covalent bond or a bivalent, straight or branched, saturated or unsaturated, optionally substituted C1.30 hydrocarbon chain wherein one or more methylene units of Y are optionally and independently replaced by -0-, -S-, -N(R)-, - C(O)-, C(0)0-, OC(O)-, -N(R)C(0)-, -C(0)N(R)-, -S(O)-, -S(0)2-, -N(R)S02-, S02N(R)-, a heterocyclic group, an aryl group, or a heteroaryl group; T is an NR, CR2, O, or S; Z is a reactive functional group selected from the group consisting of N-hydroxysuccinimidyl ester, para- nitrophenyl carbonate, para-nitrophenyl carbamate, methyl ketone, azide, hydrazine,
pentafluorophenyl, haloacetamide, maleimide, hydroxylamine, strained cycloalkyne, and heterocycloalkyne, alkyne, diene, azadiene, and heterocyclic azadiene, wherein halo is iodine (I), bromine (Br), fluorine (F), or chlorine (CI) and hetero is N, O, or S; D is a payload; each occurrence of R is independently hydrogen, a suitable protecting group, an acyl moiety, arylalkyl moiety, aliphatic moiety, aryl moiety, heteroaryl moiety, or heteroaliphatic moiety; and n is 1, 2, 3, or 4.
In particular aspect, the reactive group Z has the structure
wherein the wavy line marks the covalent bond between Z and Y, or X when Y is a covalent bond, or W when Y and X are a covalent bond.
In a further embodiment, the reactive functional group at the proximal end of the payload-phosphate-based linker may be covalently linked to a ligand or targeting moiety to provide a conjugate wherein in particular embodiments, the ligand is capable of targeting the conjugate to a particular cellular target when administered to a subject in need of the payload.
Wherein V is selected from O and S; W is selected from O, N, and CH2; X is a tuning element selected from a covalent bond; a carbon atom; a heteroatom; an optionally substituted group selected from the group consisting of acyl, aliphatic, heteroaliphatic, aryl, heteroaryl, and heterocyclic; a carbon atom linked to a trimethylammonium group by a C1-C5 hydrocarbon chain; nucleoside, protease sensitive group, cathepsin K sensitive group, or glycosidase sensitive group; Y is selected from a covalent bond or a bivalent, straight or branched, saturated or unsaturated, optionally substituted Ci .39 hydrocarbon chain wherein one or more methylene units of Y are optionally and independently replaced by -0-, -S-, -N(R)-, -C(O)-, C(0)0-, OC(O)-, -N(R)C(0)-, -C(0)N(R)-, -S(O)-, -S(0)2-, -N(R)S02-, S02N(R)-, a heterocyclic group, an aryl group, or a heteroaryl group; T is an NR, CR2, O, or S; D is a payload; Z is a linkage formed between (i) a reactive functional group selected from the group consisting of N- hydroxysuccinimide, para-nitrophenyl carbonate, para-nitrophenyl carbamate,
pentafluorophenyl, haloacetamide, maleimide, hydroxylamine, strained cycloalkyne, and heterocycloalkyne, alkyne, diene, azadiene, and heterocyclic azadiene, wherein halo is iodine (I), bromine (Br), fluorine (F), or chlorine (CI) and hetero is N, O, or S, and (ii) an S, NR, or O group on L; each occurrence of R is independently hydrogen, a suitable protecting group, an acyl moiety, arylalkyl moiety, aliphatic moiety, aryl moiety, heteroaryl moiety, or heteroaliphatic moiety; L is a cell-specific targeting ligand; and n is 1, 2, 3, or 4.
In particular aspects, the linkage Z has the structure
Y is a covalent bond, or W when Y and X are a covalent bond (on the left) and Z and L (on the right), respectively.
In particular embodiments, the payload-ligand conjugate compound comprising a cell-specific targeting ligand conjugated to a drug moiety comprises the formula (IV)
wherein wavy line 1 indicates the covalent attachment site to the payloand and wavy line 2 indicates the covalent attachment site of the cell-specific targeting ligand and wherein
V is selected from O and S; W is selected from O, N, and CH2; X is a tuning element selected from a covalent bond; a carbon atom; a heteroatom; an optionally substituted group selected from the group consisting of acyl, aliphatic, heteroaliphatic, aryl, heteroaryl, and heterocyclic; a carbon atom linked to a trimethylammonium group by a C 1 -C5 hydrocarbon chain; nucleoside, protease sensitive group, cathepsin B sensitive group, or glycosidase sensitive group; Y is optional but when present is selected from a covalent bond or a bivalent, straight or branched, saturated or unsaturated, optionally substituted Ci .30 hydrocarbon chain wherein one or more methylene units of Y are optionally and independently replaced by -0-, -S-, -N( )-, -C(O)-, 0(0)0-, OC(O)-, -N(R)C(0)-, -C(0)N(R)-, -S(O)-, -S(0)2-, -N(R)S02-, S02N(R)-, a heterocyclic group, an aryl group, or a heteroaryl group; T is an NR, CR2, O, or S of the payload; Z is a linkage formed between (i) a reactive functional group selected from the group consisting of N-hydroxysuccinimide, para-nitrophenyl carbonate, para-nitrophenyl carbamate, pentafluorophenyl, haloacetamide, maleimide, hydroxylamine, strained cycloalkyne, and heterocycloalkyne, alkyne, diene, azadiene, and heterocyclic azadiene, wherein halo is iodine (I), bromine (Br), fluorine (F), or chlorine (CI) and hetero is N, O, or S, and (ii) an S, NR, or O group on the cell-specific targeting ligand; each occurrence of R is independently hydrogen, a suitable protecting group, an acyl moiety, arylalkyl moiety, aliphatic moiety, aryl moiety, heteroaryl moiety, or heteroaliphatic moiety; and n is 1, 2, 3, or 4.
In particular aspects, the linkage Z has the structure
Y is a covalent bond, or W when Y and X are a covalent bond (on the left) and Z and L (on the right), respectively.
The phosphate-payload linkage is stabile extracellularly and labile intracellularly, for example, when present in the lysosomal compartment of the target cell. The tuning element provides a tunable stability to the phosphate-drug linkage when the conjugate is within the lysosomal compartment of the target cell. The intracellular stability of the phosphate-payload linkage or rate of intracellular release of the payload from the conjugate may be adjusted or tuned by the particular tuning element adjacent to the phosphate group and/or by adjusting the number of the phosphate groups. The conjugates disclosed herein are particularly useful in embodiments in which the ligand is an antibody or antibody fragment and the payload is a therapeutic agent, for example, a cytotoxin or a glucocorticoid receptor agonist, which herein is referred to as an "antibody drug conjugate" or "ADC".
The link between the antibody and the drug moiety plays an important role in an antibody drug conjugate (ADC), as the type and structure of the linker may significantly affect the potency, selectivity, and the pharmacokinetics of the resulting conjugate (Widdeson et al, J. Med. Chem. 49: 4392-4408 (2006); Doronina et al., Bioconj. Chem. 17: 114-124 (2006);
Hamann et al, Bioconj. Chem. 16: 346-353 (2005); King et al, J. Med. Chem. 45: 4336-4343 (2002); Alley et al., Bioconj. 19: 759-765 (2008); Blattler et al, Biochem. 24: 1517-1524 (1985). ADC delivery of a drug moiety to its intracellular target occurs via a multistep sequence of events: binding to the cell surface, endocytosis, trafficking (within an endosome) to a lysosome, proteolytic degradation of the conjugate, and diffusion of the released drug moiety across the lysosomal or endosomal membrane toward its intracellular target and its interaction with the target. Therefore, the linker should be sufficiently stable while in circulation to allow delivery of the intact ADC to the target cell but, on the other hand, sufficiently labile to allow release of the drug moiety from the ADC once inside the targeted cell. In general, four types of linkers have been used for preparation of ADCs that have currently entered the clinic: (a) acid-labile linkers, exploiting the acidic endosomal and lysosomal intracellular microenvironment (Hamann et al, op. cit; Blattler et al, op. cil); (b) linkers cleavable by lysosomal proteases (Dronina et al. op.
cit.; King et al. op. cit.); (c) chemically stable thioether linkers that release a lysyl adduct after proteolytic degradation of the antibody inside the cell; (Lewis et al Cancer Res. 68: 9280-9290 (2008); Erickson et al., Cancer Res. 66: 4426-4433 (2006) and (d) disulfide containing linkers (Chari, Adv. Drug Delivery Rev. 31 : 89-104 (1998); Widdeson et al, op. cit.), which are cleaved upon exposure to an intracellular thiol. While U.S. Patent No.5,094, 848 discloses conjugates comprising a diphosphate or amidated diposphate group and a linker arm wherein the linker arm may preferably be an oligopeptide having preferably 2-10 amino acids, in particular
embodiments the tuning element of the phosphate-based linkers disclosed herein may include a di-peptide.
The payload-linker conjugates of the present invention wherein the payload is covalently linked to a tuning element of the linker via a monophosphate, diphosphate, triphosphate, or tetraphosphate linkage have a differentiated and tunable stability of the phosphate linkage in blood vs. an intracellular environment (e.g. lysosomal compartment). Due to location of enzymes that recognize the phosphate linkage, conjugates that have a phosphate group linking a payload to a tuning element of the linker are stable in circulation (plasma or blood) but reactive in intracellular compartments (e.g., lysosomes) making them suitable for intracellular delivery of payload conjugates. The exemplary payload-phosphate-based linker conjugates in the Examples show that the payload-phosphate-based linker conjugates of the present invention are stable in blood, which is advantageous for extending the half-life and to prevent premature release of payload from the conjugates.
Importantly, the inventors have discovered that by modifying the tuning element and/or V and/or W, and/or the number of phosphate groups, the ability to tune reactivity or cleavage of the phosphate linkage in a lysosomal environment so as to release the payload from the conjugate. In general, the rate of release of the payload is dependent on the proximal substitution of the tuning element. The ability to cleave the phosphate linkage between the payload and the tuning element efficiently in a lysosome is advantageous for the release of the payload from the conjugate once it has been delivered to a cell and internalized through an endosomal pathway. Of note is that unlike other linkers known in the art, there is no need to for the phosphate-based linkers of the present invention to be self-immolative. In addition, the excellent solubility of the payload-phosphate-based linker facilitates conjugation to a ligand or cell-targeting moiety and minimizes aggregation of the conjugates. In addition, the phosphate contributes to retention of the payload to the conjugate within cell until phosphate linkage is fully cleaved and limits permeability of conjugates containing the payload from entering non- target cells.
The phosphate -based linkers provide greater solubility relative to disulfide linkers, cathepsin B-cleavable linkers, esters and acid-sensitive linkers such as hydrazones. They enable the release of the payload in its parent or unadultered form unlike some of the alternative linkers, and may offer an improved blood/lysosome stability profile. Specifically,
these phosphate -based linkers will provide superior blood stability relative to esters and disuflides. Phosphate-based linkers, following lysosomal cleavage will release an alcohol or amine-containing payload whereas the other linker formats may require self-immolative tethers to accomplish this or leave residual linker on the payload after lysosomal cleavage. The phosphate-based linker may have greater blood stability relative to the self-immolative cathepsin B linkers in the art, particularly when attached via the oxygen atom of a hydroxyl group of an alcohol-containing payload. The enzymatic hydrolysis of the phosphate linkage may be more rapid than the acid-hydrolysis of hyrdazones. The phosphate-based linkers disclosed herein minimize the propensity for conjugates comprising particular payloads to aggregate. For example, antibody-drug conjugates comprising duocarmycin are known to have a propensity to aggregate. However, antibodies conjugated to duocarmycin via a phosphate-based linker disclosed herein did not produce detectable aggregates. Thus, the phosphate-based linkers disclosed herein are particularly useful for conjugating payloads that are prone to forming aggregates to a cell-specific targeting ligand to provide a conjugate with a reduced or no detectable propensity for aggregation.
Thus, the phosphate-based linkers disclosed herein provide an ideal design for antibody-drug conjugates and the like.
Phosphate Group
The phosphate group comprising the phosphate-based linkers disclosed herein may comprise 1 , 2, 3, or 4 phosphate atoms. In particular embodiments, the phosphate group may be a phosphate ester OH ? pyrophosphate ester * 0 °H o ? triphosphate ester
.
In further embodiments, the phosphate group may be a phosphoramidate
|_| n OH u f "O OH s pyrophosphoramidate « 0 °H o ? triphosphophoramidate er rstill
The wavy lines shown indicate the covalent attachment sites to the payload at the distal end (left) and the tuning element on the proximal end (right).
Payload
Payloads, depicted as "D" herein, are provided in the current invention as part of a payload-ligand conjugate where the payload is linked to a ligand via a phosphate-based linker comprising reactive functional group selected from the group consisting of N- hydroxysuccinimidyl ester, para-nitrophenyl carbonate, para-nitrophenyl carbamate, methyl ketone, azide, hydrazine, pentafluorophenyl, haloacetamide, maleimide, hydroxylamine, strained cycloalkyne, and heterocycloalkyne, alkyne, diene, azadiene, and heterocyclic azadiene, wherein halo is iodine (I), bromine (Br), fluorine (F), or chlorine (CI) and hetero is N, O, or S. The payload must possess a desired biological activity and contain a reactive functional group capable of forming a covalent linkage to the phosphate group of the phosphate-based linker. The desired biological activity includes the diagnosis, cure, mitigation, treatment, or prevention of disease in an animal such as a human. Thus, so long as it has the needed reactive functional group, the term "payload" refers to chemicals recognized as drugs in the official United States Pharmacopeia, official Homeopathic Pharmacopeia of the United States, or official National Formulary, or any supplement thereof. Exemplary drugs are set forth in the Physician's Desk Reference (PDR) and in the Orange Book maintained by the U.S. Food and Drug Administration (FDA). New drugs are being continually being discovered and developed, and the present invention provides that these new drugs may also be incorporated into the payload-ligand complex of the current invention. In particular embodiments, the functional groups on the drug include primary or secondary amines, hydroxyls, sulfhydryls, carboxyls, aldehydes, and ketones. The drug must have at least one, but may have 2, 3, 4, 5, 6 or more reactive functional groups. The payload may also be a biomolecule such as a peptide, polypeptide, or protein; a nucleic acid molecule or analog thereof, a carbohydrate, polysaccharide, a saccharide, or any other therapeutic agent that has a biological effect.
The payload-ligand conjugate is effective for the usual purposes for which the corresponding drugs are effective, but have superior efficacy because of the ability, inherent in the ligand, to transport the drug to the desired cell where it is of particular benefit. Exemplary drugs include proteins, peptides, and small molecule drugs containing a functional group for linkage to the phosphate moiety of the linker. More specifically, these drugs include, for example, the enzyme inhibitors such as dihydrofolate reductase inhibitors, and thymidylate synthase inhibitors, DNA intercalators, glutocorticoid receptor agonists, nuclear recemptor agonists, antinflammatory agents, DNA cleavers, topoisomerase inhibitors, the anthracycline family of drugs, the vinca drugs, the mitomycins, the bleomycins, the cytotoxic nucleosides, the pteridine family of drags, diynenes, the podophyllotoxins, differentiation inducers, and taxols.
In one embodiment, the drugs of the current invention include cytotoxic drugs useful in cancer therapy and other small molecules, proteins or polypeptides with desired biological activity, such as a toxin. The drug may be selected to be activated at a tumor cells by
conjugation to a tumor- specific ligand. These tumor specific drug-ligand conjugates have tumor specificity arising from the specificity of the ligand. Examples of this are drug-ligand conjugates that are highly selective substrates for tumor specific enzymes, where these enzymes are present in the proximity of the tumor in sufficient amounts to generate cytotoxic levels of free drug in the vicinity of the tumor.
Cytotoxic drugs useful in the current invention include, for example, duocarmycins and CC-1065, and analogues thereof, including CBI (1,2,9,9a- tetrahydrocyclopropa[c]benz[e]indol-4-one)-based analogues, MCBI (7-methoxy- 1,2,9,9a- tetra- hydrocyclopropa[c]benz[e]indol-4-one)-based analogues and CCBI (7-cyano- 1,2,9,9a- tetra- hydrocyclo-propa[c]benz[e]-indol-4-one)-based analogues of the duocarmycins and CC- 1065, doxorubicin and doxorubicin conjugates such as morpholino-doxorubicin and cyanomorpholino- doxorubicin, dolastatins such as dolestatin-10, combretastatin, calicheamicin, maytansine, maytansine analogs, DM-I, auristatin E, auristatin EB (AEB), auristatin EFP (AEFP), monomethyl auristatin E (MMAE), 5-benzoylvaleric acid- AE ester (AEVB), tubulysins, disorazole, epothilones , Paclitaxel, docetaxel, SN-38, Topotecan, rhizoxin, echinomycin, colchicine, vinblastin, vindesine, estramustine, cemadotin, eleutherobin, methotrexate, methopterin, dichloro methotrexate, 5-fluorouracil, 6- mercaptopurine, cytosine arabinoside, melphalan, leurosine, leurosideine, actinomycin, daunorubicin and daunorubicin conjugates, mitomycin C, mitomycin A, carminomycin, aminopterin, tallysomycin, podophyllotoxin and podophyllotoxin derivatives such as etoposide or etoposide phosphate, vincristine, taxol, taxotere retinoic acid, butyric acid, N - acetyl spermidine, camptothecin, and their analogues.
Anti-inflammatory agents, such as glucocorticoid receptor agonists include glucocorticoids such as Cortisol, cortisone acetate, beclometasone, prednisone, prednisolone, methylprednisolone, betamethasone, trimcinolone, budesonide, dexamethasone, fluticasone, fluticasone propionate, fluticasone furoate, compound 15-5, or mometasone.
Linker arm
The linker arm of the phosphate-based linkers disclosed herein comprises a tuning element at the distal end covalently linked to a phosphate group and a functional reactive group at the proximal end capable of covalent linkage to a cell-targeting ligand. Optionally, the linker arm may further include a spacer element interposed between the tuning element and the reactive functional group. Examples of tuning elements include but are not limited to
n=0-5
Rj and R2 each independently any amino acid
n 0-5 , and Π H wherein n=l-50, or 1-30, or 1-20, or 1- 10. The wavy lines mark the covalent bond to the O, N, or CH2 of a phosphate group at the distal end (left) and the covalent bond to an atom of the functional reactive group on the proximal end (right), or optionally, a spacer element.
Further examples of tuning elements include but are not limited to
. The wavy lines mark the covalent bond to the O, N, or CH2 of a phosphate group at the distal end (left) and the covalent bond to an atom of the functional reactive group on the proximal end (right), or optionally, a spacer element.
In general, the spacer element is to allow for distance control away from the cell- targeting ligand. In some embodiments, this distance may have an impact on the
stability/cleavability of the linker. Examples of spacer elements include straight polyethylglycol (PEG) chains (of a defined length), straight carbon chains with or without solubilizing groups attached thereto, a dipeptide, a tripeptide, a tetrapeptide, an enzyme cleavage site, for eample, a cathepsin cleavage site haing the structure
wherein the wavy line on the left marks the covalent bond to an atom in the tuning element and the wavy line on the right marks the covalent bond to an atom of a reactive group Z.
The present invention further provides a compound comprising a glucocorticoid receptor agonist conjugated to a phosphate-based linker, wherein the compound has the structure of compound 1-4, 2-7, 3-4, 4-3, 5-3, 6-2, 7-1, 8-5, 9-4, 10-1, 11-5, 12-3, 13-7, 14-5, 15-5, 16-5, 17-5, 18-3, 19-5, 20-5, or 21-5. The structures of these compounds are shown in Examples 1-21.
The present invention further provides antibody drug conjugates in which one or more of compounds 1-4, 2-7, 3-4, 4-3, 5-3, 6-2, 7-1, 8-5, 9-4, 10-1, 11-5, 12-3, 13-7, 14-5, 15-5, 16-5, 17-5, 18-3, 19-5, 20-5, or 21-5 is conjugated to the antibody. In particular embodiment, the antibody comprises one or more a non-natural amino acid having a reactive site capable of binding to compound 1-4, 2-7, 3-4, 4-3, 5-3, 6-2, 7-1, 8-5, 9-4, 10-1, 11-5, 12-3, 13-7, 14-5, 15- 5, 16-5, 17-5, 18-3, 19-5, 20-5, or 21-5. In particular embodiments, the antibody comprises one or more para-azido-phenylalanine residues or para-acetyl-phenylalanine residues. In particular embodiments, the antibody-drug conjugate comprises compound 1-4, 2-7, 3-4, 4-3, 5-3, 6-2, 8-5, 9-4, 11-5, 12-3, 13-7, 14-5, 15-5, 16-5, 17-5, 18-3, or 19-5 conjugated to the azido group on a para-azido-phenylalanine residue within the antibody amino acid sequence. In particular embodiments, the antibody drug conjugate comprises compound 7-1 or 10-1 conjugated to a free thiol group within the amino acid sequence of the antibody, for example, the thio group of a cysteine residue, on the antibody. In particular embodiments, the antibody-drug conjugate comprises compound 20-5 or 21-5 conjugated to the methyl ketone group on a para-acetyl- phenylalanine residue within the antibody amino acid sequence
The present invention further provides compositions comprising one or more antibody drug conjugates wherein at least one antibody drug conjugate is conjugated to compound 1-4, 2-7, 3-4, 4-3, 5-3, 6-2, 7-1, 8-5, 9-4, 10-1, 11-5, 12-3, 13-7, 14-5, 15-5, 16-5, 17- 5, 18-3, 19-5 , 20-5, or 21-5. In particular embodiment, the antibody comprises one or more a non-natural amino acid having a reactive site capable of binding to compound 1-4, 2-7, 3-4, 4-3, 5-3, 6-2, 7-1, 8-5, 9-4, 10-1, 11-5, 12-3, 13-7, 14-5, 15-5, 16-5, 17-5, 18-3, 19-5, 20-5, or 21-5. In particular embodiments, the antibody comprises one or more para-azido-phenylalanine residues or para-acetyl-phenylalanine residues. In particular embodiments, the antibody-drug conjugate comprises compound 1-4, 2-7, 3-4, 4-3, 5-3, 6-2, 8-5, 9-4, 11-5, 12-3, 13-7, 14-5, 15- 5, 16-5, 17-5, 18-3, or 19-5 conjugated to the azido group on a para-azido-phenylalanine residue within the antibody amino acid sequence. In particular embodiments, the antibody drug conjugate comprises compound 7-1 or 10-1 conjugated to a free thiol group within the amino acid sequence of the antibody, for example, the thio group of a cysteine residue, on the antibody. In particular embodiments, the antibody-drug conjugate comprises compound 20-5 or 21-5 conjugated to the methyl ketone group on a para-acetyl-phenylalanine residue within the antibody amino acid sequence.
Targeting Ligand
The linker arm and payload of the invention may be linked to a targeting ligand
that selectively delivers a pay load to a cell, organ, or region of the body. Exemplary targeting ligands such as antibodies (e.g., chimeric, humanized and human), ligands for receptors, lectins, saccharides, antibodies, and the like are recognized in the art and are useful without limitation in practicing the present invention. Other targeting ligands include a class of compounds that do not include specific molecular recognition motifs include macromolecules such as poly(ethylene glycol), polysaccharide, polyamino acids and the like, which add molecular mass to the cytotoxin. The additional molecular mass affects the pharmacokinetics of the payload, e.g., serum half-life.
In an exemplary embodiment, the invention provides a payload, linker or payload- linker conjugate with a targeting ligand that is a biomolecule, e.g, an antibody, receptor, peptide, lectin, saccharide, nucleic acid or a combination thereof. Biomolecules useful in practicing the present invention may be derived from any source. The biomolecules may be isolated from natural sources or may be produced by synthetic methods. Proteins may be natural proteins or mutated proteins. Mutations may be effected by chemical mutagenesis, site-directed
mutagenesis or other means of inducing mutations known to those of skill in the art. Proteins useful in practicing the instant invention include, for example, enzymes, antigens, antibodies and receptors. Antibodies may be either polyclonal or monoclonal, but most preferably are monoclonal and may be human, humanized, or human chimeric antibodies. Peptides and nucleic acids may be isolated from natural sources or can be wholly or partially synthetic in origin.
In a particular embodiment, the targeting ligand is an antibody, or antibody fragment, that is selected based on its specificity for an antigen expressed on a target cell, or at a target site, of interest. A wide variety of tumor-specific or other disease-specific antigens have been identified and antibodies to those antigens have been used or proposed for use in the treatment of such tumors or other diseases. The antibodies that are known in the art may be used in the conjugates of the invention, in particular for the treatment of the disease with which the target antigen is associated. Non-limiting examples of target antigens (and their associated diseases) to which a conjugate of the invention may be targeted include: Her2 (breast cancer), CD4 (lymphomas, autoimmune diseases, including rheumatoid arthritis), CD20 (lymphomas), EGFR (solid tumors), CD22 (lymphomas, including non-Hodgkin's lymphoma), CD23 (asthma), CD25, CD52 (chronic lymphocytic leukemia), CD30 (lymphomas, including non-Hodgkin's lymphoma), CD33 (acute myelogenous leukemia), CD40L (immune thromobcytopenic purpura), CD70, CD74, CD80 (psoriasis), CD 163, Mucl8 (melanoma), integrins (solid tumors), PSMA (prostate cancer, benign prostatic hyperplasia), CEA (colorectal cancer), CD1 la (psoriasis), CTLA4 (T cell lymphomas) and BLys (autoimmune diseases, including systemic lupus erythematosus).
Targeting ligands may be attached to the linker arm by any available reactive group that can react with the reactive functional group on the proximal end of the linker arm. For example, peptides and proteins may be attached through an amine, carboxyl, sulfhydryl, or
hydroxyl group. Such a group may reside at a peptide terminus or at a site internal to the peptide chain. Nucleic acids may be attached through a reactive group on a base (e.g., exocyclic amine) or an available hydroxyl group on a sugar moiety (e.g., 3'- or 5'- hydroxyl). The peptide or protein may be further derivatized at one or more sites to allow for the attachment of appropriate reactive groups onto the peptide or protein. See, Chrisey et al. Nucleic Acids Res. 24:3031-3039 (1996). In addition, the protein or peptide may be synthesized to contain one or more non- natural amino acids which may then serve as a site for attachment of the linker arm comprising the payload-phosphate-based linker. Antibodies comprising non-natural amino acids for conjugation and methods for making such antibodies have been disclosed in U.S. Patent No. 7,632,924, which is incorporated herein in its entirety. Examples of non-natural amino acids include but are not limited to para-azido-phenylalanine and para-acetyl-phenylalanine.
Pharmaceutical Formulations and Administration The conjugates disclosed herein are useful for the manufacture of medicaments for the treatment of diseases or disorders such as an inflammatory disease or cancer. The conjugates disclosed herein may be formulated into pharmaceutical formulations for use in treating diseases or disorders such as an inflammatory disease or cancer.
The present invention provides a pharmaceutical formulation comprising a compound of the invention and a pharmaceutically acceptable carrier. The compounds described herein including pharmaceutically acceptable carriers such as addition salts or hydrates thereof, can be delivered to a patient using a wide variety of routes or modes of administration. Suitable routes of administration include, but are not limited to, inhalation, transdermal, oral, rectal, transmucosal, intestinal and parenteral administration, including intramuscular, subcutaneous and intravenous injections.
In particular embodiments, the conjugates of the invention comprising an antibody or antibody fragment as the targeting moiety are administered parenterally, more preferably intravenously. As used herein, the terms "administering" or "administration" are intended to encompass all means for directly and indirectly delivering a compound to its intended site of action. The compounds described herein, or pharmaceutically acceptable salts and/or hydrates thereof, may be administered singly, in combination with other compounds of the invention, and/or in cocktails combined with other therapeutic agents. The choice of therapeutic agents that can be co-administered with the compounds of the invention will depend, in part, on the condition being treated.
The active compound(s) of the invention are administered per se or in the form of a pharmaceutical composition wherein the active compound(s) is in admixture with one or more pharmaceutically acceptable carriers, excipients or diluents. Pharmaceutical compositions for use in accordance with the present invention are typically formulated in a conventional manner using one or more physiologically acceptable carriers comprising excipients and auxiliaries,
which facilitate processing of the active compounds into preparations which, can be used pharmaceutically. Proper formulation is dependent upon the route of administration chosen.
For transmucosal administration, penetrants appropriate to the barrier to be permeated are used in the formulation. Such penetrants are generally known in the art.
For oral administration, the compounds can be formulated readily by combining the active compound(s) with pharmaceutically acceptable carriers well known in the art. Such carriers enable the compounds of the invention to be formulated as tablets, pills, dragees, capsules, liquids, gels, syrups, slurries, suspensions and the like, for oral ingestion by a patient to be treated. Pharmaceutical preparations for oral use can be obtained solid excipient, optionally grinding a resulting mixture, and processing the mixture of granules, after adding suitable auxiliaries, if desired, to obtain tablets or dragee cores.
Suitable excipients are, in particular, fillers such as sugars, including lactose, sucrose, mannitol, or sorbitol; cellulose preparations such as, for example, maize starch, wheat starch, rice starch, potato starch, gelatin, gum tragacanth, methyl cellulose,
hydroxypropylmethyl-cellulose, sodium carboxyniethylcellulose, and/or polyvinylpyrrolidone (PVP). If desired, disintegrating agents may be added, such as the cross-linked polyvinyl pyrrolidone, agar, or alginic acid or a salt thereof such as sodium alginate.
Dragee cores are provided with suitable coatings. For this purpose, concentrated sugar solutions may be used, which may optionally contain gum arabic, talc, polyvinyl pyrrolidone, carbopol gel, polyethylene glycol, and/or titanium dioxide, lacquer solutions, and suitable organic solvents or solvent mixtures. Dyestuffs or pigments may be added to the tablets or dragee coatings for identification or to characterize different combinations of active compound doses.
Pharmaceutical preparations, which can be used orally, include push- fit capsules made of gelatin, as well as soft, sealed capsules made of gelatin and a plasticizer, such as glycerol or sorbitol. The push-fit capsules can contain the active ingredients in admixture with filler such as lactose, binders such as starches, and/or lubricants such as talc or magnesium stearate and, optionally, stabilizers. In soft capsules, the active compounds may be dissolved or suspended in suitable liquids, such as fatty oils, liquid paraffin, or liquid polyethylene glycols. In addition, stabilizers may be added. All formulations for oral administration should be in dosages suitable for such administration.
For buccal administration, the compositions may take the form of tablets or lozenges formulated in conventional manner.
For administration by inhalation, the compounds for use according to the present invention are conveniently delivered in the form of an aerosol spray presentation from pressurized packs or a nebulizer, with the use of a suitable propellant, e.g.,
dichlorodifluoromethane, trichlorofluoromethane, dichlorotetrafluoroethane, carbon dioxide or other suitable gas. In the case of a pressurized aerosol the dosage unit may be determined by
providing a valve to deliver a metered amount. Capsules and cartridges of e.g., gelatin for use in an inhaler or insufflator may be formulated containing a powder mix of the compound and a suitable powder base such as lactose or starch.
The compounds may be formulated for parenteral administration by injection, e.g., by bolus injection or continuous infusion. Injection is a preferred method of administration for the compositions of the current invention. Formulations for injection may be presented in unit dosage form, e.g., in ampoules or in multi-dose containers, with an added preservative. The compositions may take such forms as suspensions, solutions or emulsions in oily or aqueous vehicles, and may contain formulatory agents such as suspending, stabilizing and/or dispersing agents may be added, such as the cross-linked polyvinyl pyrrolidone, agar, or alginic acid or a salt thereof such as sodium alginate.
Pharmaceutical formulations for parenteral administration include aqueous solutions of the active compounds in water-soluble form. Additionally, suspensions of the active compounds may be prepared as appropriate oily injection suspensions. Suitable lipophilic solvents or vehicles include fatty oils such as sesame oil, or synthetic fatty acid esters, such as ethyl oleate or triglycerides, or liposomes. Aqueous injection suspensions may contain substances, which increase the viscosity of the suspension, such as sodium carboxymethyl cellulose, sorbitol, or dextran. Optionally, the suspension may also contain suitable stabilizers or agents, which increase the solubility of the compounds to allow for the preparation of highly, concentrated solutions. For injection, the agents of the invention may be formulated in aqueous solutions, preferably in physiologically compatible buffers such as Hanks's solution, Ringer's solution, or physiological saline buffer. Alternatively, the active ingredient may be in powder form for constitution with a suitable vehicle, e.g., sterile pyrogen-free water, before use.
The compounds may also be formulated in rectal compositions such as suppositories or retention enemas, e.g., containing conventional suppository bases such as cocoa butter or other glycerides.
In addition to the formulations described previously, the compounds may also be formulated as a depot preparation. Such long acting formulations may be administered by implantation or transcutaneous delivery (e.g., subcutaneously or intramuscularly), intramuscular injection or a transdermal patch. Thus, for example, the compounds may be formulated with suitable polymeric or hydrophobic materials (e.g., as an emulsion in an acceptable oil) or ion exchange resins, or as sparingly soluble derivatives, for example, as a sparingly soluble salt. The pharmaceutical compositions also may comprise suitable solid or gel phase carriers or excipients. Examples of such carriers or excipients include but are not limited to calcium carbonate, calcium phosphate, various sugars, starches, cellulose derivatives, gelatin, and polymers such as polyethylene glycols.
The following examples are intended to promote a further understanding of the present invention.
EXAMPLE 1
The synthesis of dexamethasone linker 2-(2-(cyclooct-2-yn-l- yloxy)acetamido)ethyl (2-((8S,9R, 10S,11 S, 13S,14S, 16R, 17R)-9-fiuoro- 1 1 ,17-dihydroxy- 10,13, 16-trimethyl-3-oxo-6,7,8,9,10, l 1,12,13, 14, 15, 16, 17-dodecahydro-3H- cyclopenta[a]phenanthren-17-yl)-2-oxoethyl) dihydrogen pyrophosphate (1-4) was as follows.
Step A : 2-((8S, 9R, 1 OS, 11S,13S,14S, 16R, 17R)-9-fluoro-ll, 17-dihydroxy- 10, 13,16-trimethyl-3- oxo-6, 7, 8, 9,10,11,12,13,14,15,16,17-dodecahydro-3H-cyclopenta[a]phenanthren-l 7-yl)-2- oxoethyl dihydrogen phosphate (1-1)
To a stirred solution of dexamethasone (0.40 g, 1.02 mmol) in THF (2.0 mL) at -40°C was added diphosphoryl chloride (0.31 mL, 2.24 mmol) and the resulting mixture was stirred at - 40°C for 1 hr. The reaction was quenched with water, and treated with saturated sodium bicarbonate solution until pH ~8. The solution was made acidic using IN HC1 solution and extracted several times with ethyl acetate. The combined organic phase washed with brine, dried over sodium sulfate and concentrated to give 1-1 as a solid (497 mg, 103%). LRMS (ES) (M+H)+ : observed = 473.3, calculated = 473.4.
Step B: (9H-fluoren-9-yl)methyl (2- ((hydroxy (lH-imidazol-l-yl)phosphoryl)oxy)ethyl)carbamate (1-2)
The title compound was prepared from N-(9- fluorenylmethoxycarbonyl)ethanolamine according to the protocol outlined in Example 1-1 to afford 1-2. LRMS (ES) (M+H)+ : observed = 414.3, calculated = 414.4 Step C: (9H-fluoren-9-yl)methyl (2-(((((2-((8S,9R,10S,llS, 13S,14S, 16R,17R)-9-fluoro-ll,17- dihydroxy-10, 13,16-trimethyl-3-oxo-6, 7, 8, 9,10,11,12, 13,14, 15,16,17-dodecahydro-3H- cyclopenta[a]phenanthren-l 7-yl)-2- oxoethoxy) (hydroxy)phosphoryl)oxy) (hydroxy)phosphoryl)oxy)ethyl)carbamate (1-3)
To a stirred solution of 1-2 (0.15 g, 0.41 mmol) in DMF (1.2 mL) was added triethylamine (0.06 mL, 0.41 mmol) and CDI (0.17 g, 1.03 mmol). The resulting solution was stirred at room temperature for 30 minutes. To this mixture was added 1-1 (0.19 g, 0.41 mmol) and ZnCl2 (0.45 g, 3.31 mmol) and the mixture was allowed to stir at room temperature overnight. The reaction was diluted with 1 N HCl and extracted several times with ethyl acetate.
The combined organic layers were concentrated and reverse phase preparative chromatography (Phenomenex Gemini -NX C18 OBD 5 uM 30 x 100mm; 5-35%MeCN/water w/ 0.1% NH4OH modifier over 20 min) gave 1-3 as a solid (134 mg, 40%). LRMS (ES) (M+H)+ : observed =
818.6, calculated = 818.7.
Step D: 2-(2-(cyclooct-2-yn-l-yloxy)acetamido)ethyl (2-((8S,9R,10S, l lS,13S, 14S,16R,17R)-9- fiuoro-11, 17 -dihydroxy-10,13,16-trimethyl-3-oxo-6, 7, 8, 9, 10,11, 12,13,14,15, 16,17-dodecahydro- 3H-cyclopenta[a]phenanthren-17-yl)-2-oxoethyl) dihydrogen pyrophosphate (1-4)
To a stirred solution of 1-3 (0.19 g, 0.23 mmol) in DCM (3 mL) was added piperidine (0.15 mL, 1. 1 mmol) and the resulting mixture was stirred at room temperature for 3 hrs. The solution was concentrated to dryness and redissolved in DCM (2 mL). In a separate vial a stirred solution of 2-(cyclooct-2-yn- 1 -yloxy)acetic acid (0.045 g, 0.25 mmol) in
dichloromethane (1 mL) was added HOAT (0.034 g, 0.25 mmol), EDC (0.056 g, 0.30 mmol) and triethylamine (0.1 mL, 0.68 mmol). The resulting solution was stirred at room temperature for 40 minutes. The two solutions were combined and stirred at room temperature. Additional 2- (cyclooct-2-yn-l-yloxy)acetic acid activated with HOAT/EDC was added as necessary to complete reaction. Upon completion, the mixture was concentrated and reverse phase preparative chromatography (Phenomenex Gemini -NX C 18 OBD 5 uM 30 x 100mm; 5-30% MeCN/water w/ 0.1% NH4OH modifier over 20 min) gave 1-4 as a solid (59 mg, 34%). LRMS (ES) (M+H)+ : observed = 760.6, calculated = 760.7. Ή NMR (400 MHz, DMSO-d6): δ 8.64 (br s, 1H), 7.29 (d, J = 9.15 Hz, 1H), 6.21 (dd, J = 10.05, 1.93 Hz, 1H), 6.00 (s, 1H), 4.57 (d, J = 8.3 Hz, 2H), 4.31 (t, J = 5.4 Hz, lH), 4.12 (d, J = 1 1.22 Hz, 1H), 3.92 (dd, J = 14.43, 8.59 Hz, 1H), 3.80-3.76 (complex, 3H), 3.30-3.16 (complex, 2H), 3.02-2.91 (complex, 2H), 2.63 (m, 1H), 2.40-2.19 (complex, 3H), 2.17-2.03 (complex, 4H), 1.96-1.82 (m, 3H), 1.80-1.72 (complex, 3H), 1.66-
1.52 (complex, 4H), 1.50 (s, 3H), 1.40-1.31 (complex, 2H), 1.07-1.02 (m, 1H), 0.88 (s, 3H), 0.77 (d, J = 7.17 Hz, 3H)
EXAMPLE 2
The synthesis of dexamethasone linker 2-(2-(cyclooct-2-yn-l- yloxy)acetamido)ethyl (2-((8S,9R, 10S,11 S, 13S,14S, 16R, 17R)-9-fluoro- 1 1 ,17-dihydroxy- 10,13, 16-trimethyl-3-oxo-6,7,8,9,10, l 1,12,13, 14, 15, 16, 17-dodecahydro-3H- cyclopenta[a]phenanthren- 17-yl)-2-oxoethyl) trihydrogen triphosphate (2-7) was as follows.
Step A: 1 ,3-dioxoisoindolin-2-yl 2-(cyclooct-2-yn-l-yloxy)acetate (2-1)
To a stirred solution of 2-(cyclooct-2-yn-l-yloxy)acetic acid (0.20 g, 1.10 mmol) in DCM (4.0 mL) was added N-hydroxyphthalimide (0.36 g, 2.20 mmol) and EDC (0.42 g, 2.20 mmol). The resulting mixture was stirred at room temperature for 45 minutes. The reaction was directly injected onto a silica gel column and flash column separation using a 0-50% ethyl acetate/ hexane gradient gave 2-1 as a solid (335 mg, 93%)
Step B: (9H-fluoren-9-yl)methyl dihydrogen phosphate (2-2)
The title compound was prepared from (9H-fluoren-9-yl)methanol according to the protocol outlined in Example 1-1 to afford 2-2. LRMS (ES) (M+H)+ : observed = 277.1, calculated = 276.2
Step C: ((9H-fluoren-9-yl)methyl) (2-((8S,9R, 10S,llS,13S,14S,16R, 17R)-9-fluoro-ll, 17- dihydroxy-10, 13,16-trimethyl-3-oxo-6, 7, 8, 9,10,11,12, 13,14, 15,16,17-dodecahydro-3H- cyclopenta[a]phenanthren-17-yl)-2-oxoethyl) dihydrogen pyrophosphate (2-3)
The title compound was prepared from 2-2 and 1-1 according to the protocol outlined in Example 1 to produce 1-3 to afford 2-3. LRMS (ES) (M+H)+ : observed = 731.2, calculated = 730.6
Step D: 2-((8S,9R,10S,l lS,13S, 14S,16R,17R)-9-fluoro-ll,17-dihydroxy-10 3,16-trimethyl-3- oxo-6, 7, 8, 9,10,11,12,13,14, 15,16, 17-dodecahydro-3H-cyclopenta[a]phenanthren-l 7-yl)-2- oxoethyl trihydrogen diphosphate (2-4)
To a stirred solution of 2-3 (0.29 g, 0.39 mmol) in DCM (2 mL) was added piperidine (0.23 mL, 2.36 mmol) and the resulting mixture was stirred at room temperature for 80 minutes. The solution was concentrated and reverse phase preparative chromatography (Phenomenex Gemini -NX C 18 OBD 5 uM 30 x 100mm; 3-25% MeCN/water w/ 0.1 % NH4OH modifier over 20 min) gave 2-4 as a solid (123 mg, 56%). LRMS (ES) (M+H)+ : observed = 553.2, calculated = 552.4
Step E: (9H-fluoren-9-yl)methyl (2-(((((((2-((8S,9R, 10S,llS, 13S,14S,16R, 17R)-9-fluoro-ll, 17- dihydroxy-10, 13,16-trimethyl-3-oxo-6, 7, 8, 9,10,11 ,12, 13,14, 15,16,17-dodecahydro-3H- cyclopenta[a]phenanthren-l 7-yl)-2- oxoethoxy) (hydroxy)phosphoryl)oxy) (hydroxy)phosphoryl)oxy) (hydroxy)phosphoryl)oxy)ethyl)ca rbamate (2-5)
The title compound was prepared from 2-4 and 1-2 according to the protocol outlined in Example 1 to produce 1-3 to afford 2-5. LRMS (ES) (M+H)+ : observed = 898.3, calculated = 897.7
Step F: 2-amionethyl (2-((8S,9R,10S,llS,13S, 14S,16R,17R)-9-fluoro-ll, 17-dihydroxy-10,13,16- trimethyl-3-oxo-6, 7, 8, 9,10, 11,12,13,14, 15,16, 17-dodecahydro-3H-cyclopenta[ a] phenanthren- 17-yl)-2-oxoethyl) trihydrogen triphosphate (2-6)
The title compound was prepared from 2-5 according to the protocol outlined in
Example 2 to produce 2-4 to afford 2-6. LRMS (ES) (M+H)+ : observed = 676.2, calculated = 675.4
Step G: 2-(2-(cyclooct-2-yn-l-yloxy)acetamido) ethyl (2-((8S,9R,10S, llS,13S, 14S,16R,17R)-9- fluoro-11, 17-dihydroxy-l 0,13,16-trimethyl-3-oxo-6, 7, 8, 9, 10,11, 12,13,14,15, 16,17 -dodecahydro- 3H-cyclopenta[a]phenanthren-17-yl)-2-oxoethyl) trihydrogen triphosphate (2-7)
To a stirred solution of 2-6 (0.027 g, 0.04 mmol) in DMF (0.8 mL) was added triethylamine (0.02 mL, 0.16 mmol) and 2-1 and the resulting mixture was stirred at room
temperature for 30 minutes. The solution was concentrated and reverse phase preparative chromatography (Phenomenex Gemini -NX C 18 OBD 5 uM 30 x 100mm; 5-40% MeCN/water w/ 0.1% NH4OH modifier over 20 min) gave 2-7 as a solid (8 mg, 24%). XH NMR (499 MHz, DMSO): 0.78 (d, J = 7.1 Hz, 3 H); 0.88 (s, 3 H); 1.10-0.99 (complex, 1 H); 1.44-1.28 (complex, 2 H); 1.50 (s, 3 H); 1.67-1.52 (complex, 4 H); 1.80-1.67 (complex, 3 H); 1.93-1.83 (m, 3 H); 2.17-2.01 (complex, 3 H); 2.42-2.17 (complex, 3 H); 2.67-2.57 (complex, 1 H); 2.81 (d, J = 79.7 Hz, 1 H); 3.02-2.91 (complex, 1 H); 3.17 (s, 1 H); 3.26-3.21 (complex, 2 H); 3.84-3.74
(complex, 2 H); 3.91 (d, J = 14.5 Hz, 1 H); 4.15 (d, J = 1 1.4 Hz, 1 H); 4.31 (t, J = 5.1 Hz, 1 H); 4.57 (dd, J = 18.0, 8.1 Hz, 1 H); 4.71 (dd, J = 17.9, 7.1 Hz, 1 H); 5.99 (s, 1 H); 6.20 (d, J = 10.1 Hz, 1 H); 7.30 (d, J = 10.6 Hz, 1 H); 8.48 (s, 1 H). LRMS (ES) (M+H)+ : observed = 840.4, calculated = 839.6
EXAMPLE 3
The synthesis of dexamethasone linker 4-(2-(cyclooct-2-yn-l- yloxy)acetamido)phenyl (2-((8S,9R,10S,l lS,13S,14S, 16R,17R)-9-fluoro-l 1 ,17-dihydroxy- 10,13, 16-trimethyl-3-oxo-6,7,8,9,10, l 1,12,13, 14, 15, 16, 17-dodecahydro-3H- cyclopenta[a]phenanthren-17-yl)-2-oxoethyl) dihydrogen pyrophosphate (3-4) was as follows.
Step A: (9H-fluoren-9-yl)methyl (4-hydroxyphenyl)carbamate (3-1)
To a stirred solution of 4-aminophenol (0.30 g, 2.75 mmol) in DCM (9 mL) was added (9H-fluoren-9-yl)methyl carbonochloridate (0.71 g, 2.75 mmol) and the resulting mixture was stirred at room temperature for 2 hours. The mixture was partitioned between ethyl acetate
and 1 N HC1 solution. To the organic phase was added methanol until the solution cleared. The organic phase was dried over sodium sulfate and concentrated onto silica gel and flash column separation using a 100% ethyl acetate gave 3-1 as a solid (634 mg, 70%). LRMS (ES) (M+H)+ : observed = 332.3, calculated = 331.3
Step B: (9H-fluoren-9-yl)methyl (4-(phosphonooxy)phenyl)carbamate (3-2)
To a stirred solution of 3-1 (0.31 g, 0.95 mmol) in THF (1.9 mL) at -40°C was added diphosphoryl chloride (0.31 mL, 2.24 mmol) and triethylamine (1.32 mL, 9.51 mmol) and the resulting mixture was stirred at -40°C for 3 hr. The reaction was quenched with water, and treated with saturated sodium bicarbonate solution until pH ~8. The solution was made acidic using IN HC1 solution and extracted several times with ethyl acetate. The combined organic phase washed with brine, dried over sodium sulfate and concentrated to give 3-2 as a solid (342 mg, 87%). LRMS (ES) (M+H)+ : observed = 412.3, calculated = 41 1.3 Step C: (9H-fluoren-9-yl)methyl (4-(((((2-((8S,9R,10S,llS, 13S,14S, 16R,17R)-9-fluoro-ll,17- dihydroxy-10, 13,16-trimethyl-3-oxo-6, 7, 8, 9,10,11,12, 13,14, 15,16,17-dodecahydro-3H- cyclopenta[a]phenanthren-17-yl)-2- oxoethoxy) (hydroxy)phosphoryl)oxy) (hydroxy)phosphoryl)oxy)phenyl)carbamate (3-3)
The title compound was prepared from 3-2 and 1-1 according to the protocol outlined in Example 1 to produce 1-3 to afford 3-3. LRMS (ES) (M+H)+ : observed = 866.5, calculated = 865.7
Step D: 4-(2-(cyclooct-2-yn-l-yloxy)acetamido)phenyl (2-((8S,9R,10S, l lS,13S,14S,16R,17R)-9- fluoro-11, 17-dihydroxy-l 0,13,16-trimethyl-3-oxo-6, 7, 8, 9, 10,11, 12,13,14,15, 16,17-dodecahydro- 3H-cyclopenta[a]phenanthren-17-yl)-2-oxoethyl) dihydrogen pyrophosphate (3-4)
The title compound was prepared from 3-3 according to the protocol outlined in Example 1 to produce 1-4 to afford 3-4. LRMS (ES) (M+H)+ : observed = 808.4, calculated = 807.7
EXAMPLE 4
The synthesis of dexamethasone linker 2-(2-(cyclooct-2-yn-l- yloxy)acetamido)ethyl (2-((8S,9R, 10S,11 S, 13S.14S, 16R, 17R)-9-fiuoro- 1 1 ,17-dihydroxy- 10,13, 16-trimethyl-3-oxo-6,7,8,9,10, l 1,12,13, 14, 15, 16, 17-dodecahydro-3H- cyclopenta[a]phenanthren- 17-yl)-2-oxoethyl) hydrogen phosphate (4-3) was as follows.
Step A: tert-butyl (2-(((2-((8S,9R, 10S, llS,13S, 14S,16R,17R)-9-fluoro-ll,17-dihydroxy-10,13, 16- trimethyl-3-oxo-6, 7, 8, 9,10, 11,12,13,14, 15,16, 17-dodecahydro-3H-cyclopenta[a]phenanthren- 17-yl)-2-oxoethoxy)(hydroxy)phosphoryl)oxy)ethyl)carbamate (4-1)
To a stirred solution of dexamethasone (0.10 g, 0.26 mmol) in THF (0.5 mL) at - 40°C was added diphosphoryl chloride (0.12 g, 0.48 mmol) and the resulting mixture was stirred at -40°C for 1 hr. To this was added tert-butyl N-(2-hydroxyethyl)carbamate (0.12 g, 0.76 mmol) and triethylamine (0.14 mL, l .O mmol). The resulting mixture was stirred at -40° C for 4 hr. The reaction was quenched with water, and treated with saturated sodium bicarbonate solution until pH ~8. The solution was made acidic using IN HC1 solution and extracted several times with ethyl acetate. The combined organic phase was concentrated onto silica gel. Flash column separation using a 0-10% isopropanol/ dichloromethane gradient gave 4-1 as a solid (1 15 mg, 73%). LRMS (ES) (M+H)+ : observed = 616.5, calculated = 616.6.
Step B: 2-aminoethyl (2-((8S,9R,10S,llS,13S, 14S,16R,17R)-9-fluoro-ll, 17-dihydroxy-10,13,16- trimethyl-3-oxo-6, 7, 8, 9,10, 11,12,13,14, 15,16, 17-dodecahydro-3H-cyclopenta[a]phenanthren- 17-yl)-2-oxoethyl) hydrogen phosphate, HCl (4-2)
To a stirred solution of 4-1 (0.11 g, 0.18 mmol) in ethyl acetate ( 1 mL) at 0°C was bubbled in HCl gas until saturated. The resulting solution was stirred at 0°C for 1 hr and concentrated to give 4-2 as a solid (99 mg, 100%). LRMS (ES) (M+H)+ : observed = 16.4, calculated = 516.5. Step C: 2-(2-(cyclooct-2-yn-l-yloxy)acetamido)ethyl (2-((8S,9R,10S, llS,13S, 14S,16R, 17R)-9- fluoro-11, 17-dihydroxy-l 0,13,16-trimethyl-3-oxo-6, 7, 8, 9, 10,11, 12,13,14,15, 16,17-dodecahydro- 3H-cyclopenta[a] phenanthren- 17-yl)-2-oxoethyl) hydrogen phosphate (4-3)
To a stirred solution of 2-(cyclooct-2-yn-l-yloxy)acetic acid (0.036 g, 0.20 mmol) in dichloromethane (1 ml) was added HOAT (0.027 g, 0.20 mmol), EDC (0.041 g, 0.22 mmol) and triethylamine (0.05 mL, 0.36 mmol). The resulting solution was stirred at room temperature for 40 minutes. This solution was added to 4-2 (0.10 g, 0.18 mmol) in DCM (1 mL). Additional 2-(cyclooct-2-yn-l-yloxy)acetic acid activated with HOAT/EDC was added as necessary to complete reaction. Upon completion, the mixture was concentrated and reverse phase preparative chromatography (Phenomenex Gemini -NX C 18 OBD 5 uM 30 x 100mm; 10-50% MeCN/water w/ 0.1% NH4OH modifier over 20 min) gave 4-3 as a solid (45 mg, 37%). LRMS (ES) (M+H)+ : observed = 680.6, calculated = 680.7. Ή NMR (400 MHz, DMSO-d6): δ 8.05 (br t, J = 5.6 Hz, 1H), 7.30 (d, J = 10.15 Hz, 1H), 6.21 (d, J = 10.12 Hz, 1H), 6.00 (s, 1H), 5.55 (s, 1H), 5.37 (s, 1H), 4.70 (dd, J = 17.2, 6.7 Hz, 1H), 4.29 (br t, J = 6.4 Hz, 1H), 4.18-4.10 (complex, 2H), 3.87 (d, J = 14.8 Hz, 1H), 3.74 (d, J = 14.8 Hz, 1H), 3.69-3.64 (complex, 2H), 3.27-3.18 (complex, 2H), 2.91 (m, 1H), 2.61 (m, 1H), 2.39-2.05 (complex, 7H), 1.97-1.83 (complex, 2H), 1.80-1.69 (complex, 3H), 1.64-1.52 (complex, 3H), 1.48 (s, 3H), 1.47-1.30 (complex, 3H), 1.05 (m, 1H), 0.85 (s, 3H), 0.76 (d, J = 7.13 Hz, 3H).
EXAMPLE 5
The synthesis of dexamethasone linker 4-(2-(cyclooct-2-yn-l- yloxy)acetamido)phenyl (2-((8S,9R,10S,l lS,13S,14S, 16R,17R)-9-fluoro-l 1 , 17-dihydroxy- 10,13, 16-trimethyl-3-oxo-6,7,8,9,10, l 1,12,13, 14, 15, 16, 17-dodecahydro-3H- cyclopenta[a]phenanthren-17-yl)-2-oxoethyl) hydrogen phosphate (5-3) was as follows.
Step A: tert-butyl (4-(((2-((8S,9R, 10S, llS,13S, 14S,16R,17R)-9-fluoro-ll,17-dihydroxy-10,13, 16- trimethyl-3-oxo-6, 7, 8, 9,10, 11,12,13,14, 15,16, 17-dodecahydro-3H-cyclopenta[ a] phenanthren- 17-yl)-2-oxoethoxy)(hydroxy)phosphoryl)oxy)phenyl)carbamate (5-1)
To a stirred solution of dexamethasone (0.20 g, 0.51 mmol) in THF (1.0 mL) at - 40°C was added diphosphoryl chloride (0.24 g, 0.97 mmol) and the resulting mixture was stirred at -40°C for lhr 15min. To this was added N-BOC-4-aminophenol (0.32 g, 1.53 mmol) and triethylamine (0.56 mL, 4.0 mmol). The resulting mixture was stirred at -40°C for 30 minutes. The reaction was quenched with water, and treated with saturated sodium bicarbonate solution until pH ~8. The solution was made acidic using IN HC1 solution and extracted several times with ethyl acetate. The combined organic phase was concentrated onto silica gel. Flash column separation using a 0-70% isopropanol/ dichloromethane gradient gave 5-1 as a solid (370 mg, 88%). LRMS (ES) (M+H)+ : observed = 664.5, calculated = 664.6.
Step B: 4-aminophenyl (2-((8S,9R,10S, llS,13S, 14S,16R, 17R)-9-fluoro-ll,17-dihydroxy- 10,13,16-trimethyl-3-oxo-6, 7, 8,9, 10,11, 12,13,14,15,16,17-dodecahydro-3H-cycl
openta[a]phenanthren-17-yl)-2-oxoethyl) hydrogen phosphate, HCl (5-2)
The title compound was prepared from 5-1 according to the protocol outlined in Example 4 to produce 4-2 to afford 2-2. LRMS (ES) (M+H)+ : observed = 564.4, calculated = 564.5
Step C: 4-(2-(cyclooct-2-yn-l-yloxy)acetamido)phenyl (2-((8S,9R,10S, llS, 13S,14S, 16R,17R)-9- fluoro-11, 17-dihydroxy-l 0,13,16-trimethyl-3-oxo-6, 7, 8, 9, 10,11, 12,13,14,15, 16,17 -dodecahydro- 3H-cyclopenta[a] phenanthren- 17-yl)-2-oxoethyl) hydrogen phosphate (5-3)
The title compound was prepared from 5-2 according to the protocol outlined in Example 4 to produce 4-3 to afford 5-3. LRMS (ES) (M+H)+ : observed = 728.6, calculated = 728.7 Ή NMR (400 MHz, DMSO-d6): δ 9.53 (s, 1H), 7.43 (d, J = 8.54 Hz, 2H), 7.30 (d, J = 10.14 Hz, 1H), 7.04 (d, J = 8.54 Hz, 2H), 6.22 (dd, J = 10.08, 1.92 Hz, 1H), 6.00 (s, 1H), 5.41 (s, 1H), 5.37 (d, J = 4.22 Hz, 1H), 4.78 (dd, J = 17.50, 6.20 Hz, 1H), 4.37 (t, J = 5.59 Hz, 1H), 4.27 (dd, J = 17.47, 9.02, 1H), 4.15-4.12 (m, 1H), 4.06 (d, J = 14.53 Hz, 1H), 3.94 (d, J = 14.59 Hz, 1H), 3.05 (q, J = 7.26 Hz, 1H), 2.92 (m, 1H), 2.61 (m, 1H), 2.40-2.06 (complex, 7H), 1.98 (m, 1H), 1.87 (m, 1H), 1.82-1.73 (complex, 3H), 1.67-1.52 (complex, 3H), 1.48 (s, 3H), 1.43 (d, J = 13.54 Hz, 2H), 1.35 (m, 1H), 1.05 (m, 1H), 0.84 (s, 3H), 0.76 (d, J = 7.14 Hz, 3H).
EXAMPLE 6
The synthesis of dexamethasone linker 2-((8S,9R,10S, l lS,13S, 14S,16R,17R)-9- fiuoro-l l,17-dihydroxy-10,13, 16-trimethyl-3-oxo-6,7,8,9,10, l 1 ,12, 13,14,15, 16,17-dodecahydro- 3H-cyclopenta[a]phenanthren- 17-yl)-2-oxoethyl hydrogen (2-(2-(cyclooct-2-yn- 1 - yloxy)acetamido)ethyl)phosphoramidate (6-2) was as follows.
Step A: N-(2-aminoethyl)-2-(cyclooct-2-yn-l-yloxy)acetamide (6-1)
To a stirred solution of 2-(cyclooct-2-yn-l-yloxy)acetic acid (0.10 g, 0.55 mmol) in dichloromethane (2 ml) was added HOAT (0.075 g, 0.55 mmol) and EDC (0.126 g, 0.66 mmol). The resulting solution was stirred at room temperature for 20 minutes. This solution was added to 1 ,2-ethylenediamine (0.49 g, 8.23 mmol) in DCM (1 mL) dropwise. The mixture was concentrated and purified. (Phenomenex Gemini NX C18, 5um particle size, 21.2mm i.d. by 5 cm length, 10-50% CH3CN/water w/ 0.1% NH40H modifier over 10 min at 40mL/min) (50 mg, 40%).
Step B: 2-((8S, 9R, 1 OS, 11S,13S,14S, 16R, 17R)-9-fluoro-ll, 17-dihydroxy-10, 13, 16-trimethyl-3- oxo-6, 7, 8, 9,10,11,12,13,14, 15,16, 17-dodecahydro-3H-cyclopenta[ a] phenanthren- 17-yl)-2- oxoethyl hydrogen (2-(2-(cyclooct-2-yn-l-yloxy)acetamido)ethyl)phosphoramidate (6-2)
To a stirred solution of 6-1 (0.05 g, 0.22 mmol) and 1-1 (0.035 g, 0.074 mmol) in a solution of t-butanol (1.2 mL) and water ( 0.25 mL) was added DCC ( 0.06 g, 0.30 mmol) and the resulting mixture was heated to 1 OOC for 4 hr. The reaction mixture was allowed to cool and concentrated. The residue was dissolved in a 1 : 1 : 1 MeOH:water:MeCN solution and syringe filtered. The mixture was purified using reverse phase preparative chromatography
(Phenomenex Gemini -NX C 18 OBD 5 uM 30 x 100mm; 5-45% MeCN/water w/ 0.1 % NH4OH modifier over 20 min) to give 6-2 as a solid (15 mg, 30%). LRMS (ES) (M+H)+ : observed = 679.5, calculated = 678.7.
EXAMPLE 7
The synthesis of dexamethasone linker 2-(3-(2,5-dioxo-2,5-dihydro-lH-pyrrol-l- yl)propanamido)ethyl (2-((8S,9R, 10S,l l S,13S, 14S, 16R, 17R)-9-fluoro-l 1 , 17-dihydroxy- 10,13, 16-trimethyl-3-oxo-6,7,8,9,10, l 1,12,13, 14, 15, 16, 17-dodecahydro-3H- cyclopenta[a]phenanthren- 17-yl)-2-oxoethyl) dihydrogen pyrophosphate (7-1) was as follows.
To a stirred solution of 1-3 (0.19 g, 0.23 mmol) in DCM (3 mL) was added piperidine (0.15 mL, 1.51 mmol) and the resulting mixture was stirred at room temperature for 3 hrs. The solution was concentrated to dryness. The crude mixture was taken into a 2: 1 : 1 methanol:acetonitrile:water mixture and filtered. The filtrate was purified using reverse phase preparative chromatography (Phenomenex Gemini -NX CI 8 OBD 5 uM 30 x 100mm; 5-35% MeCN/water w/ 0.1% NH4OH modifier over 20 min). A portion of the resulting purified amine (0.07 g, 0.11 mmol) was dissolved in DMF (0.8 mL). To this solution was added 2,5- dioxopyrrolidin-l-yl 3-(2,5-dioxo-2,5-dihydro-lH-pyrrol-l-yl)propanoate (0.09 mg, 0.34 mmol) and DMAP (0.014 g, 0.1 1 mmol) and the resulting solution was stirred 20 minutes. The crude reaction mixture was directly purified using reverse phase preparative chromatography (Sunfire Prep C18 OBD 5 urn 30 x 150 mm; 10-35% CH3CN/water w/ 0.1% TFA modifier over 20 min) gave 7-1 as a solid (13 mg, 15%). LRMS (ES) (M+H)+ : observed = 747.2, calculated = 746.6.
EXAMPLE 8
The synthesis of dexamethasone linker ((2R,3S,4R,5 )-5-(2,4-dioxo-3,4- dihydropyrimidin-l(2H)-yl)-3-(((2-((8S,9R,10S,H S,13S, 14S,16R,17R)-9-fluoro-l l,17- dihydroxy-10,13, 16-trimethyl-3-oxo-6,7,8,9, 10,l 1,12,13, 14,15, 16,17-dodecahydro-3H- cyclopenta[a]phenanthren-17-yl)-2-oxoethoxy)(hydroxy)phosphoryl)oxy)-4- hydroxytetrahydrofuran-2-yl)methyl (2-(2-(cyclooct-2-yn- 1 -yloxy)acetamido)ethyl)carbamate (8-5) was as follows.
Step A: (2R,3R,4R,5R)-2-((bis(4-methoxyphenyl)(phenyl)methoxy)methyl)-4-((tert- butyldimethylsilyl)oxy)-5-(2,4-dioxo-3,4-dihydropyrimidin-l(2H) (2- cyanoethyl) (2-((8S,9R,10S,l 1S,13S,14S, 16R, 17R)-9-fluoro-ll, 17-dihydroxy- 10,13, 16-trimethyl- 3-oxo-6, 7, 8, 9, 10,11,12,13, 14,15, 16,17-dodecahydro-3H-cyclopenta[ a] phenanthren- 17-yl)-2- oxoethyl) phosphite (8-1)
To a stirred mixture of (2R,3R,4R,5R)-2-((bis(4- methoxyphenyl)(^henyl)methoxy)methyl)-4^
dihydropyrimidin- 1 (2H)-yl)tetrahydrofuran-3-yl (2-cyanoethyl) diisopropylphosphoramidite (1.20 g, 1.40 mmol) and dexamethasone (0.50 g, 1.27 mmol) in acetonitrile (12 mL) was added 5-(ethylthio)-lH-tetrazole (0.33 g, 2.55 mmol). The resulting mixture was stirred for 20 minutes.
To the homogenous solution that resulted was added 5M tert-butyl hydroperoxide (0.51 mL, 2.55 mmol). The reaction was stirred 1 hr at room temperature and concentrated onto silica gel. Flash column separation using a 0-100% ethyl acetate/ hexane gradient gave 8-1 as a solid (1.67 g, 100%) LRMS (ES) (M+H)+ : observed = 1168.3, calculated = 1168.3.
Step B: (2R,3R,4R,5R)-4-((tert-butyldimethylsilyl)oxy)-5-(2,4-dioxo-3,4-dihydropyrimidin- l(2H)-yl)-2-(hydroxymethyl)tetrahydrofuran-3-yl (2-cyanoethyl) (2-
((8S, 9R, 1 OS, 11S,13S,14S, 16R, 17R)-9-fluoro-ll, 17-dihydroxy-10, 13, 16-trimethyl-3-oxo-
6, 7, 8,9, 10,11, 12,13, 14,15,16,17-dodecahydro-3H-cyclopenta[a]phenanthren-l 7 -yl)-2-oxoethyl) phosphate (8-2)
To a stirred solution of 8-1 (1.48 g, 1.26 mmol) in DCM (30 mL) was added TFA (0.3 mL, 3.89 mmol) at room temperature. The reaction was stirred for 30 minutes, washed with saturated bicarbonate solution and the organic phase was concentrated onto silica gel. Flash column separation using a 0-10% isopropanol/ DCM gradient gave 8-2 as a solid (0.79 g, 72%) LRMS (ES) (M+H)+ : observed = 866.5, calculated = 865.9.
Step C: ((2R,3R,4R,5R)-4-((tert-bu1yldimethylsilyl)oxy)-5-(2,4-dioxo-3,4-dihydropyrimidin- l(2H)-yl)-3-(((2-((8S,9R,10S,US, 13S,14S, 16R,17R)-9-fluoro-ll,17-dihyd
trimethyl-3-oxo-6, 7, 8, 9,10, 11,12,13,14, 15,16, 17-dodecahydro-3H-cyclopenta[ a] phenanthren- / 7-yl)-2-oxoethoxy)(hydroxy)phosphoryl)oxy)tetrahydrofuran-2-yl)methyl (4-nitrophenyl) carbonate (8-3)
To a stirred solution of 8-2 (0.30 g, 0.35 mmol) in DCM (5 mL) was added triethylamine (0.15 mL, 1.04 mmol) and 4-nitrophenyl carbonochloridate (0.15 g, 0.76 mmol) and the resulting solution was stirred at room temperature. Additional 4-nitrophenyl
carbonochloridate was added until reaction was complete by LCMS. The reaction was directly loaded onto a silica gel column and flash column separation using a 0-50% isopropanol/ DCM gradient gave 8-3 as a solid (0.32 g, 93%) LRMS (ES) (M+H)+ : observed = 978.4, calculated = 977.9. Step D: ((2R,3R,4R,5R)-4-((tert-butyldimethylsilyl)oxy)-5-(2,4-dioxo-3,4-dihydropyrimidin- l(2H)-yl)-3-(((2-((8S,9R,10S,llS 3S,14S, 16R,17R)-9-fluoro-ll,17-dihydroxy- trimethyl-3-oxo-6, 7, 8, 9,10, 11,12,13,14, 15,16, 17-dodecahydro-3H-cyclopenta[ a] phenanthren- 17-yl)-2-oxoethoxy) (hydroxy)phosphoryl)oxy)tetrahydrofuran-2-yl)methyl (2- aminoethyl)carbamate (8-4)
To a stirred solution of ethylenediamine (0.28 mL, 4.17 mmol) in DMF (1 mL) was added a solution of 8-3 (0.20 g, 0.20 mmol) in DMF (1 mL) dropwise. The reaction was stirred at room temperature for 10 minutes, then purified directly using reverse phase preparative chromatography (Phenomenex Gemini -NX C 18 OBD 5 uM 30 x 100mm; 10-50% MeCN/water
w/ 0.1% NH4OH modifier over 20 min) to give 8-4 as a solid (115 mg, 61%). LRMS (ES) (M+H)+ : observed = 899.5, calculated = 898.9.
Step E: ((2R, 3S, 4R, 5R)-5-(2, 4-dioxo-3, 4-dihydropyrimidin- 1 (2H)-yl)-3-(((2- ((8S, 9R, 1 OS, 11S,13S,14S, 16R, 17R)-9-fluoro-ll, 17-dihydroxy-10, 13, 16-trimethyl-3-oxo- 6, 7, 8,9, 10,11, 12,13, 14,15,16,17-dodecahydro-3H-cyclopenta[a]phenanthren-l 7-yl)-2- oxoethoxy)(hydroxy)phosphoryl)oxy)-4-hydroxytetrahydrofuran-2-yl)methyl (2-(2-(cyclooct-2- yn-l-yloxy)acetamido)ethyl)carbamate (8-5)
The title compound was prepared from 8-4 according to the protocol outlined in Example 4 to produce 4-3 to afford 8-5. LRMS (ES) (M+H)+ : observed = 949.4, calculated = 948.9
EXAMPLE 9
The synthesis of Budesonide linker 2-(2-(cyclooct-2-yn-l-yloxy)acetamido)ethyl (2-((6aR,6bS,7S,8aS,8bS,l laR, 12aS,12bS)-7-hydroxy-6a,8a-dimethyl-4-oxo-10-propyl-
2,4,6a,6b,7,8,8a,8b, l la,12,12a,12b-dodecahydro-lH-naphtho[2',l':4,5]indeno[l ,2-d][l ,3]dioxol- 8b-yl)-2-oxoethyl) dihydrogen pyrophosphate (9-4) was as follows.
Step A: 2-((6aR,6bS, 7S,8aS,8bS, l laR,12aS,12bS)-7-hydroxy-6a,8a-dimethyl-4-oxo-10-propyl- 2,4, 6a, 6b, 7,8,8a,8b, lla,12, 12a,12b-dodecahydro-lH-naphtho[2 ', 1 ':4,5]indeno[ 1,2- d] [l,3]dioxol-8b-yl)-2-oxoethyl dihydrogen phosphate (9-1)
The title compound was prepared from budesonide according to the protocol outlined in Example 1 to produce 1-1 to afford 9-1. LRMS (ES) (M+H)+ : observed = 51 1.2, calculated = 510.5
Step B: (9H-fluoren-9-yl)methyl (2-((hydroxy((hydroxy(2- ((6aR, 6bS, 7S, 8aS,8bS, llaR, 12aS, 12bS)- 7 -hydroxy-6a, 8a-dimethyl-4-oxo-l 0-propyl-
2,4, 6a, 6b, 7 ,8,8a,8b, lla,12, 12a,l 2b-dodecahydro-lH-naphtho[2 ', 1 ':4,5]indeno[ 1,2- d] [ 1 ,3] dioxol-8b-yl)-2-oxoethoxy)phosphoryl)oxy)phosphoryl)oxy)ethyl)carbamate (9-2)
The title compound was prepared from 9-1 according to the protocol outlined in
Example 1 to produce 1-3 to afford 9-2. LRMS (ES) (M+H)+ : observed = 856.3, calculated = 855.8
Step C: 2-aminoethyl (2-((6aR,6bS, 7S,8aS,8bS,llaR,12aS, 12bS)-7-hydroxy-6a,8a-dimethyl-4- oxo-1 O-propyl-2, 4, 6a, 6b, 7, 8, 8a, 8b, 11a, 12, 12a, 12b-dodecahydro-lH- naphtho[2 ', Γ : 4,5]indeno[ 1 ,2-d] [ 1 ,3] dioxol-8b-yl)-2-oxoethyl) dihydrogen pyrophosphate (9-3)
The title compound was prepared from 9-2 according to the protocol outlined in
Example 2 to produce 2-6 to afford 9-3. LRMS (ES) (M+H)+ : observed = 634.3, calculated = 633.5
Step D: 2-(2-(cyclooct-2-yn-l-yloxy)acetamido)ethyl (2-((6aR, 6bS, 7S,8aS,8bS, llaR, 12aS,12bS)- 7-hydroxy-6a, 8a-dimethyl-4-oxo-l O-propyl-2, 4, 6a, 6b, 7, 8, 8a, 8b, 11a, 12, 12a, 12b-dodecahydro- lH-naphtho[2',l ':4,5]indeno[l,2-d] [l,3]dioxol-8b-yl)-2-oxoethyl) dihydrogen pyrophosphate (9-4)
The title compound was prepared from 9-3 according to the protocol outlined in Example 2-7 to afford 9-4. Mixture of isomers XH NMR (499 MHz, DMSO): 0.86-0.83
(complex, 6 H); 0.89 (s, 6 H); 0.99-0.90 (complex, 2 H); 1.09 (t, J = 7.0 Hz, 2 H); 1.15 (t, J = 7.2 Hz, 6 H); 1.35-1.25 (complex, 6 H); 1.39 (s, 6 H); 2.32-1.46 (complex, 32 H); 3.02 (q, J = 7.0 Hz, 4 H); 3.21 (br s, 2 H); 3.81-3.73 (complex, 6 H); 3.94-3.89 (complex, 2 H); 4.33-4.25 (complex, 4 H); 4.39 (d, J = 18.4 Hz, 2 H); 4.56 (t, J = 4.3 Hz, 1 H); 4.79-4.63 (complex, 3 H); 5.01 (d, J = 7.2 Hz, 1 H); 5.17 (dd, J = 4.9, 4.6 Hz, 1 H); 5.91 (s, 2 H); 6.15 (d, J = 10.1 Hz, 2 H); 7.31 (d, J = 10.3 Hz, 2 H); 8.84 (br s, 2 H). LRMS (ES) (M+H)+ : observed = 798.4, calculated = 797.7
EXAMPLE 10
The synthesis of Budesonide linker 2-(3-(2,5-dioxo-2,5-dihydro-lH-pyrrol-l- yl)propanamido)ethyl (2-((6aR,6bS,7S,8aS,8bS,l laR,12aS,12bS)-7-hydroxy-6a,8a-dimethyl-4- oxo-10-propyl-2,4,6a,6b,7,8,8a,8b,l la,12, 12a,12b-dodecahydro-lH- naphtho[2',l':4,5]indeno[l,2-d][l,3]dioxol-8b-yl)-2-oxoethyl) dihydrogen pyrophosphate (10-1) was as follows.
The title compound was prepared from 9-2 according to the protocol outlined in Example 7 to produce 7-1 to afford 10-1. LRMS (ES) (M+H)+ : observed = 785.4, calculated = 784.6
EXAMPLE 11
The synthesis of Budesonide linker l-(cyclooct-2-yn-l-yloxy)-2-oxo-6,9,12- trioxa-3-azatetradecan-14-yl (2-((6aR,6bS,7S,8aS,8bS,l laR,12aS,12bS)-7-hydroxy-6a,8a- dimethyl-4-oxo-10-propyl-2,4,6a,6b,7,8,8a,8b,l la,12,12a, 12b-dodecahydro-lH- naphtho[2', :4,5]indeno[l,2-d][l,3]dioxol-8b-yl)-2-oxoethyl) dihydrogen pyrophosphate (11-5) was as follows.
Step A: (9H-fluoren-9-yl)methyl (2-(2-(2-(2-hydroxyethoxy)ethoxy)ethoxy)ethyl)carbamate (11- 1)
To a stirred solution of 2-(2-(2-(2-aminoethoxy)ethoxy)ethoxy)ethanol (1.00 g, 5.17 mmol) in DCM (15 mL) was added 9-fluorenylmethyl chloroformate (1.34 g, 5.17 mmol) and triethylamine ( 1.08 mL, 7.76 mmol). The resulting solution was stirred at room temperature for 10 minutes. The reaction was concentrated onto silica gel and flash column separation using a 0-10% isopropanol/ dichloromethane gradient gave 11-1 as an oil (1.43 g, 66%) LRMS (ES) (M+H)+ : observed = 416.1, calculated = 415.4.
Step B: (9H-fluoren-9-yl)methyl (2-(2-(2-(2- (phosphonooxy)ethoxy)ethoxy)ethoxy) ethyl) carbamate (11-2)
The title compound was prepared from 11-1 according to the protocol outlined in
Example 1 to produce 1-1 to afford 11-2. LRMS (ES) (M+H)+ : observed = 496.3, calculated = 495.4
Step C: (9H-fluoren-9-yl)methyl (2-(2-(2-(2-((hydroxy((hydroxy(2- (( 6aR, 6bS, 7S, 8aS,8bS, llaR, 12aS, 12bS)- 7-hydroxy-6a, 8a-dimethyl-4-oxo-l 0-propyl- 2,4, 6a, 6b, 7,8,8a,8b, lla,12, 12a,12b-dodecahydro-lH-naphtho[2 ', 1 ':4,5]indeno[ 1,2-
djfl, 3 ] dioxol-8b-yl)-2- oxoethoxy)phosphoryl)oxy)phosphoryl)oxy)ethoxy)ethoxy)ethoxy)ethyl)carbamate
(11-3)
The title compound was prepared from 11-2 and 9-1 according to the protocol outlined in Example 1 to produce 1-3 to afford 11-3. LRMS (ES) (M+H)+ : observed =988.6, calculated = 987.9
Step D: 2-(2-(2-(2-aminoethoxy)ethoxy)ethoxy)ethyl (2-((6aR,6bS, 7S,8aS,8bS,llaR,12aS,12bS)- 7-hydroxy-6a, 8a-dimethyl-4-oxo-l 0-propyl-2, 4, 6a, 6b, 7, 8, 8a, 8b, 11a, 12, 12a, 12b-dodecahydro- lH-naphtho[2',l ':4,5]indeno[l,2-d] [l,3]dioxol-8b-yl)-2-oxoethyl) dihydrogen pyrophosphate (11-4)
The title compound was prepared from 11-3 according to the protocol outlined in Example 2 to produce 2-6 to afford 11-4. LRMS (ES) (M+H)+ : observed = 766.5, calculated = 765.7
Step E: l-(cyclooct-2-yn-l-yloxy)-2-oxo-6,9,12-trioxa-3-azatetradecan-14-yl (2- ( ( 6aR, 6bS, 7S, 8aS,8bS, llaR, 12aS, 12bS)- 7 -hydroxy-6a, 8a-dimethyl-4-oxo-l 0-propyl- 2, 4, 6a, 6b, 7, 8, 8a, 8b, lla,12, 12 a, 12b-dodecahydro-lH-naphtho[2 ', 1 ':4,5Jindeno[l,2- d] [l,3]dioxol-8b-yl)-2-oxoethyl) dihydrogen pyrophosphate (11-5)
The title compound was prepared from 11-4 according to the protocol outlined in Example 2 to produce 2-7 to afford 11-5. LRMS (ES) (M+H)+ : observed = 930.6, calculated = 929.9
EXAMPLE 12
The synthesis of Budesonide linker 4-((2S)-2-((2S)-2-(2-(cyclooct-2-yn-l- yloxy)acetamido)-3-methylbutanamido)-5-ureidopentanarnido)benzyl (2- ((6aR,6bS,7S,8aS,8bS,l laR,12aS, 12bS)-7-hydroxy-6a,8a-dimethyl-4-oxo-10-propyl- 2,4,6a,6b,7,8,8a,8b, l la,12,12a,12b-dodecahydro-lH-naphtho[2',l':4,5]indeno[l ,2-d][l ,3]dioxol- 8b-yl)-2-oxoethyl) hydrogen phosphate (12-3) was as follows.
Step A: (9H-fluoren-9-yl)methyl ((2S)-l-(((2S)-l-((4-((((2- cyanoethoxy)(2(( 6aR, 6bS, 7S,8aS, 8bS,llaR, 12aS, 12bS)- 7-hydroxy-6a, 8a-dimethyl-4-oxo-l 0- propyl-2,4, 6a, 6b, 7,8,8a,8b,lla, 12, 12a,12b-dodecahydro-lH-naphtho[2 ', 1 ':4, 5]indeno[l,2- d] [1,3] dioxol-8b-yl)-2-oxoethoxy)phosphoryl)oxy)methyl)phenyl) amino)- l-oxo-5-ureidopentan- 2-yl)amino)-3-methyl-l-oxobutan-2-yl)carbamate (12-1)
To a stirred solution of (9H-fluoren-9-yl)methyl ((S)-1-(((S)-1- ((4(hydroxymethyl)phenyl)amino)- 1 -oxo-5-ureidopentan-2-yl)amino)-3-methyl- 1 -oxobutan-2- yl)carbamate (0.20 g, 0.33 mmol) in DMF (4.7 mL) was added 3-
((bis(diisopropylamino)phosphino)oxy)propanenitrile (0.11 g, 0.37 mmol). To this mixture was added 0.45M tetrazole in acetonitrile (0.81 mL, 0.37 mmol) dropwise and the resulting mixture was stirred for 20 minutes at room temperature. To this was added Budesonide (0.22 g, 0.50 mmol) and 5-(ethylthio)-lH-tetrazole (0.09 g, 0.67 mmol) and allowed to stir to 30 minutes at room temperature. To this was added 6 M tertbutyl hydroperoxide in decane (0.12 mL, 0.73
mmol) and allowed to stir at room temperature for 1 hour. The crude reaction was loaded directly onto silica gel and flash column separation using a 0- 100% ethyl acetate/ hexane gradient followed by a 0-50% isopropanol DCM gradient gave 12-1 as a solid. (0.10 g, 27%) LRMS (ES) (M+H)+ : observed = 1 147.7, calculated = 1147.2.
Step B: 4-((S)-2-((S)-2-amino-3-methylbutanamido)-5-ureidopentanamido)benzyl
(2(( 6aR, 6bS, 7S, 8aS,8bS, 1 laR, 12aS,12bS)- 7-hydroxy-6a, 8a-dimethyl-4-oxo-l 0-propyl- 2,4, 6a, 6b, 7,8,8a,8b, lla,12, 12a,12b-dodecahydro-lH-naphtho[2 ', 1 ':4,5]indeno[ 1,2- d][l,3]dioxol-8b-yl)-2-oxoethyl) hydrogen phosphate (12-2)
To a stirred solution of 12-1 (0.10 g, 0.09 mmol) in DCM (1.8 mL) was added
DBU (0.05 mL, 0.3 mmol) and the resulting solution was stirred 20 minutes at room
temperature. The reaction was concentrated and dissolved in a 2: 1 : 1 methanol:water:acetonitrile mixture and syringe filtered. The filtrate was purified using reverse phase preparative chromatography (Phenomenex Gemini -NX C 18 OBD 5 uM 30 x 100mm; 10-50% MeCN/water w/ 0.1% NH4OH modifier over 20 min) to give 12-2 as a solid (42 mg, 53%). LRMS (ES) (M+H)+ : observed = 872.6, calculated = 871.9.
Step C: 4-( (2S)-2-( (2S)-2-(2-(cyclooct-2-yn-l-yloxy)acetamido)-3-methylbutanamido)-5- ureidopentanamido)benzyl (2-( ( 6aR, 6bS, 7S,8aS,8bS, l laR, 12aS, 12bS)-7-hydroxy-6a,8a- dimethyl-4-oxo-10-propyl-2, 4, 6a, 6b, 7, 8, 8a, 8b, 1 la, 12, 12a, 12b-dodecahydro-lH- naphtho[2 ', l ':4,5]indeno[l,2-d] [l,3]dioxol-8b-yl)-2-oxoethyl) hydrogen phosphate (12-3)
The title compound was prepared from 12-2 according to the protocol outlined in Example 4 to produce 4-3 to afford 12-3. LRMS (ES) (M+H)+ : observed = 1036.8, calculated = 1036.1
EXAMPLE 13
The synthesis of Budesonide linker 2-((6aR,6bS,7S,8aS,8bS,l laR,12aS, 12bS)-7- hydroxy-6a,8a-dimethyl-4-oxo-10-propyl-2,4,6a,6b,7,8,8a,8b,l la,12, 12a,12b-dodecahydro-lH- naphtho[2',l':4,5]indeno[l,2-d][l,3]dioxol-8b-yl)-2-oxoethyl acetate (13-1) was as follows.
Step A : synthesis 2-(( 6aR, 6bS, 7S, 8aS, 8bS, llaR, 12aS, 12bS)- 7-hydroxy-6a, 8a-dimethyl-4-oxo-10- propyl-2, 4, 6a, 6b, 7, 8, 8a, 8b,lla,12, 12a, 12b-dodecahydro- lH-naphtho[2',l ': 4, 5]indeno[ 1,2- d] [1,3] dioxol-8b-yl)-2-oxoethyl acetate (13-1)
To a stirred solution of budesonide (2.00 g, 4.65 mmol) in pyridine (20.0 mL) at room temperature was added acetic anhydride (2.0 mL, 21.20 mmol) and the resulting mixture was stirred for 2.5 hours. The reaction was chilled in an ice bath and quenched with saturated sodium bicarbonate solution (20.0 mL). The solution was extracted several times with ethyl acetate. The combined organic phase washed with brine, dried over sodium sulfate and concentrated to give 13-1 as a solid (2.30g, 105%). LRMS (ES) (M+H)+ : observed = 473.4, calculated = 472.5.
Step B: 2-((6aR,6bS, 7S,8aS,8bS, llaR,12aS,12bS)-7-((hydroxyhydrophosphoryl)oxy)-6a,8a- dimethyl-4-oxo-10-propyl-2, 4, 6a, 6b, 7, 8, 8a, 8b, 1 la, 12, 12a, 12b-dodecahydro-lH- naphtho[2 ', l ':4,5]indeno[l,2-d] [l,3]dioxol-8b-yl)-2-oxoethyl acetate (13-2)
To a stirred solution of 13-1 (0.50 g, 1.06 mmol) in THF (10.0 mL) at -78°C was added phosphorus trichloride (0.18 mL, 2.12 mmol) dissolved in THF (2.0 mL) followed by triethylamine (0.74 mL, 5.29 mmol) dissolved in THF (2.0 mL). The resulting mixture was stirred at -78°C for 10 minutes and allowed to warm to room temperature for 45 minutes. The reaction was chilled in an ice bath and quenched with water (0.50 mL). The solution was allowed to warm to room temperature and saturated sodium bicarbonate solution was added until pH 9 and stirred for 10 minutes. The mixture was acidified with IN HC1 and was extracted several times with ethyl acetate. The combined organic phase was dried over sodium sulfate and
concentrated to give 13-2 as a solid (0.55g, 97%). LRMS (ES) (M+H)+ : observed = 537.3, calculated = 536.5.
Step C: 2-((6aR,6bS, 7S,8aS,8bS, llaR, 12aS,12bS)-7-((hydroxy(lH-imidazol-l-yl)
phosphoryl)oxy)-6a,8a-dimethyl-4-oxo-10-propyl-2,4, 6a, 6b, 7,8, 8a, 8b, 11 a, 12, 12a, 12b- dodecahydro-lH-naphtho[2',l ' : 4,5]indeno[ 1 ,2-d] [ 1 ,3] dioxol-8b-yl)-2-oxoethyl acetate (13-3)
To a stirred solution of 13-2 (0.55 g, 1.03 mmol) and imidazole (0.35 g, 5.13 mmol) in pyridine (8.0 mL) at room temperature was added TMS-C1 (1.31 mL, 10.25 mmol) and the resulting solution was stirred for 10 minutes. To this mixture was added iodine (0.52 g, 2.05 mmol) dissolved in pyridine (2 mL) and stirred room temperature for 50 minutes. The reaction was then cooled in and ice bath and quenched with water (0.5 mL). The reaction was concentrated, dissolved in aqueous acetonitrile and purified using reverse phase preparative chromatography (Phenomenex Gemini -NX CI 8 OBD 5 μΜ 30 x 100mm; 10-50% MeCN/water w/ 0.1% NH4OH modifier over 20 min) to give 13-3 as a solid (282 mg, 45%). LRMS (ES) (M+H)+ : observed = 603.4, calculated = 602.6.
Step D: 2-((6aR,6bS, 7S,8aS,8bS,llaR, 12aS,12bS)-7-(((((2-((((9H-fluoren-9- yl)methoxy)carbonyl)amino)ethoxy)(hydroxy)phosphoryl)oxy)(hydroxy)phosphoryl)oxy)-6a,8a- dimethyl-4-oxo-10-propyl-2, 4, 6a, 6b, 7, 8, 8a, 8b, 1 la, 12, 12a, 12b-dodecahydro-lH- naphtho[2 ' ':4,5]indeno[l,2-d] [l,3]dioxol-8b-yl)-2-oxoethyl acetate (13-4)
To a stirred solution of 13-3 (0.20 g, 0.33 mmol) and 1-2 (0.12 g, 0.33 mmol) in DMF (1.4 mL) was added ZnCl2 (0.36 g, 2.66 mmol) and the mixure was allowed to stir at room temperature overnight. The reaction was diluted with 1 N HC1 and extracted several times with ethyl acetate. The combined organic layers were concentrated, dissolved in aqueous acetonitrile and purified using reverse phase preparative chromatography (Phenomenex Gemini -NX C 18 OBD 5 μΜ 30 x 100mm; 10-50% MeCN/water w/ 0.1% NH4OH modifier over 20 min) to give 13-4 as a solid (166 mg, 55%). LRMS (ES) (M+H)+ : observed = 898.4, calculated = 897.8.
Step E: 2-((6aR,6bS, 7S,8aS,8bS, llaR,12aS,12bS)-7-(((((2- aminoethoxy) (hydroxy)phosphoryl)oxy) (hydroxy)phosphoryl)oxy)-6a, 8a-dimethyl-4-oxo-10- propyl-2,4, 6a, 6b, 7 ,8,8a,8b,lla, 12, 12a,12b-dodecahydro-lH-naphtho[2 ', 1 ':4, 5]indeno[l,2- d] [l,3]dioxol-8b-yl)-2-oxoethyl acetate (13-5)
The title compound was prepared from 13-4 according to the protocol outlined in
Example 2 to prepare 2-4 to afford 13-5. LRMS (ES) (M+H)+ : observed = 676.4, calculated = 675.6.
Step F: 2-((6aR,6bS, 7S,8aS,8bS,llaR,12aS,12bS)-7-(((((2-(2-(cyclooct-2-yn-l- yloxy)acetamido)ethoxy) (hydroxy)phosphoryl)oxy) (hydroxy)phosphoryl)oxy)-6a, 8a-dimethyl-4-
oxo-10-propyl-2, 4, 6a, 6b, 7, 8, 8a, 8b, 11a, 12, 12a, 12b-dodecahydro-lH- naphtho[2' ':4,5Jindeno[l,2-dJ ' [l,3]dioxol-8b-yl)-2-oxoethyl acetate (13-6)
To a stirred solution of 13-5 (0.037 g, 0.055 mmol) and 2-(cyclooct-2-yn-l- yloxy)acetic acid (0.032 g, 0.175 mmol) in DMF (0.8 mL) was added HATU (0.066 g, 0.175 mmol) and triethylamine (0.03 mL, 0.22 mmol). The reaction was stirred at room temperature for 20 minutes, then puri ied directly using reverse phase preparative chromatography
(Phenomenex Gemini -NX C18 OBD 5 μΜ 30 x 100mm; 10-50% MeCN/water w/ 0.1% NH4OH modifier over 20 min) to give 13-6 as a solid (36 mg, 78%). LRMS (ES) (M+H)+ : observed = 840.5, calculated = 839.8.
Step G: 2-((6aR,6bS, 7S,8aS,8bS,llaR,12aS,12bS)-7-hydroxy-6a,8a-dimethyl-4-oxo-10-propyl- 2,4, 6a, 6b, 7,8,8a,8b,lla,12, 12a,l 2b-dodecahydro-lH-naphtho[2', 1 ':4,5]indeno[ 1,2- d] [l,3]dioxol-8b-yl)-2-oxoethyl acetate (13-7)
To a stirred solution of 13-6 (0.035 mg, 0.042 mmol) in methanol (0.50 mL) was added 70% perchloric acid (7.2 μί, 0.083 mmol) and the resulting solution was stirred room temperature overnight. The reaction was purified directly using reverse phase preparative chromatography (Phenomenex Gemini -NX CI 8 OBD 5 μΜ 30 x 100mm; 10-50% MeCN/water w/ 0.1% NH4OH modifier over 20 min) to give 13-7 as a solid (16 mg, 47%). LRMS (ES)
(M+H)+ : observed = 798.4, calculated = 797.7.
EXAMPLE 14
The synthesis of Fluticasone proprionate linker
(6S,8S,9R,10S, l l S,13S, 14S,16R, 17R)-l l-(((((2-(2-(cyclooct-2-yn-l- yloxy)acetamido)ethoxy)(hydroxy)phosphoryl)oxy)(hydroxy)phosphoryl)oxy)-6,9-difluoro-17- (((fiuoromethyl)thio)carbonyl)-10, 13, 16-trimethyl-3-oxo-6,7,8,9,10, l 1 ,12, 13,14,15, 16,17- dodecahydro-3H-cyclopenta[a]phenanthren-17-yl propionate (14-5) was as follows.
Step A : (6S, 8S,9R, 1 OS, 11S 3S 4S 6R, 17R)-6, 9-difluoro-l 7-(((fluoromethyl)thio)carbonyl)-ll- ( (hydroxyhydrophosphoryl)oxy)-! 0,13, 16-trim ethyl-3-oxo- 6, 7,8,9,10,11,12, 13,14, 15,16,17- dodecahydro-3H-cyclopenta[a]phenanthren-l 7-yl propionate (14-1)
The title compound was prepared from fluticasone propionate according to the protocol outlined in Example 13 to prepare 13-2 to afford 14-1. LRMS (ES) (M+H)+ : observed = 565.3, calculated = 564.5. Step B: (6S,8S,9R,10S, 1 lS,13S, 14S,16R,17R)-6,9-difluoro-17-(((fluoromethyl)thio)carbonyl)-ll- ((hydroxy(lH-imidazol-l-yl)phosphoryl)oxy)-10,13,16-trimethyl-3-oxo- 6, 7, 8,9, 10,11, 12,13, 14,15,16,17-dodecahydro-3H-cyclopenta[a]phenanthren-l 7-yl propionate (14-2)
The title compound was prepared from 14-1 according to the protocol outlined in Example 13 to prepare 13-3 to afford 14-2. LRMS (ES) (M+H)+ : observed = 631.3, calculated = 630.6.
Step C: (6S,8S,9R,10S, llS,13S,14S,16R, 17R)-ll-(((((2-((((9H-fluoren-9- yl)methoxy)carbonyl)amino)ethoxy)(hydroxy)phosphoryl)oxy)(hydroxy)phosphoryl)oxy)-6,9- difluoro-17-( ( (fluoromethyl)thio)carbonyl)-10, 13, 16-trimethyl-3-oxo-
6, 7, 8,9, 10,11, 12,13, 14,15,16,17-dodecahydro-3H-cyclopenta[a]phenanthren-l 7-yl propionate (14-3)
The title compound was prepared from 14-2 according to the protocol outlined in Example 13 to prepare 13-4 to afford 14-3. LRMS (ES) (M+H)+ : observed = 943.4
(M+H+NH3), calculated = 925.8. Step D: (6S,8S,9R,10S,llS,13S,14S,16R,17R)-ll-(((((2- aminoethoxy) (hydroxy)phosphoryl)oxy) (hydroxy)phosphoryl)oxy)-6, 9-difluoro-l 7- (((fluoromethyl)thio)carbonyl)-10, 13,16-trimethyl-3-oxo-6, 7, 8, 9,10,11,12,13,14,15,16,17- dodecahydro-3H-cyclopenta[a]phenanthren-l 7-yl propionate (14-4)
The title compound was prepared from 14-3 according to the protocol outlined in Example 2 to prepare 2-4 to afford 14-4. LRMS (ES) (M+H)+ : observed = 704.3, calculated = 703.6.
Step F: (6S,8S,9R,10S,llS,13S,14S,16R,17R)-ll-(((((2-(2-(cyclooct-2-yn-l- yloxy)acetamido)ethoxy)(hydroxy)phosphoryl)oxy)(hydroxy)phosphoryl)oxy)-6,9-difluoro-17- (((fluoromethyl)thio)carbonyl)-10, 13,16-trimethyl-3-oxo-6, 7, 8, 9,10,11,12,13,14,15,16,17- dodecahydro-3H-cyclopenta[a]phenanthren-l 7-yl propionate (14-5)
The title compound was prepared from 14-4 according to the protocol outlined in Example 13 to prepare 13-6 to afford 14-5. LRMS (ES) (M+H)+ : observed = 868.4, calculated = 867.8.
EXAMPLE 15
The synthesis of (6S,8S,9R,10S,11S,13S,14S,16R,17R)-1 l-((((((2-(2-(cyclooct-2- yn-l-yloxy)acetamido)ethoxy)(hydroxy)phosphoryl)oxy)(hydroxy)phosphoryl)oxy)methoxy)- 6,9-difluoro- 17-(((fluoromethyl)thio)carbonyl)- 10,13,16-trimethyl-3 -oxo- 6,7,8,9,10,11,12,13, 14, 15,16, 17-dodecahydro-3H-cyclopenta[a]phenanthren-17-yl propionate (15-5) was as follows.
Step A: (6S,8S,9R,10S,llS,13S,14S, 16R, 17R)-6,9-difluoro-17-(((fluoromethyl)thio)carbonyl)^ 10,13, 16-trimethyl-ll-((methylthio)methoxy)-3-oxo-6, 7,8,9, 10, 11,12, 13, 14, 15, 16, 17- dodecahydro-3H-cyclopenta[a ]phenanthren-l 7-yl propionate (15-1,)
To a stirred solution of fluticasone propionate (0.50 g, 1.00 mmol) in MeCN (5.0 mL) at 0°C was added dimethyl sulfide (0.59 mL, 8.00 mmol) followed by benzoyl peroxide (0.97 g, 4.00 mmol) added in four portions over 20 minutes. The resulting mixture was stirred at 0°C for 1 hour. The reaction was concentrated, taken up in ethyl acetate and washed with saturated sodium bicarbonate. The combined organic phase was concentrated. The crude was purified directly using reverse phase preparative chromatography (Phenomenex Gemini -NX CI 8 OBD 5 uM 30 x 100mm; 40-80% MeCN/water w/ 0.1% NH4OH modifier over 20 min) to give to give 15-1 as a solid (0.07 g, 12.7%). LRMS (ES) (M+H)+ : observed = 561.3, calculated = 560.6.
Step B: (6S, 8S, 9R, 1 OS, 1 IS, 13S, 14S, 16R, 17R)-6, 9-difluoro-l 7-(((fluoromethyl) thio)carbonyl)- 10,13,16-trim ethyl-3-oxo- ll-( (phosphonooxy)m ethoxy)-6, 7 ',8,9, 10, 11,12, 13,14, 15,16, 17- dodecahydro-3H-cyclopenta[a]phenanthren-l 7-yl propionate (15-2)
Phosphoric acid (0.09 g, 0.89 mmol) was heated under nitrogen at 120°C for 30minutes. This was allowed to cool and to it was added molecular seives and 15-1 (0.07 g, 0.13 mmol). This mixture was dissolved in THF (1.3 mL) and NIS (0.04 g, 0.19 mmol) was added.
The resulting solution was allowed to stir overnight at room temperature. The mixture was filtered and concentrated. The crude was purified directly using reverse phase preparative chromatography (Phenomenex Gemini -NX C 18 OBD 5 uM 30 x 100mm; 10-50% MeCN/water w/ 0.1% NH4OH modifier over 20 min) to give to give 15-2 as a solid (0.05 g, 63%). LRMS (ES) (M+H)+ : observed = 611.3, calculated = 610.5.
Step C: (6S,8S,9R,10S, llS,13S,14S,16R, 17R)-ll-((((((2-((((9H-fluoren-9- yl)methoxy)carbonyl)amino)ethoxy)(hydroxy)phosphoryl)oxy)( ydroxy)phosphoryl)oxy)methoxy) -6, 9-difluoro-l 7-(( (fluoromethyl)thio)carbonyl)-10, 13, 16-trimethyl-3-oxo- 6, 7, 8,9, 10,11, 12,13, 14,15,16,17-dodecahydro-3H-cyclopenta[a]phenanthren-l 7-yl propionate
The title compound was prepared from 15-2 according to the protocol outlined in Example 1-3 to afford 15-3. LRMS (ES) (M+H)+ : observed = 956.5, calculated = 955.8. Step D: (6S,8S,9R,10S,llS,13S, 14S,16R,17R)-ll-((((((2- aminoethoxy) (hydroxy)phosphoryl)oxy) (hydroxy)phosphoryl)oxy)methoxy)-6, 9-difluoro-l 7- ( ( (fluoromethyl)thio)carbonyl)-10, 13, 16-trimethyl-3 -oxo-6, 7, , 9,10, 11,12,13,14, 15,16, 17- dodecahydro-3H-cyclopenta[a]phenanthren-l 7-yl propionate (15-4)
The title compound was prepared from 15-3 according to the protocol outlined in Example 12-2 to afford 15-4. LRMS (ES) (M+H)+ : observed = 734.5, calculated = 733.6.
Step E: (6S, 8S,9R,10S,11S,13S,14S, 16R, 17R)-ll-((((((2-(2-(cyclooct-2-yn-l- yloxy)acetamido)ethoxy) (hydroxy)phosphoryl)oxy) (hydroxy)phosphoryl)oxy)methoxy)-6, 9- difluoro-l 7-( ( (fluoromethyl)thio)carbonyl)-10, 13, 16-trimethyl-3-oxo-
6, 7, 8,9, 10,11, 12,13, 14,15,16,17-dodecahydro-3H-cyclopenta[a]phenanthren-l 7-yl propiona (15-5)
The title compound was prepared from 15-4 according to the protocol outlined Example 13-6 to afford 15-5. LRMS (ES) (M+H)+ : observed = 898.4, calculated = 897.8. EXAMPLE 16
The synthesis of Budesonide linker l-(cyclooct-2-yn-l-yloxy)-2-oxo-3-aza- 6,9, 12,15,18,21 ,24,27,30,33,36,39,42,45,48,51 ,54,57,60,63,66,69,72-tricosaoxahenheptacont-74- yl (2-((6aR,6bS,7S,8aS,8bS, l laR, 12aS,12bS)-7-hydroxy-6a,8a-dimethyl-4-oxo-10-propyl- 2,4,6a,6b,7,8,8a,8b, l la,12,12a,12b-dodecahydro-lH-naphtho[2',l':4,5]indeno[l ,2-d][l ,3]dioxol- 8b-yl)-2-oxoethyl) dihydrogen pyrophosphate (16-5) was as follows.
Step A: (9H-fluoren-9-yl)methyl (71-hydroxy- 3,6,9,12,15,18,21,24,27,30,33,36,39,42,45,48,51,54,57, 60, 63, 66, 69- tricosaoxahenheptacontyl)carbamate (16-1)
The title compound was prepared from 71-amino- 3,6,9,12,15,18,21,24,27,30,33,36,39,42,45,48,51,54,57,60,63,66,69-tricosaoxahenheptacontan-l- ol and (9H-fluoren-9-yl)methyl (2,5-dioxopyrrolidin-l-yl) carbonate according to the protocol outlined in Example 11 to produce 11-1 to afford 16-1. LRMS (ES) (M+H)+ : observed = 1314.1, calculated = 1296.5
Step B: (9H-fluoren-9-yl)methyl (71 -(phosphonooxy)- 3,6,9,12,15,18,21,24,27,30,33,36,39,42,45,48,51,54,57,60,63,66,69- tricosaoxahenheptacontyljcarbamate (16-2)
The title compound was prepared from 16-1 according to the protocol outlined in Example 1 to produce 1-1 to afford 16-2. LRMS (ES) (M+H)+ : observed = 1394.0, calculated = 1376.5
Step C: (9H-fluoren-9-yl)methyl (71 -((hydroxy ((hydroxy (2-
( ( 6aR, 6bS, 7S, 8aS,8bS, llaR, 12aS, 12bS)- 7-hydroxy-6a, 8a-dimethyl-4-oxo-l 0-propyl- 2,4, 6a, 6b, 7,8,8a,8b,lla,12, 12a,l 2b-dodecahydro-lH-naphtho[2', 1 ':4,5Jindeno[ 1,2- d] [ 1 ,3] dioxol-8b-yl)-2-oxoethoxy)phosphoryl)oxy)phosphoryl)oxy)- 3,6,9,12,15,18,21,24,27,30,33,36,39,42,45,48,51,54,57, 60, 63, 66, 69- tricosaoxahenheptacontyl)carbamate (16-3)
The title compound was prepared from 16-2 and 9-1 according to the protocol outlined in Example 1 to produce 1-3 to afford 16-3. LRMS (ES) (M+H)+ : observed = 1886.7, calculated = 1869.0
Step D: 72-amino-3,6,9,12, 15, 18,21,24,27,30,33,36,39,42,45,48,51,54,57,60,63,66,69- tricosaoxahenheptacontanyl (2-(( 6aR, 6bS, 7S, 8aS, 8bS, HaR,12aS, 12bS)- 7 -hydroxy-6a, 8a- dimethyl-4-oxo-10-propyl-2, 4, 6a, 6b, 7, 8, 8a, 8b, 1 la, 12, 12a, 12b-dodecahydro-lH- naphtho[2', l ':4,5]indeno[l ,2-d] [1 ,3] dioxol-8b-yl)-2-oxoethyl) dihydrogen pyrophosphate (16-4)
The title compound was prepared from 16-3 according to the protocol outlined in
Example 12 to produce 12-2 to afford 16-4. LRMS (ES) (M+H)+ : observed = 1664.0, calculated = 1646.7
Step E:l-(cyclooct-2-yn-l-yloxy)-2-oxo-3-aza- 6,9, 12,15, 18,21,24,27,30,33,36,39,42,45,48,51, 54,57,60,63,66,69, 72-tricosaoxahenheptacont-
74-yl (2-(( 6aR, 6bS, 7S, 8aS, 8bS, 11 aR, 12aS,l 2bS) - 7 -hydroxy- 6a, 8a-dimethyl-4-oxo- 10-propyl-
2, 4, 6a, 6b, 7, 8, 8a, 8b,lla,12, 12 a, 12b-dodecahydro-lH-naphtho[2 ', 1 ':4,5Jindeno[l,2- d] [l,3]dioxol-8b-yl)-2-oxoethyl) dihydrogen pyrophosphate (16-5)
The title compound was prepared from 16-4 according to the protocol outlined in Example 13 to produce 13-6 to afford 16-5. LRMS (ES) (M+H)+ : observed = 1828.7, calculated
= 1810.9
EXAMPLE 17
The synthesis of Budesonide linker 4-((2S)-2-((2S)-2-(2-(cyclooct-2-yn-l- yloxy)acetamido)-3-methylbutanamido)-5-ureidopentanamido)benzyl (2-
((6aR,6bS,7S,8aS,8bS,l laR,12aS,12bS)-7-hydroxy-6a,8a-dimethyl-4-oxo-10-propyl- 2,4,6a,6b,7,8,8a,8b,l la,12,12a,12b-dodecahydro-lH-naphtho[2',l':4,5]indeno[l,2-d][l,3]dioxol- 8b-yl)-2-oxoethyl) dihydrogen pyrophosphate (17-2) was as follows.
Step A: 4-((S)-2-((S)-2-amino-3-methylbutanamido)-5-ureidopentanamido)benzyl
(2(( 6aR, 6bS, 7S, 8aS,8bS, 1 laR, 12aS,12bS)- 7-hydroxy-6a, 8a-dimethyl-4-oxo-l 0-propyl- 2, 4, 6a, 6b, 7, 8, 8a, 8b, lla,12, 12 a, 12b-dodecahydro-lH-naphtho[2 ', 1 ':4,5]indeno[l,2- dJ[l,3Jdioxol-8b-yl)-2-oxoethyl) dihydrogen pyrophosphate (17-1)
To a stirred solution of (9H-fluoren-9-yl)methyl ((S)-1-(((S)-1- ((4(hydroxymethyl)phenyl)amino)- 1 -oxo-5-ureidopentan-2-yl)amino)-3-methyl- 1 -oxobutan-2- yl)carbamate (0.05 g, 0.083 mmol) in DMF (1.2 ml) was added 3-
((bis(diisopropylamino)phosphino)oxy)propanenitrile (29uL, 0.09 mmol). To this mixture was added 0.45M tetrazole in acetonitrile (0.20 mL, 0.09 mmol) dropwise and the resulting mixture was stirred for 20 minutes at room temperature. To this was added 9-1 (0.042 g, 0.083 mmol) and 5-(ethylthio)-lH-tetrazole (0.02 g, 0.16 mmol) and allowed to stir to 30 minutes at room temperature. To this was added 6 M tertbutyl hydroperoxide in decane (0.03 mL, 0.18 mmol) and allowed to stir at room temperature for 30 minutes. To this was added DBU (0.12 mL, 0.83 mmol) and the resulting solution was stirred overnight at room temperature. The crude reaction was purified by direct injection using reverse phase preparative chromatography (Phenomenex Gemini -NX CI 8 OBD 5 uM 30 x 100mm; 5-40% MeCN/water w/ 0.1% NH4OH modifier over 20 min) to give 17-1 as a solid (18.5 mg, 23%). LRMS (ES) (M+H)+ : observed = 952.6, calculated = 951.9.
Step B: 4-( (2S)-2-((2S)-2-(2-(cyclooct-2-yn-l-yloxy)acetamido)-3-methylbutanamido)-5- ureidopentanamido) benzyl (2-( ( 6aR, 6bS, 7S,8aS,8bS, llaR, 12aS, 12bS)-7-hydroxy-6a,8a-
dimethyl-4-oxo-l 0-propyl-2, 4, 6a, 6b, 7, 8, 8a, 8b, 1 la, 12, 12a, 12b-dodecahydro-lH- naphtho[2 ', Γ : 4,5]indeno[ 1 ,2-d] [ 1 ,3] dioxol-8b-yl)-2-oxoethyl) dihydrogen pyrophosphate (17-2)
The title compound was prepared from 17-1 according to the protocol outlined in Example 13 to produce 13-6 to afford 17-2. LRMS (ES) (M+H)+ : observed = 1 116.6, calculated = 11 16.1
EXAMPLE 18
The synthesis of Fluticasone linker (6S,8S,9R, 10S,11 S,13S,14S,16R, 17R)-1 1- ((((((4-((2S)-2-((2S)-2-(2-(cyclooct-2-yn-l-yloxy)acetamido)-3-methylbutanamido)-5- ureidopentanamido)benzyl)oxy)(hydroxy)phosphoryl)oxy)(hydroxy)phosphoryl)oxy)-6,9- difluoro- 17-(((fluoromethyl)thio)carbonyl)- 10,13,16-trimethyl-3 -oxo-
6,7,8,9, 10,1 1, 12,13,14,15,16,17-dodecahydro-3H-cyclopenta[a]phenanthren- 17-yl propionate (18-3) was as follows.
Step A : (6S, 8S, 9R, 1 OS, 1 IS, 13S, 14S, 16R, 17R)-6, 9-difluoro-l 7-(((fluoromethyl) thiojcarbonyl)- 10,13,16-trim ethyl-3-oxo- 11- (phosphonooxy)-6, 7, 8, 9,10, 11,12,13,14,15,16, 17-dodecahydro-3H- cyclopenta[a]phenanthren-l 7-yl propionate (18-1)
To a stirred solution of 14-1 (0.20 g, 0.35 mmol) in pyridine (3.0 mL) at room temperature was added TMS-C1 (0.45 mL, 3.54 mmol) and the resulting solution was stirred for 10 minutes. To this mixture was added iodine (0.10 g, 0.42 mmol) dissolved in pyridine (0.5 mL) and stirred room temperature for 10 minutes. The reaction was then cooled in an ice bath and quenched with water (0.5 mL) and allowed to stir overnight at room temperature. The reaction was paritioned between ethyl acetate and IN HCl. The organic phase was concentrated and dissolved in aqueous acetonitrile and purified using reverse phase preparative
chromatography (Phenomenex Gemini -NX CI 8 OBD 5 μΜ 30 x 100mm; 5-40% MeCN/water w/ 0.1% NH4OH modifier over 20 min) to give 18-1 as a solid (89 mg, 44%). LRMS (ES) (M+H)+ : observed = 581.3, calculated = 580.5.
Step B: (6S, 8S, 9R, 10S 1S 3S, 14S, 16R, 17R)-ll-((((((4-((S)-2-((S)-2-amino-3- methylbutanamido)-5- ureidopentanamido)benzyl)oxy)(hydroxy)phosphoryl)oxy)(hydroxy)phosphoryl)oxy)-6,9- difluoro-17-( ( (fluoromethyl)thio)carbonyl)-10, 13, 16-trimethyl-3-oxo-
6, 7, 8,9, 10,11, 12,13, 14,15,16,17-dodecahydro-3H-cyclopenta[a]phenanthren-l 7-yl propionate (18-2)
The title compound was prepared from 18-1 according to the protocol outlined in Example 17 to produce 17-1 to afford 18-2. LRMS (ES) (M+H)+ : observed = 1022.6, calculated = 1021.9
Step C: (6S,8S,9R,10S, llS,13S, 14S,16R,17R)-ll-((((((4-((2S)-2-((2S)-2-(2-^
yloxy)acetamido)-3-methylbutanamido)-5- ureidopentanamido)benzyl)oxy)(hydroxy)phosphoryl)oxy)(hydroxy)phosphoryl)oxy)-6,9- difluoro-17-( ( (fluoromethyl)thio)carbonyl)-10, 13, 16-trimethyl-3-oxo-
6, 7, 8,9, 10,11, 12,13, 14,15,16,17-dodecahydro-3H-cyclopenta[a]phenanthren-l 7-yl propionate (18-3)
The title compound was prepared from 18-2 according to the protocol outlined in Example 13 to produce 13-6 to afford 18-3. LRMS (ES) (M+H)+ : observed = 1 186.5, calculated = 1186.1
EXAMPLE 19
The synthesis of Budesonide linker 4-(2-(cyclooct-2-yn-l-yloxy)acetamido)-l- (trimethylammonio)butan-2-yl (2-((6aR,6bS,7S,8aS,8bS,l laR,12aS, 12bS)-7-hydroxy-6a,8a- dimethyl-4-oxo-10-propyl-2,4,6a,6b,7,8,8a,8b,l la,12,12a, 12b-dodecahydro-lH- naphtho[2', :4,5]indeno[l,2-d][l,3]dioxol-8b-yl)-2-oxoethyl) phosphate (19-5) was as follows.
Step A: tert-butyl (2-(oxiran-2-yl)ethyl)carbamate (19-1)
To a stirred solution of tert-butyl but-3-enylcarbamate (0.95 mL, 5.16 mmol) in chloroform (20 mL) chilled in an ice bath was added mCBPA (1.38g, 8.0 mmol) and the resulting solution was stirred for 30 minutes. The reaction was allowed to warm to room temperature and monitored by TLC. Additional 1.5 equivalents of mCPBA was added every 30 minutes until complete. The mixture was diluted with additional 50mL chloroform and washed with 10% aq sodium sulfite solution 3 times, and washed once with brine. The organic phase as dried over sodium sulfate and concentrated. The crude mixture was purified with flash column separation using a 0-50% ethyl acetate/ hexane gradient to give 19-1 (800 mg, 83%). LRMS (ES) (M+H)+ : observed = 188.0, calculated = 187.2.
Step B: tert-butyl (4-(dimethylamino)-3-hydroxybutyl)carbamate (19-2)
Compound 19-1 (0.79 g, 4.21 mmol) was dissolved in a solution of dimethylamine 2M (8.0 mL, 16.0 mmol) and microwave irradiated to 60°C for 30 minutes. The reaction was allowed to cool and concentrated. The mixture was dissolved in aqueous acetonitnle and purified using reverse phase preparative chromatography (Phenomenex Gemini -NX CI 8 OBD 5 μΜ 30 x 100mm; 10-50% MeCN/water w/ 0.1% NH4OH modifier over 20 min) to give 19-2 (528 mg, 54%). LRMS (ES) (M+H)+ : observed = 234.2, calculated = 232.3
Step C: 4-((tert-butoxycarbonyl)amino)-2-hydroxy-N,N,N-trimethylbutan-l-aminium (19-3)
To a stirred solution of 9-2 (0.48 g, 2.05 mmol) in acetonitrile (9.5 mL) was added methyl iodide (0.13 mL, 2.05 mmol) and the resulting solution was stined at room
temperature for 1 hour and concentrated to give 19-3 as a white hydroscopic solid (509 mg, 100%). LRMS (ES) (M+H)+ : observed = 248.3, calculated = 247.3
Step D: 4-((tert-butoxycarbonyl)amino)-2-((hydroxy(2-((6aR, 6bS, 7S, 8aS, 8bS,l laR,12aS, 12bS)- 7- hydroxy-6a, 8a-dimethyl-4-oxo-10-propyl-2, 4, 6a, 6b, 7,8, 8a, 8b, 11 a, 12, 12a, 12b-dodecahydro-lH- naphtho[2',l ':4,5]indeno[l,2-d] [l,3]dioxol-8b-yl)-2-oxoethoxy)phosphoryl)oxy)-N,N,N-trimethylbutan-l- aminium (19-4)
The title compound was prepared from 19-3 and Budesonide according to the protocol outlined in Example 17 to produce 17-1 to afford 19-4. LRMS (ES) (M+H)+ : observed = 739.5, calculated = 739.8
Step E: 4-(2-(cyclooct-2-yn-l-yloxy)acetamido)-l-(trimethylammonio)butan-2-yl
(2( ( 6aR, 6bS, 7S, 8aS, 8bS, llaR, 12aS, 12bS)-7-hydroxy-6a, 8a-dimethyl-4-oxo-l 0-propyl-
2, 4, 6a, 6b, 7, 8, 8a, 8b, 11 a, 12, 12a, 12b-dodecahydro-lH-naphtho[2', 1 ':4, 5]indeno[l,2-d] [1, 3] ' dioxol-8b-yl)- 2-oxoethyl) phosphate (19-5)
To a stirred solution of 19-4 (0.03 g, 0.04 mmol) in dichloromethane (0.6 mL) in an ice bath was added TFA (0.3 mL, 3.89 mmol) and the resulting solution was allowed to stir 1 hour and concentrated. The resulting crude material was dissolved in DMF (0.4 mL) and 2- (cyclooct-2-yn- 1 -yloxy)acetic acid (9.6 mg, 0.053 mmol) and HATU (0.022 g, 0.057 mmol) and triethylamine (0.04 mL, 0.28 mmol) was added. The reaction was stirred at room temperature for 20 minutes, then purified directly using reverse phase preparative chromatography
(Phenomenex Gemini -NX CI 8 OBD 5 μΜ 30 x 100mm; 10-60% MeCN/water w/ 0.1% NH4OH modifier over 20 min) to give 19-5 as a solid (22 mg, 67%). LRMS (ES) (M+H)+ : observed = 803.6, calculated = 802.9.
EXAMPLE 20
This example shows the synthesis of a duocarmycin analog comprising a diphosphate linker.
Step A: (9H-fluoren-9-yl)methyl 2-((((S)-l-(chloromethyl)-3-(5,6, 7-trimethoxy-lH-indole-2- carbonyl)-2, 3-dihydro-lH-benzo[e]indol-5- yloxy)(hydroxy)phosphoryloxy)(hydroxy)phosphoryloxy)ethylcarbamate (20-2)
(S)-(l-(chloromethyl)-5-hydroxy-lH-benzo[e]indol-3(2H)-yl)(5,6,7-trimethoxy- lH-indol-2-yl)methanone (20-1) (60.0 mg, 0.13 mmol) was dissolved in dichloromethane (5 mL) and treated with phosphoryl chloride (36 μί, 0.39 mmol) and diisopropylethylamine (67 μί, 0.39 mmol) at 0 °C for 5 min. The reaction mixture was cooled down to -30 °C and (9H- fluoren-9-yl)methyl 2-(phosphonooxy)ethylcarbamate (234 mg, 0.64 mmol) was then added followed by another portion of diisopropylethylamine (1 15 μί, 0.64 mmol). The reaction was kept at -30°C for 30 min then allowed to warm up to 0°C for 40 min. Additional amount of 1.0 eq of (9H-fluoren-9-yl)methyl 2-(phosphonooxy)ethylcarbamate (46.8 mg, 0.13 mmol) and diisopropylethylamine (22 μί, 0.13 mmol) were added and kept for another 10 min at 0 °C. The reaction was quenched with sodium phosphate monobasic (1M) at 4 °C overnight and purified by RP-HPLC (Phenomenex Gemini -NX CI 8 5 μιη 100 x 30mm; MeCN/water with 0.05% TFA) to give the compound 20-2 as white powder (55 mg) with little impurity which is used directly for the next step without further purification . MS m/z 892 (M+H)+.
Step B: 2-((( (S)-l-(chloromethyl)-3-( 5, 6, 7-trimethoxy-lH-indole-2-carbonyl)-2, 3-dihydro-lH- benzo[e]indol-5-yloxy)(hydroxy)phosphoryloxy)(hydroxy)phosphoryloxy)ethylamine (20-3)
Compound 20-2 ( 5mg from last step) was dissolved in DMF (4.5 mL) and treated with diethylamine (0.6 ml) at rt for 10 min and immediately purified by RP-HPLC (Phenomenex Gemini -NX C 18 5 μιη 100 x 30mm; MeCN/water with 0.05% TFA) and lyophilized to obtain a white powder as TFA salt of compound 20-3 (24 mg, 24 % from compound 20-1). 'H-NM (500 MHz, CDCl3/MeOH-J4) δ 8.52 (bs, 1H), 8.32 (d, J = 8.5 Hz, 1H), 7.82 (d, J= 8.5 Hz, 1H), 7.56 (t, J = 7.0 Hz, 1H), 7.45 (t, J= 7.0 Hz, 1H), 7.08 (s, 1H), 6.95
(s, 1H), 4.73-4.72 (m, 2H), 4.28-4.20 (m ,3H), 4.04 (s, 3H), 3.99-3.96 (m, 1H), 3.90 (3, 3H), 3.89 (s, 3H), 3.69-3.65 (m, 1H), 3.21 (m, 2H). MS m/z 670 (M+H)+.
Step C: tert-Butyl 2-(2-( ( ( (S)-l-(chloromethyl)-3-(5, 6, 7-trimethoxy-lH-indole-2-carbonyl)-2, 3- dihydro-lH-benzo[e]indol-5- yloxy)(hydroxy)phosphoryloxy)(hydroxy)phosphoryloxy)ethylamino)-2-oxoethoxycarbamate (20- 4)
A solution of 20-3 mono TFA salt (10 mg, 0.0128 mmol) in DMF (0.5 mL) was treated with 2,5-dioxopyrrolidin-l-yl 2-(tert-butoxycarbonylaminooxy)acetate (7.35 mg, 0.0256 mmol) and diisopropylethyl amine (8.9 μί, 0.0512 mmol) at 0°C for 10 min. The reaction mixture was purified by RP-HPLC (Phenomenex Gemini -NX CI 8 5 μηι 100 x 30mm;
MeCN/water with 0.05% TFA) to obtain a white powder as compound 20-4 (8.6 mg, 80 %). MS m z 843 (M+H)+. Step D: 2-(Aminooxy)-N-(2-((((S)-l-(chloromethyl)-3-(5,6, 7-trimethoxy-lH-indole-2-carbonyl)- 2, 3-dihydro-lH-benzo[e]indol-5-yloxy) (hydroxy)phosphoryloxy) (hydroxy)phosphoryloxy)ethyl)- acetamide (20-5)
Compound 20-4 (8.5 mg, 0.010 mmol) was dissolved in dichloromethane (0.5 mL) and treated with TFA (0.1 mL) at rt for 15 min. The reaction mixture was concentrated in vacuum and co-evaporated with toluene (0.5 mL x 2). The residue was purified by RP-HPLC
(Phenomenex Gemini -NX CI 8 5 μιη 100 x 30mm; MeCN/water with 0.05% TFA) to obtain the target compound 20-5 as TFA salt (3.7 mg, 50 %). ^-NMR (500 MHz, MeOH- 4) δ 8.53 (d, J = 13.5 Hz, 1H), 8.3 (t, J = 7.5 Hz, 1H), 7.84 (d, J = 8.5 Hz, 1H), 7.60-7.57 (m, 1H), 7.47 (t, J = 7.5 Hz, 1H), 7.12 (d, J = 12.0 Hz, 1H), 6.99 (d, J= 2.0 Hz, 1H), 4.76-4.74 (m, 2H), 4.58 (s, 1H), 4.37-4.34 (m ,1H), 4.25 (m, 1H), 4.20-4.14 (m, 2H), 4.06 (d, J= 6.0 Hz, 3H), 4.02-4.00 (m, 1H), 3.90 (s, 6H), 3.76-3.70 (m, 1H), 3.45-3.44 (m, 2H). MS m z 743 (M+H)+ .
EXAMPLE 21
This example shows the synthesis of duocarmycin comprising a diphosphate linker.
Step A: (S)-methyl 8-(chloromethyl)-4-(phosphonooxy)-6-(5, 6, 7-trimethoxy-lH-indole-2- carbonyl)-3 ,6, 7 ,8-tetrahydropyrrolo[3 ,2-e] indole-2-carboxylate (21-2)
Duocarmycin 21-1 ( 85.0 mg, 0.165 mmol) was dissolved in THF/acetonitrile (3 mL / 3 mL) and treated with phosphoryl chloride (0.139 mL, 1.49 mmol) and diisopropylethyl amine (0.144 mL, 0.825 mmol) with ice-water bath cooling. The reaction was kept at the same temperature for lh and sodium phosphate monobasic solution (1M, 10 mL) was added and kept the mixture at 4 °C overnight. The mixture was then subjected to the RP-HPLC purification (Phenomenex Gemini -NX C 18 5 μιη 100 x 30mm; MeCN/water with 0.05% TFA) to obtain compound 21-2 (55 mg, %). MS m/z 594 (M+H)+.
Step B: (8S) -methyl 4-(((2-aminoethoxy)(hydroxy)phosphoryloxy)(hydroxy)phosphoryloxy)-8- (chloromethyl)-6-(5,6, 7-trimethoxy-lH-indole-2-carbonyl)-3,6, 7,8-tetrahydropyrrolo[3,2- e] indole-2-carboxylate (21-3)
A solution of (9H-fluoren-9-yl)methyl 2-(phosphonooxy)ethylcarbamate (68.0 mg, 0.185 mmol) in DMF (1.5 mL) was treated with carbonyldiimidazole (90.0 mg, 0.558 mmol) and triethylamine (25.0 \iL, 0.186mmol) at room temperature for 3 h. A drop of MeOH was added and stirred at room temperature for 10 min. The volatile was completely removed and co-evaporated with toluene. The residue was dissolved in DMF (1.85 mL) and compound 21-2 (55.0 mg, 0.093 mmol) was added. The mixture was kept room temperature for 19 h and then treated with diethylamine at room temperature for 4 min. The reaction was immediately purified by RP-HPLC (Phenomenex Gemini -NX C 18 5 μιη 100 x 30mm; MeCN/water with 0.05% TFA) to obtain compound 21-3 TFA salt (19 mg, 14 %). MS m/z 717 (M+H)+.
Step C: (SS)-methyl 8-(chloromethyl)-4-( ((2, 2-dimethyl-4, 8-dioxo-3, 6-dioxa-5, 9-diazaundecan- ll-yloxy)(hydroxy)phosphoryloxy)(hydroxy)phosphoryloxy)-6-(5,6, 7-trimethoxy-lH-indole-2- carbonyl)-3 ,6, 7 ,8-tetrahydropyrrolo[3 ,2-e] indole-2-carboxylate (21-4)
A solution of 21-3 (16 mg, 0.019 mmol) in dichloromethane (2 mL) was treated with 2,5-dioxopyrrolidin-l-yl 2-(tert-butoxycarbonylaminooxy)acetate (1 1.0 mg, 0.038 mmol) and triethylamine (10.1 μί, 0.076 mmol) at 0°C for 10 min. The reaction mixture directly purified by RP-HPLC (Phenomenex Gemini -NX C18 5 μιη 100 x 30mm; MeCN/water with 0.05% TFA) to obtain a white powder 21-4 (14 mg, 83 %). MS m z 890 (M+H)+.
Step D: (8S)-methyl 4-(((2-(2-
(aminooxy)acetamido)ethoxy)(hydroxy)phosphoryloxy)(hydroxy)phosphoryloxy)-8- (chloromethyl)-6-(5,6, 7-tnmethoxy-lH-indole-2-carbonyl)-3,6, 7,8-tetrahydropyrrolo[3,2- eJindole-2-carboxylate (21-5)
Compound 21-4 (14 mg, 0.0157 mmol) was dissolved in dichloromethane (1 mL) and treated with TFA (0.2 mL) for 20 min. The reaction mixture was concentrated in vacuum and co-evaporated with toluene (0.5 mL X 2). The residue was purified by RP-HPLC
(Phenomenex Gemini -NX CI 8 5 μιη 100 x 30mm; MeCN/water with 0.05% TFA) to obtain the target compound 21-5 (Duocarmycin-405) as TFA salt (5.5 mg, 39 %). XH-NMR (500 MHz, CDCl3/MeOH-<«) δ 8.28 (br, 1H), 7.21 (s, 1H), 7.02 (s, 1H), 6.95 (s, 1H), 4.77(2H buried in solvent peak), 4.58 (bs, 1H), 4.39 (m, 1H), 4.06-3.75 (m, 1 1H), 3.5 (m, 2H). MS m/z 790 (M+H)+ .
EXAMPLE 22
The solubility of exemplary drug-linker conjugates in aqueous solutions was evaluated. Linkers utilized in drug conjugates may have aqueous solubility to enable conjugation in aqueous media amenable to protein solubilization. Furthermore, linkers with aqueous solubility are considered hydrophilic, and may confer to the drug conjugate a reduced propensity to aggregate relative to standard hydrophobic linkers in the literature. The following exemplary drug-linkers were tested in an aqueous solution comprising 20% acetonitrile
(MeC /H20) for solubility at a concentration of 10 mg/mL. As shown in Table 1, the exemplary linker-drug conjugates displayed high solubility, which may be a result of the contribution of the polarity and charge of the phosphate containing linker to the drug-linker conjugate.
EXAMPLE 23
In Vitro Stability Studies of Exemplary Drug-Linkers in Blood and Lysosomal Lysates.
Exemplary dexamethasone-linkers 4-3, 5-3, 1-4, 3-4, and 2-7 were incubated in relevant biomatrices to measure their stability and propensity to release free drug (Tables 2 to 4).
The exemplary dexamethasone-linkers were studied for their stability (Table 1) and propensity to release dexamethasone (Table 2) in human blood. As shown in the tables, all the dexamethasone linkers were stable in blood with little detectable degradation or release of free dexamethasone.
General Experimental Procedure
Human Blood incubation
Human blood was collected the morning of the experiment from at least 3 individuals using K2EDTA as the anticoagulant. An equal volume from each individual was combined for use in the experiment. The experiment started no more than 2 hours after the blood collection. All drug-linker conjugates were solubilized in DMSO to form each 10 mM
stock solution. Dosing solution for each linker was prepared by serial dilution of each stock solution using 1 :3 acetonitrile: water. All solutions were kept on ice during the experiment.
Human blood was pre -warmed in a 37°C water bath in an appropriate volume to collect samples over a time course from 0 through 6 hours. Incubating blood was mixed well just prior to sampling to give a homogenous mixture. Aliquots of blood were removed at appropriate time points, added to cold stopping solution, which was methanol containing an appropriate internal standard, and mixed rigorously. The samples were centrifuged at 4000 RPM for 10 minutes after which equal volumes of the supernatant fractions were diluted with cold deionized water. The samples were then ready for analysis. A time 0 sample was prepared by spiking blood, which had been pretreated with the same stopping reagent used above with the drug-linker. This sample is referred to in the tables as the matrix spiking.
Representative dexamethasone-linkers 4-3, 5-3, 1-4, 3-4, and 2-7 were studied for their stability (Table 4) and propensity to release dexamethasone (Table 5) in purified rat liver lysosomal lysates. Tables 4 and 5 show that the different dexamethasone-linkers released dexamethasone at different rates depending on the structure of the tuning element. For example,
3- 4 was no longer detectable after 10 minutes incubation in the rat lysosomal extract whereas for
4- 3 and 5-3 the dexamethasone was more slowly released with 5-3 releasing dexamethasone faster than 4-3.
ix wWisfj : 2059.0 1590.7 2555.29 2487.3 3128.83
1456.4 888.8 1394.08 1148.2 1252 1851.2 1156.1 1295.86 158.2 501.28 1640.8 983.4 1278.4 19.0 149.18 1666.7 1032.6 1407.73 3.7
1602.6 980.1 1175.39
1576.8 882.4 970.65
1681.0 880.1 743.45
1689.7 903.8 500.41
1689.8 858.9 221.03
2059.0 17:
1456.4 0.9 4.7 15.74
1851.2 14.5 10.25 320.7 100.44 415:
1640.8 14.2 21.56 559.4 209.07 682:
1666.7 22.3 31.68 831.7 285.67 808;
1602.6 28.9 78.6 1059.6 425.28 1039:
1576.8 41.6 162.45 1148.8 526.5 1159:
1681.0 72.5 290.66 854.5 534.84 1309:
1689.7 90.2 379.36 841.9 584.61 1207:
General Experimental Procedure
Rat Lysosome Incubation:
Rat Liver lysosomes were available commercially with a pool of 6 animals. All linker compounds were solubilized in DMSO to form each lOmM stock solution. Dosing
solution for each linker was prepared by serial dilution of each stock solution using 1 :3 acetonitrile: water. All solutions were kept on ice during the experiment.
Rat lysosomes were pre -warmed in a 37°C water bath in an appropriate volume to collect samples over a time course from 0 minutes through 6 hours. Incubating lysosomes were mixed well just prior to sampling to give a homogenous mixture. Aliquots of lysosomes were removed at appropriate time points, added to cold stopping solution, which was methanol containing an appropriate internal standard, and mixed rigorously. The samples were centrifuged at 4000 RPM for 10 minutes after which equal volumes of supernatant were diluted with cold deionized water. The samples were ready for analysis. A time 0 sample was prepared by spiking the drug-linker to lysosomes which had been pretreated with the same stopping reagent as above. This sample is referred to as matrix spiking in the tables.
Liquid chromatography - tandem mass spectrometry analysis
A Thermo LX-2 ultra-performance liquid chromatography system coupled with a Sciex API5000 triple quadrupole mass spectrometer was used for the analysis. The payload and drug-linkers were retained and separated by a C18 column and detected by the mass
spectrometer. The standard curve for each analyte was prepared to obtain the quantitative results. Samples were kept in cold stack set at 5°C. EXAMPLE 24
Synthesis, Purification and Analysis of ADC Using Exemplary Drug-Linker 1-4
To establish the chemical reactivity of this linker design to form a drug conjugate, exemplary drug-linker 1-4 was conjugated to an anti-mouse CD25 antibody (IgGl) (mCD25) to produce antibody-drug conjugate ADC 12-1 or anti-human CD70 antibody 2H5 antibody (hCD70) to produce ADC 12-2. Specifically, the drug-linker was conjugated to the unnatural amino acid para-azido-phenylalanine (pAF) replacing the alanine at position 1 of CHI of the antibody using copper- free 3+2 cycloaddition chemistry as shown in Figure 1. The amino acid sequence of the anti-mouse CD25 heavy chain comprising the pAF at position 115 is shown in SEQ ID NO:3 and the amino acid sequence of the light chain is shown in SEQ ID NO:4. The amino acid sequence of the anti-human CD70 heavy chain comprising pAF at position 119 is shown in SEQ ID NO: 1 and the amino acid sequence of the light chain is shown in SEQ ID NO:2. Synthesis of antibodies containing an unnatural amino acid has been described in US 7,632,924, incorporated herein by reference, and copper-free 3+2 cycloaddition chemistry has been described in US 7,807,619, incorporated herein by reference. Conjugation, purification, and analysis confirmed synthesis of the Anti-CD25 antibody-drug conjugate ADC 12-1 and the anti-CD70 ADC 12-2.
Experimental for Conjugation of Phosphate Linker 1-4 to anti-mouse CD25
Antibodies were purified over protein A column (NovaSep) followed by SP 650S column (Tosoh Biosciences).
Site specific conjugation using click (2+3) chemistry. Para-azido phenylalanine containing antibodies were buffer exchanged into 50 mM Histidine; 100 mM NaCl; 2.5%
Trehalose; 0-20% Dimethylamine, pH 6.0 and concentrated to l-20mg/mL. 10-15 molar equivalents of cyclooctyne drug-linker were added and reacted for 16- 72 hours at 28-30°C. The antibody conjugates were purified over a SP 650S column (Tosoh Biosciences) to remove excess reagents. The conjugates were buffer exchanged into 50 mM Histidine; 100 mM NaCl; 2.5% Trehalose; pH 6.0, 0.22μιη filtered, and stored at 4°C.
Site specific conjugation using oxime chemistry. Para-acetyl phenylalanine
(pAcF) containing antibodies were buffer exchanged into 50mM sodium acetate; 2.5% trehalose; 0-20%) Dimethylamine, pH 4.0-4.5 and concentrated to l-20mg/mL. 10-15 molar equivalents of amino-oxy drug-linker were added and reacted for 16-72 hours at 28-30°C. The antibody conjugates were purified over a SP 650S column (Tosoh Biosciences) to remove excess reagents. The conjugates were buffer exchanged into 50 mM Histidine; 100 mM NaCl; 2.5% Trehalose; pH 6.0, 0.22μιη filtered, and stored at 4°C.
Conjugation analysis. Conjugation efficiency and DAR values were determined by reversed phase HPLC. The ADC was run over a Zorbax 300SB-C3 column, 4.6x150mm (Agilent) at 80°C and eluted with a linear gradient from 30% B to 90%B (A: water, 0.1% TFA; B: acetonitrile, 0.1% TFA). An Agilent 1200 series HPLC system and Chemstation software were used to resolve and quantify percentage of antibody conjugated with drug-linker.
EXAMPLE 25
Serum Stability of ADC 12-1
Drug conjugates may be designed with a stable linker to ensure that the attached payload adopts the pharmacokinetic properties of the carrier. In the example of antibody drug conjugates, premature release of the payload will reduce the total payload delivered to a target cell. To establish the potential for circulatory stability of this linker design in the context of a drug conjugate, ADC 12-1 was incubated in mouse serum and monitored for degradation or loss of payload (dexamethasone). As shown in Figure 2, no measurable loss of dexamethasone was observed over three weeks incubation in serum.
In vitro Stability Study Design in DBA I Mice Serum
For the in vitro stability study, the ADC 12-1 was spiked in DBA1 mice serum at 0.1 mg/niL. Samples were sealed under nitrogen, placed at 37°C in a cell culture incubator and stored at -80°C until analysis. Time points from 0 min to 21 days of incubation were evaluated.
In vitro Stability - Free Payload Analysis
Samples were evaluated for free dexamethasone by LC-MS/MS. For the in vitro stability study, 40
of serum for each time point underwent protein precipitation with 400 μΐ, acetonitrile containing dexamethasone-d4 (internal standard). Tubes were centnfuged at 14000 RPM (4°C) for 10 minutes and the supernatant fraction removed and dried in a speed vac.
Samples were reconstituted with methanol/water (50/50) and injected in an Acquity/TSQ Vantage triple quad mass spectrometer equipped with an Xbridge C18 column (Waters, Milford). Mobile phases consisted of buffers A (water: acetonitrile: formic acid, 95:5:0.1%) and B (acetonitrile:water:formic acid, 80:20:0.1%)) and a linear gradient was performed with buffer B increasing from 30 to 65%> in 3 minutes. Flow rate was set at 0.3 mL/minutes. Transitions for acetate adduct of dexamethasone and dexamethasone d-4 were 437>361 and 441>363, respectively. Compounds were detected using negative electrospray ionization. Free dexamethasone was not be detected in the in vitro stability serum samples over the period evaluated. In vitro Stability - Immunoprecipitation coupled to Intact Mass Analysis
ADC 12-1 was pulled down from mice serum using immunoprecipitation (IP) with streptavidin magnetic beads (Dynabeads M-280) coupled to biotinylated CD25 (antigen). Beads were washed 3 times with 100 \L of TBS lx. Two microliters of 1 mg/mL biotinylated CD25 was added to 30 μΐ^ of each sample (serum from each time point) and incubated for 10 minures at room temperature (RT). Samples were added to the pre-washed beads and incubated for 30 minutes at RT under gentle shaking. The flow through was discarded and beads were washed twice with 0.02% Rapigest in TBS lx. Elution was performed with 30 of TFA 0.1% and 5 μΤ of each sample was analyzed in an UPLC/Synapt G2-S (Waters, Milford) equipped with a POROS column (ABSciex) using reverse phase gradient.
Spectra deconvolution was performed using MaxEntl software (Waters, Milford) and results were compared against the intact mass obtained for the ADC from a stock solution (Figure 3). Figure 3 shows a deconvoluted intact mass spectrum for the ADC 12-1 stock solution. G0F, GIF and G2F in the figure refer to the carbohydrate iso forms on the antibody portion of the antibody-drug conjugate.
The deconvoluted spectra of the stock solution (Figure 3) revealed that the antibody-drug conjugate 12-1 intact mass in its predominant DAR 2 form contained two G0F sugar motifs. Additional peaks at about 162 Da apart showed two other glycoforms containing G0F/G1F (peak at 148701 Da) and 2 x GIF (peak at 148863 Da). The glycan profile is typical of that for an IgG.
Figure 4 shows the deconvoluted spectra of time points 1 hour, 8 hours, 14 days and 21 days from the in vitro stability study. The data analysis showed that no significant mass change occurred for the ADC over the incubation period evaluated in the study (Table 6: intact mass results for the in-vitro stability study).
In Vivo Stability of ADC 12-1
Effective linker designs will not only provide stable tethering to a carrier in drug conjugates, but should also have minimal to no effect on the pharmacokinetic properties of the carrier itself. To establish the potential of this linker design for in vivo circulatory stability and to understand its impact on the pharmacokinetics of the conjugated carrier in the context of a drug conjugate, ADC 12-1 was dosed to DB1 mice and was monitored for degradation of the mAb, intactness of the antibody-drug conjugate, and loss of payload (dexamethasone).
Importantly, the study showed that the inherent pharmacokinetics of naked (non-conjugated) anti-mouse CD25 was not adversely affected by the conjugation of two molecules of drug-linker 1-4 to the antibody. Furthermore, the study showed that no loss of drug linker and no measurable dexamethasone were observed over the course of the 5 day study. The data shows that drug-linker 1-4 was stable in circulation and retained payload on the carrier in this example of an antibody-drug conjugate.
In vivo Pharmacokinetic (PK) /Stability Study
General Experimental for In Vivo PK Study of ADC 12-1
An in vivo study in DBA1 mice was performed in order to evaluate stability and pharmacokinetics of ADC 12-1. Naked antibody was administered intravenously in a single bolus to all groups. Group 1 was given a dose of 2mpk; Group 2 and Group 3 were dosed 2 and 4 mpk of ADC 12-1, respectively. Plasma samples were taken from all three groups at 1, 2, 6, 16 hrs and 1, 2, 3, 5 days after dosing. At each of these time points, three animals per group were sacrificed to obtain plasma sample. Samples from group 1 were analyzed for total naked antibody contents, samples from groups 2 and 3 were submitted for total antibody, intact antibody and free-payload analysis. Figure 5 shows the In vivo stability of ADC 12-1 following IV dosing to DBA1 mice.
In vivo Pharmacokinetic (PK) /Stability Study - Free Paylo ad Analysis
PK study samples were evaluated for free dexamethasone using the method described above. For increased sensitivity, 100 of serum from one mice of each time point was submitted to protein precipitation with acetonitrile. Free dexamethasone was not detected in any PK samples.
In vivo Pharmacokinetic (PK) /Stability Study - Intact Antibody Drug Conjugate Mass Analysis
Samples from the ADC 12-1 PK study were also evaluated for stability using immunoprecipitation coupled to intact mass analysis. 50 \L of each sample was processed as described above. The results showed no molecular weight change for the antibody-drug conjugate over the study time range (from 1 hour to 5 days) (Figure 6, Table 7).
ays
In vivo Pharmacokinetic (PK)/Stability Study - naked/total mAb analysis
Plasma samples from in vivo P study were analyzed for naked Antibody/total Antibody ADC 12-1 concentrations using Meso Scale Discovery (MSD) based electro- chemiluminescence method. The capture reagent is recombinant mouse IL-2R alpha (CD25) for both assays. The detection reagent may be goat anti-rat IgG for naked antibody/total Antibody and anti-dex mAb (e.g., Rabbit polyclonal anti-dexamethasone (Abeam Cat# ab35000)) may be used to detect ADC 12-1, respectively. Briefly, 96 well MSD plates were coated with the capture reagent and then washed. Plates were blocked for 1 hour and washed again. Samples were then added and incubated for 2 hours. Following incubation, plates were washed, incubated with the detection antibody for 1 hour, and washed again. The reading buffer was added and the plates were read using MSD plate reader. EXAMPLE 26
The payload-linkers made in Examples 20 and 21 were conjugated to an anti- human Her2 antibody (hHer2) comprising a para-acetyl phenylalanine (pAcF). Methods for making antibodies comprising an unnatural amino acid and conjugating molecules thereto is disclosed in U.S. Patent No. 7,632,924 to Cho et al., which is incorporated by reference in its entirety.
Site specific conjugation using oxime chemistry.
Para-acetyl phenylalanine (pAcF) containing antibodies were buffer exchanged into 50mM sodium acetate; 2.5% trehalose; 0-20% Dimethylamine, pH 4.0-4.5 and concentrated to l-20mg/mL. 10-15 molar equivalents of amino-oxy drug-linker were added and reacted for 16-72 hours at 28-30°C. The antibody conjugates were purified over a SP 650S column (Tosoh Biosciences) to remove excess reagents. The conjugates were buffer exchanged into 50 mM Histidine; 100 mM NaCl; 2.5% Trehalose; pH 6.0, 0.22μιη filtered, and stored at 4°C. Conjugation analysis.
Conjugation efficiency and DAR values were determined by reversed phase HPLC. The antibody-drug conjugate was run over a Zorbax 300SB-C3 column, 4.6x150mm (Agilent) at 80°C and eluted with a linear gradient from 30% B to 90% B (A: water, 0.1% TFA; B: acetonitrile, 0.1 % TFA). An Agilent 1200 series HPLC system and Chemstation software were used to resolve and quantify percentage of antibody conjugated with drug-linker.
Cell assay
Her2 positive SKBR3 and Her2 negative MDA-MD-468 breast adenocarcinoma cell lines (ATCC Manassas, VA, USA) were cultured in DMEM medium supplemented with 10% FBS and 100 μ/mL penicillin, 100 μg/mL streptomycin, or DMEM/F12 supplemented with 10%) FBS and 100 μ/mL penicillin, 100 μg mL streptomycin respectively. The cells were incubated with serial dilutions of Duocarmycin-405 conjugated to anti-Her2 or a non-targeting antibody, Duocarmycin free drug and naked anti-Her2 controls for 6 days. Live cells were measured with CellTiter Glo luminescent cell viability assay kit (Promega, Madison, WI, USA) and the percentage of live cells determined relative to untreated cells.
The results are shown in Figures 8 and 9. Figure 8 shows that aHer2-Duo-405 was able to deliver its payload to Her2 expressing SKBR3 cells whereas a non-targeting antibody conjugated to Duo-405 was unable to. The Figure shows the specificity of the aHer2- Duo-405 conjugate and its ability to effectively deliver the payload. Figure 9 shows that aHer2- Duo-405 had no activity on Her2 negative MDA-MD-468 cells.
EXAMPLE 27
The example shows that conjugates comprising the phosphate-based links have little or no propensity to form aggregates.
Aggregation assay
An SE-HPLC method was used to conduct the aggregation/%monomer analysis. An isocratic gradient using 0.2 M potassium phosphate, 0.25 M potassium chloride pH 6.0 was used as the mobile phase at a flowrate of 0.5mL/min. The column used was a Sepax Zenix-C SEC-300, 3μιη, 300 A, 7.8 x 300mm (Cat# 233300-7830). Detection of signal was monitored at 214nm (280 for FIO). For a representative run, the analyte load was 10 μg.
The results are shown in Table 8.
Table 8
Sample % High Molecular Weight %
Name Drug-Linker (aggregate) Monomer
mCD25 Phos-21Dex365 (1-4) 1.4 98.6
hCD70 Phos-21Dex365 (1-4) 0.9 99.1
hHer2 Phos-Duo405 (21-5) 0.5 99.5
EXAMPLE 28
ADC 12-2 (Figure 1) is anti-CD70 antibody 2H5 conjugated to exemplary drug- linker 1-4 as described in Example 24. In vitro activity and targeted delivery of ADC 12-2, naked antibody, and anti-hexon conjugate control were assessed by transfecting into 786-0 (renal cell) and then measuring glucocorticoid-induced leucine zipper (GILZ) mRNA, a widely expressed dexamethasone-induced mRNA transcript. As shown in Figure 7, ADC 12-2 displayed potent in vitro activity (0.7 ug/ml IP value) in 786-0 cells that were confirmed to express CD70. This activity reflects dexamethasone conjugation and targeted delivery as the nonconjugated IgG variant and anti-hexon controls did not induce and observable GILZ in this cell line.
786-0 cells were plated at 30K cells/well overnight at 37°C in RPMI Media as suggested by ATCC (+ 10% HI FBS). Cells were stimulated with ADCs for 2, 6, or 24 hours at 37°C. Cells were lysed using RLT and RNA is isolated using RNeasy 96 Kits. PCR was used to measure GAPDH, PERI , or TSC22D3
Quantitation of Glucocorticoid-induced leucine zipper (GILZ) mRNA expression was determined as follows. Cellular quantitation of GILZ mRNA was conducted using the following method. Cells suspension were prepared in HBSS +2%FBS (assay buffer) and plated at 5xl04 cells per well. Dosing solutions for free drug, ADCs and parental antibodies were prepared by serial dilution of each stock solution using 1 :3 in in HBSS+2% FBS supplemented with 1% final concentration of (50mM Histidine, lOOmM NaCl, 5% Trehalose, pH 6.0), and incubated with cells final concentrations ranging from 20 to 0.002 μg/ml and 100 to 0.0 lng dexamethasone/ml for 18 hours. Cell lysis, cDNA synthesis, and real-time PCR were performed according to manufacturer's instructions using TaqMan Gene Expression Cells-to-C^TM Kit (Invitrogen, Carlsbad, CA). Specific primers against human GILZ and GAPDH were purchased from the Life Technologies (Invitrogen, Carlsbad, CA). Real-time PCR reactions were performed on the Applied Biosystems 7900 HT Fast Real-Time PCR System. Thermal cycling conditions consisted of an initial UDG incubation hold (50°C, 2 min) denaturing and enzyme activation step (95°C, 2 min) followed by 40 cycles of denaturing (95°C, 15 s), annealing and extending (60°C, lmin). The mRNA levels were normalized to GAPDH (internal control) using the formula Δ threshold cycle (CT) = CT target - CT reference. The differential expression signal were expressed as delta Ct (ACt) by subtracting the Ct values of the un-stimulated samples (containing only assay buffer or DMSO vehicle) from those of the stimulated samples and expressed as relative fold of change using the formula: 2AACT.
Table of Sequences
SEQ ID Description Amino Acid Sequence
NO:
1 Anti-CD70 2H5 IgGl OVOLVESGGGVVOPGRSLRLSCAASGFTFSSYIM X at position 119 is HWVROAPGKGLEWVAVISYDGRNKYYADSVKG para-azido- RFTISRDNSI NTLYLQMNSLRAEDTAVYYCARDT phenylalanine (pAF) DGYDFDYWGOGTLVTVSSXSTKGPSVFPLAPSSK (CDR 1,2, and 3 bold STSGGTAALGCLVKDYFPEPVTVSWNSGALTSGV type; Fc underlined) HTFPAVLOSSGLYSLSSVVTVPSSSLGTOTYICNV
NHKP SNTKVDKKVEPKS CDKTHTCPPCPAPELLG
GPSVFLFPPi PKDTLMISRTPEVTCWVDVSHEDP
EVKFNWYVDGVEVHNAKTKPREEOYNSTYRVVS
VLTVLHODWLNGKEYKCKVSNKALPAPIEKTISK
AKGOPREPOVYTLPPSRDELTKNOVSLTCLVKGF
YPSDIAVEWESNGOPENNYKTTPPVLDSDGSFFLY
SKLTVDKSRWOOGNVFSCSVMHEALHNHYTOKS
LSLSPG
2 Anti-CD70 Kappa light EIVLTOSPATLSLSPGERATLSCRASOSVSSYLAW chain YOOKPGOAPRLLIYDASNRATGIPARFSGSGSGTD
(CDR 1,2, and 3 bold FTLTISSLEPEDFAVYYCOORTNWPLTFGGGTKV type) EIKRTVAAPSVFIFPPSDEQLKSGTASVVCLLNNFY
PREAKVQWKVDNALQSGNSQESVTEQDSKDSTY
SLSSTLTLSKADYEKHKVYACEVTHQGLSSPVTKS
FNRGEC
3 Anti-murine CD25 QVKLLQSGAALVKPGASVKMSCKASGYSFPDSW mulgGI D265A VTWVKQSHGKSLEWIGDIFPNSGATNFNEKFKGK X at position 115 is ATLTVDKSTSTAYMELSRLTSEDSAIYYCTRLDYG para-azido- YWGQGVMVTVSSXKTTPPSVYPLAPGSAAQTNS phenylalanine (pAF) MVTLGCLVKGYFPEPVTVTWNSGSLSSGVHTFPA
VLQSDLYTLSSSVTVPSSTWPSETVTCNVAHPASS
TKVDKKIVPRDCGCKPCICTVPEVSSVFIFPPKPKD
VLTITLTPKVTCVVVAISKDDPEVQFSWFVDDVEV
HTAQTQPREEQFNSTFRSVSELPIMHQDWLNGKE
FKCRVNSAAFPAPIEKTISKTKGRPKAPQVYTIPPP
KEQMAKDKVSLTCMITDFFPEDITVEWQWNGQP
AENYKNTQPIMDTDGSYFVYSKLNVQKSNWEAG
NTFTCSVLHEGLHNHHTEKSLSHSPGK
4 Anti-murine CD25 DVVLTQTPPTLSATIGQSVSISCRSSQSLLHSNGNT
muKappa YLNWLLQRPGQPPQLLIYLASRLESGVPNRFSGSG
SGTDFTLKISGVEAEDLGVYYCVQSSHFPNTFGVG
TKLELKRADAAPTVSIFPPSSEQLTSGGASVVCFL
NNFYPKDINVKWKIDGSERQNGVLNSWTDQDSK
DSTYSMSSTLTLTKDEYERHNSYTCEATHKTSTSP
IV SFNR EC
While the present invention is described herein with reference to illustrated embodiments, it should be understood that the invention is not limited hereto. Those having ordinary skill in the art and access to the teachings herein will recognize additional modifications and embodiments within the scope thereof. Therefore, the present invention is limited only by the claims attached herein.
Claims
WHAT IS CLAIMED:
A compound comprising the formula
wherein
V is selected from O and S;
W is selected from O, N, and CH2;
X is selected from a covalent bond; a carbon atom; a heteroatom; an optionally substituted group selected from the group consisting of acyl, aliphatic, heteroaliphatic, aryl, heteroaryl, and heterocyclic; a carbon atom linked to a trimethylammonium group by a C1-C5 hydrocarbon chain; nucleoside, protease sensitive group, cathepsin B sensitive group, or glycosidase sensitive group;
Y is selected from a covalent bond or a bivalent, straight or branched, saturated or unsaturated, optionally substituted CI -30 hydrocarbon chain wherein one or more methylene units of Y are optionally and independently replaced by -0-, -S-, -N(R)-, -C(O)-, C(0)0-, OC(O)-, -N(R)C(0)-, -C(0)N(R , -S(O)-, -S(0)2-, -N(R)S02-, S02N(R , a heterocyclic group, an aryl group, or a heteroaryl group;
T is an R, CR2, O, or S;
Z is a reactive functional group selected from the group consisting of N- hydroxysuccinimidyl ester, para-nitrophenyl carbonate, para-nitrophenyl carbamate, methyl ketone, azide, hydrazine, pentafluorophenyl, haloacetamide, maleimide, hydroxylamine, strained cycloalkyne, and heterocycloalkyne, alkyne, diene, azadiene, and heterocyclic azadiene, wherein halo is iodine (I), bromine (Br), fluorine (F), or chlorine (CI) and hetero is N, O, or S;
D is a payload;
Each occurrence of R is independently hydrogen, a suitable protecting group, an acyl moiety, arylalkyl moiety, aliphatic moiety, aryl moiety, heteroaryl moiety, or heteroaliphatic moiety; and
n is 1, 2, 3, or 4.
2. The compound of claim 1 , wherein the payload is a therapeutic agent, a detectable label, radionuclide, or protecting group.
3. The compound of claim 1, wherein the therapeutic agent is a cytotoxic agent, an anti-inflammatory agent, peptide, or nucleic acid or nucleic acid analog.
4. The compound of claim 3, wherein the anti-inflammatory agent is a glucocorticoid receptor agonist.
5. The compound of claim 3, wherein the anti-inflammatory agent is Cortisol, cortisone acetate, beclometasone, prednisone, prednisolone, methylprednisolone, betamethasone, trimcinolone, budesonide, dexamethasone, fluticasone, fluticasone propionate, fluticasone furoate, compound 15-5, or mometasone.
6. A payload-ligand conjugate compound comprising a cell-specific targeting ligand conjugated to a payload wherein said conjugate comprises the formula
wherein
V is selected from O and S;
W is selected from O, N, and CH2;
X is selected from a covalent bond; a carbon atom; a heteroatom; an optionally substituted group selected from the group consisting of acyl, aliphatic, heteroaliphatic, aryl, heteroaryl, and heterocyclic; a carbon atom linked to a trimethylammonium group by a C1-C5 hydrocarbon chain; nucleoside, protease sensitive group, cathepsin B sensitive group, or glycosidase sensitive group;
Y is selected from a covalent bond or a bivalent, straight or branched, saturated or unsaturated, optionally substituted Ci .39 hydrocarbon chain wherein one or more methylene units of Y are optionally and independently replaced by -0-, -S-, -N(R)-, -C(O)-, C(0)0-, OC(O)-, -N(R)C(0)-, -C(0)N(R)-, -S(O)-, -S(0)2-, -N(R)S02-, S02N(R)-, a heterocyclic group, an aryl group, or a heteroaryl group;
T is an R, CR2, O, or S;
D is a payload;
Z is a linkage formed between (i) a reactive functional group selected from the group consisting of N-hydroxysuccinimide, para-nitrophenyl carbonate, para-nitrophenyl carbamate, methyl ketone, azide, pentafluorophenyl, haloacetamide, maleimide, hydroxylamine, strained cycloalkyne, and heterocycloalkyne, alkyne, diene, azadiene, and heterocyclic azadiene, wherein halo is iodine (I), bromine (Br), fluorine (F), or chlorine (CI) and hetero is N, O, or S, and (ii) an S, NR, or O group on the cell-specific targeting ligand (L);
Each occurrence of R is independently hydrogen, a suitable protecting group, an acyl moiety, arylalkyl moiety, aliphatic moiety, aryl moiety, heteroaryl moiety, or heteroaliphatic moiety;
L is a cell-specific targeting ligand; and
n is 1, 2, 3, or 4.
7. The compound of claim 6, wherein the payload is a therapeutic agent, a detectable label, radionuclide, or protecting group.
8. The compound of claim 6, wherein the therapeutic agent is a cytotoxic agent, an anti-inflammatory agent, peptide, or nucleic acid or nucleic acid analog.
9. The compound of claim 8, wherein the anti-inflammatory agent is a glucocorticoid receptor agonist.
10. The compound of claim 8, wherein the anti-inflammatory agent is Cortisol, cortisone acetate, beclometasone, prednisone, prednisolone, methylprednisolone, betamethasone, trimcinolone, budesonide, dexamethasone, fluticasone, fluticasone propionate, fluticasone furoate, compound 15-5, or mometasone.
11. The compound of claim 6, wherein the targeting ligand is an antibody or monoclonal antibody (e.g., chimeric, humanized, or human), ligand for a receptor, lectin, saccharide, poly(ethylene glycol), polysaccharide, or polyamino acid.
12. The compound of claim 6, wherein the targeting ligand is a chimeric, humanized, or human anti-Her2 antibody, anti-CD4 antibody, anti-CD20 antibody, anti-EGFR antibody, anti-CD22 antibody, anti-CD23 antibody, anti-CD25 antibody, anti-CD52 antibody, anti-CD30 antibody, anti-CD33 antibody, anti-CD40L antibody, anti-CD70 antibody, anti-CD74 antibody, anti-CD80 antibody, anti-CD 163 antibody, anti-Mucl8 antibody, anti-integrin antibody, anti-PSMA antibody, anti-CEA antibody, anti-CDl la antibody, anti-CTLA4 antibody, or anti-BLys antibody.
13. A payload- ligand conjugate compound comprising a cell-specific targeting ligand conjugated to a drug moiety wherein said conjugate comprises the formula
wherein wavy line 1 indicates the covalent attachment site to the payloand and wavy line 2 indicates the covalent attachment site of the cell-specific targeting ligand and wherein
V is selected from O and S;
W is selected from O, N, and CH2;
X is selected from a covalent bond; a carbon atom; a heteroatom; an optionally substituted group selected from the group consisting of acyl, aliphatic, heteroaliphatic, aryl, heteroaryl, and heterocyclic; a carbon atom linked to a trimethylammonium group by a C1-C5 hydrocarbon chain; nucleoside, protease sensitive group, cathepsin B sensitive group, or glycosidase sensitive group;
Y is selected from a covalent bond or a bivalent, straight or branched, saturated or unsaturated, optionally substituted CI -30 hydrocarbon chain wherein one or more methylene units of Y are optionally and independently replaced by -0-, -S-, -N(R)-, -C(O)-, C(0)0-, OC(O)-, -N(R)C(0)-, -C(0)N(R , -S(O)-, -S(0)2-, -N(R)S02-, S02N(R , a heterocyclic group, an aryl group, or a heteroaryl group;
T is an NR, CR2, O, or S of the payload;
Z is a linkage formed between (i) a reactive functional group selected from the group consisting of N-hydroxysuccinimide, para-nitrophenyl carbonate, para-nitrophenyl carbamate, methyl ketone, azide, pentafluorophenyl, haloacetamide, maleimide, hydroxylamine, strained cycloalkyne, and heterocycloalkyne, alkyne, diene, azadiene, and heterocyclic azadiene, wherein halo is iodine (I), bromine (Br), fluorine (F), or chlorine (CI) and hetero is N, O, or S, and (ii) an S, NR, or O group on the cell-specific targeting ligand;
each occurrence of R is independently hydrogen, a suitable protecting group, an acyl moiety, arylalkyl moiety, aliphatic moiety, aryl moiety, heteroaryl moiety, or heteroaliphatic moiety; and
n is 1, 2, 3, or 4.
14. A method for treating a disease or disorder by providing to a subject having the disease or disorder a composition comprising a compound having formula (III)
wherein V is selected from O and S; W is selected from O, N, and CH2; X is a tuning element selected from a covalent bond; a carbon atom; a heteroatom; an optionally substituted group selected from the group consisting of acyl, aliphatic, heteroaliphatic, aryl, heteroaryl, and heterocyclic; a carbon atom linked to a trimethylammonium group by a C 1-C5 hydrocarbon chain; nucleoside, protease sensitive group, cathepsin B sensitive group, or glycosidase sensitive group; Y is selected from a covalent bond or a bivalent, straight or branched, saturated or unsaturated, optionally substituted C\ .39 hydrocarbon chain wherein one or more methylene units of Y are optionally and independently replaced by -0-, -S-, -N(R)-, -C(O)-, C(0)0-, OC(O)-, -N(R)C(0)-, -C(0)N(R)-, -S(O)-, -S(0)2-, -N(R)S02-, S02N(R)-, a heterocyclic group, an aryl group, or a heteroaryl group; T is an NR, CR2, O, or S; D is a payload; Z is a linkage formed between (i) a reactive functional group selected from the group consisting of N- hydroxysuccinimide, para-nitrophenyl carbonate, para-nitrophenyl carbamate,
pentafluorophenyl, haloacetamide, maleimide, hydroxylamine, strained cycloalkyne, and heterocycloalkyne, alkyne, diene, azadiene, and heterocyclic azadiene, wherein halo is iodine (I), bromine (Br), fluorine (F), or chlorine (CI) and hetero is N, O, or S, and (ii) an S, NR, or O group on L; each occurrence of R is independently hydrogen, a suitable protecting group, an acyl moiety, arylalkyl moiety, aliphatic moiety, aryl moiety, heteroaryl moiety, or heteroaliphatic moiety; L is a cell-specific targeting ligand; and n is 1 , 2, 3, or 4; and a pharmaceutically acceptable salt or carrier.
15. The method of claim 14, wherein the payload is a therapeutic agent.
16. The method of claim 15 wherein the therapeutic agent is a cytotoxic agent, an anti-inflammatory agent, peptide, or nucleic acid or nucleic acid analog.
17. The method of claim 16, wherein the anti-inflammatory agent is a glucocorticoid receptor agonist.
18. The method of claim 17, wherein the anti-inflammatory agent is Cortisol, cortisone acetate, beclometasone, prednisone, prednisolone, methylprednisolone, betamethasone, trimcinolone, budesonide, dexamethasone, fluticasone, fluticasone propionate, fluticasone furoate, compound 15-5, or mometasone.
19. The method of claim 14, wherein the targeting ligand is an antibody or monoclonal antibody (e.g., chimeric, humanized, or human), ligand for a receptor, lectin, saccharide, poly(ethylene glycol), polysaccharide, or polyamino acid.
20. The method of claim 14, wherein the targeting ligand is a chimeric, humanized, or human anti-Her2 antibody, anti-CD4 antibody, anti-CD20 antibody, anti-EGFR antibody, anti-CD22 antibody, anti-CD23 antibody, anti-CD25 antibody, anti-CD52 antibody, anti-CD30 antibody, anti-CD33 antibody, anti-CD40L antibody, anti-CD70 antibody, anti-CD74 antibody, anti-CD80 antibody, anti-CD 163 antibody, anti-Mucl8 antibody, anti-integrin antibody, anti-PSMA antibody, anti-CEA antibody, anti-CDl la antibody, anti-CTLA4 antibody, or anti-BLys antibody.
21. An anti-inflammatory compound comprising the formula
wherein
V is selected from O and S;
W is selected from O, N, and CH2;
X is selected from a covalent bond; a carbon atom; a heteroatom; an optionally substituted group selected from the group consisting of acyl, aliphatic, heteroaliphatic, aryl, heteroaryl, and heterocyclic; a carbon atom linked to a trimethylammonium group by a C1-C5 hydrocarbon chain; nucleoside, protease sensitive group, cathepsin B sensitive group, or glycosidase sensitive group;
Y is selected from a covalent bond or a bivalent, straight or branched, saturated or unsaturated, optionally substituted C1.30 hydrocarbon chain wherein one or more methylene units of Y are optionally and independently replaced by -0-, -S-, -N(R)-, -C(O)-, C(0)0-, OC(O)-, -N(Pv)C(0)-, -C(0)N(R)-, -S(O)-, -S(0) -, -N(R)S02-, S0 N(R)-, a heterocyclic group, an aryl group, or a heteroaryl group;
T is an R, CR2, O, or S;
D is an anti-inflammatory agent;
Z is a linkage formed between (i) a reactive functional group selected from the group consisting of N-hydroxysuccinimide, para-nitrophenyl carbonate, para-nitrophenyl carbamate, methyl ketone, azide, pentafluorophenyl, haloacetamide, maleimide, hydroxylamine, strained cycloalkyne, and heterocycloalkyne, alkyne, diene, azadiene, and heterocyclic azadiene, wherein halo is iodine (I), bromine (Br), fluorine (F), or chlorine (CI) and hetero is N, O, or S, and (ii) an S, NR, or O group on the cell-specific targeting ligand (L);
Each occurrence of R is independently hydrogen, a suitable protecting group, an acyl moiety, arylalkyl moiety, aliphatic moiety, aryl moiety, heteroaryl moiety, or heteroaliphatic moiety;
L is a cell-specific targeting ligand; and
n is 1, 2, 3, or 4.
22. The compound of claim 21 , wherein the anti-inflammatory agent is a glucocorticoid receptor agonist.
23. The compound of claim 21 , wherein the anti-inflammatory agent is Cortisol, cortisone acetate, beclometasone, prednisone, prednisolone, methylprednisolone, betamethasone, trimcinolone, budesonide, dexamethasone, fluticasone, fluticasone propionate, fluticasone furoate, compound 15-5, or mometasone.
24. The compound of claim 21 , wherein the targeting ligand is an antibody or monoclonal antibody (e.g., chimeric, humanized, or human), ligand for a receptor, lectin, saccharide, poly(ethylene glycol), polysaccharide, or polyamino acid.
25. The compound of claim 21 , wherein the targeting ligand is a chimeric, humanized, or human anti-Her2 antibody, anti-CD4 antibody, anti-CD20 antibody, anti-EGFR antibody, anti-CD22 antibody, anti-CD23 antibody, anti-CD25 antibody, anti-CD52 antibody, anti-CD30 antibody, anti-CD33 antibody, anti-CD40L antibody, anti-CD70 antibody, anti-CD74 antibody, anti-CD80 antibody, anti-CD 163 antibody, anti-Mucl8 antibody, anti-integrin antibody, anti-PSMA antibody, anti-CEA antibody, anti-CDl la antibody, anti-CTLA4 antibody, or anti-BLys antibody.
26. An anti-cancer compound comprising the formula
wherein
V is selected from O and S;
W is selected from O, N, and CH2;
X is selected from a covalent bond; a carbon atom; a heteroatom; an optionally substituted group selected from the group consisting of acyl, aliphatic, heteroaliphatic, aryl, heteroaryl, and heterocyclic; a carbon atom linked to a trimethylammonium group by a C1-C5 hydrocarbon chain; nucleoside, protease sensitive group, cathepsin B sensitive group, or glycosidase sensitive group;
Y is selected from a covalent bond or a bivalent, straight or branched, saturated or unsaturated, optionally substituted Ci .39 hydrocarbon chain wherein one or more methylene units of Y are optionally and independently replaced by -0-, -S-, -N(R)-, -C(O)-, C(0)0-,
OC(O)-, -N(R)C(0)-, -C(0)N(R)-, -S(O)-, -S(0)2-, -N(R)S02-, S02N(R)-, a heterocyclic group, an aryl group, or a heteroaryl group;
T is an R, CR2, O, or S;
D is a cytotoxic agent;
Z is a linkage formed between (i) a reactive functional group selected from the group consisting of N-hydroxysuccinimide, para-nitrophenyl carbonate, para-nitrophenyl carbamate, methyl ketone, azide, pentafluorophenyl, haloacetamide, maleimide, hydroxylamine, strained cycloalkyne, and heterocycloalkyne, alkyne, diene, azadiene, and heterocyclic azadiene, wherein halo is iodine (I), bromine (Br), fluorine (F), or chlorine (CI) and hetero is N, O, or S, and (ii) an S, NR, or O group on the cell-specific targeting ligand (L);
Each occurrence of R is independently hydrogen, a suitable protecting group, an acyl moiety, arylalkyl moiety, aliphatic moiety, aryl moiety, heteroaryl moiety, or heteroaliphatic moiety;
L is a cell-specific targeting ligand; and
n is 1, 2, 3, or 4.
27. The compound of claim 26, wherein the cytotoxic agent is selected from duocarmycins and CC-1065.
28. The compound of claim 26, wherein the cytotoxic agent is selected from a
CBI (1,2,9,9a- tetrahydrocyclopropa[c]benz[e]indol-4-one)-based analogues, MCBI (7-methoxy- 1,2,9,9a- tetra-hydrocyclopropa[c]benz[e]indol-4-one)-based analogues and CCBI (7-cyano- 1,2,9,9a- tetra-hydrocyclo-propa[c]benz[e]-indol-4-one)-based analogue of the duocarmycins and CC- 1065.
29. The compound of claim 26, wherein the cytotoxic agent is selected from doxorubicin and doxorubicin conjugates such as morpholino-doxorubicin and cyanomorpholino- doxorubicin.
30. The compound of claim 26, wherein the cytotoxic agent is selected from dolastatins such as dolestatin-10, combretastatin, calicheamicin, maytansine, maytansine analogs, DM-I, auristatin E, auristatin EB (AEB), auristatin EFP (AEFP), monomethyl auristatin E (MMAE), 5-benzoylvaleric acid- AE ester (AEVB), tubulysins, disorazole, epothilones, Paclitaxel, docetaxel, SN-38, Topotecan, rhizoxin, echinomycin, colchicine, vinblastin, vindesine, estramustine, cemadotin, eleutherobin, methotrexate, methopterin, dichloro methotrexate, 5-fluorouracil, 6- mercaptopurine, cytosine arabinoside, melphalan, leurosine, leurosideine, actinomycin, daunorubicin and daunorubicin conjugates, mitomycin C, mitomycin A, carminomycin, aminopterin, tallysomycin, podophyllotoxin and podophyllotoxin derivatives
such as etoposide or etoposide phosphate, vincristine, taxol, taxotere retinoic acid, butyric acid, N - acetyl spermidine, camptothecin, and analogs thereof.
31. The compound of claim 26, wherein the targeting ligand is an antibody or monoclonal antibody (e.g., chimeric, humanized, or human), ligand for a receptor, lectin, saccharide, poly(ethylene glycol), polysaccharide, or polyamino acid.
32. The method of claim 26, wherein the targeting ligand is a chimeric, humanized, or human anti-Her2 antibody, anti-CD4 antibody, anti-CD20 antibody, anti-EGFR antibody, anti-CD22 antibody, anti-CD23 antibody, anti-CD25 antibody, anti-CD52 antibody, anti-CD30 antibody, anti-CD33 antibody, anti-CD40L antibody, anti-CD70 antibody, anti-CD74 antibody, anti-CD80 antibody, anti-CD 163 antibody, anti-Mucl8 antibody, anti-integrin antibody, anti-PSMA antibody, anti-CEA antibody, anti-CDl la antibody, anti-CTLA4 antibody, or anti-BLys antibody.
33. A method for making an antibody-drug conjugate that has reduced propensity for forming aggregates comprising:
(a) providing a compound comprising the formula
wherein
V is selected from O and S;
W is selected from O, N, and CH2;
X is selected from a covalent bond; a carbon atom; a heteroatom; an optionally substituted group selected from the group consisting of acyl, aliphatic, heteroaliphatic, aryl, heteroaryl, and heterocyclic; a carbon atom linked to a trimethylammonium group by a C1-C5 hydrocarbon chain; nucleoside, protease sensitive group, cathepsin B sensitive group, or glycosidase sensitive group;
Y is selected from a covalent bond or a bivalent, straight or branched, saturated or unsaturated, optionally substituted CI -30 hydrocarbon chain wherein one or more methylene units of Y are optionally and independently replaced by -0-, -S-, -N(R)-, -C(O)-, C(0)0-, OC(O)-, -N(R)C(0)-, -C(0)N(R , -S(O)-, -S(0) -, -N(R)S0 -, S0 N(R , a heterocyclic group, an aryl group, or a heteroaryl group;
T is an R, CR2, O, or S;
Z is a reactive functional group selected from the group consisting of N- hydroxysuccinimidyl ester, para-nitrophenyl carbonate, para-nitrophenyl carbamate, methyl
- I l l -
ketone, azide, hydrazine, pentafluorophenyl, haloacetamide, maleimide, hydroxylamine, strained cycloalkyne, and heterocycloalkyne, alkyne, diene, azadiene, and heterocyclic azadiene, wherein halo is iodine (I), bromine (Br), fluorine (F), or chlorine (CI) and hetero is N, O, or S;
D is a payload;
Each occurrence of R is independently hydrogen, a suitable protecting group, an acyl moiety, arylalkyl moiety, aliphatic moiety, aryl moiety, heteroaryl moiety, or heteroaliphatic moiety; and
n is 1, 2, 3, or 4; and
(b) conjugating the compound to an antibody to make the antibody-drug conjugate that has reduced propensity for forming aggregates.
34. The method of claim 33, wherein the payload is a therapeutic agent, a detectable label, radionuclide, or protecting group.
35. The method of claim 33, wherein the therapeutic agent is a cytotoxic agent, an anti-inflammatory agent, peptide, or nucleic acid or nucleic acid analog.
36. The method of claim 35, wherein the anti-inflammatory agent is a glucocorticoid receptor agonist.
37. The method of claim 35, wherein the anti-inflammatory agent is Cortisol, cortisone acetate, beclometasone, prednisone, prednisolone, methylprednisolone, betamethasone, trimcinolone, budesonide, dexamethasone, fluticasone, fluticasone propionate, fluticasone furoate, compound 15-5, or mometasone.
38. The method of claim 35, wherein the cytotoxic agent is selected from duocarmycins and CC-1065.
39. The method of claim 35, wherein the cytotoxic agent is selected from a CBI (1 ,2,9,9a- tetrahydrocyclopropa[c]benz[e]indol-4-one)-based analogues, MCBI (7-methoxy-
1,2,9,9a- tetra-hydrocyclopropa[c]benz[e]indol-4-one)-based analogues and CCBI (7-cyano- 1,2,9,9a- tetra-hydrocyclo-propa[c]benz[e]-indol-4-one)-based analogue of the duocarmycins and CC- 1065.
40. The method of claim 35, wherein the cytotoxic agent is selected from doxorubicin and doxorubicin conjugates such as mo holino-do orubicin and cyanomorpholino- doxorubicin.
The method of claim 35, wherein the cytotoxic agent is selected from dolastatins such as dolestatin-10, combretastatin, calicheamicin, maytansine, maytansine analogs, DM-I, auristatin E, auristatin EB (AEB), auristatin EFP (AEFP), monomethyl auristatin E (MMAE), 5-benzoylvaleric acid- AE ester (AEVB), tubulysins, disorazole, epothilones, Paclitaxel, docetaxel, SN-38, Topotecan, rhizoxin, echinomycin, colchicine, vinblastin, vindesine, estramustine, cemadotin, eleutherobin, methotrexate, methopterin, dichloro methotrexate, 5-fluorouracil, 6- mercaptopurine, cytosine arabinoside, melphalan, leurosine, leurosideine, actinomycin, daunorubicin and daunorubicin conjugates, mitomycin C, mitomycin A, carminomycin, aminopterin, tallysomycin, podophyllotoxin and podophyllotoxin derivatives such as etoposide or etoposide phosphate, vincristine, taxol, taxotere retinoic acid, butyric acid, N - acetyl spermidine, camptothecin, and analogs thereof.
42. The method of claim 33, wherein the targeting ligand is an antibody or monoclonal antibody (e.g., chimeric, humanized, or human), ligand for a receptor, lectin, saccharide, poly(ethylene glycol), polysaccharide, or polyamino acid.
The method of claim 33, wherein the targeting ligand is a chimeric, humanized, or human anti-Her2 antibody, anti-CD4 antibody, anti-CD20 antibody, anti-EGFR antibody, anti-CD22 antibody, anti-CD23 antibody, anti-CD25 antibody, anti-CD52 antibody, anti-CD30 antibody, anti-CD33 antibody, anti-CD40L antibody, anti-CD70 antibody, anti-CD74 antibody, anti-CD80 antibody, anti-CD 163 antibody, anti-Mucl8 antibody, anti-integrin antibody, anti-PSMA antibody, anti-CEA antibody, anti-CDl la antibody, anti-CTLA4 antibody, or anti-BLys antibody.
44. A method for making a composition of antibody-drug conjugates in which the propensity of the antibody-drug conjugates in the composition to form aggregates is reduced comprising:
(a) providing a multiplicity of compounds comprising the formula
wherein
V is selected from O and S;
W is selected from O, N, and CH2;
X is selected from a covalent bond; a carbon atom; a heteroatom; an optionally substituted group selected from the group consisting of acyl, aliphatic, heteroaliphatic, aryl, heteroaryl, and heterocyclic; a carbon atom linked to a trimethylammonium group by a C1-C5
hydrocarbon chain; nucleoside, protease sensitive group, cathepsin B sensitive group, or glycosidase sensitive group;
Y is selected from a covalent bond or a bivalent, straight or branched, saturated or unsaturated, optionally substituted CI -30 hydrocarbon chain wherein one or more methylene units of Y are optionally and independently replaced by -0-, -S-, -N(R)-, -C(O)-, C(0)0-, OC(O)-, -N(R)C(0)-, -C(0)N(R , -S(O)-, -S(0)2-, -N(R)S02-, S02N(R , a heterocyclic group, an aryl group, or a heteroaryl group;
T is an R, CR2, O, or S;
Z is a reactive functional group selected from the group consisting of N- hydroxysuccinimidyl ester, para-nitrophenyl carbonate, para-nitrophenyl carbamate, methyl ketone, azide, hydrazine, pentafluorophenyl, haloacetamide, maleimide, hydroxylamine, strained cycloalkyne, and heterocycloalkyne, alkyne, diene, azadiene, and heterocyclic azadiene, wherein halo is iodine (I), bromine (Br), fluorine (F), or chlorine (CI) and hetero is N, O, or S;
D is a payload;
each occurrence of R is independently hydrogen, a suitable protecting group, an acyl moiety, arylalkyl moiety, aliphatic moiety, aryl moiety, heteroaryl moiety, or heteroaliphatic moiety; and
n is 1, 2, 3, or 4; and
(b) conjugating the compounds to a multiplicity of antibodies to make the composition in which the propensity of the antibody-drug conjugates therein to form aggregates is reduced.
45. The method of claim 44, wherein the payload is a therapeutic agent, a detectable label, radionuclide, or protecting group.
46. The method of claim 44, wherein the therapeutic agent is a cytotoxic agent, an anti-inflammatory agent, peptide, or nucleic acid or nucleic acid analog.
47. The method of claim 46, wherein the anti-inflammatory agent is a glucocorticoid receptor agonist.
48. The method of claim 46, wherein the anti-inflammatory agent is Cortisol, cortisone acetate, beclometasone, prednisone, prednisolone, methylprednisolone, betamethasone, trimcinolone, budesonide, dexamethasone, fluticasone, fluticasone propionate, fluticasone furoate, compound 15-5, or mometasone.
49. The method of claim 46, wherein the cytotoxic agent is selected from duocarmycins and CC-1065.
50. The method of claim 46, wherein the cytotoxic agent is selected from a CBI (1,2,9,9a- tetrahydrocyclopropa[c]benz[e]indol-4-one)-based analogues, MCBI (7-methoxy- 1,2,9,9a- tetra-hydrocyclopropa[c]benz[e]indol-4-one)-based analogues and CCBI (7-cyano- 1,2,9,9a- tetra-hydrocyclo-propa[c]benz[e]-indol-4-one)-based analogue of the duocarmycins and CC- 1065.
51. The method of claim 46, wherein the cytotoxic agent is selected from doxorubicin and doxorubicin conjugates such as mo holino-doxorubicin and cyanomorpholino- doxorubicin.
52. The method of claim 46, wherein the cytotoxic agent is selected from dolastatins such as dolestatin-10, combretastatin, calicheamicin, maytansine, maytansine analogs, DM-I, auristatin E, auristatin EB (AEB), auristatin EFP (AEFP), monomethyl auristatin E (MMAE), 5-benzoylvaleric acid- AE ester (AEVB), tubulysins, disorazole, epothilones, Paclitaxel, docetaxel, SN-38, Topotecan, rhizoxin, echinomycin, colchicine, vinblastin, vindesine, estramustine, cemadotin, eleutherobin, methotrexate, methopterin, dichloro methotrexate, 5-fluorouracil, 6- mercaptopurine, cytosine arabinoside, melphalan, leurosine, leurosideine, actinomycin, daunorubicin and daunorubicin conjugates, mitomycin C, mitomycin A, carminomycin, aminopterin, tallysomycin, podophyllotoxin and podophyllotoxin derivatives such as etoposide or etoposide phosphate, vincristine, taxol, taxotere retinoic acid, butyric acid, N - acetyl spermidine, camptothecin, and analogs thereof.
53. The method of claim 44, wherein the percent of aggregated antibody-drug- conjugate in the composition is 2% or less, 1.5% or less, 1.0% or less, 5% or less, 1% or less, or undetectable.
54. The method of claim 44, wherein at least 90%, 95%, 96%, 97% 98%, 99%), 99.5%, 99.4%, 99.3%, or 99.2% of the antibody-drug conjugates in the composition is not aggregated.
55. The method of claim 44, wherein the targeting ligand is an antibody or monoclonal antibody (e.g., chimeric, humanized, or human), ligand for a receptor, lectin, saccharide, poly(ethylene glycol), polysaccharide, or polyamino acid.
56. The method of claim 44, wherein the targeting ligand is a chimeric, humanized, or human anti-Her2 antibody, anti-CD4 antibody, anti-CD20 antibody, anti-EGFR antibody, anti-CD22 antibody, anti-CD23 antibody, anti-CD25 antibody, anti-CD52 antibody,
anti-CD30 antibody, anti-CD33 antibody, anti-CD40L antibody, anti-CD70 antibody, anti-CD74 antibody, anti-CD80 antibody, anti-CD 163 antibody, anti-Mucl8 antibody, anti-integrin antibody, anti-PSMA antibody, anti-CEA antibody, anti-CDl la antibody, anti-CTLA4 antibody, or anti-BLys antibody.
Priority Applications (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US15/301,564 US10550190B2 (en) | 2014-04-04 | 2015-03-30 | Phosphate based linkers for intracellular delivery of drug conjugates |
EP15773458.3A EP3125943A4 (en) | 2014-04-04 | 2015-03-30 | Phosphate based linkers for intracellular delivery of drug conjugates |
Applications Claiming Priority (4)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201461975407P | 2014-04-04 | 2014-04-04 | |
US61/975,407 | 2014-04-04 | ||
US201562112222P | 2015-02-05 | 2015-02-05 | |
US62/112,222 | 2015-02-05 |
Publications (1)
Publication Number | Publication Date |
---|---|
WO2015153401A1 true WO2015153401A1 (en) | 2015-10-08 |
Family
ID=54241148
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/US2015/023247 WO2015153401A1 (en) | 2014-04-04 | 2015-03-30 | Phosphate based linkers for intracellular delivery of drug conjugates |
Country Status (3)
Country | Link |
---|---|
US (1) | US10550190B2 (en) |
EP (1) | EP3125943A4 (en) |
WO (1) | WO2015153401A1 (en) |
Cited By (20)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
KR101704379B1 (en) * | 2015-10-27 | 2017-02-08 | (주)알테오젠 | Antibody-Drug Conjugate and Method of Producing the Same |
WO2017062271A3 (en) * | 2015-10-06 | 2017-06-01 | Merck Sharp & Dohme Corp. | Antibody drug conjugate for anti-inflammatory applications |
WO2017132103A2 (en) | 2016-01-29 | 2017-08-03 | Merck Sharp & Dohme Corp. | Phosphonate linkers and their use to facilitate cellular retention of compounds |
WO2017210471A1 (en) * | 2016-06-02 | 2017-12-07 | Abbvie Inc. | Glucocorticoid receptor agonist and immunoconjugates thereof |
WO2018039605A1 (en) * | 2015-08-28 | 2018-03-01 | Ventana Medical Systems, Inc. | Protein proximity assay in formalin fixed paraffin embedded tissue using caged haptens |
WO2018089373A3 (en) * | 2016-11-08 | 2018-06-21 | Regeneron Pharmaceuticals, Inc. | Steroids and protein-conjugates thereof |
WO2019106609A1 (en) * | 2017-12-01 | 2019-06-06 | Abbvie Inc. | Glucocorticoid receptor agonist and immunoconjugates thereof |
WO2019136487A2 (en) | 2018-01-08 | 2019-07-11 | Regeneron Pharmaceuticals, Inc. | Steroids and antibody-conjugates thereof |
US10703745B2 (en) | 2018-04-30 | 2020-07-07 | Unity Biotechnology, Inc. | Acyl phosphonamidates and acyl benzylamines that are Bcl family antagonists for use in clinical management of conditions caused or mediated by senescent cells and for treating cancer |
US10800826B2 (en) | 2015-10-05 | 2020-10-13 | Merck Sharp & Dohme Corp. | Antibody peptide conjugates that have agonist activity at both the glucagon and glucagon-like peptide 1 receptors |
JP2021504430A (en) * | 2017-12-01 | 2021-02-15 | アッヴィ・インコーポレイテッド | Anti-CD40 antibody drug conjugate |
US11111259B2 (en) | 2015-12-18 | 2021-09-07 | Unity Biotechnology, Inc. | Acylsulfonamide derivatives for treating senescence-associated diseases and disorders |
IT202000006442A1 (en) | 2020-03-27 | 2021-09-27 | Genetic S P A | BUDESONIDE 21-PHOSPHATE SALTS AND PHARMACEUTICAL COMPOSITIONS CONTAINING THE SAME |
WO2022135332A1 (en) * | 2020-12-21 | 2022-06-30 | 映恩生物制药(苏州)有限公司 | Steroid conjugate |
US11377502B2 (en) | 2018-05-09 | 2022-07-05 | Regeneron Pharmaceuticals, Inc. | Anti-MSR1 antibodies and methods of use thereof |
US11491237B2 (en) | 2017-05-18 | 2022-11-08 | Regeneron Pharmaceuticals, Inc. | Cyclodextrin protein drug conjugates |
AU2021201765B2 (en) * | 2015-06-15 | 2022-12-08 | Hangzhou Dac Biotech Co., Ltd | Hydrophilic Linkers for Conjugate |
CN115636863A (en) * | 2022-10-19 | 2023-01-24 | 中国医学科学院医药生物技术研究所 | Dexamethasone derivative containing maleimide segment and preparation method thereof |
US11779649B2 (en) | 2018-12-21 | 2023-10-10 | Novartis Ag | Antibodies to PMEL17 and conjugates thereof |
WO2024077277A1 (en) | 2022-10-07 | 2024-04-11 | Ambrx, Inc. | Drug linkers and antibody conjugates thereof |
Families Citing this family (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN110520161A (en) * | 2017-02-10 | 2019-11-29 | 伊利诺伊大学评议会 | The glycoconjugate that the trigger for marking and targeting for cancer selective can activate |
BR112021015832A2 (en) | 2019-02-12 | 2022-01-18 | Ambrx Inc | Compositions containing antibody-tlr agonist conjugates, methods and uses thereof |
CA3133155A1 (en) | 2019-03-19 | 2020-09-24 | Fundacio Privada Institut D'investigacio Oncologica De Vall Hebron | Combination therapy for the treatment for cancer |
AU2021327396A1 (en) | 2020-08-20 | 2023-03-23 | Ambrx, Inc. | Antibody-TLR agonist conjugates, methods and uses thereof |
Citations (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20020102590A1 (en) * | 2000-10-11 | 2002-08-01 | Pe Corporation (Ny) | Fluorescent nucleobase conjugates having anionic linkers |
US20060122143A1 (en) * | 2000-08-21 | 2006-06-08 | Boyer Jose L | Drug-eluting stents coated with P2Y12 receptor antagonist compound |
US20070048773A1 (en) * | 2005-07-29 | 2007-03-01 | Applera Corporation | Detection of polyphosphate using fluorescently labeled polyphosphate acceptor substrates |
US20100249072A1 (en) * | 2007-08-31 | 2010-09-30 | Purdue Research Foundation | Prodrugs and conjugates of prenylation inhibitors |
US20120058473A1 (en) * | 2010-08-25 | 2012-03-08 | Pacific Biosciences Of California, Inc. | Molecular Adaptors for Dye Conjugates |
Family Cites Families (16)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5094848A (en) | 1989-06-30 | 1992-03-10 | Neorx Corporation | Cleavable diphosphate and amidated diphosphate linkers |
US6214345B1 (en) | 1993-05-14 | 2001-04-10 | Bristol-Myers Squibb Co. | Lysosomal enzyme-cleavable antitumor drug conjugates |
EP0647450A1 (en) | 1993-09-09 | 1995-04-12 | BEHRINGWERKE Aktiengesellschaft | Improved prodrugs for enzyme mediated activation |
US6218519B1 (en) | 1996-04-12 | 2001-04-17 | Pro-Neuron, Inc. | Compounds and methods for the selective treatment of cancer and bacterial infections |
AU739028B2 (en) | 1996-09-27 | 2001-10-04 | Bristol-Myers Squibb Company | Hydrolyzable prodrugs for delivery of anticancer drugs to metastatic cells |
US6759509B1 (en) | 1996-11-05 | 2004-07-06 | Bristol-Myers Squibb Company | Branched peptide linkers |
US6835807B1 (en) | 1998-05-22 | 2004-12-28 | Daiichi Pharmaceuticals Co., Ltd. | Drug complex and drug delivery system |
US6268488B1 (en) | 1999-05-25 | 2001-07-31 | Barbas, Iii Carlos F. | Prodrug activation using catalytic antibodies |
US20040052793A1 (en) | 2001-02-22 | 2004-03-18 | Carter Paul J. | Caspase activivated prodrugs therapy |
US20040018194A1 (en) | 2000-11-28 | 2004-01-29 | Francisco Joseph A. | Recombinant anti-CD30 antibodies and uses thereof |
EP1243276A1 (en) | 2001-03-23 | 2002-09-25 | Franciscus Marinus Hendrikus De Groot | Elongated and multiple spacers containing activatible prodrugs |
US7091186B2 (en) | 2001-09-24 | 2006-08-15 | Seattle Genetics, Inc. | p-Amidobenzylethers in drug delivery agents |
US20050180972A1 (en) | 2002-07-31 | 2005-08-18 | Wahl Alan F. | Anti-CD20 antibody-drug conjugates for the treatment of cancer and immune disorders |
ES2545533T3 (en) * | 2004-11-01 | 2015-09-11 | The Regents Of The University Of California | Compositions and methods for biomolecule modification |
EP2486023A4 (en) * | 2009-10-06 | 2014-05-07 | Immunogen Inc | Potent conjugates and hydrophilic linkers |
MX346635B (en) * | 2011-02-15 | 2017-03-27 | Immunogen Inc | Cytotoxic benzodiazepine derivatives. |
-
2015
- 2015-03-30 WO PCT/US2015/023247 patent/WO2015153401A1/en active Application Filing
- 2015-03-30 US US15/301,564 patent/US10550190B2/en active Active
- 2015-03-30 EP EP15773458.3A patent/EP3125943A4/en active Pending
Patent Citations (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20060122143A1 (en) * | 2000-08-21 | 2006-06-08 | Boyer Jose L | Drug-eluting stents coated with P2Y12 receptor antagonist compound |
US20020102590A1 (en) * | 2000-10-11 | 2002-08-01 | Pe Corporation (Ny) | Fluorescent nucleobase conjugates having anionic linkers |
US20070048773A1 (en) * | 2005-07-29 | 2007-03-01 | Applera Corporation | Detection of polyphosphate using fluorescently labeled polyphosphate acceptor substrates |
US20100249072A1 (en) * | 2007-08-31 | 2010-09-30 | Purdue Research Foundation | Prodrugs and conjugates of prenylation inhibitors |
US20120058473A1 (en) * | 2010-08-25 | 2012-03-08 | Pacific Biosciences Of California, Inc. | Molecular Adaptors for Dye Conjugates |
Non-Patent Citations (2)
Title |
---|
CHEMICAL ABSTRACTS, Columbus, Ohio, US; XP055229215 * |
See also references of EP3125943A4 * |
Cited By (53)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
AU2021201765B2 (en) * | 2015-06-15 | 2022-12-08 | Hangzhou Dac Biotech Co., Ltd | Hydrophilic Linkers for Conjugate |
JP2019532275A (en) * | 2015-08-28 | 2019-11-07 | ヴェンタナ メディカル システムズ, インク. | Protein proximity assay in formalin-fixed paraffin-embedded tissue using caged haptens |
US11053266B2 (en) | 2015-08-28 | 2021-07-06 | Ventana Medical Systems, Inc. | Protein proximity assay in formalin fixed paffafin embedded tissue using caged haptens |
JP7033122B2 (en) | 2015-08-28 | 2022-03-09 | ヴェンタナ メディカル システムズ, インク. | Protein proximity assay in formalin-fixed paraffin-embedded tissue using caged haptens |
WO2018039605A1 (en) * | 2015-08-28 | 2018-03-01 | Ventana Medical Systems, Inc. | Protein proximity assay in formalin fixed paraffin embedded tissue using caged haptens |
US11345719B2 (en) | 2015-08-28 | 2022-05-31 | Vetana Medical Systems, Inc. | Protein proximity assay in formalin fixed paraffin embedded tissue using caged haptens |
US10800826B2 (en) | 2015-10-05 | 2020-10-13 | Merck Sharp & Dohme Corp. | Antibody peptide conjugates that have agonist activity at both the glucagon and glucagon-like peptide 1 receptors |
US11773150B2 (en) | 2015-10-05 | 2023-10-03 | Merck Sharp & Dohme Llc | Antibody peptide conjugates that have agonist activity at both the glucagon and glucagon-like peptide 1 receptors |
WO2017062271A3 (en) * | 2015-10-06 | 2017-06-01 | Merck Sharp & Dohme Corp. | Antibody drug conjugate for anti-inflammatory applications |
US11510993B2 (en) | 2015-10-06 | 2022-11-29 | Merck Sharp & Dohme Llc | Antibody drug conjugate for anti-inflammatory applications |
KR101704379B1 (en) * | 2015-10-27 | 2017-02-08 | (주)알테오젠 | Antibody-Drug Conjugate and Method of Producing the Same |
US11111259B2 (en) | 2015-12-18 | 2021-09-07 | Unity Biotechnology, Inc. | Acylsulfonamide derivatives for treating senescence-associated diseases and disorders |
US11883500B2 (en) | 2016-01-29 | 2024-01-30 | Merck Sharp & Dohme Llc | Phosphonate linkers and their use to facilitate cellular retention of compounds |
WO2017132103A2 (en) | 2016-01-29 | 2017-08-03 | Merck Sharp & Dohme Corp. | Phosphonate linkers and their use to facilitate cellular retention of compounds |
US10869929B2 (en) | 2016-01-29 | 2020-12-22 | Merck Sharp & Dohme Corp. | Phosphonate linkers and their use to facilitate cellular retention of compounds |
US11554172B2 (en) | 2016-01-29 | 2023-01-17 | Merck Sharp & Dohme Llc | Phosphonate linkers and their use to facilitate cellular retention of compounds |
WO2017132103A3 (en) * | 2016-01-29 | 2018-06-07 | Merck Sharp & Dohme Corp. | Phosphonate linkers and their use to facilitate cellular retention of compounds |
KR20190014542A (en) * | 2016-06-02 | 2019-02-12 | 애브비 인코포레이티드 | Glucocorticoid receptor agonists and their immunoconjugates |
KR102435599B1 (en) | 2016-06-02 | 2022-08-29 | 애브비 인코포레이티드 | Glucocorticoid receptor agonists and immunoconjugates thereof |
CN109476699A (en) * | 2016-06-02 | 2019-03-15 | 艾伯维公司 | Glucocorticoid receptor agonist and its immune conjugate |
WO2017210471A1 (en) * | 2016-06-02 | 2017-12-07 | Abbvie Inc. | Glucocorticoid receptor agonist and immunoconjugates thereof |
EP3901162A1 (en) * | 2016-06-02 | 2021-10-27 | AbbVie Inc. | Glucocorticoid receptor agonist and immunoconjugates thereof |
RU2745748C2 (en) * | 2016-06-02 | 2021-03-31 | Эббви Инк. | Agonist of the glucocorticoid receptor and its immunoconjugates |
CN109476699B (en) * | 2016-06-02 | 2021-10-12 | 艾伯维公司 | Glucocorticoid receptor agonists and immunoconjugates thereof |
TWI728118B (en) * | 2016-06-02 | 2021-05-21 | 美商艾伯維有限公司 | Glucocorticoid receptor agonist and immunoconjugates thereof |
US10668167B2 (en) | 2016-06-02 | 2020-06-02 | Abbvie Inc. | Glucocorticoid receptor agonist and immunoconjugates thereof |
AU2017274442B2 (en) * | 2016-06-02 | 2021-08-19 | Abbvie Inc. | Glucocorticoid receptor agonist and immunoconjugates thereof |
JP2019536765A (en) * | 2016-11-08 | 2019-12-19 | レゲネロン ファーマシューティカルス,インコーポレーテッド | Steroids and their protein conjugates |
JP7330101B2 (en) | 2016-11-08 | 2023-08-21 | レゲネロン ファーマシューティカルス,インコーポレーテッド | Steroids and their protein conjugates |
WO2018089373A3 (en) * | 2016-11-08 | 2018-06-21 | Regeneron Pharmaceuticals, Inc. | Steroids and protein-conjugates thereof |
US11760775B2 (en) * | 2016-11-08 | 2023-09-19 | Regeneron Pharmaceuticals, Inc. | Steroids and protein-conjugates thereof |
US10711032B2 (en) | 2016-11-08 | 2020-07-14 | Regeneron Pharmaceuticals, Inc. | Steroids and protein-conjugates thereof |
US11491237B2 (en) | 2017-05-18 | 2022-11-08 | Regeneron Pharmaceuticals, Inc. | Cyclodextrin protein drug conjugates |
JP2021504430A (en) * | 2017-12-01 | 2021-02-15 | アッヴィ・インコーポレイテッド | Anti-CD40 antibody drug conjugate |
JP2021501124A (en) * | 2017-12-01 | 2021-01-14 | アッヴィ・インコーポレイテッド | Glucocorticoid receptor agonist and its immunoconjugate |
US10772970B2 (en) | 2017-12-01 | 2020-09-15 | Abbvie Inc. | Glucocorticoid receptor agonist and immunoconjugates thereof |
EP3884962A1 (en) * | 2017-12-01 | 2021-09-29 | AbbVie Inc. | Glucocorticoid receptor agonist and immunoconjugates thereof |
WO2019106609A1 (en) * | 2017-12-01 | 2019-06-06 | Abbvie Inc. | Glucocorticoid receptor agonist and immunoconjugates thereof |
CN111417410A (en) * | 2017-12-01 | 2020-07-14 | 艾伯维公司 | Glucocorticoid receptor agonists and immunoconjugates thereof |
CN111417410B (en) * | 2017-12-01 | 2023-06-23 | 艾伯维公司 | Glucocorticoid receptor agonists and immunoconjugates thereof |
JP2021054845A (en) * | 2017-12-01 | 2021-04-08 | アッヴィ・インコーポレイテッド | Glucocorticoid receptor agonist and immunoconjugates thereof |
TWI803542B (en) * | 2017-12-01 | 2023-06-01 | 美商艾伯維有限公司 | Glucocorticoid receptor agonist and immunoconjugates thereof |
WO2019136487A2 (en) | 2018-01-08 | 2019-07-11 | Regeneron Pharmaceuticals, Inc. | Steroids and antibody-conjugates thereof |
US10703745B2 (en) | 2018-04-30 | 2020-07-07 | Unity Biotechnology, Inc. | Acyl phosphonamidates and acyl benzylamines that are Bcl family antagonists for use in clinical management of conditions caused or mediated by senescent cells and for treating cancer |
US11377502B2 (en) | 2018-05-09 | 2022-07-05 | Regeneron Pharmaceuticals, Inc. | Anti-MSR1 antibodies and methods of use thereof |
US11779649B2 (en) | 2018-12-21 | 2023-10-10 | Novartis Ag | Antibodies to PMEL17 and conjugates thereof |
CN115315431A (en) * | 2020-03-27 | 2022-11-08 | 基因股份公司 | Budesonide 21-phosphate ester salt and pharmaceutical composition containing same |
IT202000006442A1 (en) | 2020-03-27 | 2021-09-27 | Genetic S P A | BUDESONIDE 21-PHOSPHATE SALTS AND PHARMACEUTICAL COMPOSITIONS CONTAINING THE SAME |
WO2021191366A1 (en) | 2020-03-27 | 2021-09-30 | Genetic S.P.A. | Budesonide 21-phosphate salts and pharmaceutical compositions containing the same |
WO2022135332A1 (en) * | 2020-12-21 | 2022-06-30 | 映恩生物制药(苏州)有限公司 | Steroid conjugate |
WO2024077277A1 (en) | 2022-10-07 | 2024-04-11 | Ambrx, Inc. | Drug linkers and antibody conjugates thereof |
CN115636863A (en) * | 2022-10-19 | 2023-01-24 | 中国医学科学院医药生物技术研究所 | Dexamethasone derivative containing maleimide segment and preparation method thereof |
CN115636863B (en) * | 2022-10-19 | 2024-03-12 | 中国医学科学院医药生物技术研究所 | Dexamethasone derivative containing maleimide fragment and preparation method thereof |
Also Published As
Publication number | Publication date |
---|---|
US10550190B2 (en) | 2020-02-04 |
EP3125943A4 (en) | 2017-12-06 |
US20170182181A1 (en) | 2017-06-29 |
EP3125943A1 (en) | 2017-02-08 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
US10550190B2 (en) | Phosphate based linkers for intracellular delivery of drug conjugates | |
US20230099074A1 (en) | Antibody drug conjugate for anti-inflammatory applications | |
EP3407916B1 (en) | Phosphonate linkers and their use to facilitate cellular retention of compounds | |
EP3897738B1 (en) | Saponin conjugates | |
EP3240573B1 (en) | Enzymatic conjugation of polypeptides | |
AU2018295540B2 (en) | Compounds comprising cleavable linker and uses thereof | |
MX2013013069A (en) | Protein-active agent conjugates and method for preparing the same. | |
CN113423431A (en) | Compounds comprising a cleavable linker and uses thereof | |
CN114306634A (en) | Compounds comprising a cleavable linker and uses thereof | |
Coyne et al. | Gemcitabine‐(5′‐phosphoramidate)‐[anti‐IGF‐1R]: molecular design, synthetic organic chemistry reactions, and antineoplastic cytotoxic potency in populations of pulmonary adenocarcinoma (A549) | |
US20240115712A1 (en) | Semicarbazone-based saponin conjugate |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
121 | Ep: the epo has been informed by wipo that ep was designated in this application |
Ref document number: 15773458 Country of ref document: EP Kind code of ref document: A1 |
|
WWE | Wipo information: entry into national phase |
Ref document number: 15301564 Country of ref document: US |
|
NENP | Non-entry into the national phase |
Ref country code: DE |
|
REEP | Request for entry into the european phase |
Ref document number: 2015773458 Country of ref document: EP |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2015773458 Country of ref document: EP |